US20110190344A1 - Benzimidazole modulators of vr1 - Google Patents
Benzimidazole modulators of vr1 Download PDFInfo
- Publication number
- US20110190344A1 US20110190344A1 US13/084,705 US201113084705A US2011190344A1 US 20110190344 A1 US20110190344 A1 US 20110190344A1 US 201113084705 A US201113084705 A US 201113084705A US 2011190344 A1 US2011190344 A1 US 2011190344A1
- Authority
- US
- United States
- Prior art keywords
- phenyl
- benzimidazol
- ethyl
- benzenesulfonamide
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 265
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 147
- -1 haloC1-6alkyl Chemical group 0.000 claims description 141
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 52
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 19
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 15
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 14
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 claims description 13
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 12
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 11
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 11
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- XUNXMEAZSAXRRK-UHFFFAOYSA-N 2-[2-[2-[3-fluoro-5-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(C=C(F)C=2)C(F)(F)F)=N2)C2=C1 XUNXMEAZSAXRRK-UHFFFAOYSA-N 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- QYPSRKORKQKKBB-UHFFFAOYSA-N 2-[2-[2-(2,3,4-trifluorophenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C(=C(F)C(F)=CC=2)F)=N2)C2=C1 QYPSRKORKQKKBB-UHFFFAOYSA-N 0.000 claims description 8
- ZXDOTNLOEJMIAY-UHFFFAOYSA-N 2-[2-[2-(2,3-difluorophenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C(=C(F)C=CC=2)F)=N2)C2=C1 ZXDOTNLOEJMIAY-UHFFFAOYSA-N 0.000 claims description 8
- BRLXLXKMAJHYAM-UHFFFAOYSA-N 2-[2-[2-[2-[4-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 BRLXLXKMAJHYAM-UHFFFAOYSA-N 0.000 claims description 8
- GBWRUJLELUNGFG-UHFFFAOYSA-N 2-[2-[2-[3-(trifluoromethoxy)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(OC(F)(F)F)C=CC=2)=N2)C2=C1 GBWRUJLELUNGFG-UHFFFAOYSA-N 0.000 claims description 8
- BYXNUXUMQOLVTB-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 BYXNUXUMQOLVTB-UHFFFAOYSA-N 0.000 claims description 8
- LQUSZLASZYQZER-UHFFFAOYSA-N 2-[2-[2-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(C(Cl)=CC=2)C(F)(F)F)=N2)C2=C1 LQUSZLASZYQZER-UHFFFAOYSA-N 0.000 claims description 8
- CXOMNPIIWUWJQR-UHFFFAOYSA-N 4-(trifluoromethyl)-2-[2-[2-[4-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 CXOMNPIIWUWJQR-UHFFFAOYSA-N 0.000 claims description 8
- IZKPWTOIFVHXAY-UHFFFAOYSA-N n,n-dimethyl-2-[2-[2-[4-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 IZKPWTOIFVHXAY-UHFFFAOYSA-N 0.000 claims description 8
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 7
- AQMXQOTTWVAIFI-UHFFFAOYSA-N 1-[2-[2-[2-[4-(trifluoromethylsulfonyl)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N2)C2=C1 AQMXQOTTWVAIFI-UHFFFAOYSA-N 0.000 claims description 7
- WFLSBLOTCDGYNM-XNTDXEJSSA-N 1-[4-[(e)-2-[6-[2-(2-hydroxypropan-2-yl)phenyl]-1h-benzimidazol-2-yl]ethenyl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)C(C)(C)O)=CC=C2N1 WFLSBLOTCDGYNM-XNTDXEJSSA-N 0.000 claims description 7
- PEVAFHDGPRBCNH-UHFFFAOYSA-N 2-[1-(2-phenylethyl)benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(N(CCC=2C=CC=CC=2)C=N2)C2=C1 PEVAFHDGPRBCNH-UHFFFAOYSA-N 0.000 claims description 7
- BKBFEWSBNAYARN-UHFFFAOYSA-N 2-[2-[1-(2-phenylethynyl)benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(N(C=N2)C#CC=3C=CC=CC=3)C2=C1 BKBFEWSBNAYARN-UHFFFAOYSA-N 0.000 claims description 7
- HZXBIDDLVUPRBG-UHFFFAOYSA-N 2-[2-[2-(2,4,5-trifluorophenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C(=CC(F)=C(F)C=2)F)=N2)C2=C1 HZXBIDDLVUPRBG-UHFFFAOYSA-N 0.000 claims description 7
- KEOUCUAYLWZHMO-UHFFFAOYSA-N 2-[2-[2-(2,4-difluorophenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C(=CC(F)=CC=2)F)=N2)C2=C1 KEOUCUAYLWZHMO-UHFFFAOYSA-N 0.000 claims description 7
- LRMYDJFTVMIQOM-UHFFFAOYSA-N 2-[2-[2-(2,5-difluorophenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C(=CC=C(F)C=2)F)=N2)C2=C1 LRMYDJFTVMIQOM-UHFFFAOYSA-N 0.000 claims description 7
- JDCCVURROMCHEG-UHFFFAOYSA-N 2-[2-[2-(2,6-difluorophenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C(=CC=CC=2F)F)=N2)C2=C1 JDCCVURROMCHEG-UHFFFAOYSA-N 0.000 claims description 7
- HTFRZLFBUSZVDV-UHFFFAOYSA-N 2-[2-[2-(2-chlorophenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C(=CC=CC=2)Cl)=N2)C2=C1 HTFRZLFBUSZVDV-UHFFFAOYSA-N 0.000 claims description 7
- ITHPWEVBOFKMDA-UHFFFAOYSA-N 2-[2-[2-(2-fluorophenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C(=CC=CC=2)F)=N2)C2=C1 ITHPWEVBOFKMDA-UHFFFAOYSA-N 0.000 claims description 7
- JYSDJWXNXZVXMY-UHFFFAOYSA-N 2-[2-[2-(3,4-difluorophenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(F)C(F)=CC=2)=N2)C2=C1 JYSDJWXNXZVXMY-UHFFFAOYSA-N 0.000 claims description 7
- QGFULFHRGWUPGO-UHFFFAOYSA-N 2-[2-[2-(3,5-difluorophenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(F)C=C(F)C=2)=N2)C2=C1 QGFULFHRGWUPGO-UHFFFAOYSA-N 0.000 claims description 7
- DTFVLGKNGYXAMF-UHFFFAOYSA-N 2-[2-[2-(4-chlorophenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(Cl)=CC=2)=N2)C2=C1 DTFVLGKNGYXAMF-UHFFFAOYSA-N 0.000 claims description 7
- ZDPNWICWCXGKPB-UHFFFAOYSA-N 2-[2-[2-(4-fluorophenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(F)=CC=2)=N2)C2=C1 ZDPNWICWCXGKPB-UHFFFAOYSA-N 0.000 claims description 7
- IXPJLNPWNIZEDD-UHFFFAOYSA-N 2-[2-[2-(4-propan-2-ylphenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound C1=CC(C(C)C)=CC=C1CCC1=NC2=CC(C=3C(=CC=CC=3)S(N)(=O)=O)=CC=C2N1 IXPJLNPWNIZEDD-UHFFFAOYSA-N 0.000 claims description 7
- DKXLHDARQMLBDL-NTCAYCPXSA-N 2-[2-[2-[(e)-2-phenylethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC=CC=2)=N2)C2=C1 DKXLHDARQMLBDL-NTCAYCPXSA-N 0.000 claims description 7
- VHZQCUYJVXVYQK-UHFFFAOYSA-N 2-[2-[2-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C(=C(C=CC=2)C(F)(F)F)F)=N2)C2=C1 VHZQCUYJVXVYQK-UHFFFAOYSA-N 0.000 claims description 7
- AWJGVLKFDMDDRR-UHFFFAOYSA-N 2-[2-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=N2)C2=C1 AWJGVLKFDMDDRR-UHFFFAOYSA-N 0.000 claims description 7
- CESXYIASNYQWIG-UHFFFAOYSA-N 2-[2-[2-[3-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(C=CC=2)C(F)(F)F)=N2)C2=C1 CESXYIASNYQWIG-UHFFFAOYSA-N 0.000 claims description 7
- PEAUYDWZPFBVNL-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethylsulfonyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N2)C2=C1 PEAUYDWZPFBVNL-UHFFFAOYSA-N 0.000 claims description 7
- WKHHUUIJOIXTBS-UHFFFAOYSA-N 2-[2-[2-[4-fluoro-2-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C(=CC(F)=CC=2)C(F)(F)F)=N2)C2=C1 WKHHUUIJOIXTBS-UHFFFAOYSA-N 0.000 claims description 7
- 239000004305 biphenyl Substances 0.000 claims description 7
- 235000010290 biphenyl Nutrition 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 7
- BJOJCPSLOVPOQY-UHFFFAOYSA-N n-[2-[2-[2-[4-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 BJOJCPSLOVPOQY-UHFFFAOYSA-N 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 7
- YJPSUAGGJKRFRD-UHFFFAOYSA-N 2-[1-(2-phenylethynyl)benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(N(C=N2)C#CC=3C=CC=CC=3)C2=C1 YJPSUAGGJKRFRD-UHFFFAOYSA-N 0.000 claims description 6
- XUFVYQDEMHHBAM-UHFFFAOYSA-N 2-[2-[2-[2,5-bis(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)=N2)C2=C1 XUFVYQDEMHHBAM-UHFFFAOYSA-N 0.000 claims description 6
- PUCIPJPJEKCTFC-UHFFFAOYSA-N 2-[2-[2-[2-(3-chlorophenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(Cl)C=CC=2)=N2)C2=C1 PUCIPJPJEKCTFC-UHFFFAOYSA-N 0.000 claims description 6
- LMJVOQDKKWXNCL-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethoxy)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OC(F)(F)F)=CC=2)=N2)C2=C1 LMJVOQDKKWXNCL-UHFFFAOYSA-N 0.000 claims description 6
- SHDCQNDLAGXLEV-UHFFFAOYSA-N 2-[2-[2-[4-fluoro-3-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(C(F)=CC=2)C(F)(F)F)=N2)C2=C1 SHDCQNDLAGXLEV-UHFFFAOYSA-N 0.000 claims description 6
- NDUKYQAXWHTOGI-UHFFFAOYSA-N 4-[2-[2-(4-tert-butylphenyl)ethyl]-3h-benzimidazol-5-yl]phenol Chemical compound C1=CC(C(C)(C)C)=CC=C1CCC1=NC2=CC(C=3C=CC(O)=CC=3)=CC=C2N1 NDUKYQAXWHTOGI-UHFFFAOYSA-N 0.000 claims description 6
- WBVSBVBJQJJFEV-XCVCLJGOSA-N 5-(trifluoromethyl)-2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC(C(F)(F)F)=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 WBVSBVBJQJJFEV-XCVCLJGOSA-N 0.000 claims description 6
- XFCPPWQPZYKGFG-UHFFFAOYSA-N 5-(trifluoromethyl)-2-[2-[2-[4-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC(C(F)(F)F)=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 XFCPPWQPZYKGFG-UHFFFAOYSA-N 0.000 claims description 6
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 6
- SXHIBOQWOWZGEE-UHFFFAOYSA-N n-[2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OCC(F)(F)F)=CC=2)=N2)C2=C1 SXHIBOQWOWZGEE-UHFFFAOYSA-N 0.000 claims description 6
- SFWZAUWDLUETGP-UHFFFAOYSA-N n-methyl-2-[2-[2-[3-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(C=CC=2)C(F)(F)F)=N2)C2=C1 SFWZAUWDLUETGP-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims description 5
- JSJBYUABYQOWMK-UHFFFAOYSA-N 1-[2-[2-[2-(3-chlorophenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(Cl)C=CC=2)=N2)C2=C1 JSJBYUABYQOWMK-UHFFFAOYSA-N 0.000 claims description 5
- YPNQFAWZQAEJLM-UHFFFAOYSA-N 1-[2-[2-[2-(3-chlorophenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(Cl)C=CC=2)=N2)C2=C1 YPNQFAWZQAEJLM-UHFFFAOYSA-N 0.000 claims description 5
- GROZRFOBYUAQFX-UHFFFAOYSA-N 1-[2-[2-[2-(4-chlorophenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(Cl)=CC=2)=N2)C2=C1 GROZRFOBYUAQFX-UHFFFAOYSA-N 0.000 claims description 5
- NJLKQDNGYKBIGN-UHFFFAOYSA-N 1-[2-[2-[2-(4-chlorophenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(Cl)=CC=2)=N2)C2=C1 NJLKQDNGYKBIGN-UHFFFAOYSA-N 0.000 claims description 5
- KCIZRKQERXGBIS-UHFFFAOYSA-N 1-[2-[2-[2-(4-methylsulfonylphenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)S(C)(=O)=O)=N2)C2=C1 KCIZRKQERXGBIS-UHFFFAOYSA-N 0.000 claims description 5
- DEHGAWHTOVYNHN-UHFFFAOYSA-N 1-[2-[2-[2-(4-methylsulfonylphenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)S(C)(=O)=O)=N2)C2=C1 DEHGAWHTOVYNHN-UHFFFAOYSA-N 0.000 claims description 5
- JXSKFQGEDRDCNV-UHFFFAOYSA-N 1-[2-[2-[2-[3-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(C=CC=2)C(F)(F)F)=N2)C2=C1 JXSKFQGEDRDCNV-UHFFFAOYSA-N 0.000 claims description 5
- BOPHQCRVDBLNDK-UHFFFAOYSA-N 1-[2-[2-[2-[3-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(C=CC=2)C(F)(F)F)=N2)C2=C1 BOPHQCRVDBLNDK-UHFFFAOYSA-N 0.000 claims description 5
- YQVSQPWVMZYLSE-UHFFFAOYSA-N 1-[2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=2)=N2)C2=C1 YQVSQPWVMZYLSE-UHFFFAOYSA-N 0.000 claims description 5
- UMJRAEVJDJKPDI-UHFFFAOYSA-N 1-[2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=2)=N2)C2=C1 UMJRAEVJDJKPDI-UHFFFAOYSA-N 0.000 claims description 5
- JRTDDYUKAAOTBV-UHFFFAOYSA-N 1-[2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OCC(F)(F)F)=CC=2)=N2)C2=C1 JRTDDYUKAAOTBV-UHFFFAOYSA-N 0.000 claims description 5
- ZOROYSISSPXKRJ-UHFFFAOYSA-N 1-[2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OCC(F)(F)F)=CC=2)=N2)C2=C1 ZOROYSISSPXKRJ-UHFFFAOYSA-N 0.000 claims description 5
- DSSCTOXJXZJPQU-UHFFFAOYSA-N 1-[2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OCC(F)(F)C(F)(F)F)=CC=2)=N2)C2=C1 DSSCTOXJXZJPQU-UHFFFAOYSA-N 0.000 claims description 5
- GGBYWVLZBALXIO-UHFFFAOYSA-N 1-[2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OCC(F)(F)C(F)(F)F)=CC=2)=N2)C2=C1 GGBYWVLZBALXIO-UHFFFAOYSA-N 0.000 claims description 5
- BZYUIZINJBVNMV-UHFFFAOYSA-N 2-[2-[2-(4-methylsulfonylphenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CCC1=NC2=CC(C=3C(=CC=CC=3)S(N)(=O)=O)=CC=C2N1 BZYUIZINJBVNMV-UHFFFAOYSA-N 0.000 claims description 5
- DJXYPJVWZURHPY-UHFFFAOYSA-N 2-[2-[2-(4-tert-butylphenyl)ethyl]-3h-benzimidazol-5-yl]phenol Chemical compound C1=CC(C(C)(C)C)=CC=C1CCC1=NC2=CC(C=3C(=CC=CC=3)O)=CC=C2N1 DJXYPJVWZURHPY-UHFFFAOYSA-N 0.000 claims description 5
- IPECOUYCECUHLV-UHFFFAOYSA-N 2-[2-[2-[2-(4-chlorophenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(Cl)=CC=2)=N2)C2=C1 IPECOUYCECUHLV-UHFFFAOYSA-N 0.000 claims description 5
- GEKWETXATUFBHL-UHFFFAOYSA-N 2-[2-[2-[2-(4-methylsulfonylphenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)S(C)(=O)=O)=N2)C2=C1 GEKWETXATUFBHL-UHFFFAOYSA-N 0.000 claims description 5
- NFVOEHHLMKVORI-UHFFFAOYSA-N 2-[2-[2-[2-[3-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(C=CC=2)C(F)(F)F)=N2)C2=C1 NFVOEHHLMKVORI-UHFFFAOYSA-N 0.000 claims description 5
- QPVJPYOXHGOESR-UHFFFAOYSA-N 2-[2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=2)=N2)C2=C1 QPVJPYOXHGOESR-UHFFFAOYSA-N 0.000 claims description 5
- GZMABIIINXTAOO-UHFFFAOYSA-N 2-[2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OCC(F)(F)F)=CC=2)=N2)C2=C1 GZMABIIINXTAOO-UHFFFAOYSA-N 0.000 claims description 5
- HOEDHHAUKCMGQD-UHFFFAOYSA-N 2-[2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OCC(F)(F)C(F)(F)F)=CC=2)=N2)C2=C1 HOEDHHAUKCMGQD-UHFFFAOYSA-N 0.000 claims description 5
- JSCVRRIMQDGOJB-UHFFFAOYSA-N 2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=2)=N2)C2=C1 JSCVRRIMQDGOJB-UHFFFAOYSA-N 0.000 claims description 5
- APVKJLMEVVFREF-UHFFFAOYSA-N 2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OCC(F)(F)F)=CC=2)=N2)C2=C1 APVKJLMEVVFREF-UHFFFAOYSA-N 0.000 claims description 5
- FQPORUABNKGWOR-UHFFFAOYSA-N 2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OCC(F)(F)C(F)(F)F)=CC=2)=N2)C2=C1 FQPORUABNKGWOR-UHFFFAOYSA-N 0.000 claims description 5
- AEXADWOLKALVTC-UHFFFAOYSA-N 2-[2-[2-[4-(methanesulfonamido)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1CCC1=NC2=CC(C=3C(=CC=CC=3)S(N)(=O)=O)=CC=C2N1 AEXADWOLKALVTC-UHFFFAOYSA-N 0.000 claims description 5
- HADYXERELBRGPV-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethylsulfonylamino)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(NS(=O)(=O)C(F)(F)F)=CC=2)=N2)C2=C1 HADYXERELBRGPV-UHFFFAOYSA-N 0.000 claims description 5
- IHIAQIQWLGGCKC-UHFFFAOYSA-N 2-[2-[3-(4-tert-butylphenyl)propyl]-3h-benzimidazol-5-yl]phenol Chemical compound C1=CC(C(C)(C)C)=CC=C1CCCC1=NC2=CC(C=3C(=CC=CC=3)O)=CC=C2N1 IHIAQIQWLGGCKC-UHFFFAOYSA-N 0.000 claims description 5
- UZPKQMOMZKBVQI-UHFFFAOYSA-N 3-[2-[2-(4-tert-butylphenyl)ethyl]-3h-benzimidazol-5-yl]phenol Chemical compound C1=CC(C(C)(C)C)=CC=C1CCC1=NC2=CC(C=3C=C(O)C=CC=3)=CC=C2N1 UZPKQMOMZKBVQI-UHFFFAOYSA-N 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- RHAVIAZRBUILNB-UHFFFAOYSA-N [2-[2-[2-[4-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]methanamine Chemical compound NCC1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 RHAVIAZRBUILNB-UHFFFAOYSA-N 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- ZUWWKLHLRHDDLC-UHFFFAOYSA-N n-[2-[2-[2-(3-chlorophenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(Cl)C=CC=2)=N2)C2=C1 ZUWWKLHLRHDDLC-UHFFFAOYSA-N 0.000 claims description 5
- AQCPYXQGWVKNGP-UHFFFAOYSA-N n-[2-[2-[2-(3-chlorophenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(Cl)C=CC=2)=N2)C2=C1 AQCPYXQGWVKNGP-UHFFFAOYSA-N 0.000 claims description 5
- CGMKCOMERDILRK-UHFFFAOYSA-N n-[2-[2-[2-(4-chlorophenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(Cl)=CC=2)=N2)C2=C1 CGMKCOMERDILRK-UHFFFAOYSA-N 0.000 claims description 5
- WDMCUOVVNZAHRD-UHFFFAOYSA-N n-[2-[2-[2-(4-chlorophenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(Cl)=CC=2)=N2)C2=C1 WDMCUOVVNZAHRD-UHFFFAOYSA-N 0.000 claims description 5
- VIEDKAAIJYTGKI-UHFFFAOYSA-N n-[2-[2-[2-(4-methylsulfonylphenyl)ethyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)S(C)(=O)=O)=N2)C2=C1 VIEDKAAIJYTGKI-UHFFFAOYSA-N 0.000 claims description 5
- HCMZWJFBUIANTC-UHFFFAOYSA-N n-[2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=2)=N2)C2=C1 HCMZWJFBUIANTC-UHFFFAOYSA-N 0.000 claims description 5
- LEMIIIRXCMGVQJ-UHFFFAOYSA-N n-[2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(OCC(F)(F)C(F)(F)F)=CC=2)=N2)C2=C1 LEMIIIRXCMGVQJ-UHFFFAOYSA-N 0.000 claims description 5
- DGWKDJYGEKQHMV-UHFFFAOYSA-N n-[2-[2-[2-[4-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 DGWKDJYGEKQHMV-UHFFFAOYSA-N 0.000 claims description 5
- XEABIAFVAJGRSA-UHFFFAOYSA-N n-[4-[2-[6-(2-acetylphenyl)-1h-benzimidazol-2-yl]ethyl]phenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(NS(=O)(=O)C(F)(F)F)=CC=2)=N2)C2=C1 XEABIAFVAJGRSA-UHFFFAOYSA-N 0.000 claims description 5
- TZOXGNWXHWPYNX-UHFFFAOYSA-N n-[4-[2-[6-(2-acetylphenyl)-1h-benzimidazol-2-yl]ethyl]phenyl]methanesulfonamide Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(NS(C)(=O)=O)=CC=2)=N2)C2=C1 TZOXGNWXHWPYNX-UHFFFAOYSA-N 0.000 claims description 5
- XYRFLBWHSNIKRR-UHFFFAOYSA-N n-[4-[2-[6-[2-(1-hydroxyethyl)phenyl]-1h-benzimidazol-2-yl]ethyl]phenyl]methanesulfonamide Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(NS(C)(=O)=O)=CC=2)=N2)C2=C1 XYRFLBWHSNIKRR-UHFFFAOYSA-N 0.000 claims description 5
- XFNFMSPZRSSTBE-UHFFFAOYSA-N n-[4-[2-[6-[2-(2-hydroxypropan-2-yl)phenyl]-1h-benzimidazol-2-yl]ethyl]phenyl]methanesulfonamide Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(NS(C)(=O)=O)=CC=2)=N2)C2=C1 XFNFMSPZRSSTBE-UHFFFAOYSA-N 0.000 claims description 5
- WVMQMOARIOIVQG-UHFFFAOYSA-N n-[4-[2-[6-[2-(methanesulfonamido)phenyl]-1h-benzimidazol-2-yl]ethyl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1CCC1=NC2=CC(C=3C(=CC=CC=3)NS(C)(=O)=O)=CC=C2N1 WVMQMOARIOIVQG-UHFFFAOYSA-N 0.000 claims description 5
- WCQYCOTVGSVNSU-UHFFFAOYSA-N n-methyl-2-[2-[2-[4-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 WCQYCOTVGSVNSU-UHFFFAOYSA-N 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- KVEBPPCEJAQDKX-UHFFFAOYSA-N 2-[2-[2-(3-chlorophenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(Cl)C=CC=2)=N2)C2=C1 KVEBPPCEJAQDKX-UHFFFAOYSA-N 0.000 claims description 4
- QKDCBALNFDBFAN-UHFFFAOYSA-N 2-[2-[2-(4-chloro-2-methylsulfonylphenyl)ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CS(=O)(=O)C1=CC(Cl)=CC=C1CCC1=NC2=CC(C=3C(=CC=CC=3)S(N)(=O)=O)=CC=C2N1 QKDCBALNFDBFAN-UHFFFAOYSA-N 0.000 claims description 4
- QSHQWADZWXOQPD-UHFFFAOYSA-N 2-[3-(4-tert-butylphenyl)propyl]-6-(3-methylphenyl)-1h-benzimidazole Chemical compound CC1=CC=CC(C=2C=C3N=C(CCCC=4C=CC(=CC=4)C(C)(C)C)NC3=CC=2)=C1 QSHQWADZWXOQPD-UHFFFAOYSA-N 0.000 claims description 4
- ZUSALYSDLWFMNZ-XNTDXEJSSA-N 4-[(e)-2-[6-[2-(methylsulfamoyl)phenyl]-1h-benzimidazol-2-yl]ethenyl]-n-propan-2-ylbenzamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(=O)NC(C)C)=N2)C2=C1 ZUSALYSDLWFMNZ-XNTDXEJSSA-N 0.000 claims description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- AGZRHYZLUBYNOW-UHFFFAOYSA-N n-[2-[2-[2-[3-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(CCC=2C=C(C=CC=2)C(F)(F)F)=N2)C2=C1 AGZRHYZLUBYNOW-UHFFFAOYSA-N 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims description 2
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- 229940001468 citrate Drugs 0.000 claims description 2
- 229940090805 clavulanate Drugs 0.000 claims description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 2
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 claims description 2
- 239000001177 diphosphate Substances 0.000 claims description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 2
- 235000011180 diphosphates Nutrition 0.000 claims description 2
- 229940009662 edetate Drugs 0.000 claims description 2
- 229940050411 fumarate Drugs 0.000 claims description 2
- 229940050410 gluconate Drugs 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- 229940049906 glutamate Drugs 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 2
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-N sodium;2-hydroxybenzoic acid Chemical compound [Na+].OC(=O)C1=CC=CC=C1O ABBQHOQBGMUPJH-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 70
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 414
- 238000005160 1H NMR spectroscopy Methods 0.000 description 284
- 150000002500 ions Chemical class 0.000 description 192
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 121
- 238000006243 chemical reaction Methods 0.000 description 95
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 83
- 238000001819 mass spectrum Methods 0.000 description 83
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 71
- 239000000243 solution Substances 0.000 description 68
- 239000000203 mixture Substances 0.000 description 66
- 239000007787 solid Substances 0.000 description 64
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 61
- 235000019439 ethyl acetate Nutrition 0.000 description 51
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 50
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 43
- 150000003254 radicals Chemical class 0.000 description 41
- 0 CC(C)(C)c1ccc(C=CC(C)=Nc(cc(c(*)c2)-c3ccccc3*)c2N)cc1 Chemical compound CC(C)(C)c1ccc(C=CC(C)=Nc(cc(c(*)c2)-c3ccccc3*)c2N)cc1 0.000 description 40
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 29
- 229910001868 water Inorganic materials 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 208000002193 Pain Diseases 0.000 description 26
- 239000000706 filtrate Substances 0.000 description 26
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000002253 acid Substances 0.000 description 24
- 239000003153 chemical reaction reagent Substances 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000007858 starting material Substances 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 22
- 239000002904 solvent Substances 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- 238000004587 chromatography analysis Methods 0.000 description 19
- 239000005557 antagonist Substances 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- WLWNRAWQDZRXMB-YLFCFFPRSA-N (2r,3r,4r,5s)-n,3,4,5-tetrahydroxy-1-(4-phenoxyphenyl)sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 WLWNRAWQDZRXMB-YLFCFFPRSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 239000000556 agonist Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 239000007832 Na2SO4 Substances 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 125000005843 halogen group Chemical group 0.000 description 14
- 239000012267 brine Substances 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 230000001404 mediated effect Effects 0.000 description 13
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- WIHHVKUARKTSBU-UHFFFAOYSA-N 4-bromobenzene-1,2-diamine Chemical compound NC1=CC=C(Br)C=C1N WIHHVKUARKTSBU-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 150000001408 amides Chemical class 0.000 description 12
- 229960002504 capsaicin Drugs 0.000 description 12
- 235000017663 capsaicin Nutrition 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- MUJNAWXXOJRNGK-UHFFFAOYSA-N n-[3-(6-methyl-1,2,3,4-tetrahydrocarbazol-9-yl)propyl]cyclohexanamine Chemical compound C1=2CCCCC=2C2=CC(C)=CC=C2N1CCCNC1CCCCC1 MUJNAWXXOJRNGK-UHFFFAOYSA-N 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 229920002554 vinyl polymer Polymers 0.000 description 11
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 206010065390 Inflammatory pain Diseases 0.000 description 10
- SSTLSWSVWBJMBQ-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethyl)phenyl]ethenyl]-3H-benzimidazol-5-yl]aniline Chemical compound NC1=CC=CC=C1C1=CC=C(N=C(C=CC=2C=CC(=CC=2)C(F)(F)F)N2)C2=C1 SSTLSWSVWBJMBQ-UHFFFAOYSA-N 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 9
- 230000003197 catalytic effect Effects 0.000 description 9
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- ORDHXXHTBUZRCN-NTEUORMPSA-N 2-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 ORDHXXHTBUZRCN-NTEUORMPSA-N 0.000 description 8
- PHPYXVIHDRDPDI-UHFFFAOYSA-N 2-bromo-1h-benzimidazole Chemical compound C1=CC=C2NC(Br)=NC2=C1 PHPYXVIHDRDPDI-UHFFFAOYSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- ZZMXKPXEMOPFCL-XNTDXEJSSA-N n-[2-[2-[(e)-2-(4-propan-2-ylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound C1=CC(C(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(C)(=O)=O)=CC=C2N1 ZZMXKPXEMOPFCL-XNTDXEJSSA-N 0.000 description 7
- 238000012746 preparative thin layer chromatography Methods 0.000 description 7
- 239000000651 prodrug Chemical group 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- ZKAOVABYLXQUTI-UHFFFAOYSA-N (2-acetylphenyl)boronic acid Chemical compound CC(=O)C1=CC=CC=C1B(O)O ZKAOVABYLXQUTI-UHFFFAOYSA-N 0.000 description 6
- NUJWKQSEJDYCDB-GNRVTEMESA-N (3s)-1-[(1s,2r,4r)-4-[methyl(propan-2-yl)amino]-2-propylcyclohexyl]-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-2-one Chemical compound CCC[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 NUJWKQSEJDYCDB-GNRVTEMESA-N 0.000 description 6
- CWVYHHGFLJFAPN-LFIBNONCSA-N 1-[2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(C)(C)C)=N2)C2=C1 CWVYHHGFLJFAPN-LFIBNONCSA-N 0.000 description 6
- DXTVHUVIFZQBMN-JXMROGBWSA-N 2-[2-[(e)-2-(2,4-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(F)=CC=2)F)=N2)C2=C1 DXTVHUVIFZQBMN-JXMROGBWSA-N 0.000 description 6
- QBPVSTDAAWAVHD-UXBLZVDNSA-N 2-[2-[(e)-2-(3,4-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(F)C(F)=CC=2)=N2)C2=C1 QBPVSTDAAWAVHD-UXBLZVDNSA-N 0.000 description 6
- QGRHJSLTPDFLPU-UXBLZVDNSA-N 2-[2-[(e)-2-(3-bromo-4-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Br)C(F)=CC=2)=N2)C2=C1 QGRHJSLTPDFLPU-UXBLZVDNSA-N 0.000 description 6
- OMZINXGWSYLCOS-YRNVUSSQSA-N 2-[2-[(e)-2-(3-chloro-4-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Cl)C(F)=CC=2)=N2)C2=C1 OMZINXGWSYLCOS-YRNVUSSQSA-N 0.000 description 6
- PQHDODTVCNVMQY-MDWZMJQESA-N 2-[2-[(e)-2-(4-bromophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(Br)=CC=2)=N2)C2=C1 PQHDODTVCNVMQY-MDWZMJQESA-N 0.000 description 6
- MWLHFAJYWTXIPO-JXMROGBWSA-N 2-[2-[(e)-2-(4-chloro-2-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(Cl)=CC=2)F)=N2)C2=C1 MWLHFAJYWTXIPO-JXMROGBWSA-N 0.000 description 6
- XSPHTXOVEYDIGR-KPKJPENVSA-N 2-[2-[(e)-2-(4-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(Cl)=CC=2)=N2)C2=C1 XSPHTXOVEYDIGR-KPKJPENVSA-N 0.000 description 6
- DUELRCOKXDCVQL-KPKJPENVSA-N 2-[2-[(e)-2-(4-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(F)=CC=2)=N2)C2=C1 DUELRCOKXDCVQL-KPKJPENVSA-N 0.000 description 6
- BBLUYPCATKHLOG-JLHYYAGUSA-N 2-[2-[(e)-2-(4-methylphenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)S(N)(=O)=O)=CC=C2N1 BBLUYPCATKHLOG-JLHYYAGUSA-N 0.000 description 6
- QXZGBUYHWGJGNT-NTEUORMPSA-N 2-[2-[(e)-2-(4-propan-2-ylphenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound C1=CC(C(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)S(N)(=O)=O)=CC=C2N1 QXZGBUYHWGJGNT-NTEUORMPSA-N 0.000 description 6
- JAWYCUCOUVBJQW-XNTDXEJSSA-N 2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-3h-benzimidazol-5-yl]benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)C(N)=O)=CC=C2N1 JAWYCUCOUVBJQW-XNTDXEJSSA-N 0.000 description 6
- NAXZIWYWPIHHJP-ZRDIBKRKSA-N 2-[2-[(e)-2-[2-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=CC=2)C(F)(F)F)=N2)C2=C1 NAXZIWYWPIHHJP-ZRDIBKRKSA-N 0.000 description 6
- UFFSJAAGRZSPRR-YRNVUSSQSA-N 2-[2-[(e)-2-[3-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(F)C(=CC=2)C(F)(F)F)=N2)C2=C1 UFFSJAAGRZSPRR-YRNVUSSQSA-N 0.000 description 6
- OEDVPJOHKMEERN-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OC(F)(F)F)=CC=2)=N2)C2=C1 OEDVPJOHKMEERN-KPKJPENVSA-N 0.000 description 6
- GNBVSCWQHRHPOS-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 GNBVSCWQHRHPOS-KPKJPENVSA-N 0.000 description 6
- XDSALFFQVKJDRZ-UXBLZVDNSA-N 2-[2-[(e)-2-[4-fluoro-3-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(C(F)=CC=2)C(F)(F)F)=N2)C2=C1 XDSALFFQVKJDRZ-UXBLZVDNSA-N 0.000 description 6
- NNMIYXODOSQCAM-NTEUORMPSA-N 2-[2-[2-[(e)-2-(4-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(Cl)=CC=2)=N2)C2=C1 NNMIYXODOSQCAM-NTEUORMPSA-N 0.000 description 6
- DEPBBRAWAGMCKY-JLHYYAGUSA-N 2-[2-[2-[(e)-2-[3-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(C=CC=2)C(F)(F)F)=N2)C2=C1 DEPBBRAWAGMCKY-JLHYYAGUSA-N 0.000 description 6
- JXRBFIZVMBNSFX-GXDHUFHOSA-N 2-[2-[2-[(e)-2-quinolin-6-ylethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C3C=CC=NC3=CC=2)=N2)C2=C1 JXRBFIZVMBNSFX-GXDHUFHOSA-N 0.000 description 6
- ORDHXXHTBUZRCN-ZROIWOOFSA-N 2-[2-[2-[(z)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C/C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 ORDHXXHTBUZRCN-ZROIWOOFSA-N 0.000 description 6
- CWSNBNRBBOOWDE-UHFFFAOYSA-N 2-[2-[2-[2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 CWSNBNRBBOOWDE-UHFFFAOYSA-N 0.000 description 6
- SUKMTWBHAUNRSW-UHFFFAOYSA-N 2-[2-[2-[2-[4-(trifluoromethyl)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(=CC=3)C(F)(F)F)C2=C1 SUKMTWBHAUNRSW-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 6
- OROOGJWXBBLLFR-XNTDXEJSSA-N [2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanol Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)CO)=CC=C2N1 OROOGJWXBBLLFR-XNTDXEJSSA-N 0.000 description 6
- 235000013985 cinnamic acid Nutrition 0.000 description 6
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid group Chemical class C(C=CC1=CC=CC=C1)(=O)O WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- LDAJUELOMSYISK-NTEUORMPSA-N n,n-dimethyl-2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 LDAJUELOMSYISK-NTEUORMPSA-N 0.000 description 6
- PEYYAOOSJPQYED-LFIBNONCSA-N n-[2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(C)(=O)=O)=CC=C2N1 PEYYAOOSJPQYED-LFIBNONCSA-N 0.000 description 6
- DOPAAWGONQMHIP-MDWZMJQESA-N n-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 DOPAAWGONQMHIP-MDWZMJQESA-N 0.000 description 6
- IYRITDNEHXFBIY-MDWZMJQESA-N n-methyl-2-[2-[(e)-2-[4-(trifluoromethylsulfanyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(SC(F)(F)F)=CC=2)=N2)C2=C1 IYRITDNEHXFBIY-MDWZMJQESA-N 0.000 description 6
- 210000000929 nociceptor Anatomy 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 6
- YDMRDHQUQIVWBE-UHFFFAOYSA-N (2-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1O YDMRDHQUQIVWBE-UHFFFAOYSA-N 0.000 description 5
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 5
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 5
- JOVJTERTKUPLKL-LFIBNONCSA-N 1-[2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(C)(C)C)=N2)C2=C1 JOVJTERTKUPLKL-LFIBNONCSA-N 0.000 description 5
- WDSYYVXPVIETFO-MDWZMJQESA-N 1-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 WDSYYVXPVIETFO-MDWZMJQESA-N 0.000 description 5
- WGEYEGJSZQCJOM-MDWZMJQESA-N 1-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 WGEYEGJSZQCJOM-MDWZMJQESA-N 0.000 description 5
- MAHSFTCGIOZKAF-MDWZMJQESA-N 1-[2-[2-[(e)-2-[4-(trifluoromethylsulfonyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N2)C2=C1 MAHSFTCGIOZKAF-MDWZMJQESA-N 0.000 description 5
- BVVORTPCTWMIFI-MDWZMJQESA-N 1-[2-[2-[(e)-2-[4-(trifluoromethylsulfonyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N2)C2=C1 BVVORTPCTWMIFI-MDWZMJQESA-N 0.000 description 5
- SMULEHKLKQBAGG-MSOLQXFVSA-N 2-[2-[(1s,2s)-2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)[C@@H]3[C@H](C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 SMULEHKLKQBAGG-MSOLQXFVSA-N 0.000 description 5
- NYYYTUGAKFXKQP-JXMROGBWSA-N 2-[2-[(e)-2-(2,3,4-trifluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=C(F)C(F)=CC=2)F)=N2)C2=C1 NYYYTUGAKFXKQP-JXMROGBWSA-N 0.000 description 5
- QONNZZIAUNKZJE-PKNBQFBNSA-N 2-[2-[(e)-2-(2,3-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=C(F)C=CC=2)F)=N2)C2=C1 QONNZZIAUNKZJE-PKNBQFBNSA-N 0.000 description 5
- BSWYBPFACDLQCL-SOFGYWHQSA-N 2-[2-[(e)-2-(2,4,5-trifluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(F)=C(F)C=2)F)=N2)C2=C1 BSWYBPFACDLQCL-SOFGYWHQSA-N 0.000 description 5
- ISXYOIVPSWMGBW-DHZHZOJOSA-N 2-[2-[(e)-2-(2,4-dichlorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(Cl)=CC=2)Cl)=N2)C2=C1 ISXYOIVPSWMGBW-DHZHZOJOSA-N 0.000 description 5
- HUWLVLLLDPHUTE-JXMROGBWSA-N 2-[2-[(e)-2-(2,4-dichlorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(Cl)=CC=2)Cl)=N2)C2=C1 HUWLVLLLDPHUTE-JXMROGBWSA-N 0.000 description 5
- UYVQTYDXYOALGS-DHZHZOJOSA-N 2-[2-[(e)-2-(2,4-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(F)=CC=2)F)=N2)C2=C1 UYVQTYDXYOALGS-DHZHZOJOSA-N 0.000 description 5
- GOGJSMQYYQBVHM-UXBLZVDNSA-N 2-[2-[(e)-2-(2,5-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=C(F)C=2)F)=N2)C2=C1 GOGJSMQYYQBVHM-UXBLZVDNSA-N 0.000 description 5
- KTFIZVKDAOHYHB-PKNBQFBNSA-N 2-[2-[(e)-2-(2,6-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=CC=2F)F)=N2)C2=C1 KTFIZVKDAOHYHB-PKNBQFBNSA-N 0.000 description 5
- JDDNCBYWOUHMSU-ZRDIBKRKSA-N 2-[2-[(e)-2-(2-bromophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=CC=2)Br)=N2)C2=C1 JDDNCBYWOUHMSU-ZRDIBKRKSA-N 0.000 description 5
- XTTPZJIVQZBPRK-ZRDIBKRKSA-N 2-[2-[(e)-2-(2-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=CC=2)Cl)=N2)C2=C1 XTTPZJIVQZBPRK-ZRDIBKRKSA-N 0.000 description 5
- XUNDPOPJKWZBTD-YRNVUSSQSA-N 2-[2-[(e)-2-(3,4-dichlorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Cl)C(Cl)=CC=2)=N2)C2=C1 XUNDPOPJKWZBTD-YRNVUSSQSA-N 0.000 description 5
- NLMKWXOEOOMGCZ-UXBLZVDNSA-N 2-[2-[(e)-2-(3,4-dichlorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Cl)C(Cl)=CC=2)=N2)C2=C1 NLMKWXOEOOMGCZ-UXBLZVDNSA-N 0.000 description 5
- XYOXTEYWEZQAHB-YRNVUSSQSA-N 2-[2-[(e)-2-(3,4-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(F)C(F)=CC=2)=N2)C2=C1 XYOXTEYWEZQAHB-YRNVUSSQSA-N 0.000 description 5
- QNCKMUIUKHPWQC-RMKNXTFCSA-N 2-[2-[(e)-2-(3,5-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(F)C=C(F)C=2)=N2)C2=C1 QNCKMUIUKHPWQC-RMKNXTFCSA-N 0.000 description 5
- XIPCJOYTSUIJAP-VMPITWQZSA-N 2-[2-[(e)-2-(3,5-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(F)C=C(F)C=2)=N2)C2=C1 XIPCJOYTSUIJAP-VMPITWQZSA-N 0.000 description 5
- QWZFQFVEPVJBFT-DHZHZOJOSA-N 2-[2-[(e)-2-(3-bromophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Br)C=CC=2)=N2)C2=C1 QWZFQFVEPVJBFT-DHZHZOJOSA-N 0.000 description 5
- UBUUUOKWSHLZMO-ZRDIBKRKSA-N 2-[2-[(e)-2-(3-chloro-2-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=C(Cl)C=CC=2)F)=N2)C2=C1 UBUUUOKWSHLZMO-ZRDIBKRKSA-N 0.000 description 5
- VRLPGBABIBIGPC-UXBLZVDNSA-N 2-[2-[(e)-2-(3-chloro-4-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Cl)C(F)=CC=2)=N2)C2=C1 VRLPGBABIBIGPC-UXBLZVDNSA-N 0.000 description 5
- CICFKZKJYQUXLY-NTEUORMPSA-N 2-[2-[(e)-2-(4-acetylphenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(C)=O)=N2)C2=C1 CICFKZKJYQUXLY-NTEUORMPSA-N 0.000 description 5
- TVRGEEHHVZCTOZ-KPKJPENVSA-N 2-[2-[(e)-2-(4-bromophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(Br)=CC=2)=N2)C2=C1 TVRGEEHHVZCTOZ-KPKJPENVSA-N 0.000 description 5
- KYPSKPBORGVSML-FMIVXFBMSA-N 2-[2-[(e)-2-(4-chloro-2-methylsulfonylphenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(Cl)=CC=2)S(C)(=O)=O)=N2)C2=C1 KYPSKPBORGVSML-FMIVXFBMSA-N 0.000 description 5
- OMSTWXZEFXXGEE-MDWZMJQESA-N 2-[2-[(e)-2-(4-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(Cl)=CC=2)=N2)C2=C1 OMSTWXZEFXXGEE-MDWZMJQESA-N 0.000 description 5
- JABBGEQEEYVUSO-JLHYYAGUSA-N 2-[2-[(e)-2-(4-cyanophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C#N)=N2)C2=C1 JABBGEQEEYVUSO-JLHYYAGUSA-N 0.000 description 5
- DFAHWUTXWLAMPL-MDWZMJQESA-N 2-[2-[(e)-2-(4-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(F)=CC=2)=N2)C2=C1 DFAHWUTXWLAMPL-MDWZMJQESA-N 0.000 description 5
- WPOATJOHKLKELS-JLHYYAGUSA-N 2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-6-(trifluoromethyl)-1h-benzimidazol-5-yl]benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)C(N)=O)=C(C(F)(F)F)C=C2N1 WPOATJOHKLKELS-JLHYYAGUSA-N 0.000 description 5
- HJQXOKMZCBVVFW-UXBLZVDNSA-N 2-[2-[(e)-2-(5-bromo-2-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=C(Br)C=2)F)=N2)C2=C1 HJQXOKMZCBVVFW-UXBLZVDNSA-N 0.000 description 5
- FLRQHZHIYOZJAL-DHZHZOJOSA-N 2-[2-[(e)-2-[2,4-bis(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(=CC=2)C(F)(F)F)C(F)(F)F)=N2)C2=C1 FLRQHZHIYOZJAL-DHZHZOJOSA-N 0.000 description 5
- ZYBOFRIIYXGLJF-UXBLZVDNSA-N 2-[2-[(e)-2-[2,5-bis(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)=N2)C2=C1 ZYBOFRIIYXGLJF-UXBLZVDNSA-N 0.000 description 5
- ZOOQABFYGPJIIX-ZRDIBKRKSA-N 2-[2-[(e)-2-[2-fluoro-3-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=C(C=CC=2)C(F)(F)F)F)=N2)C2=C1 ZOOQABFYGPJIIX-ZRDIBKRKSA-N 0.000 description 5
- QOLYMEMVMSXPPI-PKNBQFBNSA-N 2-[2-[(e)-2-[2-fluoro-3-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=C(C=CC=2)C(F)(F)F)F)=N2)C2=C1 QOLYMEMVMSXPPI-PKNBQFBNSA-N 0.000 description 5
- OLUXUFAWYYLFSZ-DHZHZOJOSA-N 2-[2-[(e)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(=CC=2)C(F)(F)F)F)=N2)C2=C1 OLUXUFAWYYLFSZ-DHZHZOJOSA-N 0.000 description 5
- ZATQSVCMKWFHEO-JXMROGBWSA-N 2-[2-[(e)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(=CC=2)C(F)(F)F)F)=N2)C2=C1 ZATQSVCMKWFHEO-JXMROGBWSA-N 0.000 description 5
- LNDICEXTOUNCHJ-RMKNXTFCSA-N 2-[2-[(e)-2-[3,5-bis(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=N2)C2=C1 LNDICEXTOUNCHJ-RMKNXTFCSA-N 0.000 description 5
- APVIXDIGQQAILT-VMPITWQZSA-N 2-[2-[(e)-2-[3,5-bis(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=N2)C2=C1 APVIXDIGQQAILT-VMPITWQZSA-N 0.000 description 5
- ACWIOMFHXSSBEZ-UXBLZVDNSA-N 2-[2-[(e)-2-[3-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(F)C(=CC=2)C(F)(F)F)=N2)C2=C1 ACWIOMFHXSSBEZ-UXBLZVDNSA-N 0.000 description 5
- WTNONNFDOZWZHO-RMKNXTFCSA-N 2-[2-[(e)-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(C=C(F)C=2)C(F)(F)F)=N2)C2=C1 WTNONNFDOZWZHO-RMKNXTFCSA-N 0.000 description 5
- FJOLXRMMXMUMHG-VMPITWQZSA-N 2-[2-[(e)-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(C=C(F)C=2)C(F)(F)F)=N2)C2=C1 FJOLXRMMXMUMHG-VMPITWQZSA-N 0.000 description 5
- KPSHSFPVQYYLJC-XNTDXEJSSA-N 2-[2-[(e)-2-[4-(dimethylamino)phenyl]ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)N(C)C)=N2)C2=C1 KPSHSFPVQYYLJC-XNTDXEJSSA-N 0.000 description 5
- RICHUFIPOKYOBA-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethylsulfonyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N2)C2=C1 RICHUFIPOKYOBA-KPKJPENVSA-N 0.000 description 5
- DDFFVECJYUJIFH-UXBLZVDNSA-N 2-[2-[(e)-2-[4-chloro-3-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(C(Cl)=CC=2)C(F)(F)F)=N2)C2=C1 DDFFVECJYUJIFH-UXBLZVDNSA-N 0.000 description 5
- XNTRQEUEEWPHOU-JXMROGBWSA-N 2-[2-[(e)-2-[4-fluoro-2-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(F)=CC=2)C(F)(F)F)=N2)C2=C1 XNTRQEUEEWPHOU-JXMROGBWSA-N 0.000 description 5
- KRLKOFGWSIQYPI-YRNVUSSQSA-N 2-[2-[(e)-2-[4-fluoro-3-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(C(F)=CC=2)C(F)(F)F)=N2)C2=C1 KRLKOFGWSIQYPI-YRNVUSSQSA-N 0.000 description 5
- MGLUNOWPTMUWKF-GXDHUFHOSA-N 2-[2-[(e)-2-naphthalen-2-ylethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C3C=CC=CC3=CC=2)=N2)C2=C1 MGLUNOWPTMUWKF-GXDHUFHOSA-N 0.000 description 5
- TYGHUKPXISIAIZ-JLHYYAGUSA-N 2-[2-[(e)-2-phenylethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC=CC=2)=N2)C2=C1 TYGHUKPXISIAIZ-JLHYYAGUSA-N 0.000 description 5
- CWSNBNRBBOOWDE-UXHICEINSA-N 2-[2-[2-[(1s,2s)-2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)[C@@H]3[C@H](C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 CWSNBNRBBOOWDE-UXHICEINSA-N 0.000 description 5
- NYVNFNIEMBCGSH-XNTDXEJSSA-N 2-[2-[2-[(e)-2-(4-methylsulfonylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(C)(=O)=O)=N2)C2=C1 NYVNFNIEMBCGSH-XNTDXEJSSA-N 0.000 description 5
- XYYPBLPRKDDEMD-SFQUDFHCSA-N 2-[2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)C(C)(C)O)=CC=C2N1 XYYPBLPRKDDEMD-SFQUDFHCSA-N 0.000 description 5
- HZTDHVDOWLGLQH-WYMLVPIESA-N 2-[2-[2-[(e)-2-[2-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=CC=2)C(F)(F)F)=N2)C2=C1 HZTDHVDOWLGLQH-WYMLVPIESA-N 0.000 description 5
- ZJMZJFZVCIVNBL-NTEUORMPSA-N 2-[2-[2-[(e)-2-[4-(trifluoromethylsulfonyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N2)C2=C1 ZJMZJFZVCIVNBL-NTEUORMPSA-N 0.000 description 5
- OJFGNDDTAFIFBB-UHFFFAOYSA-N 2-[2-[2-[2-(4-methoxyphenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound C1=CC(OC)=CC=C1C1C(C=2NC3=CC=C(C=C3N=2)C=2C(=CC=CC=2)C(C)(C)O)C1 OJFGNDDTAFIFBB-UHFFFAOYSA-N 0.000 description 5
- DGNFUOFORGAZPZ-UHFFFAOYSA-N 2-[2-[2-[2-[3-(trifluoromethyl)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=C(C=CC=3)C(F)(F)F)C2=C1 DGNFUOFORGAZPZ-UHFFFAOYSA-N 0.000 description 5
- YKLJJWDEAICOPD-UHFFFAOYSA-N 2-[2-[2-[2-[4-(trifluoromethoxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OC(F)(F)F)=CC=3)C2=C1 YKLJJWDEAICOPD-UHFFFAOYSA-N 0.000 description 5
- OXAJRAKWLYDMKG-UHFFFAOYSA-N 2-[2-[2-[3-(trifluoromethyl)phenyl]ethynyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=C(C=CC=3)C(F)(F)F)C2=C1 OXAJRAKWLYDMKG-UHFFFAOYSA-N 0.000 description 5
- RUOHDIPMFNOGTD-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 RUOHDIPMFNOGTD-UHFFFAOYSA-N 0.000 description 5
- SMULEHKLKQBAGG-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 SMULEHKLKQBAGG-UHFFFAOYSA-N 0.000 description 5
- SYGWQFIVYUDURB-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethyl)phenyl]ethynyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(=CC=3)C(F)(F)F)C2=C1 SYGWQFIVYUDURB-UHFFFAOYSA-N 0.000 description 5
- LBUOXUPGSPWIFV-XCVCLJGOSA-N 4-(trifluoromethyl)-2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 LBUOXUPGSPWIFV-XCVCLJGOSA-N 0.000 description 5
- BFYCPVGFDKNWLM-MDWZMJQESA-N 6-(2-methylsulfonylphenyl)-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazole Chemical compound CS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 BFYCPVGFDKNWLM-MDWZMJQESA-N 0.000 description 5
- OZVHKPWATIZWIL-UHFFFAOYSA-N 6-(2-methylsulfonylphenyl)-2-[2-[4-(trifluoromethyl)phenyl]cyclopropyl]-1h-benzimidazole Chemical compound CS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 OZVHKPWATIZWIL-UHFFFAOYSA-N 0.000 description 5
- YSASLEUEEAUPKA-KPKJPENVSA-N 6-[2-(sulfamoylamino)phenyl]-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazole Chemical compound NS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 YSASLEUEEAUPKA-KPKJPENVSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 208000000094 Chronic Pain Diseases 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000006069 Suzuki reaction reaction Methods 0.000 description 5
- 108010062740 TRPV Cation Channels Proteins 0.000 description 5
- 102000011040 TRPV Cation Channels Human genes 0.000 description 5
- AFHOBSCDNXGFMO-UHFFFAOYSA-N [2-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=CC=C1B(O)O AFHOBSCDNXGFMO-UHFFFAOYSA-N 0.000 description 5
- JKWYWMYUFHXAEJ-JLHYYAGUSA-N [2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-6-(trifluoromethyl)-1h-benzimidazol-5-yl]phenyl]methanol Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)CO)=C(C(F)(F)F)C=C2N1 JKWYWMYUFHXAEJ-JLHYYAGUSA-N 0.000 description 5
- QYHGGNWVPRPKMP-KPKJPENVSA-N [2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanol Chemical compound OCC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 QYHGGNWVPRPKMP-KPKJPENVSA-N 0.000 description 5
- CVPOQHFKYVQWJH-KPKJPENVSA-N [2-[2-[(e)-2-[4-(trifluoromethylsulfanyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanol Chemical compound OCC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(SC(F)(F)F)=CC=2)=N2)C2=C1 CVPOQHFKYVQWJH-KPKJPENVSA-N 0.000 description 5
- OXYKPFXXMLUREQ-KPKJPENVSA-N [2-[2-[(e)-2-[4-(trifluoromethylsulfonyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanol Chemical compound OCC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N2)C2=C1 OXYKPFXXMLUREQ-KPKJPENVSA-N 0.000 description 5
- NENRRCWWLTXRQU-JXMROGBWSA-N [2-[6-(trifluoromethyl)-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazol-5-yl]phenyl]methanol Chemical compound OCC1=CC=CC=C1C(C(=C1)C(F)(F)F)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(F)(F)F)=N2 NENRRCWWLTXRQU-JXMROGBWSA-N 0.000 description 5
- PHBDKKIHETWYOU-JXMROGBWSA-N [2-[6-chloro-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazol-5-yl]phenyl]methanol Chemical compound OCC1=CC=CC=C1C(C(=C1)Cl)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(F)(F)F)=N2 PHBDKKIHETWYOU-JXMROGBWSA-N 0.000 description 5
- QMTWXJWADGAZRS-JXMROGBWSA-N [2-[6-fluoro-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazol-5-yl]phenyl]methanol Chemical compound OCC1=CC=CC=C1C(C(=C1)F)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(F)(F)F)=N2 QMTWXJWADGAZRS-JXMROGBWSA-N 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 208000005298 acute pain Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 5
- LKYJZALHPLXMQH-NTEUORMPSA-N ethyl 2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 LKYJZALHPLXMQH-NTEUORMPSA-N 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- AWDSKGJAQCDOGB-MDWZMJQESA-N methyl n-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]carbamate Chemical compound COC(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 AWDSKGJAQCDOGB-MDWZMJQESA-N 0.000 description 5
- WFXDLMXRMQDIGV-MDWZMJQESA-N n-[2-[2-[(e)-2-(4-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(Cl)=CC=2)=N2)C2=C1 WFXDLMXRMQDIGV-MDWZMJQESA-N 0.000 description 5
- DJNHRYJWFCUYHS-QGOAFFKASA-N n-[2-[2-[(e)-2-(4-phenylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C=2C=CC=CC=2)=N2)C2=C1 DJNHRYJWFCUYHS-QGOAFFKASA-N 0.000 description 5
- GEVKFYGTGFJHID-LFIBNONCSA-N n-[2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(C)(C)C)=N2)C2=C1 GEVKFYGTGFJHID-LFIBNONCSA-N 0.000 description 5
- MSTKUTCNGYWRFT-DHZHZOJOSA-N n-[2-[2-[(e)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(=CC=2)C(F)(F)F)F)=N2)C2=C1 MSTKUTCNGYWRFT-DHZHZOJOSA-N 0.000 description 5
- RGBVQTDDPHMCIH-YRNVUSSQSA-N n-[2-[2-[(e)-2-[3-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(F)C(=CC=2)C(F)(F)F)=N2)C2=C1 RGBVQTDDPHMCIH-YRNVUSSQSA-N 0.000 description 5
- WOGDLBWDHJPLGV-MDWZMJQESA-N n-[2-[2-[(e)-2-[4-(trifluoromethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OC(F)(F)F)=CC=2)=N2)C2=C1 WOGDLBWDHJPLGV-MDWZMJQESA-N 0.000 description 5
- MUPVEZJVQYOYCQ-DHZHZOJOSA-N n-methyl-2-[2-[(e)-2-(2,3,4-trifluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=C(F)C(F)=CC=2)F)=N2)C2=C1 MUPVEZJVQYOYCQ-DHZHZOJOSA-N 0.000 description 5
- AHZBGDVZHVGGHC-VQHVLOKHSA-N n-methyl-2-[2-[(e)-2-(2,4,5-trifluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(F)=C(F)C=2)F)=N2)C2=C1 AHZBGDVZHVGGHC-VQHVLOKHSA-N 0.000 description 5
- XCJPGLJKNVROMJ-SDNWHVSQSA-N n-methyl-2-[2-[(e)-2-(4-methylphenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(C)=CC=2)=N2)C2=C1 XCJPGLJKNVROMJ-SDNWHVSQSA-N 0.000 description 5
- HPTLFVKNPAOJBP-FMIVXFBMSA-N n-methyl-2-[2-[(e)-2-[3-(trifluoromethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(OC(F)(F)F)C=CC=2)=N2)C2=C1 HPTLFVKNPAOJBP-FMIVXFBMSA-N 0.000 description 5
- XNEOVAIWXSENIE-MDWZMJQESA-N n-methyl-2-[2-[(e)-2-[4-(trifluoromethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OC(F)(F)F)=CC=2)=N2)C2=C1 XNEOVAIWXSENIE-MDWZMJQESA-N 0.000 description 5
- GJJAHNVOKULWAV-MDWZMJQESA-N n-methyl-2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 GJJAHNVOKULWAV-MDWZMJQESA-N 0.000 description 5
- HNWYCOMISLINMK-MDWZMJQESA-N n-methyl-2-[2-[(e)-2-[4-(trifluoromethylsulfonyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N2)C2=C1 HNWYCOMISLINMK-MDWZMJQESA-N 0.000 description 5
- 108091008700 nociceptors Proteins 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 description 5
- 229940073454 resiniferatoxin Drugs 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- NWCRPUDZGTWWAP-QGOAFFKASA-N tert-butyl n-[2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(C)(C)C)=N2)C2=C1 NWCRPUDZGTWWAP-QGOAFFKASA-N 0.000 description 5
- QNEPDLPUJDVQRQ-YRNVUSSQSA-N 1-[2-[2-[(e)-2-(3,4-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(F)C(F)=CC=2)=N2)C2=C1 QNEPDLPUJDVQRQ-YRNVUSSQSA-N 0.000 description 4
- GJOHTWXMHDYHNF-MDWZMJQESA-N 1-[2-[2-[(e)-2-[4-(trifluoromethylsulfanyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(SC(F)(F)F)=CC=2)=N2)C2=C1 GJOHTWXMHDYHNF-MDWZMJQESA-N 0.000 description 4
- YKNCVHKGUFQXPR-UHFFFAOYSA-N 1-[2-[2-[2-(4-chlorophenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(Cl)=CC=3)C2=C1 YKNCVHKGUFQXPR-UHFFFAOYSA-N 0.000 description 4
- PEQYHFGXXQCZDU-UHFFFAOYSA-N 1-[2-[2-[2-(4-chlorophenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(Cl)=CC=3)C2=C1 PEQYHFGXXQCZDU-UHFFFAOYSA-N 0.000 description 4
- NHKBCBSJZHDBFF-DHZHZOJOSA-N 1-[2-[6-chloro-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C(C(=C1)Cl)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(F)(F)F)=N2 NHKBCBSJZHDBFF-DHZHZOJOSA-N 0.000 description 4
- WTNOETMEVDIRFY-DHZHZOJOSA-N 1-[2-[6-fluoro-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C(C(=C1)F)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(F)(F)F)=N2 WTNOETMEVDIRFY-DHZHZOJOSA-N 0.000 description 4
- SMULEHKLKQBAGG-ZWKOTPCHSA-N 2-[2-[(1r,2r)-2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)[C@H]3[C@@H](C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 SMULEHKLKQBAGG-ZWKOTPCHSA-N 0.000 description 4
- JBWYXMQPRUSHRF-ZRDIBKRKSA-N 2-[2-[(e)-2-(2,3-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=C(F)C=CC=2)F)=N2)C2=C1 JBWYXMQPRUSHRF-ZRDIBKRKSA-N 0.000 description 4
- MIKIRRMSKLVJKA-YRNVUSSQSA-N 2-[2-[(e)-2-(2,5-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=C(F)C=2)F)=N2)C2=C1 MIKIRRMSKLVJKA-YRNVUSSQSA-N 0.000 description 4
- VZBXVIPBWRRJBH-ZRDIBKRKSA-N 2-[2-[(e)-2-(2,6-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=CC=2F)F)=N2)C2=C1 VZBXVIPBWRRJBH-ZRDIBKRKSA-N 0.000 description 4
- FWMOWWBXXOIIKC-ACCUITESSA-N 2-[2-[(e)-2-(2-bromophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=CC=2)Br)=N2)C2=C1 FWMOWWBXXOIIKC-ACCUITESSA-N 0.000 description 4
- VTMZWYCPUWVRCH-ZRDIBKRKSA-N 2-[2-[(e)-2-(2-chloro-6-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=CC=2F)Cl)=N2)C2=C1 VTMZWYCPUWVRCH-ZRDIBKRKSA-N 0.000 description 4
- PZSWYOZAPJXKSE-PKNBQFBNSA-N 2-[2-[(e)-2-(2-chloro-6-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=CC=2F)Cl)=N2)C2=C1 PZSWYOZAPJXKSE-PKNBQFBNSA-N 0.000 description 4
- NAIHJEHKRCRAQE-ACCUITESSA-N 2-[2-[(e)-2-(2-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=CC=2)Cl)=N2)C2=C1 NAIHJEHKRCRAQE-ACCUITESSA-N 0.000 description 4
- KCCMHTRPRBPDDI-YRNVUSSQSA-N 2-[2-[(e)-2-(3-bromo-4-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Br)C(F)=CC=2)=N2)C2=C1 KCCMHTRPRBPDDI-YRNVUSSQSA-N 0.000 description 4
- WOTRWENPURLKBJ-FMIVXFBMSA-N 2-[2-[(e)-2-(3-bromophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Br)C=CC=2)=N2)C2=C1 WOTRWENPURLKBJ-FMIVXFBMSA-N 0.000 description 4
- YOLJTJOBYYAAAY-PKNBQFBNSA-N 2-[2-[(e)-2-(3-chloro-2-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=C(Cl)C=CC=2)F)=N2)C2=C1 YOLJTJOBYYAAAY-PKNBQFBNSA-N 0.000 description 4
- KWQGTNGWCKANHL-JLHYYAGUSA-N 2-[2-[(e)-2-(3-ethoxyphenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CCOC1=CC=CC(\C=C\C=2NC3=CC=C(C=C3N=2)C=2C(=CC=CC=2)S(N)(=O)=O)=C1 KWQGTNGWCKANHL-JLHYYAGUSA-N 0.000 description 4
- BBSYQYOXIVKUBJ-DHZHZOJOSA-N 2-[2-[(e)-2-(4-chloro-2-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(Cl)=CC=2)F)=N2)C2=C1 BBSYQYOXIVKUBJ-DHZHZOJOSA-N 0.000 description 4
- LTNKRMQAQRMJRB-DHZHZOJOSA-N 2-[2-[(e)-2-(4-chloro-2-methylsulfonylphenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CS(=O)(=O)C1=CC(Cl)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)S(N)(=O)=O)=CC=C2N1 LTNKRMQAQRMJRB-DHZHZOJOSA-N 0.000 description 4
- JMQNNKRJCWFHKC-NTEUORMPSA-N 2-[2-[(e)-2-(4-ethoxyphenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound C1=CC(OCC)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)S(N)(=O)=O)=CC=C2N1 JMQNNKRJCWFHKC-NTEUORMPSA-N 0.000 description 4
- XHARVNDXBPUMDR-XNTDXEJSSA-N 2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-3h-benzimidazol-5-yl]aniline Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)N)=CC=C2N1 XHARVNDXBPUMDR-XNTDXEJSSA-N 0.000 description 4
- JLWSAKLQYQDRPS-XNTDXEJSSA-N 2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenol Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)O)=CC=C2N1 JLWSAKLQYQDRPS-XNTDXEJSSA-N 0.000 description 4
- WGRANAJJRZFHDA-YRNVUSSQSA-N 2-[2-[(e)-2-[2,5-bis(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)=N2)C2=C1 WGRANAJJRZFHDA-YRNVUSSQSA-N 0.000 description 4
- FJLOLWSIYRFDNS-DHZHZOJOSA-N 2-[2-[(e)-2-[3-(trifluoromethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(OC(F)(F)F)C=CC=2)=N2)C2=C1 FJLOLWSIYRFDNS-DHZHZOJOSA-N 0.000 description 4
- IMMYOOVLNPOUJD-KPKJPENVSA-N 2-[2-[(e)-2-[4-(difluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)F)=N2)C2=C1 IMMYOOVLNPOUJD-KPKJPENVSA-N 0.000 description 4
- SSTLSWSVWBJMBQ-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]aniline Chemical compound NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 SSTLSWSVWBJMBQ-KPKJPENVSA-N 0.000 description 4
- QFCXDPRWLCRUGV-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 QFCXDPRWLCRUGV-KPKJPENVSA-N 0.000 description 4
- QXGVGNJUIDXJPM-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethylsulfanyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(SC(F)(F)F)=CC=2)=N2)C2=C1 QXGVGNJUIDXJPM-KPKJPENVSA-N 0.000 description 4
- IEMJSXHUWCZIME-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethylsulfanyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(SC(F)(F)F)=CC=2)=N2)C2=C1 IEMJSXHUWCZIME-KPKJPENVSA-N 0.000 description 4
- OLKNKHWLUXGMMW-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethylsulfonyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N2)C2=C1 OLKNKHWLUXGMMW-KPKJPENVSA-N 0.000 description 4
- IAZMJSMVPYPBIL-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethylsulfonyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenol Chemical compound OC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N2)C2=C1 IAZMJSMVPYPBIL-KPKJPENVSA-N 0.000 description 4
- PMODLEWJZQDASX-DHZHZOJOSA-N 2-[2-[(e)-2-[4-fluoro-2-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC(F)=CC=2)C(F)(F)F)=N2)C2=C1 PMODLEWJZQDASX-DHZHZOJOSA-N 0.000 description 4
- CWSNBNRBBOOWDE-VQTJNVASSA-N 2-[2-[2-[(1r,2r)-2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)[C@H]3[C@@H](C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 CWSNBNRBBOOWDE-VQTJNVASSA-N 0.000 description 4
- BECLOSXOCNEAEN-UHFFFAOYSA-N 2-[2-[2-[2-(4-chlorophenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(Cl)=CC=3)C2=C1 BECLOSXOCNEAEN-UHFFFAOYSA-N 0.000 description 4
- DAVPFQWQPCOAIO-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethylsulfonylamino)phenyl]ethynyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(NS(=O)(=O)C(F)(F)F)=CC=3)C2=C1 DAVPFQWQPCOAIO-UHFFFAOYSA-N 0.000 description 4
- IXJNNTLBLILFLZ-JXMROGBWSA-N 2-[6-chloro-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazol-5-yl]phenol Chemical compound OC1=CC=CC=C1C(C(=C1)Cl)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(F)(F)F)=N2 IXJNNTLBLILFLZ-JXMROGBWSA-N 0.000 description 4
- SVUVTVGISAFBEE-JXMROGBWSA-N 2-[6-fluoro-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazol-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC=C1C(C(=C1)F)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(F)(F)F)=N2 SVUVTVGISAFBEE-JXMROGBWSA-N 0.000 description 4
- PASWFOTTYAJBNR-JXMROGBWSA-N 2-[6-fluoro-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazol-5-yl]phenol Chemical compound OC1=CC=CC=C1C(C(=C1)F)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(F)(F)F)=N2 PASWFOTTYAJBNR-JXMROGBWSA-N 0.000 description 4
- QGXSTQSQWFSTHM-KPKJPENVSA-N 2-hydroxy-1-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound OCC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 QGXSTQSQWFSTHM-KPKJPENVSA-N 0.000 description 4
- TWFMOXLCLDCRGN-NTEUORMPSA-N 3-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-3h-benzimidazol-5-yl]benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C=C(C=CC=3)C(N)=O)=CC=C2N1 TWFMOXLCLDCRGN-NTEUORMPSA-N 0.000 description 4
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 4
- PKEPYDJABOGYKC-KPKJPENVSA-N 6-[3-methyl-2-(sulfamoylamino)phenyl]-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazole Chemical compound CC1=CC=CC(C=2C=C3NC(\C=C\C=4C=CC(=CC=4)C(F)(F)F)=NC3=CC=2)=C1NS(N)(=O)=O PKEPYDJABOGYKC-KPKJPENVSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 229910002666 PdCl2 Inorganic materials 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- RPRMOEFOTPSWBO-UHFFFAOYSA-N [2-(methanesulfonamido)phenyl]boronic acid Chemical compound CS(=O)(=O)NC1=CC=CC=C1B(O)O RPRMOEFOTPSWBO-UHFFFAOYSA-N 0.000 description 4
- TUEIURIZJQRMQE-UHFFFAOYSA-N [2-(tert-butylsulfamoyl)phenyl]boronic acid Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=CC=C1B(O)O TUEIURIZJQRMQE-UHFFFAOYSA-N 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- DRCMAZOSEIMCHM-UHFFFAOYSA-N capsazepine Chemical compound C1C=2C=C(O)C(O)=CC=2CCCN1C(=S)NCCC1=CC=C(Cl)C=C1 DRCMAZOSEIMCHM-UHFFFAOYSA-N 0.000 description 4
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- CRXXEWUEDXFDDT-YRNVUSSQSA-N n-[2-[2-[(e)-2-(3,4-dichlorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Cl)C(Cl)=CC=2)=N2)C2=C1 CRXXEWUEDXFDDT-YRNVUSSQSA-N 0.000 description 4
- HXIMJNUHEWBMQU-YRNVUSSQSA-N n-[2-[2-[(e)-2-(3,4-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(F)C(F)=CC=2)=N2)C2=C1 HXIMJNUHEWBMQU-YRNVUSSQSA-N 0.000 description 4
- GGBQTRCNAYHLMB-MDWZMJQESA-N n-[2-[2-[(e)-2-(4-bromophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(Br)=CC=2)=N2)C2=C1 GGBQTRCNAYHLMB-MDWZMJQESA-N 0.000 description 4
- DZHDMYLIEUOKKW-XNTDXEJSSA-N n-[2-[2-[(e)-2-(4-ethoxyphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound C1=CC(OCC)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(C)(=O)=O)=CC=C2N1 DZHDMYLIEUOKKW-XNTDXEJSSA-N 0.000 description 4
- YYAOTCPTWXCDQT-SDNWHVSQSA-N n-[2-[2-[(e)-2-(4-methylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound C1=CC(C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(C)(=O)=O)=CC=C2N1 YYAOTCPTWXCDQT-SDNWHVSQSA-N 0.000 description 4
- RKSXDFSAWMMVRH-SDNWHVSQSA-N n-[2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-6-(trifluoromethyl)-1h-benzimidazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C(C(=C1)C(F)(F)F)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(C)(C)C)=N2 RKSXDFSAWMMVRH-SDNWHVSQSA-N 0.000 description 4
- IGZRXYVKMNLZAU-RMKNXTFCSA-N n-[2-[2-[(e)-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(C=C(F)C=2)C(F)(F)F)=N2)C2=C1 IGZRXYVKMNLZAU-RMKNXTFCSA-N 0.000 description 4
- CZRADHIUKWGGHF-MDWZMJQESA-N n-[2-[2-[(e)-2-[4-(2,2,2-trifluoroethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OCC(F)(F)F)=CC=2)=N2)C2=C1 CZRADHIUKWGGHF-MDWZMJQESA-N 0.000 description 4
- DUJMIOHMXXVFHL-MDWZMJQESA-N n-[2-[2-[(e)-2-[4-(difluoromethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OC(F)F)=CC=2)=N2)C2=C1 DUJMIOHMXXVFHL-MDWZMJQESA-N 0.000 description 4
- GRUYEJOLVKNPLX-XNTDXEJSSA-N n-[2-[2-[(e)-2-[4-(dimethylamino)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound C1=CC(N(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(C)(=O)=O)=CC=C2N1 GRUYEJOLVKNPLX-XNTDXEJSSA-N 0.000 description 4
- VDDHGPBRUIMMGY-RVDMUPIBSA-N n-[2-[2-[(e)-2-naphthalen-2-ylethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C3C=CC=CC3=CC=2)=N2)C2=C1 VDDHGPBRUIMMGY-RVDMUPIBSA-N 0.000 description 4
- PTUFJZZJPVMWET-UHFFFAOYSA-N n-[2-[2-[2-(3-chlorophenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=C(Cl)C=CC=3)C2=C1 PTUFJZZJPVMWET-UHFFFAOYSA-N 0.000 description 4
- LFOYMLBHUPSIFU-UHFFFAOYSA-N n-[2-[2-[2-(4-chlorophenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(Cl)=CC=3)C2=C1 LFOYMLBHUPSIFU-UHFFFAOYSA-N 0.000 description 4
- TVGASHPPPRUREP-UHFFFAOYSA-N n-[2-[2-[2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 TVGASHPPPRUREP-UHFFFAOYSA-N 0.000 description 4
- JDHSDTMLCFFLDI-DHZHZOJOSA-N n-[2-[6-(trifluoromethyl)-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C(C(=C1)C(F)(F)F)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(F)(F)F)=N2 JDHSDTMLCFFLDI-DHZHZOJOSA-N 0.000 description 4
- OQIZTZHOLPGOFG-ACCUITESSA-N n-methyl-2-[2-[(e)-2-[2-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C(=CC=CC=2)C(F)(F)F)=N2)C2=C1 OQIZTZHOLPGOFG-ACCUITESSA-N 0.000 description 4
- HUZQFZUODLGHNQ-XNTDXEJSSA-N n-tert-butyl-2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 HUZQFZUODLGHNQ-XNTDXEJSSA-N 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 230000001473 noxious effect Effects 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- LBWJTKOVBMVJJX-UHFFFAOYSA-N (2-carbamoylphenyl)boronic acid Chemical compound NC(=O)C1=CC=CC=C1B(O)O LBWJTKOVBMVJJX-UHFFFAOYSA-N 0.000 description 3
- WFWQWTPAPNEOFE-UHFFFAOYSA-N (3-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(O)=C1 WFWQWTPAPNEOFE-UHFFFAOYSA-N 0.000 description 3
- JHLIGYPHPBLDDL-UHFFFAOYSA-N (5-pyridin-3-ylthiophen-2-yl)methanamine Chemical compound S1C(CN)=CC=C1C1=CC=CN=C1 JHLIGYPHPBLDDL-UHFFFAOYSA-N 0.000 description 3
- APJSHECCIRQQDV-ZRDIBKRKSA-N (e)-3-[4-hydroxy-3-(5,5,8,8-tetramethyl-3-pentoxy-6,7-dihydronaphthalen-2-yl)phenyl]prop-2-enoic acid Chemical compound CCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1=CC(\C=C\C(O)=O)=CC=C1O APJSHECCIRQQDV-ZRDIBKRKSA-N 0.000 description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 3
- RMYUWPBHYTUDCS-DHZHZOJOSA-N 1,1,1-trifluoro-n-[2-[2-[(e)-2-[3-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound FC(F)(F)C1=CC=CC(\C=C\C=2NC3=CC=C(C=C3N=2)C=2C(=CC=CC=2)NS(=O)(=O)C(F)(F)F)=C1 RMYUWPBHYTUDCS-DHZHZOJOSA-N 0.000 description 3
- HTOQNHAORDNUPW-KPKJPENVSA-N 1,1,1-trifluoro-n-[2-[2-[(e)-2-[4-(2,2,2-trifluoroethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound C1=CC(OCC(F)(F)F)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(=O)(=O)C(F)(F)F)=CC=C2N1 HTOQNHAORDNUPW-KPKJPENVSA-N 0.000 description 3
- VALKQJYNHSJULX-KPKJPENVSA-N 1,1,1-trifluoro-n-[2-[2-[(e)-2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound C1=CC(OCC(F)(F)C(F)(F)F)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(=O)(=O)C(F)(F)F)=CC=C2N1 VALKQJYNHSJULX-KPKJPENVSA-N 0.000 description 3
- NMMHCPAPYNUFGI-MDWZMJQESA-N 1,1,1-trifluoro-n-[2-[2-[(e)-2-[4-(methanesulfonamido)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(=O)(=O)C(F)(F)F)=CC=C2N1 NMMHCPAPYNUFGI-MDWZMJQESA-N 0.000 description 3
- OURJLHJHHATHII-KPKJPENVSA-N 1,1,1-trifluoro-n-[2-[2-[(e)-2-[4-(trifluoromethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(=O)(=O)C(F)(F)F)=CC=C2N1 OURJLHJHHATHII-KPKJPENVSA-N 0.000 description 3
- OLBWLFFAXVNSKT-KPKJPENVSA-N 1,1,1-trifluoro-n-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(=O)(=O)C(F)(F)F)=CC=C2N1 OLBWLFFAXVNSKT-KPKJPENVSA-N 0.000 description 3
- DPMZVIUXFUOSJP-KPKJPENVSA-N 1,1,1-trifluoro-n-[2-[2-[(e)-2-[4-(trifluoromethylsulfonyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N2)C2=C1 DPMZVIUXFUOSJP-KPKJPENVSA-N 0.000 description 3
- BJYQAYVQSUUVSY-MDWZMJQESA-N 1,1,1-trifluoro-n-[4-[(e)-2-[6-[2-(1-hydroxyethyl)phenyl]-1h-benzimidazol-2-yl]ethenyl]phenyl]methanesulfonamide Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(NS(=O)(=O)C(F)(F)F)=CC=2)=N2)C2=C1 BJYQAYVQSUUVSY-MDWZMJQESA-N 0.000 description 3
- IRNCUJDEBZFVCW-NTEUORMPSA-N 1,1,1-trifluoro-n-[4-[(e)-2-[6-[2-(2-hydroxypropan-2-yl)phenyl]-1h-benzimidazol-2-yl]ethenyl]phenyl]methanesulfonamide Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(NS(=O)(=O)C(F)(F)F)=CC=2)=N2)C2=C1 IRNCUJDEBZFVCW-NTEUORMPSA-N 0.000 description 3
- UMSKYNDACMJCOY-MDWZMJQESA-N 1,1,1-trifluoro-n-[4-[(e)-2-[6-[2-(methanesulfonamido)phenyl]-1h-benzimidazol-2-yl]ethenyl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(NS(=O)(=O)C(F)(F)F)=CC=2)=N2)C2=C1 UMSKYNDACMJCOY-MDWZMJQESA-N 0.000 description 3
- WEUZGXUZNWDRNN-KPKJPENVSA-N 1,1,1-trifluoro-n-[4-[(e)-2-[6-[2-(trifluoromethylsulfonylamino)phenyl]-1h-benzimidazol-2-yl]ethenyl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C(F)(F)F)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(=O)(=O)C(F)(F)F)=CC=C2N1 WEUZGXUZNWDRNN-KPKJPENVSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- RMZRLEQDQOVXEH-FMIVXFBMSA-N 1-[2-[2-[(e)-2-(3-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Cl)C=CC=2)=N2)C2=C1 RMZRLEQDQOVXEH-FMIVXFBMSA-N 0.000 description 3
- SIAFYHRFGFJTKJ-FMIVXFBMSA-N 1-[2-[2-[(e)-2-(3-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Cl)C=CC=2)=N2)C2=C1 SIAFYHRFGFJTKJ-FMIVXFBMSA-N 0.000 description 3
- DOBYBTDREXZSRE-MDWZMJQESA-N 1-[2-[2-[(e)-2-(4-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(Cl)=CC=2)=N2)C2=C1 DOBYBTDREXZSRE-MDWZMJQESA-N 0.000 description 3
- BKIKWZWDGLOZJN-MDWZMJQESA-N 1-[2-[2-[(e)-2-(4-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(Cl)=CC=2)=N2)C2=C1 BKIKWZWDGLOZJN-MDWZMJQESA-N 0.000 description 3
- GLUAJSOBTZOIAJ-NTEUORMPSA-N 1-[2-[2-[(e)-2-(4-methylsulfonylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(C)(=O)=O)=N2)C2=C1 GLUAJSOBTZOIAJ-NTEUORMPSA-N 0.000 description 3
- XBZXXPBCTCSCEK-NTEUORMPSA-N 1-[2-[2-[(e)-2-(4-methylsulfonylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(C)(=O)=O)=N2)C2=C1 XBZXXPBCTCSCEK-NTEUORMPSA-N 0.000 description 3
- XKHSXRVQINCDME-FMIVXFBMSA-N 1-[2-[2-[(e)-2-[3-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(C=CC=2)C(F)(F)F)=N2)C2=C1 XKHSXRVQINCDME-FMIVXFBMSA-N 0.000 description 3
- ZRLGPOJALWYIIZ-FMIVXFBMSA-N 1-[2-[2-[(e)-2-[3-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(C=CC=2)C(F)(F)F)=N2)C2=C1 ZRLGPOJALWYIIZ-FMIVXFBMSA-N 0.000 description 3
- VCNUVCORKMPDMF-MDWZMJQESA-N 1-[2-[2-[(e)-2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=2)=N2)C2=C1 VCNUVCORKMPDMF-MDWZMJQESA-N 0.000 description 3
- WWWHYEJJYPVBPH-MDWZMJQESA-N 1-[2-[2-[(e)-2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=2)=N2)C2=C1 WWWHYEJJYPVBPH-MDWZMJQESA-N 0.000 description 3
- KEOATIRZHZAAIP-MDWZMJQESA-N 1-[2-[2-[(e)-2-[4-(2,2,2-trifluoroethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OCC(F)(F)F)=CC=2)=N2)C2=C1 KEOATIRZHZAAIP-MDWZMJQESA-N 0.000 description 3
- YYLXOHKXOJCGLO-MDWZMJQESA-N 1-[2-[2-[(e)-2-[4-(2,2,2-trifluoroethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OCC(F)(F)F)=CC=2)=N2)C2=C1 YYLXOHKXOJCGLO-MDWZMJQESA-N 0.000 description 3
- WKKZWCAAXHUSTA-MDWZMJQESA-N 1-[2-[2-[(e)-2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OCC(F)(F)C(F)(F)F)=CC=2)=N2)C2=C1 WKKZWCAAXHUSTA-MDWZMJQESA-N 0.000 description 3
- NCUKYYGIZDMUSA-MDWZMJQESA-N 1-[2-[2-[(e)-2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OCC(F)(F)C(F)(F)F)=CC=2)=N2)C2=C1 NCUKYYGIZDMUSA-MDWZMJQESA-N 0.000 description 3
- OMDMAUUCSANUBX-MDWZMJQESA-N 1-[2-[2-[(e)-2-[4-(trifluoromethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OC(F)(F)F)=CC=2)=N2)C2=C1 OMDMAUUCSANUBX-MDWZMJQESA-N 0.000 description 3
- WRIIXVITTGPJTK-UHFFFAOYSA-N 1-[2-[2-[2-(3-chlorophenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=C(Cl)C=CC=3)C2=C1 WRIIXVITTGPJTK-UHFFFAOYSA-N 0.000 description 3
- NOKSEHPVJFEGQE-UHFFFAOYSA-N 1-[2-[2-[2-(3-chlorophenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=C(Cl)C=CC=3)C2=C1 NOKSEHPVJFEGQE-UHFFFAOYSA-N 0.000 description 3
- MWBAIPHVGFVOLY-UHFFFAOYSA-N 1-[2-[2-[2-(3-chlorophenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=C(Cl)C=CC=3)C2=C1 MWBAIPHVGFVOLY-UHFFFAOYSA-N 0.000 description 3
- IEFHNAXMIJUXNX-UHFFFAOYSA-N 1-[2-[2-[2-(3-chlorophenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=C(Cl)C=CC=3)C2=C1 IEFHNAXMIJUXNX-UHFFFAOYSA-N 0.000 description 3
- ULWDIVIKDPHGIO-UHFFFAOYSA-N 1-[2-[2-[2-(4-chlorophenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(Cl)=CC=3)C2=C1 ULWDIVIKDPHGIO-UHFFFAOYSA-N 0.000 description 3
- ZXTAVVQMORFPID-UHFFFAOYSA-N 1-[2-[2-[2-(4-chlorophenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(Cl)=CC=3)C2=C1 ZXTAVVQMORFPID-UHFFFAOYSA-N 0.000 description 3
- JNHINLPROKONPP-UHFFFAOYSA-N 1-[2-[2-[2-(4-methylsulfonylphenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)S(C)(=O)=O)C2=C1 JNHINLPROKONPP-UHFFFAOYSA-N 0.000 description 3
- UCBMWOVJHNKCCO-UHFFFAOYSA-N 1-[2-[2-[2-(4-methylsulfonylphenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)S(C)(=O)=O)C2=C1 UCBMWOVJHNKCCO-UHFFFAOYSA-N 0.000 description 3
- VNUDSOAFKSSPEO-UHFFFAOYSA-N 1-[2-[2-[2-(4-methylsulfonylphenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(=CC=3)S(C)(=O)=O)C2=C1 VNUDSOAFKSSPEO-UHFFFAOYSA-N 0.000 description 3
- CXLUTBPDYCQYAN-UHFFFAOYSA-N 1-[2-[2-[2-(4-methylsulfonylphenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(=CC=3)S(C)(=O)=O)C2=C1 CXLUTBPDYCQYAN-UHFFFAOYSA-N 0.000 description 3
- JWSFMPDKXKCYIO-UHFFFAOYSA-N 1-[2-[2-[2-[3-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=C(C=CC=3)C(F)(F)F)C2=C1 JWSFMPDKXKCYIO-UHFFFAOYSA-N 0.000 description 3
- MJTOSYAYDWAKHH-UHFFFAOYSA-N 1-[2-[2-[2-[3-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=C(C=CC=3)C(F)(F)F)C2=C1 MJTOSYAYDWAKHH-UHFFFAOYSA-N 0.000 description 3
- NUBYCKOSDOUEHC-UHFFFAOYSA-N 1-[2-[2-[2-[3-(trifluoromethyl)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=C(C=CC=3)C(F)(F)F)C2=C1 NUBYCKOSDOUEHC-UHFFFAOYSA-N 0.000 description 3
- JMFIDCPCTMMIJK-UHFFFAOYSA-N 1-[2-[2-[2-[3-(trifluoromethyl)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=C(C=CC=3)C(F)(F)F)C2=C1 JMFIDCPCTMMIJK-UHFFFAOYSA-N 0.000 description 3
- HTRLMLPMNFMLBO-UHFFFAOYSA-N 1-[2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=3)C2=C1 HTRLMLPMNFMLBO-UHFFFAOYSA-N 0.000 description 3
- ALLXAMPIVHAYCP-UHFFFAOYSA-N 1-[2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=3)C2=C1 ALLXAMPIVHAYCP-UHFFFAOYSA-N 0.000 description 3
- JQZQGOMCMHGMOI-UHFFFAOYSA-N 1-[2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=3)C2=C1 JQZQGOMCMHGMOI-UHFFFAOYSA-N 0.000 description 3
- BTYXCNKUCTXIJO-UHFFFAOYSA-N 1-[2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=3)C2=C1 BTYXCNKUCTXIJO-UHFFFAOYSA-N 0.000 description 3
- ABFIPEKCKAOADK-UHFFFAOYSA-N 1-[2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OCC(F)(F)F)=CC=3)C2=C1 ABFIPEKCKAOADK-UHFFFAOYSA-N 0.000 description 3
- UQGLPTSCHCUXMK-UHFFFAOYSA-N 1-[2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OCC(F)(F)F)=CC=3)C2=C1 UQGLPTSCHCUXMK-UHFFFAOYSA-N 0.000 description 3
- KRWNWTSCIQSLCR-UHFFFAOYSA-N 1-[2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OCC(F)(F)F)=CC=3)C2=C1 KRWNWTSCIQSLCR-UHFFFAOYSA-N 0.000 description 3
- IEDHQEUSMCDUBF-UHFFFAOYSA-N 1-[2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OCC(F)(F)F)=CC=3)C2=C1 IEDHQEUSMCDUBF-UHFFFAOYSA-N 0.000 description 3
- QRTHUYDYMPMUKI-UHFFFAOYSA-N 1-[2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OCC(F)(F)C(F)(F)F)=CC=3)C2=C1 QRTHUYDYMPMUKI-UHFFFAOYSA-N 0.000 description 3
- BUGMRYGJHOEYER-UHFFFAOYSA-N 1-[2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OCC(F)(F)C(F)(F)F)=CC=3)C2=C1 BUGMRYGJHOEYER-UHFFFAOYSA-N 0.000 description 3
- SCOPWQWHMUZFBO-UHFFFAOYSA-N 1-[2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OCC(F)(F)C(F)(F)F)=CC=3)C2=C1 SCOPWQWHMUZFBO-UHFFFAOYSA-N 0.000 description 3
- QETJHHBLIIPVEP-UHFFFAOYSA-N 1-[2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OCC(F)(F)C(F)(F)F)=CC=3)C2=C1 QETJHHBLIIPVEP-UHFFFAOYSA-N 0.000 description 3
- USTFFIJQFJYXBL-DHZHZOJOSA-N 1-[2-[6-(trifluoromethyl)-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C(C(=C1)C(F)(F)F)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(F)(F)F)=N2 USTFFIJQFJYXBL-DHZHZOJOSA-N 0.000 description 3
- CEWDRCQPGANDRS-UHFFFAOYSA-N 1-ethenyl-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(C=C)C=C1 CEWDRCQPGANDRS-UHFFFAOYSA-N 0.000 description 3
- XRNYIZHSTBWDJZ-KPKJPENVSA-N 2,2,2-trifluoro-n-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]acetamide Chemical compound FC(F)(F)C(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 XRNYIZHSTBWDJZ-KPKJPENVSA-N 0.000 description 3
- CJVGHQPAANAPHO-XNTDXEJSSA-N 2,2-dimethyl-n-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]propanamide Chemical compound CC(C)(C)C(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 CJVGHQPAANAPHO-XNTDXEJSSA-N 0.000 description 3
- CZOWDOFBHPESCN-JLHYYAGUSA-N 2-[(e)-2-(4-tert-butylphenyl)ethenyl]-5-(2-fluorophenyl)-6-(trifluoromethyl)-1h-benzimidazole Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)F)=C(C(F)(F)F)C=C2N1 CZOWDOFBHPESCN-JLHYYAGUSA-N 0.000 description 3
- SMULEHKLKQBAGG-QZTJIDSGSA-N 2-[2-[(1r,2s)-2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)[C@H]3[C@H](C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 SMULEHKLKQBAGG-QZTJIDSGSA-N 0.000 description 3
- SMULEHKLKQBAGG-ROUUACIJSA-N 2-[2-[(1s,2r)-2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)[C@@H]3[C@@H](C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 SMULEHKLKQBAGG-ROUUACIJSA-N 0.000 description 3
- YWGDWBXRGFIPRO-YRNVUSSQSA-N 2-[2-[(e)-2-(1h-indol-6-yl)ethenyl]-3h-benzimidazol-5-yl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C3NC=CC3=CC=2)=N2)C2=C1 YWGDWBXRGFIPRO-YRNVUSSQSA-N 0.000 description 3
- BMBJWQRZENAAOR-UXBLZVDNSA-N 2-[2-[(e)-2-(3,4-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(F)C(F)=CC=2)=N2)C2=C1 BMBJWQRZENAAOR-UXBLZVDNSA-N 0.000 description 3
- FRBFUHOGTOUKFK-DHZHZOJOSA-N 2-[2-[(e)-2-(3-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Cl)C=CC=2)=N2)C2=C1 FRBFUHOGTOUKFK-DHZHZOJOSA-N 0.000 description 3
- MYPQBUZYJIDPOZ-MDWZMJQESA-N 2-[2-[(e)-2-(4-methylsulfonylphenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)S(N)(=O)=O)=CC=C2N1 MYPQBUZYJIDPOZ-MDWZMJQESA-N 0.000 description 3
- RAGRIWRGUXAZMZ-JLHYYAGUSA-N 2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-6-(trifluoromethyl)-1h-benzimidazol-5-yl]phenol Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)O)=C(C(F)(F)F)C=C2N1 RAGRIWRGUXAZMZ-JLHYYAGUSA-N 0.000 description 3
- UGUQQQHVSVKADO-DHZHZOJOSA-N 2-[2-[(e)-2-[3-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(C=CC=2)C(F)(F)F)=N2)C2=C1 UGUQQQHVSVKADO-DHZHZOJOSA-N 0.000 description 3
- UHYBEKPLECXFKX-KPKJPENVSA-N 2-[2-[(e)-2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=2)=N2)C2=C1 UHYBEKPLECXFKX-KPKJPENVSA-N 0.000 description 3
- JZJGCHDTJCCZJK-KPKJPENVSA-N 2-[2-[(e)-2-[4-(2,2,2-trifluoroethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OCC(F)(F)F)=CC=2)=N2)C2=C1 JZJGCHDTJCCZJK-KPKJPENVSA-N 0.000 description 3
- GFUWXLYNKIHDDI-KPKJPENVSA-N 2-[2-[(e)-2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OCC(F)(F)C(F)(F)F)=CC=2)=N2)C2=C1 GFUWXLYNKIHDDI-KPKJPENVSA-N 0.000 description 3
- WODGUVXGKKXBRT-MDWZMJQESA-N 2-[2-[(e)-2-[4-(methanesulfonamido)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)S(N)(=O)=O)=CC=C2N1 WODGUVXGKKXBRT-MDWZMJQESA-N 0.000 description 3
- CIZBJTYXRJPRHY-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OC(F)(F)F)=CC=2)=N2)C2=C1 CIZBJTYXRJPRHY-KPKJPENVSA-N 0.000 description 3
- JUEQQMOCMNIXTQ-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzaldehyde Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)C=O)=CC=C2N1 JUEQQMOCMNIXTQ-KPKJPENVSA-N 0.000 description 3
- GMNUCSBZMKQAAZ-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenol Chemical compound OC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 GMNUCSBZMKQAAZ-KPKJPENVSA-N 0.000 description 3
- VGGIHFXAIHTKOW-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethylsulfanyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenol Chemical compound OC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(SC(F)(F)F)=CC=2)=N2)C2=C1 VGGIHFXAIHTKOW-KPKJPENVSA-N 0.000 description 3
- DCEFJNIDEHGAHJ-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethylsulfonylamino)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(NS(=O)(=O)C(F)(F)F)=CC=2)=N2)C2=C1 DCEFJNIDEHGAHJ-KPKJPENVSA-N 0.000 description 3
- WKUHGMMRGVDSHO-UHFFFAOYSA-N 2-[2-[2-(3-chlorophenyl)cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=C(Cl)C=CC=3)C2=C1 WKUHGMMRGVDSHO-UHFFFAOYSA-N 0.000 description 3
- OYGDDBFLVUZEHG-UHFFFAOYSA-N 2-[2-[2-(3-chlorophenyl)ethynyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=C(Cl)C=CC=3)C2=C1 OYGDDBFLVUZEHG-UHFFFAOYSA-N 0.000 description 3
- VGQVTXANZZYAET-UHFFFAOYSA-N 2-[2-[2-(4-chlorophenyl)cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(Cl)=CC=3)C2=C1 VGQVTXANZZYAET-UHFFFAOYSA-N 0.000 description 3
- QCSJCUSEBVQWDM-UHFFFAOYSA-N 2-[2-[2-(4-chlorophenyl)ethynyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(Cl)=CC=3)C2=C1 QCSJCUSEBVQWDM-UHFFFAOYSA-N 0.000 description 3
- AHSMNGUKFKDYAU-UHFFFAOYSA-N 2-[2-[2-(4-methylsulfonylphenyl)cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1C(C=2NC3=CC=C(C=C3N=2)C=2C(=CC=CC=2)S(N)(=O)=O)C1 AHSMNGUKFKDYAU-UHFFFAOYSA-N 0.000 description 3
- RPKYGMDQYFEIDP-UHFFFAOYSA-N 2-[2-[2-(4-methylsulfonylphenyl)ethynyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C#CC1=NC2=CC(C=3C(=CC=CC=3)S(N)(=O)=O)=CC=C2N1 RPKYGMDQYFEIDP-UHFFFAOYSA-N 0.000 description 3
- CWSNBNRBBOOWDE-WOJBJXKFSA-N 2-[2-[2-[(1r,2s)-2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)[C@H]3[C@H](C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 CWSNBNRBBOOWDE-WOJBJXKFSA-N 0.000 description 3
- CWSNBNRBBOOWDE-PMACEKPBSA-N 2-[2-[2-[(1s,2r)-2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)[C@@H]3[C@@H](C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 CWSNBNRBBOOWDE-PMACEKPBSA-N 0.000 description 3
- JZDVIJPEJRKMCD-JLHYYAGUSA-N 2-[2-[2-[(e)-2-(3-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Cl)C=CC=2)=N2)C2=C1 JZDVIJPEJRKMCD-JLHYYAGUSA-N 0.000 description 3
- BNPHCKRUBAMHSZ-NTEUORMPSA-N 2-[2-[2-[(e)-2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=2)=N2)C2=C1 BNPHCKRUBAMHSZ-NTEUORMPSA-N 0.000 description 3
- SIQDIPPHMLPSRC-NTEUORMPSA-N 2-[2-[2-[(e)-2-[4-(2,2,2-trifluoroethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OCC(F)(F)F)=CC=2)=N2)C2=C1 SIQDIPPHMLPSRC-NTEUORMPSA-N 0.000 description 3
- VRPIENCRGASDQK-NTEUORMPSA-N 2-[2-[2-[(e)-2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OCC(F)(F)C(F)(F)F)=CC=2)=N2)C2=C1 VRPIENCRGASDQK-NTEUORMPSA-N 0.000 description 3
- JARKBRAORHFMDK-NTEUORMPSA-N 2-[2-[2-[(e)-2-[4-(trifluoromethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OC(F)(F)F)=CC=2)=N2)C2=C1 JARKBRAORHFMDK-NTEUORMPSA-N 0.000 description 3
- WKFRKBSODPCRSG-UHFFFAOYSA-N 2-[2-[2-[2-(3-chlorophenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=C(Cl)C=CC=3)C2=C1 WKFRKBSODPCRSG-UHFFFAOYSA-N 0.000 description 3
- NLAWVCQRIOISSE-UHFFFAOYSA-N 2-[2-[2-[2-(3-chlorophenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=C(Cl)C=CC=3)C2=C1 NLAWVCQRIOISSE-UHFFFAOYSA-N 0.000 description 3
- STPAVZOUKKVDRX-UHFFFAOYSA-N 2-[2-[2-[2-(4-chlorophenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(Cl)=CC=3)C2=C1 STPAVZOUKKVDRX-UHFFFAOYSA-N 0.000 description 3
- NVSPGVPXZYGPDB-UHFFFAOYSA-N 2-[2-[2-[2-(4-methylsulfonylphenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)S(C)(=O)=O)C2=C1 NVSPGVPXZYGPDB-UHFFFAOYSA-N 0.000 description 3
- VCEWHBKSEYATIC-UHFFFAOYSA-N 2-[2-[2-[2-(4-methylsulfonylphenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(=CC=3)S(C)(=O)=O)C2=C1 VCEWHBKSEYATIC-UHFFFAOYSA-N 0.000 description 3
- PSVWNKMBWXXBFY-UHFFFAOYSA-N 2-[2-[2-[2-[3-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=C(C=CC=3)C(F)(F)F)C2=C1 PSVWNKMBWXXBFY-UHFFFAOYSA-N 0.000 description 3
- DJUOGYKXVSKOCM-UHFFFAOYSA-N 2-[2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=3)C2=C1 DJUOGYKXVSKOCM-UHFFFAOYSA-N 0.000 description 3
- ASZZTCUHQMPYRU-UHFFFAOYSA-N 2-[2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=3)C2=C1 ASZZTCUHQMPYRU-UHFFFAOYSA-N 0.000 description 3
- ASUWHTPYSYJYAH-UHFFFAOYSA-N 2-[2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OCC(F)(F)F)=CC=3)C2=C1 ASUWHTPYSYJYAH-UHFFFAOYSA-N 0.000 description 3
- VERSVXPYCTYNTH-UHFFFAOYSA-N 2-[2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OCC(F)(F)F)=CC=3)C2=C1 VERSVXPYCTYNTH-UHFFFAOYSA-N 0.000 description 3
- CWTOPLMRQKHIDQ-UHFFFAOYSA-N 2-[2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OCC(F)(F)C(F)(F)F)=CC=3)C2=C1 CWTOPLMRQKHIDQ-UHFFFAOYSA-N 0.000 description 3
- XJZZJOTXFDATQC-UHFFFAOYSA-N 2-[2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OCC(F)(F)C(F)(F)F)=CC=3)C2=C1 XJZZJOTXFDATQC-UHFFFAOYSA-N 0.000 description 3
- HNLOEQDWLOQWAM-UHFFFAOYSA-N 2-[2-[2-[3-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=C(C=CC=3)C(F)(F)F)C2=C1 HNLOEQDWLOQWAM-UHFFFAOYSA-N 0.000 description 3
- MAOPLAQZXPCHJZ-UHFFFAOYSA-N 2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=3)C2=C1 MAOPLAQZXPCHJZ-UHFFFAOYSA-N 0.000 description 3
- SGMXTGCRHFEUOM-UHFFFAOYSA-N 2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=3)C2=C1 SGMXTGCRHFEUOM-UHFFFAOYSA-N 0.000 description 3
- WQNPOUXNDTVLCW-UHFFFAOYSA-N 2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OCC(F)(F)F)=CC=3)C2=C1 WQNPOUXNDTVLCW-UHFFFAOYSA-N 0.000 description 3
- WJOVYONNRVEGTA-UHFFFAOYSA-N 2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OCC(F)(F)F)=CC=3)C2=C1 WJOVYONNRVEGTA-UHFFFAOYSA-N 0.000 description 3
- FAZOEZNUKOGCAX-UHFFFAOYSA-N 2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OCC(F)(F)C(F)(F)F)=CC=3)C2=C1 FAZOEZNUKOGCAX-UHFFFAOYSA-N 0.000 description 3
- FNSCKZUORHOMPZ-UHFFFAOYSA-N 2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OCC(F)(F)C(F)(F)F)=CC=3)C2=C1 FNSCKZUORHOMPZ-UHFFFAOYSA-N 0.000 description 3
- XEOHUKYRZSCNPG-UHFFFAOYSA-N 2-[2-[2-[4-(methanesulfonamido)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1C1C(C=2NC3=CC=C(C=C3N=2)C=2C(=CC=CC=2)S(N)(=O)=O)C1 XEOHUKYRZSCNPG-UHFFFAOYSA-N 0.000 description 3
- CAAZEDOEHGENLB-UHFFFAOYSA-N 2-[2-[2-[4-(methanesulfonamido)phenyl]ethynyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1C#CC1=NC2=CC(C=3C(=CC=CC=3)S(N)(=O)=O)=CC=C2N1 CAAZEDOEHGENLB-UHFFFAOYSA-N 0.000 description 3
- VOVBIXGVBXHCCH-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethoxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OC(F)(F)F)=CC=3)C2=C1 VOVBIXGVBXHCCH-UHFFFAOYSA-N 0.000 description 3
- AUJKOOMRQJQRQG-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethoxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OC(F)(F)F)=CC=3)C2=C1 AUJKOOMRQJQRQG-UHFFFAOYSA-N 0.000 description 3
- ZGECJSDWNGNIQK-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenol Chemical compound OC1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 ZGECJSDWNGNIQK-UHFFFAOYSA-N 0.000 description 3
- REMRBINPUAJCJO-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethylsulfonyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)S(=O)(=O)C(F)(F)F)C2=C1 REMRBINPUAJCJO-UHFFFAOYSA-N 0.000 description 3
- YMACGESPXWBGER-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethylsulfonyl)phenyl]ethynyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(=CC=3)S(=O)(=O)C(F)(F)F)C2=C1 YMACGESPXWBGER-UHFFFAOYSA-N 0.000 description 3
- PCSQUZDWMFTHRS-UHFFFAOYSA-N 2-[2-[2-[4-(trifluoromethylsulfonylamino)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(NS(=O)(=O)C(F)(F)F)=CC=3)C2=C1 PCSQUZDWMFTHRS-UHFFFAOYSA-N 0.000 description 3
- KWPQTFXULUUCGD-UHFFFAOYSA-N 3,4,5,7,8,9,10,10a-octahydropyrido[1,2-a][1,4]diazepine Chemical compound C1CCN=CC2CCCCN21 KWPQTFXULUUCGD-UHFFFAOYSA-N 0.000 description 3
- REJGNEWSESJCKL-FMIVXFBMSA-N 3-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-6-(trifluoromethyl)-1h-benzimidazol-5-yl]phenol Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C=C(O)C=CC=3)=C(C(F)(F)F)C=C2N1 REJGNEWSESJCKL-FMIVXFBMSA-N 0.000 description 3
- DLDOFEOUZNRQDQ-RMKNXTFCSA-N 3-[6-fluoro-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazol-5-yl]phenol Chemical compound OC1=CC=CC(C=2C(=CC=3NC(\C=C\C=4C=CC(=CC=4)C(F)(F)F)=NC=3C=2)F)=C1 DLDOFEOUZNRQDQ-RMKNXTFCSA-N 0.000 description 3
- FXTUVSBEMXGFPY-MDWZMJQESA-N 4-[(e)-2-[6-[2-(methylsulfamoyl)phenyl]-1h-benzimidazol-2-yl]ethenyl]benzoic acid Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(O)=O)=N2)C2=C1 FXTUVSBEMXGFPY-MDWZMJQESA-N 0.000 description 3
- WVQLSISPEBZWBG-GIDUJCDVSA-N 4-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-3h-benzimidazol-5-yl]benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C=CC(=CC=3)C(N)=O)=CC=C2N1 WVQLSISPEBZWBG-GIDUJCDVSA-N 0.000 description 3
- YQYHYZFIDRHTBA-XCVCLJGOSA-N 4-fluoro-2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(F)C=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 YQYHYZFIDRHTBA-XCVCLJGOSA-N 0.000 description 3
- VHEHSAUDUSDSIL-MDWZMJQESA-N 6-(2-methylsulfanylphenyl)-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazole Chemical compound CSC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 VHEHSAUDUSDSIL-MDWZMJQESA-N 0.000 description 3
- HJWCMUOJXUOFJB-KPKJPENVSA-N 6-[2-(trifluoromethoxy)phenyl]-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazole Chemical compound FC(F)(F)OC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 HJWCMUOJXUOFJB-KPKJPENVSA-N 0.000 description 3
- NUCMHTKIVGRITP-KPKJPENVSA-N 6-[2-(trifluoromethyl)phenyl]-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazole Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)C(F)(F)F)=CC=C2N1 NUCMHTKIVGRITP-KPKJPENVSA-N 0.000 description 3
- KHRWYPMPTPAZCZ-KPKJPENVSA-N 6-[2-(trifluoromethyl)phenyl]-2-[(e)-2-[4-(trifluoromethylsulfonyl)phenyl]ethenyl]-1h-benzimidazole Chemical compound FC(F)(F)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N2)C2=C1 KHRWYPMPTPAZCZ-KPKJPENVSA-N 0.000 description 3
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 3
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 208000004550 Postoperative Pain Diseases 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- CQTZJDHJZISVRA-UHFFFAOYSA-N [2-[2-[2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]methanol Chemical compound OCC1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 CQTZJDHJZISVRA-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 229940114081 cinnamate Drugs 0.000 description 3
- 229930016911 cinnamic acid Natural products 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- KPINXTKNOWSVTG-NTEUORMPSA-N n,n-dimethyl-1-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanamine Chemical compound CN(C)CC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 KPINXTKNOWSVTG-NTEUORMPSA-N 0.000 description 3
- CIKPKECUWZSXHR-NTEUORMPSA-N n-[2-[1-methyl-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound N=1C2=CC(C=3C(=CC=CC=3)NS(C)(=O)=O)=CC=C2N(C)C=1\C=C\C1=CC=C(C(F)(F)F)C=C1 CIKPKECUWZSXHR-NTEUORMPSA-N 0.000 description 3
- PSPPKVAGIOWSQJ-YRNVUSSQSA-N n-[2-[2-[(e)-2-(3,4-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(F)C(F)=CC=2)=N2)C2=C1 PSPPKVAGIOWSQJ-YRNVUSSQSA-N 0.000 description 3
- KUUZSHSRDHONJH-YRNVUSSQSA-N n-[2-[2-[(e)-2-(3-bromo-4-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Br)C(F)=CC=2)=N2)C2=C1 KUUZSHSRDHONJH-YRNVUSSQSA-N 0.000 description 3
- XFGZXMNAXHQWEU-YRNVUSSQSA-N n-[2-[2-[(e)-2-(3-chloro-4-fluorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Cl)C(F)=CC=2)=N2)C2=C1 XFGZXMNAXHQWEU-YRNVUSSQSA-N 0.000 description 3
- MABHIWHZIVJLID-DHZHZOJOSA-N n-[2-[2-[(e)-2-(3-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Cl)C=CC=2)=N2)C2=C1 MABHIWHZIVJLID-DHZHZOJOSA-N 0.000 description 3
- MYQVXRVJHIABGR-KPKJPENVSA-N n-[2-[2-[(e)-2-(4-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(Cl)=CC=2)=N2)C2=C1 MYQVXRVJHIABGR-KPKJPENVSA-N 0.000 description 3
- TVDBIDURCYNCOW-NTEUORMPSA-N n-[2-[2-[(e)-2-(4-methylsulfonylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(C)(=O)=O)=N2)C2=C1 TVDBIDURCYNCOW-NTEUORMPSA-N 0.000 description 3
- SAWFZSSSSYONEJ-SDNWHVSQSA-N n-[2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-6-(trifluoromethyl)-1h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(C)(=O)=O)=C(C(F)(F)F)C=C2N1 SAWFZSSSSYONEJ-SDNWHVSQSA-N 0.000 description 3
- ODDRMWHLXBTFDG-FMIVXFBMSA-N n-[2-[2-[(e)-2-[3-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(C=CC=2)C(F)(F)F)=N2)C2=C1 ODDRMWHLXBTFDG-FMIVXFBMSA-N 0.000 description 3
- XVFCGAOAQYWTAG-MDWZMJQESA-N n-[2-[2-[(e)-2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OCC(F)(F)C(F)(F)F)=CC=2)=N2)C2=C1 XVFCGAOAQYWTAG-MDWZMJQESA-N 0.000 description 3
- QZSBBBCMIJDUGS-MDWZMJQESA-N n-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 QZSBBBCMIJDUGS-MDWZMJQESA-N 0.000 description 3
- YGHNGJYBXLAGIO-MDWZMJQESA-N n-[2-[2-[(e)-2-[4-(trifluoromethylsulfanyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(SC(F)(F)F)=CC=2)=N2)C2=C1 YGHNGJYBXLAGIO-MDWZMJQESA-N 0.000 description 3
- MEZKIOOYXPCMCO-MDWZMJQESA-N n-[2-[2-[(e)-2-[4-(trifluoromethylsulfonyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N2)C2=C1 MEZKIOOYXPCMCO-MDWZMJQESA-N 0.000 description 3
- KIAWMYPKLZSKCV-UHFFFAOYSA-N n-[2-[2-[2-(3-chlorophenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=C(Cl)C=CC=3)C2=C1 KIAWMYPKLZSKCV-UHFFFAOYSA-N 0.000 description 3
- GVZDHLMLCAPVQD-UHFFFAOYSA-N n-[2-[2-[2-(3-chlorophenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=C(Cl)C=CC=3)C2=C1 GVZDHLMLCAPVQD-UHFFFAOYSA-N 0.000 description 3
- WNLGJJBCUJZFPR-UHFFFAOYSA-N n-[2-[2-[2-(4-chlorophenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(Cl)=CC=3)C2=C1 WNLGJJBCUJZFPR-UHFFFAOYSA-N 0.000 description 3
- SVDGQYGWKGTDNK-UHFFFAOYSA-N n-[2-[2-[2-(4-chlorophenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(Cl)=CC=3)C2=C1 SVDGQYGWKGTDNK-UHFFFAOYSA-N 0.000 description 3
- GJIYJXVKRXZWIJ-UHFFFAOYSA-N n-[2-[2-[2-(4-chlorophenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(Cl)=CC=3)C2=C1 GJIYJXVKRXZWIJ-UHFFFAOYSA-N 0.000 description 3
- RBMBEBJBHYEONL-UHFFFAOYSA-N n-[2-[2-[2-(4-methylsulfonylphenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)S(C)(=O)=O)C2=C1 RBMBEBJBHYEONL-UHFFFAOYSA-N 0.000 description 3
- QWTMSIQPQYKPCM-UHFFFAOYSA-N n-[2-[2-[2-(4-methylsulfonylphenyl)ethynyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(=CC=3)S(C)(=O)=O)C2=C1 QWTMSIQPQYKPCM-UHFFFAOYSA-N 0.000 description 3
- MNLWZERKNXWUCA-UHFFFAOYSA-N n-[2-[2-[2-[3-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=C(C=CC=3)C(F)(F)F)C2=C1 MNLWZERKNXWUCA-UHFFFAOYSA-N 0.000 description 3
- LIDKYJQJNBZHJF-UHFFFAOYSA-N n-[2-[2-[2-[3-(trifluoromethyl)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=C(C=CC=3)C(F)(F)F)C2=C1 LIDKYJQJNBZHJF-UHFFFAOYSA-N 0.000 description 3
- GSRQCYJNLYIEJA-UHFFFAOYSA-N n-[2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=3)C2=C1 GSRQCYJNLYIEJA-UHFFFAOYSA-N 0.000 description 3
- AGLHFKOSDOENKW-UHFFFAOYSA-N n-[2-[2-[2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=3)C2=C1 AGLHFKOSDOENKW-UHFFFAOYSA-N 0.000 description 3
- UZPZTIVSWZVIKQ-UHFFFAOYSA-N n-[2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OCC(F)(F)F)=CC=3)C2=C1 UZPZTIVSWZVIKQ-UHFFFAOYSA-N 0.000 description 3
- CROAGQHUIIMQNJ-UHFFFAOYSA-N n-[2-[2-[2-[4-(2,2,2-trifluoroethoxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OCC(F)(F)F)=CC=3)C2=C1 CROAGQHUIIMQNJ-UHFFFAOYSA-N 0.000 description 3
- ZPRFKHREUOQFMS-UHFFFAOYSA-N n-[2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(OCC(F)(F)C(F)(F)F)=CC=3)C2=C1 ZPRFKHREUOQFMS-UHFFFAOYSA-N 0.000 description 3
- ZTOKSXVCSJWSHD-UHFFFAOYSA-N n-[2-[2-[2-[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]ethynyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(OCC(F)(F)C(F)(F)F)=CC=3)C2=C1 ZTOKSXVCSJWSHD-UHFFFAOYSA-N 0.000 description 3
- PHTNJRXLQGCEEX-NTEUORMPSA-N n-[2-[3-methyl-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound N=1C2=CC=C(C=3C(=CC=CC=3)NS(C)(=O)=O)C=C2N(C)C=1\C=C\C1=CC=C(C(F)(F)F)C=C1 PHTNJRXLQGCEEX-NTEUORMPSA-N 0.000 description 3
- OYKYBXWFGZCBSB-DHZHZOJOSA-N n-[2-[6-fluoro-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C(C(=C1)F)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(F)(F)F)=N2 OYKYBXWFGZCBSB-DHZHZOJOSA-N 0.000 description 3
- MXCUZTMIIRDRMO-DHZHZOJOSA-N n-[2-[6-fluoro-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C(C(=C1)F)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(F)(F)F)=N2 MXCUZTMIIRDRMO-DHZHZOJOSA-N 0.000 description 3
- MDVPNGHBAZWNGY-UXBLZVDNSA-N n-[3-[2-[(e)-2-(3,4-difluorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2C=C3N=C(\C=C\C=4C=C(F)C(F)=CC=4)NC3=CC=2)=C1 MDVPNGHBAZWNGY-UXBLZVDNSA-N 0.000 description 3
- QSVRVRXVCUVLFA-MDWZMJQESA-N n-[4-[(e)-2-[6-(2-acetylphenyl)-1h-benzimidazol-2-yl]ethenyl]phenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(NS(=O)(=O)C(F)(F)F)=CC=2)=N2)C2=C1 QSVRVRXVCUVLFA-MDWZMJQESA-N 0.000 description 3
- PRSWWABXYGINLV-NTEUORMPSA-N n-[4-[(e)-2-[6-(2-acetylphenyl)-1h-benzimidazol-2-yl]ethenyl]phenyl]methanesulfonamide Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(NS(C)(=O)=O)=CC=2)=N2)C2=C1 PRSWWABXYGINLV-NTEUORMPSA-N 0.000 description 3
- KTSVYQDKJCKWFA-NTEUORMPSA-N n-[4-[(e)-2-[6-[2-(1-hydroxyethyl)phenyl]-1h-benzimidazol-2-yl]ethenyl]phenyl]methanesulfonamide Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(NS(C)(=O)=O)=CC=2)=N2)C2=C1 KTSVYQDKJCKWFA-NTEUORMPSA-N 0.000 description 3
- XKRVJLLPBQQLJC-XNTDXEJSSA-N n-[4-[(e)-2-[6-[2-(2-hydroxypropan-2-yl)phenyl]-1h-benzimidazol-2-yl]ethenyl]phenyl]methanesulfonamide Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(NS(C)(=O)=O)=CC=2)=N2)C2=C1 XKRVJLLPBQQLJC-XNTDXEJSSA-N 0.000 description 3
- SHPQNTMGTDLNPP-NTEUORMPSA-N n-[4-[(e)-2-[6-[2-(methanesulfonamido)phenyl]-1h-benzimidazol-2-yl]ethenyl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(C)(=O)=O)=CC=C2N1 SHPQNTMGTDLNPP-NTEUORMPSA-N 0.000 description 3
- BFDYBTWXSCBKFM-NTEUORMPSA-N n-[4-[(e)-2-[6-[2-(methylsulfamoyl)phenyl]-1h-benzimidazol-2-yl]ethenyl]phenyl]acetamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(NC(C)=O)=CC=2)=N2)C2=C1 BFDYBTWXSCBKFM-NTEUORMPSA-N 0.000 description 3
- CLJKPPFPTNVVAQ-FRKPEAEDSA-N n-[4-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(C)(C)C)=N2)C2=C1 CLJKPPFPTNVVAQ-FRKPEAEDSA-N 0.000 description 3
- RCUHGDMDEJFUSW-UHFFFAOYSA-N n-[4-[2-[6-(2-acetylphenyl)-1h-benzimidazol-2-yl]cyclopropyl]phenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(NS(=O)(=O)C(F)(F)F)=CC=3)C2=C1 RCUHGDMDEJFUSW-UHFFFAOYSA-N 0.000 description 3
- IPBWYMMTXXMDOM-UHFFFAOYSA-N n-[4-[2-[6-(2-acetylphenyl)-1h-benzimidazol-2-yl]cyclopropyl]phenyl]methanesulfonamide Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(NS(C)(=O)=O)=CC=3)C2=C1 IPBWYMMTXXMDOM-UHFFFAOYSA-N 0.000 description 3
- MHENKQYSTVYVRH-UHFFFAOYSA-N n-[4-[2-[6-(2-acetylphenyl)-1h-benzimidazol-2-yl]ethynyl]phenyl]-1,1,1-trifluoromethanesulfonamide Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(NS(=O)(=O)C(F)(F)F)=CC=3)C2=C1 MHENKQYSTVYVRH-UHFFFAOYSA-N 0.000 description 3
- YTWGCMYSQJNMMQ-UHFFFAOYSA-N n-[4-[2-[6-(2-acetylphenyl)-1h-benzimidazol-2-yl]ethynyl]phenyl]methanesulfonamide Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(NS(C)(=O)=O)=CC=3)C2=C1 YTWGCMYSQJNMMQ-UHFFFAOYSA-N 0.000 description 3
- HHTROHMGHNGCTJ-UHFFFAOYSA-N n-[4-[2-[6-[2-(1-hydroxyethyl)phenyl]-1h-benzimidazol-2-yl]cyclopropyl]phenyl]methanesulfonamide Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(NS(C)(=O)=O)=CC=3)C2=C1 HHTROHMGHNGCTJ-UHFFFAOYSA-N 0.000 description 3
- BAVMNGAPAPNOKD-UHFFFAOYSA-N n-[4-[2-[6-[2-(1-hydroxyethyl)phenyl]-1h-benzimidazol-2-yl]ethynyl]phenyl]methanesulfonamide Chemical compound CC(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(NS(C)(=O)=O)=CC=3)C2=C1 BAVMNGAPAPNOKD-UHFFFAOYSA-N 0.000 description 3
- DZZQHJACOYHCPI-UHFFFAOYSA-N n-[4-[2-[6-[2-(2-hydroxypropan-2-yl)phenyl]-1h-benzimidazol-2-yl]cyclopropyl]phenyl]methanesulfonamide Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(NS(C)(=O)=O)=CC=3)C2=C1 DZZQHJACOYHCPI-UHFFFAOYSA-N 0.000 description 3
- WJEIBHZBFCKZDW-UHFFFAOYSA-N n-[4-[2-[6-[2-(2-hydroxypropan-2-yl)phenyl]-1h-benzimidazol-2-yl]ethynyl]phenyl]methanesulfonamide Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(=N2)C#CC=3C=CC(NS(C)(=O)=O)=CC=3)C2=C1 WJEIBHZBFCKZDW-UHFFFAOYSA-N 0.000 description 3
- GEGQKKUGOWZKTO-UHFFFAOYSA-N n-[4-[2-[6-[2-(methanesulfonamido)phenyl]-1h-benzimidazol-2-yl]cyclopropyl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1C1C(C=2NC3=CC=C(C=C3N=2)C=2C(=CC=CC=2)NS(C)(=O)=O)C1 GEGQKKUGOWZKTO-UHFFFAOYSA-N 0.000 description 3
- INTXSKWYOZHJFZ-MDWZMJQESA-N n-methyl-1-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanamine Chemical compound CNCC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 INTXSKWYOZHJFZ-MDWZMJQESA-N 0.000 description 3
- JRVSZRCAYXVZIA-NTEUORMPSA-N n-methyl-2-[2-[(e)-2-(4-methylsulfonylphenyl)ethenyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)S(C)(=O)=O)=N2)C2=C1 JRVSZRCAYXVZIA-NTEUORMPSA-N 0.000 description 3
- WIRAOFWRVYIVNI-UHFFFAOYSA-N n-tert-butyl-2-[2-[2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 WIRAOFWRVYIVNI-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 239000001294 propane Substances 0.000 description 3
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical class OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- ZEDNOLUBKUPAKN-DTQAZKPQSA-N tert-butyl n-[2-[2-[(e)-2-(4-tert-butylphenyl)ethenyl]-6-(trifluoromethyl)-1h-benzimidazol-5-yl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1C(C(=C1)C(F)(F)F)=CC2=C1NC(\C=C\C=1C=CC(=CC=1)C(C)(C)C)=N2 ZEDNOLUBKUPAKN-DTQAZKPQSA-N 0.000 description 3
- MNJUIBCQFMZAFO-XNTDXEJSSA-N tert-butyl n-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 MNJUIBCQFMZAFO-XNTDXEJSSA-N 0.000 description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 3
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 3
- 238000003828 vacuum filtration Methods 0.000 description 3
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 2
- UMOPBIVXPOETPG-UHFFFAOYSA-N (2-acetamidophenyl)boronic acid Chemical compound CC(=O)NC1=CC=CC=C1B(O)O UMOPBIVXPOETPG-UHFFFAOYSA-N 0.000 description 2
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 2
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 2
- AEVBPXDFDKBGLT-YOUFYPILSA-N (2s,3s,4r,5r)-n-[2-[4-(diethoxyphosphorylmethyl)anilino]-2-oxoethyl]-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolane-2-carboxamide Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1NC(=O)CNC(=O)[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 AEVBPXDFDKBGLT-YOUFYPILSA-N 0.000 description 2
- TWYYFYNJOJGNFP-CUXYNZQBSA-N (2s,4r,5s,6s)-2-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-2-carbamoyl-4-[[(e,4s,6s)-4,6-dimethyloct-2-enoyl]oxymethyl]-5-hydroxy-1,3-dioxane-4,5,6-tricarboxylic acid Chemical compound O1[C@H](C(O)=O)[C@](C(O)=O)(O)[C@](COC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)(C(O)=O)O[C@]1(C(N)=O)CCC(=C)[C@@H](OC(C)=O)[C@H](C)CC1=CC=CC=C1 TWYYFYNJOJGNFP-CUXYNZQBSA-N 0.000 description 2
- RLNBLYOTPVWMEI-UHFFFAOYSA-N (3-amino-2-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=C(N)C=CC=C1B(O)O RLNBLYOTPVWMEI-UHFFFAOYSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- LVUPPUBMFPJXLP-MDWZMJQESA-N 1,1,1-trifluoro-n-[2-[2-[(e)-2-(4-methylsulfonylphenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)NS(=O)(=O)C(F)(F)F)=CC=C2N1 LVUPPUBMFPJXLP-MDWZMJQESA-N 0.000 description 2
- DHYUUMACGLDIMG-MDWZMJQESA-N 1-[2-[2-[(e)-2-[4-(trifluoromethoxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OC(F)(F)F)=CC=2)=N2)C2=C1 DHYUUMACGLDIMG-MDWZMJQESA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 description 2
- ANRMAUMHJREENI-UHFFFAOYSA-N 3-[4-(trifluoromethyl)phenyl]prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=C(C(F)(F)F)C=C1 ANRMAUMHJREENI-UHFFFAOYSA-N 0.000 description 2
- KTFKRVMXIVSARW-UHFFFAOYSA-N 4-acetylbenzaldehyde Chemical compound CC(=O)C1=CC=C(C=O)C=C1 KTFKRVMXIVSARW-UHFFFAOYSA-N 0.000 description 2
- IEIQKCTUUPDVMG-UHFFFAOYSA-N 4-bromobenzene-1,2-diamine;dihydrochloride Chemical compound Cl.Cl.NC1=CC=C(Br)C=C1N IEIQKCTUUPDVMG-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 2
- FCBOUJYKAGWYQM-DEOSSOPVSA-N 6-[[(2s)-1-hydroxy-3-phenylpropan-2-yl]amino]-n-(2-phenoxyethyl)-2-(3,4,5-trimethoxyphenyl)pyridine-3-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=C(N[C@H](CO)CC=3C=CC=CC=3)N=2)C(=O)NCCOC=2C=CC=CC=2)=C1 FCBOUJYKAGWYQM-DEOSSOPVSA-N 0.000 description 2
- XYMVRDSWTGTUDJ-UHFFFAOYSA-N 6-bromo-2-[3-(4-tert-butylphenyl)propyl]-1h-benzimidazole Chemical compound C1=CC(C(C)(C)C)=CC=C1CCCC1=NC2=CC(Br)=CC=C2N1 XYMVRDSWTGTUDJ-UHFFFAOYSA-N 0.000 description 2
- TYYCNSUODPEVQP-UHFFFAOYSA-N 8-[(4-fluorophenyl)sulfonylamino]-4-(3-pyridin-3-ylpropyl)octanoic acid Chemical compound C=1C=CN=CC=1CCCC(CCC(=O)O)CCCCNS(=O)(=O)C1=CC=C(F)C=C1 TYYCNSUODPEVQP-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- XMMDPQMPTUNIAX-UHFFFAOYSA-N OBO.NC(=O)C1=CC=CC=C1 Chemical compound OBO.NC(=O)C1=CC=CC=C1 XMMDPQMPTUNIAX-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229910020008 S(O) Inorganic materials 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical class ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 229940127206 compound 14d Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- HWWVAHCWJLGKLW-UHFFFAOYSA-N n,n-dimethylhydroxylamine;hydron;chloride Chemical compound Cl.CN(C)O HWWVAHCWJLGKLW-UHFFFAOYSA-N 0.000 description 2
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 2
- FTLANOKZIXLBML-UHFFFAOYSA-N n-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1B1OC(C)(C)C(C)(C)O1 FTLANOKZIXLBML-UHFFFAOYSA-N 0.000 description 2
- VPMUMQNNLKURIA-FMIVXFBMSA-N n-[2-[2-[(e)-2-(3-chlorophenyl)ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=C(Cl)C=CC=2)=N2)C2=C1 VPMUMQNNLKURIA-FMIVXFBMSA-N 0.000 description 2
- YMWPZVZIGPOTKY-MDWZMJQESA-N n-[2-[2-[(e)-2-[4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(OC(C(F)(F)F)C(F)(F)F)=CC=2)=N2)C2=C1 YMWPZVZIGPOTKY-MDWZMJQESA-N 0.000 description 2
- NWAJSWMHBNTFTE-UHFFFAOYSA-N n-[2-[2-[2-(3-chlorophenyl)cyclopropyl]-3h-benzimidazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=C(Cl)C=CC=3)C2=C1 NWAJSWMHBNTFTE-UHFFFAOYSA-N 0.000 description 2
- DOIQILBKJNWXQO-UHFFFAOYSA-N n-[4-[2-[6-[2-(methanesulfonamido)phenyl]-1h-benzimidazol-2-yl]ethynyl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1C#CC1=NC2=CC(C=3C(=CC=CC=3)NS(C)(=O)=O)=CC=C2N1 DOIQILBKJNWXQO-UHFFFAOYSA-N 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 210000001044 sensory neuron Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 230000006103 sulfonylation Effects 0.000 description 2
- 238000005694 sulfonylation reaction Methods 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- QMHYKBFONNVRDR-UHFFFAOYSA-N tert-butyl n-[2-[2-[2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1C1=CC=C(NC(=N2)C3C(C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 QMHYKBFONNVRDR-UHFFFAOYSA-N 0.000 description 2
- 230000008542 thermal sensitivity Effects 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 2
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- 208000009935 visceral pain Diseases 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- ICZHJFWIOPYQCA-OAHLLOKOSA-N (1r)-1-anthracen-9-yl-2,2,2-trifluoroethanol Chemical compound C1=CC=C2C([C@@H](O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 ICZHJFWIOPYQCA-OAHLLOKOSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- UKRIUIRBTVRYAH-RKDXNWHRSA-N (1r,2s)-2-[4-(trifluoromethyl)phenyl]cyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@@H]1C[C@@H]1C1=CC=C(C(F)(F)F)C=C1 UKRIUIRBTVRYAH-RKDXNWHRSA-N 0.000 description 1
- UKRIUIRBTVRYAH-IUCAKERBSA-N (1s,2r)-2-[4-(trifluoromethyl)phenyl]cyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@H]1C1=CC=C(C(F)(F)F)C=C1 UKRIUIRBTVRYAH-IUCAKERBSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- NPLZNDDFVCGRAG-UHFFFAOYSA-N (2-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1C#N NPLZNDDFVCGRAG-UHFFFAOYSA-N 0.000 description 1
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
- MSQFFCRGQPVQRS-UHFFFAOYSA-N (2-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1B(O)O MSQFFCRGQPVQRS-UHFFFAOYSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- WDGWHKRJEBENCE-UHFFFAOYSA-N (3-carbamoylphenyl)boronic acid Chemical compound NC(=O)C1=CC=CC(B(O)O)=C1 WDGWHKRJEBENCE-UHFFFAOYSA-N 0.000 description 1
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- DPMGLJUMNRDNMX-RYUDHWBXSA-N (4r)-4-tert-butyl-2-[2-[(4r)-4-tert-butyl-4,5-dihydro-1,3-oxazol-2-yl]propan-2-yl]-4,5-dihydro-1,3-oxazole Chemical compound CC(C)(C)[C@@H]1COC(C(C)(C)C=2OC[C@H](N=2)C(C)(C)C)=N1 DPMGLJUMNRDNMX-RYUDHWBXSA-N 0.000 description 1
- DPMGLJUMNRDNMX-VXGBXAGGSA-N (4s)-4-tert-butyl-2-[2-[(4s)-4-tert-butyl-4,5-dihydro-1,3-oxazol-2-yl]propan-2-yl]-4,5-dihydro-1,3-oxazole Chemical compound CC(C)(C)[C@H]1COC(C(C)(C)C=2OC[C@@H](N=2)C(C)(C)C)=N1 DPMGLJUMNRDNMX-VXGBXAGGSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
- ANRMAUMHJREENI-ZZXKWVIFSA-N (E)-4-(trifluoromethyl)cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=C(C(F)(F)F)C=C1 ANRMAUMHJREENI-ZZXKWVIFSA-N 0.000 description 1
- QFSPZKLJQZSLQU-RMKNXTFCSA-N (e)-3-(4-tert-butylphenyl)prop-2-enoic acid Chemical compound CC(C)(C)C1=CC=C(\C=C\C(O)=O)C=C1 QFSPZKLJQZSLQU-RMKNXTFCSA-N 0.000 description 1
- AEZGJMFJYFQDOO-ZZXKWVIFSA-N (e)-3-[4-(trifluoromethylsulfonyl)phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 AEZGJMFJYFQDOO-ZZXKWVIFSA-N 0.000 description 1
- XLYMOEINVGRTEX-ONEGZZNKSA-N (e)-4-ethoxy-4-oxobut-2-enoic acid Chemical compound CCOC(=O)\C=C\C(O)=O XLYMOEINVGRTEX-ONEGZZNKSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- OPCMVVKRCLOEDQ-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(methylamino)pentan-1-one Chemical compound ClC1=CC=C(C=C1)C(C(CCC)NC)=O OPCMVVKRCLOEDQ-UHFFFAOYSA-N 0.000 description 1
- SZCBDIVMCGFVPW-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 SZCBDIVMCGFVPW-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- XTKBMZQCDBHHKY-UHFFFAOYSA-N 1-ethynyl-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(C#C)C=C1 XTKBMZQCDBHHKY-UHFFFAOYSA-N 0.000 description 1
- ROGUAPYLUCHQGK-UHFFFAOYSA-N 1-piperazinecarboxamide, 4-(3-chloro-2-pyridinyl)-n-[4-(1,1-dimethylethyl)phenyl]- Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)N1CCN(C=2C(=CC=CN=2)Cl)CC1 ROGUAPYLUCHQGK-UHFFFAOYSA-N 0.000 description 1
- VSPBWOAEHQDXRD-UHFFFAOYSA-N 1h-indole-6-carbaldehyde Chemical compound O=CC1=CC=C2C=CNC2=C1 VSPBWOAEHQDXRD-UHFFFAOYSA-N 0.000 description 1
- WSUYAJLYJNJPES-UHFFFAOYSA-N 2,2,2-trifluoro-1-(1h-imidazol-2-yl)ethanone Chemical compound FC(F)(F)C(=O)C1=NC=CN1 WSUYAJLYJNJPES-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- DLRCWXOCZIUZBS-UHFFFAOYSA-N 2,4-bis(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C(C(F)(F)F)=C1 DLRCWXOCZIUZBS-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- HZNHHKQUAUGNCF-UHFFFAOYSA-N 2-(2-chloroethenyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(C=CCl)=NC2=C1 HZNHHKQUAUGNCF-UHFFFAOYSA-N 0.000 description 1
- 125000000301 2-(3-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- SPMLMLQATWNZEE-UHFFFAOYSA-N 2-(chloromethyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(CCl)=NC2=C1 SPMLMLQATWNZEE-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- DQHLNZJWVWEPMZ-KPKJPENVSA-N 2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]benzonitrile Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC2=CC(C=3C(=CC=CC=3)C#N)=CC=C2N1 DQHLNZJWVWEPMZ-KPKJPENVSA-N 0.000 description 1
- GLUIJLZSKCANJZ-KYIGKLDSSA-N 2-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol;hydrochloride Chemical compound Cl.CC(C)(O)C1=CC=CC=C1C1=CC=C(NC(\C=C\C=2C=CC(=CC=2)C(F)(F)F)=N2)C2=C1 GLUIJLZSKCANJZ-KYIGKLDSSA-N 0.000 description 1
- QYYDJAGVSAXHEC-UHFFFAOYSA-N 2-[2-[2-[2-(trifluoromethyl)phenyl]ethyl]-3h-benzimidazol-5-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C(NC(CCC=2C(=CC=CC=2)C(F)(F)F)=N2)C2=C1 QYYDJAGVSAXHEC-UHFFFAOYSA-N 0.000 description 1
- JUQMRSYCLKEWAV-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC(C(F)(F)F)=C1 JUQMRSYCLKEWAV-UHFFFAOYSA-N 0.000 description 1
- RSLAPCSAZMQDSO-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]propanoic acid Chemical compound OC(=O)C(C)C1=CC=C(C(F)(F)F)C=C1 RSLAPCSAZMQDSO-UHFFFAOYSA-N 0.000 description 1
- WWIDKIQGWWRDSV-UHFFFAOYSA-N 2-phenyl-n-[2-(trifluoromethyl)phenyl]quinoline-4-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1NC(=O)C1=CC(C=2C=CC=CC=2)=NC2=CC=CC=C12 WWIDKIQGWWRDSV-UHFFFAOYSA-N 0.000 description 1
- JZIBVTUXIVIFGC-UHFFFAOYSA-N 2H-pyrrole Chemical compound C1C=CC=N1 JZIBVTUXIVIFGC-UHFFFAOYSA-N 0.000 description 1
- UUKWKUSGGZNXGA-UHFFFAOYSA-N 3,5-dinitrobenzamide Chemical compound NC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UUKWKUSGGZNXGA-UHFFFAOYSA-N 0.000 description 1
- VGOALPIDEXVYQI-UHFFFAOYSA-N 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-n-[3-imidazol-1-yl-5-(trifluoromethyl)phenyl]-4-methylbenzamide Chemical compound C1=C(C#CC=2N3N=CC=CC3=NC=2)C(C)=CC=C1C(=O)NC(C=C(C=1)C(F)(F)F)=CC=1N1C=CN=C1 VGOALPIDEXVYQI-UHFFFAOYSA-N 0.000 description 1
- RNYVTJANWYBGPW-UHFFFAOYSA-N 3-[4-(trifluoromethoxy)phenyl]prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=C(OC(F)(F)F)C=C1 RNYVTJANWYBGPW-UHFFFAOYSA-N 0.000 description 1
- XOCLMGDPIQZXDW-UHFFFAOYSA-N 3-[4-(trifluoromethyl)phenyl]prop-2-ynoic acid Chemical compound OC(=O)C#CC1=CC=C(C(F)(F)F)C=C1 XOCLMGDPIQZXDW-UHFFFAOYSA-N 0.000 description 1
- OEIUMLSCWINLBB-UHFFFAOYSA-N 3-[4-(trifluoromethyl)phenyl]propanoic acid Chemical compound OC(=O)CCC1=CC=C(C(F)(F)F)C=C1 OEIUMLSCWINLBB-UHFFFAOYSA-N 0.000 description 1
- UNSHMXUHOHBLIQ-UHFFFAOYSA-N 3-[4-chloro-3-(2-methylphenoxy)naphthalen-1-yl]-6-(trifluoromethyl)-1H-pyrimidine-2,4-dione Chemical compound ClC1=C(C=C(C2=CC=CC=C12)N1C(NC(=CC1=O)C(F)(F)F)=O)OC1=C(C=CC=C1)C UNSHMXUHOHBLIQ-UHFFFAOYSA-N 0.000 description 1
- HSRUZXHIEFFBHR-UHFFFAOYSA-N 3-amino-2-(3-amino-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(N)C(OC)=CC=C1C1=C(N)C(=O)C2=CC=CC=C2O1 HSRUZXHIEFFBHR-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- MDPZCXXNCSUROL-UHFFFAOYSA-N 4-(4-tert-butylphenyl)butanoic acid Chemical compound CC(C)(C)C1=CC=C(CCCC(O)=O)C=C1 MDPZCXXNCSUROL-UHFFFAOYSA-N 0.000 description 1
- XQNVDQZWOBPLQZ-UHFFFAOYSA-N 4-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC=C(C=O)C=C1 XQNVDQZWOBPLQZ-UHFFFAOYSA-N 0.000 description 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
- OPAXHVNZGUGCKW-UHFFFAOYSA-N 4-(trifluoromethylsulfanyl)benzaldehyde Chemical compound FC(F)(F)SC1=CC=C(C=O)C=C1 OPAXHVNZGUGCKW-UHFFFAOYSA-N 0.000 description 1
- SKLUWKYNZNXSLX-UHFFFAOYSA-N 4-Acetamidobenzaldehyde Chemical compound CC(=O)NC1=CC=C(C=O)C=C1 SKLUWKYNZNXSLX-UHFFFAOYSA-N 0.000 description 1
- JOFDSYLCZIHGGO-UHFFFAOYSA-N 4-[(4-cyclohexylphenyl)methyl-[2-[[5-(dimethylamino)naphthalen-1-yl]sulfonyl-methylamino]acetyl]amino]-2-hydroxybenzoic acid Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N(C)CC(=O)N(C=1C=C(O)C(C(O)=O)=CC=1)CC(C=C1)=CC=C1C1CCCCC1 JOFDSYLCZIHGGO-UHFFFAOYSA-N 0.000 description 1
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- OSVHVZRABGZBJD-UHFFFAOYSA-N 4-bromo-3-(chloromethyl)aniline Chemical compound NC1=CC=C(Br)C(CCl)=C1 OSVHVZRABGZBJD-UHFFFAOYSA-N 0.000 description 1
- AMZPDVWUYAHFPQ-UHFFFAOYSA-N 4-bromo-3-(fluoromethyl)aniline Chemical compound NC1=CC=C(Br)C(CF)=C1 AMZPDVWUYAHFPQ-UHFFFAOYSA-N 0.000 description 1
- YGNISOAUPSJDJE-UHFFFAOYSA-N 4-bromo-3-(trifluoromethyl)aniline Chemical compound NC1=CC=C(Br)C(C(F)(F)F)=C1 YGNISOAUPSJDJE-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-IDEBNGHGSA-N 4-bromoaniline Chemical class N[13C]1=[13CH][13CH]=[13C](Br)[13CH]=[13CH]1 WDFQBORIUYODSI-IDEBNGHGSA-N 0.000 description 1
- WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- UXMNWWDNJUISFR-RUDMXATFSA-N 5-bromo-1-methyl-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]benzimidazole Chemical compound N=1C2=CC(Br)=CC=C2N(C)C=1\C=C\C1=CC=C(C(F)(F)F)C=C1 UXMNWWDNJUISFR-RUDMXATFSA-N 0.000 description 1
- LLERNHXGEVKNJV-ZZXKWVIFSA-N 5-bromo-6-(trifluoromethyl)-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazole Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC2=CC(Br)=C(C(F)(F)F)C=C2N1 LLERNHXGEVKNJV-ZZXKWVIFSA-N 0.000 description 1
- CFGFDCFMKDVSLN-RUDMXATFSA-N 6-bromo-1-methyl-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]benzimidazole Chemical compound N=1C2=CC=C(Br)C=C2N(C)C=1\C=C\C1=CC=C(C(F)(F)F)C=C1 CFGFDCFMKDVSLN-RUDMXATFSA-N 0.000 description 1
- OWLMBJLZMJBNQJ-UHFFFAOYSA-N 6-bromo-2-(chloromethyl)-1h-benzimidazole Chemical compound C1=C(Br)C=C2NC(CCl)=NC2=C1 OWLMBJLZMJBNQJ-UHFFFAOYSA-N 0.000 description 1
- SOMKSZDOISRODR-QHHAFSJGSA-N 6-bromo-2-[(e)-2-(3,4-difluorophenyl)ethenyl]-1h-benzimidazole Chemical compound C1=C(F)C(F)=CC=C1\C=C\C1=NC2=CC=C(Br)C=C2N1 SOMKSZDOISRODR-QHHAFSJGSA-N 0.000 description 1
- JWGPMLBFHXFLGP-IZZDOVSWSA-N 6-bromo-2-[(e)-2-(4-tert-butylphenyl)ethenyl]-1h-benzimidazole Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=C\C1=NC2=CC(Br)=CC=C2N1 JWGPMLBFHXFLGP-IZZDOVSWSA-N 0.000 description 1
- USEUBUGAEKZGDP-FPYGCLRLSA-N 6-bromo-2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1h-benzimidazole Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC2=CC(Br)=CC=C2N1 USEUBUGAEKZGDP-FPYGCLRLSA-N 0.000 description 1
- JJIGBYFYUBAHRU-FMIVXFBMSA-N 6-bromo-2-[(e)-2-chloro-2-phenylethenyl]-1h-benzimidazole Chemical compound N=1C2=CC(Br)=CC=C2NC=1/C=C(/Cl)C1=CC=CC=C1 JJIGBYFYUBAHRU-FMIVXFBMSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- DNJOGORYAIRDIN-UHFFFAOYSA-N B(O)O.CC=1C=C(C=CC1)C1=CC=CC=C1 Chemical compound B(O)O.CC=1C=C(C=CC1)C1=CC=CC=C1 DNJOGORYAIRDIN-UHFFFAOYSA-N 0.000 description 1
- MVAVQVXBQFNEMU-UHFFFAOYSA-N BB(B)B.BBB.O=C=O.[H]CCC Chemical compound BB(B)B.BBB.O=C=O.[H]CCC MVAVQVXBQFNEMU-UHFFFAOYSA-N 0.000 description 1
- HAABYCMNZURFRR-UHFFFAOYSA-N BB.BBB.C=C=COOCC.CCOC.O=C=O.[H]/C=C/CC Chemical compound BB.BBB.C=C=COOCC.CCOC.O=C=O.[H]/C=C/CC HAABYCMNZURFRR-UHFFFAOYSA-N 0.000 description 1
- MXJMQKMQWUNYNO-UHFFFAOYSA-N BB.BBB.CCOC.O=C(O)CC(=O)O.O=C=O.[H]/C=C/CC Chemical compound BB.BBB.CCOC.O=C(O)CC(=O)O.O=C=O.[H]/C=C/CC MXJMQKMQWUNYNO-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006429 Bronchial conditions Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- CJVVHPCHYRQSTJ-UHFFFAOYSA-N C#C.C#CC.CC.CC.NC1=CC=C(Br)C=C1.O=C(NC1=CC=C(Br)C=C1[N+](=O)[O-])C(F)(F)F.O=C(OC(=O)C(F)(F)F)C(F)(F)F Chemical compound C#C.C#CC.CC.CC.NC1=CC=C(Br)C=C1.O=C(NC1=CC=C(Br)C=C1[N+](=O)[O-])C(F)(F)F.O=C(OC(=O)C(F)(F)F)C(F)(F)F CJVVHPCHYRQSTJ-UHFFFAOYSA-N 0.000 description 1
- AHYDDDHYSGDGRD-UHFFFAOYSA-N C#CC.CC.CC#CC.NC1=CC=C(Br)C=C1N Chemical compound C#CC.CC.CC#CC.NC1=CC=C(Br)C=C1N AHYDDDHYSGDGRD-UHFFFAOYSA-N 0.000 description 1
- SRFDWDXDIHLXTR-BPNXKZDGSA-O C.C.C.CC/C=C/C(=O)N(C)CO.CCC1CC1C(=O)N(C)CO.CNOC.CS(C)(C)(=[OH+])[IH-].O=C(Cl)C(=O)Cl.O=C=O.O=C=O.[H]/C=C/CC.[H]C1CC1CC Chemical compound C.C.C.CC/C=C/C(=O)N(C)CO.CCC1CC1C(=O)N(C)CO.CNOC.CS(C)(C)(=[OH+])[IH-].O=C(Cl)C(=O)Cl.O=C=O.O=C=O.[H]/C=C/CC.[H]C1CC1CC SRFDWDXDIHLXTR-BPNXKZDGSA-O 0.000 description 1
- MUMAQYGBXDZQGY-XPUYHENFSA-N C/C=C(/C=C/c1cccc(C(F)(F)F)c1)\Nc(cc1)c(C)cc1-c1c(C(N)OC=[ClH])cccc1 Chemical compound C/C=C(/C=C/c1cccc(C(F)(F)F)c1)\Nc(cc1)c(C)cc1-c1c(C(N)OC=[ClH])cccc1 MUMAQYGBXDZQGY-XPUYHENFSA-N 0.000 description 1
- GKZMBTGCDHOMDT-ZBIQKBCZSA-N C/C=C(/C=C/c1cccc(F)c1F)\Nc(cc1)c(C)cc1-c1ccccc1S(N)(=N)=O Chemical compound C/C=C(/C=C/c1cccc(F)c1F)\Nc(cc1)c(C)cc1-c1ccccc1S(N)(=N)=O GKZMBTGCDHOMDT-ZBIQKBCZSA-N 0.000 description 1
- ZDKSIEQOXBBMKD-IGLQUIOVSA-N C/C=C(/CCc(cc1)ccc1NS(C)(=O)=O)\Nc(cc1)c(C)cc1-c(cccc1)c1S(N)(=O)=O Chemical compound C/C=C(/CCc(cc1)ccc1NS(C)(=O)=O)\Nc(cc1)c(C)cc1-c(cccc1)c1S(N)(=O)=O ZDKSIEQOXBBMKD-IGLQUIOVSA-N 0.000 description 1
- KXTNRJBNMVMUAD-GGDCSFEBSA-N C/C=C/C1=NC2=CC(C3=CC=CC=C3)=CC=C2N1.CC.CC.N=N.[N-]=[N+]=N Chemical compound C/C=C/C1=NC2=CC(C3=CC=CC=C3)=CC=C2N1.CC.CC.N=N.[N-]=[N+]=N KXTNRJBNMVMUAD-GGDCSFEBSA-N 0.000 description 1
- XGEPWXGCWVBQBR-QFSIETRKSA-N C=CCC.CCC(=O)/N=N/C=O.CC[C@@H]1C[C@H]1CC.O=C=O.O=C=O.PP.PP(P)P.PPP.[H]C1C[C@H]1CC Chemical compound C=CCC.CCC(=O)/N=N/C=O.CC[C@@H]1C[C@H]1CC.O=C=O.O=C=O.PP.PP(P)P.PPP.[H]C1C[C@H]1CC XGEPWXGCWVBQBR-QFSIETRKSA-N 0.000 description 1
- ZESKFIUGVAEIRC-KFNRSYHASA-N CC(=O)C1=C(C2=C(C(F)(F)F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.OC1=C(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.OCC1=C(C2=C(C(F)(F)F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 Chemical compound CC(=O)C1=C(C2=C(C(F)(F)F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.OC1=C(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.OCC1=C(C2=C(C(F)(F)F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 ZESKFIUGVAEIRC-KFNRSYHASA-N 0.000 description 1
- IUJAGPGJHHOVID-KFNRSYHASA-N CC(=O)C1=C(C2=C(Cl)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.OC1=C(C2=C(Cl)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.OCC1=C(C2=C(Cl)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 Chemical compound CC(=O)C1=C(C2=C(Cl)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.OC1=C(C2=C(Cl)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.OCC1=C(C2=C(Cl)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 IUJAGPGJHHOVID-KFNRSYHASA-N 0.000 description 1
- RIKBYGVVHNKMMI-FMGMAQPSSA-N CC(=O)C1=C(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.OC1=CC=CC(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)=C1.OCC1=C(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 Chemical compound CC(=O)C1=C(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.OC1=CC=CC(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)=C1.OCC1=C(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 RIKBYGVVHNKMMI-FMGMAQPSSA-N 0.000 description 1
- LUKDIRGSTRENOZ-WXVXHBNASA-N CC(=O)C1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(=O)C1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 LUKDIRGSTRENOZ-WXVXHBNASA-N 0.000 description 1
- AEKMEKOQOVWALZ-WSNDFEFKSA-N CC(=O)C1=C(C2=CC=C3NC(/C=C/C4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CSC1=CC=C(/C=C/C2=NC3=CC(C4=C(C(C)=O)C=CC=C4)=CC=C3N2)C=C1.O=S(=O)(C1=CC=C(/C=C/C2=NC3=CC(C4=C(O)C=CC=C4)=CC=C3N2)C=C1)C(F)(F)F Chemical compound CC(=O)C1=C(C2=CC=C3NC(/C=C/C4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CSC1=CC=C(/C=C/C2=NC3=CC(C4=C(C(C)=O)C=CC=C4)=CC=C3N2)C=C1.O=S(=O)(C1=CC=C(/C=C/C2=NC3=CC(C4=C(O)C=CC=C4)=CC=C3N2)C=C1)C(F)(F)F AEKMEKOQOVWALZ-WSNDFEFKSA-N 0.000 description 1
- BPXMDKKSDDNTEX-HCYAOVMWSA-N CC(=O)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C(S(N)(=O)=O)=C1.CC1=CC=C(C2=CC=C3NC(CCC4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C(S(N)(=O)=O)=C1 Chemical compound CC(=O)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C(S(N)(=O)=O)=C1.CC1=CC=C(C2=CC=C3NC(CCC4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C(S(N)(=O)=O)=C1 BPXMDKKSDDNTEX-HCYAOVMWSA-N 0.000 description 1
- VGWXUQGLZCSMHJ-SHUNOHKJSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(F)C=C3)=NC2=C1.CC(C)(C)C1=CC=C(CCCC2=NC3=CC(C4=C(O)C=CC=C4)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(F)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(F)C=C3)=NC2=C1.CC(C)(C)C1=CC=C(CCCC2=NC3=CC(C4=C(O)C=CC=C4)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(F)C=C3)=NC2=C1 VGWXUQGLZCSMHJ-SHUNOHKJSA-N 0.000 description 1
- MYEUMTMMURFTDM-VHUZYRGMSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(C)(C)C)C=C3)=NC2=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4O)=CC=C3N2)C=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(C)(C)C)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(C)(C)C)C=C3)=NC2=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4O)=CC=C3N2)C=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(C)(C)C)C=C3)=NC2=C1 MYEUMTMMURFTDM-VHUZYRGMSA-N 0.000 description 1
- DPCFUHIJTMBFQI-WXVXHBNASA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Cl)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Cl)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Cl)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Cl)C=C3)=NC2=C1 DPCFUHIJTMBFQI-WXVXHBNASA-N 0.000 description 1
- PJOFNYKEQPJYER-WXVXHBNASA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(=O)(=O)CF)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(=O)(=O)CF)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 PJOFNYKEQPJYER-WXVXHBNASA-N 0.000 description 1
- CWLVXZMOYPUMSL-VTXHIHIASA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 CWLVXZMOYPUMSL-VTXHIHIASA-N 0.000 description 1
- KDWCISOIDWLMCM-VTXHIHIASA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(OC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(OC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F KDWCISOIDWLMCM-VTXHIHIASA-N 0.000 description 1
- YDSQMZFMPQUHNX-UTFFCYGFSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1 YDSQMZFMPQUHNX-UTFFCYGFSA-N 0.000 description 1
- OWNLXSGDFZMUME-OBFWPVDISA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OCC(C)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OCC(C)(F)F)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OCC(C)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OCC(C)(F)F)C=C3)=NC2=C1 OWNLXSGDFZMUME-OBFWPVDISA-N 0.000 description 1
- AOXSBKOCNJPMKR-VTXHIHIASA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1 AOXSBKOCNJPMKR-VTXHIHIASA-N 0.000 description 1
- IGIQISVTSASFRX-ADCLUPEYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(C)=C3)=NC2=C1.CC1=CC(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)O)=CC=C3N2)=CC=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(C(F)(F)F)=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(C)=C3)=NC2=C1.CC1=CC(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)O)=CC=C3N2)=CC=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(C(F)(F)F)=C3)=NC2=C1 IGIQISVTSASFRX-ADCLUPEYSA-N 0.000 description 1
- KYJTZWHQZIALQN-UZWRXOKRSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(Cl)=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(Cl)=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(Cl)=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(Cl)=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(Cl)=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(Cl)=C3)=NC2=C1 KYJTZWHQZIALQN-UZWRXOKRSA-N 0.000 description 1
- GEUAFEIBJCYSFR-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(C)=CC=C3)=NC2=C1.CC1=CC=CC(C#CC2=NC3=CC(C4=CC=CC=C4C(C)O)=CC=C3N2)=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(Cl)=CC=C3)=NC2=C1)C(F)(F)F Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(C)=CC=C3)=NC2=C1.CC1=CC=CC(C#CC2=NC3=CC(C4=CC=CC=C4C(C)O)=CC=C3N2)=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(Cl)=CC=C3)=NC2=C1)C(F)(F)F GEUAFEIBJCYSFR-UHFFFAOYSA-N 0.000 description 1
- CQKRNXQNIZBALJ-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(Cl)=CC=C3)=NC2=C1.CC(F)(F)COC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(Cl)=CC=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(Cl)=CC=C3)=NC2=C1.CC(F)(F)COC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(Cl)=CC=C3)=NC2=C1 CQKRNXQNIZBALJ-UHFFFAOYSA-N 0.000 description 1
- RGSJRSQBDDVVTR-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(Cl)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(Cl)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(Cl)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(Cl)C=C3)=NC2=C1 RGSJRSQBDDVVTR-UHFFFAOYSA-N 0.000 description 1
- BNNGUYKPKKBFRH-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 BNNGUYKPKKBFRH-UHFFFAOYSA-N 0.000 description 1
- IPEXBDVRCHEJGE-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CC1=CC=CC(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CC1=CC=CC(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)=C1 IPEXBDVRCHEJGE-UHFFFAOYSA-N 0.000 description 1
- KBVQZLQEISRNDD-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(OC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(OC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F KBVQZLQEISRNDD-UHFFFAOYSA-N 0.000 description 1
- MLAZMLXBXFWUDX-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(OCC(C)(F)F)C=C3)=NC2=C1.CCOC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(OCC(C)(F)F)C=C3)=NC2=C1.CCOC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1 MLAZMLXBXFWUDX-UHFFFAOYSA-N 0.000 description 1
- RVBCNJCMTCEXDP-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1 RVBCNJCMTCEXDP-UHFFFAOYSA-N 0.000 description 1
- QLMGSCYCTCIRIT-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(C(F)(F)F)=CC=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(C(F)(F)F)=CC=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(C(F)(F)F)=CC=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(C(F)(F)F)=CC=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(C(F)(F)F)=CC=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(C(F)(F)F)=CC=C3)=NC2=C1 QLMGSCYCTCIRIT-UHFFFAOYSA-N 0.000 description 1
- GAPGMWLRKGFCPV-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(Cl)=CC=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(Cl)=CC=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(Cl)=CC=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(Cl)=CC=C3)=NC2=C1 GAPGMWLRKGFCPV-UHFFFAOYSA-N 0.000 description 1
- RLYPSXKKSWSRMR-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(Cl)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(Cl)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(Cl)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(Cl)C=C3)=NC2=C1 RLYPSXKKSWSRMR-UHFFFAOYSA-N 0.000 description 1
- LYMCHKPUOYBPTA-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 LYMCHKPUOYBPTA-UHFFFAOYSA-N 0.000 description 1
- YAMWTCJMBKLPIR-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 YAMWTCJMBKLPIR-UHFFFAOYSA-N 0.000 description 1
- IEWGJGDVDDDKIV-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(OC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(OC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F IEWGJGDVDDDKIV-UHFFFAOYSA-N 0.000 description 1
- BYOUACIXCGZSRB-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1 BYOUACIXCGZSRB-UHFFFAOYSA-N 0.000 description 1
- YBQPPYYPAFHQDW-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)F)C=C3)=NC2=C1 YBQPPYYPAFHQDW-UHFFFAOYSA-N 0.000 description 1
- IDTQTPZOSBXSMD-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1 IDTQTPZOSBXSMD-UHFFFAOYSA-N 0.000 description 1
- HBTUTDHXSHIEOH-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Cl)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Cl)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Cl)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Cl)C=C3)=NC2=C1 HBTUTDHXSHIEOH-UHFFFAOYSA-N 0.000 description 1
- PPIVKMLTSNVNMX-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1 PPIVKMLTSNVNMX-UHFFFAOYSA-N 0.000 description 1
- XSUBFDAGKAYTNR-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1 XSUBFDAGKAYTNR-UHFFFAOYSA-N 0.000 description 1
- CNWCBYRVZXJPHI-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(OC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OC(C)C(F)(F)F)C=C3)=NC2=C1.CC(OC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F CNWCBYRVZXJPHI-UHFFFAOYSA-N 0.000 description 1
- AUFDFLLIRCLNPJ-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OCC(C)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OC(C)(F)F)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OCC(C)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OC(C)(F)F)C=C3)=NC2=C1 AUFDFLLIRCLNPJ-UHFFFAOYSA-N 0.000 description 1
- UGNZPBGOISUFQH-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1 UGNZPBGOISUFQH-UHFFFAOYSA-N 0.000 description 1
- GMJGFTFLUNIQPY-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(C)=C3)=NC2=C1.CC1=CC(CCC2=NC3=CC(C4=CC=CC=C4C(C)O)=CC=C3N2)=CC=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(C(F)(F)F)=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(C)=C3)=NC2=C1.CC1=CC(CCC2=NC3=CC(C4=CC=CC=C4C(C)O)=CC=C3N2)=CC=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(C(F)(F)F)=C3)=NC2=C1 GMJGFTFLUNIQPY-UHFFFAOYSA-N 0.000 description 1
- QURPIFVFVWJDDT-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(Cl)=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(Cl)=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(Cl)=C3)=NC2=C1 Chemical compound CC(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(Cl)=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(Cl)=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(Cl)=C3)=NC2=C1 QURPIFVFVWJDDT-UHFFFAOYSA-N 0.000 description 1
- FEGZZYYTEODAFU-MIWVRHGHSA-N CC(=O)NC1=C(C2=C(C(F)(F)F)C=C3NC(/C=C/C4=CC=C(C(C)(C)C)C=C4)=NC3=C2)C=CC=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=C(O)C=CC=C4)=C(C(F)(F)F)C=C3N2)C=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC(O)=CC=C4)=C(C(F)(F)F)C=C3N2)C=C1 Chemical compound CC(=O)NC1=C(C2=C(C(F)(F)F)C=C3NC(/C=C/C4=CC=C(C(C)(C)C)C=C4)=NC3=C2)C=CC=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=C(O)C=CC=C4)=C(C(F)(F)F)C=C3N2)C=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC(O)=CC=C4)=C(C(F)(F)F)C=C3N2)C=C1 FEGZZYYTEODAFU-MIWVRHGHSA-N 0.000 description 1
- TXZBWMWRPTYZDY-PVBMMGNHSA-N CC(=O)NC1=C(C2=C(C(F)(F)F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=C(NS(C)(=O)=O)C=CC=C4)=C(C(F)(F)F)C=C3N2)C=C1.CC(C)(C)OC(=O)NC1=C(C2=C(C(F)(F)F)C=C3NC(/C=C/C4=CC=C(C(C)(C)C)C=C4)=NC3=C2)C=CC=C1 Chemical compound CC(=O)NC1=C(C2=C(C(F)(F)F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=C(NS(C)(=O)=O)C=CC=C4)=C(C(F)(F)F)C=C3N2)C=C1.CC(C)(C)OC(=O)NC1=C(C2=C(C(F)(F)F)C=C3NC(/C=C/C4=CC=C(C(C)(C)C)C=C4)=NC3=C2)C=CC=C1 TXZBWMWRPTYZDY-PVBMMGNHSA-N 0.000 description 1
- ROZVIPBAVVHAIP-IECPUGLCSA-N CC(=O)NC1=C(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CS(=O)(=O)NC1=C(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.NC(=O)C1=C(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 Chemical compound CC(=O)NC1=C(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CS(=O)(=O)NC1=C(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.NC(=O)C1=C(C2=C(F)C=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 ROZVIPBAVVHAIP-IECPUGLCSA-N 0.000 description 1
- CTSKPLRIJNSUDH-JJDHNMJZSA-N CC(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC(F)=C(F)C=C4)=NC3=C2)C=CC=C1.CC(=O)NC1=CC=CC(C2=CC=C3NC(/C=C/C4=CC(F)=C(F)C=C4)=NC3=C2)=C1.NC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(F)C=C3)=NC2=C1 Chemical compound CC(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC(F)=C(F)C=C4)=NC3=C2)C=CC=C1.CC(=O)NC1=CC=CC(C2=CC=C3NC(/C=C/C4=CC(F)=C(F)C=C4)=NC3=C2)=C1.NC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(F)C=C3)=NC2=C1 CTSKPLRIJNSUDH-JJDHNMJZSA-N 0.000 description 1
- MTUWMIGQVOBVTQ-HKFZPCDBSA-N CC(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CC(C)(C)C(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.O=S(=O)(CC(F)(F)F)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CC(C)(C)C(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.O=S(=O)(CC(F)(F)F)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 MTUWMIGQVOBVTQ-HKFZPCDBSA-N 0.000 description 1
- SEAMNHVCSZABIG-UTFFCYGFSA-N CC(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CN1C2=CC=C(C3=CC=CC=C3NS(C)(=O)=O)C=C2N=C1/C=C/C1=CC=C(C(F)(F)F)C=C1.OCC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CN1C2=CC=C(C3=CC=CC=C3NS(C)(=O)=O)C=C2N=C1/C=C/C1=CC=C(C(F)(F)F)C=C1.OCC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 SEAMNHVCSZABIG-UTFFCYGFSA-N 0.000 description 1
- IFNMTGTZOIVRIF-DDABGAJQSA-N CC(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.NC(=O)C1=C(C2=CC=C3NC(/C=C/C4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.O=S(=O)(C1=CC=C(/C=C/C2=NC3=CC(C4=C(CO)C=CC=C4)=CC=C3N2)C=C1)C(F)(F)F Chemical compound CC(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.NC(=O)C1=C(C2=CC=C3NC(/C=C/C4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.O=S(=O)(C1=CC=C(/C=C/C2=NC3=CC(C4=C(CO)C=CC=C4)=CC=C3N2)C=C1)C(F)(F)F IFNMTGTZOIVRIF-DDABGAJQSA-N 0.000 description 1
- JGJOZUIOSAVYQV-WDFUQAIGSA-N CC(=O)NC1=C(C2=CC=C3NC(CCC4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=C(C(F)(F)F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(C)=O)C=C3)=NC2=C1 Chemical compound CC(=O)NC1=C(C2=CC=C3NC(CCC4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=C(C(F)(F)F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(C)=O)C=C3)=NC2=C1 JGJOZUIOSAVYQV-WDFUQAIGSA-N 0.000 description 1
- NXPIAXSAAKHKCM-RWFHPNBASA-N CC(=O)NC1=CC=C(C2=CC=C3NC(/C=C/C4=CC=C(C(C)(C)C)C=C4)=NC3=C2)C=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=C(C(N)=O)C=C4)=CC=C3N2)C=C1 Chemical compound CC(=O)NC1=CC=C(C2=CC=C3NC(/C=C/C4=CC=C(C(C)(C)C)C=C4)=NC3=C2)C=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=C(C(N)=O)C=C4)=CC=C3N2)C=C1 NXPIAXSAAKHKCM-RWFHPNBASA-N 0.000 description 1
- UACYYSQHAKQLRE-PGKRTWRBSA-N CC(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(C)(C)C)C=C3)=NC2=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC(C(N)=O)=C4)=CC=C3N2)C=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(N)=O)=CC=C3N2)C=C1 Chemical compound CC(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(C)(C)C)C=C3)=NC2=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC(C(N)=O)=C4)=CC=C3N2)C=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(N)=O)=CC=C3N2)C=C1 UACYYSQHAKQLRE-PGKRTWRBSA-N 0.000 description 1
- WRPHDEUQWPBPKM-SUXOAABBSA-N CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=C(C(N)=O)C=CC=C4)=C(C(F)(F)F)C=C3N2)C=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=C(CO)C=CC=C4)=C(C(F)(F)F)C=C3N2)C=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=C(F)C=CC=C4)=C(C(F)(F)F)C=C3N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=C(C(N)=O)C=CC=C4)=C(C(F)(F)F)C=C3N2)C=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=C(CO)C=CC=C4)=C(C(F)(F)F)C=C3N2)C=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=C(F)C=CC=C4)=C(C(F)(F)F)C=C3N2)C=C1 WRPHDEUQWPBPKM-SUXOAABBSA-N 0.000 description 1
- NPDKMLJGVKGQGB-WDLXVBQQSA-N CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CCS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.COC(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 Chemical compound CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CCS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.COC(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 NPDKMLJGVKGQGB-WDLXVBQQSA-N 0.000 description 1
- SKFWHRVHYUVBII-WSCPDKNYSA-N CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4CO)=CC=C3N2)C=C1.NC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.OC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4CO)=CC=C3N2)C=C1.NC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.OC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 SKFWHRVHYUVBII-WSCPDKNYSA-N 0.000 description 1
- SLVRAKUOQYSCEV-KGTIVOESSA-N CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4N)=CC=C3N2)C=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CC(C)(C)OC(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(C)(C)C)C=C3)=NC2=C1 Chemical compound CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4N)=CC=C3N2)C=C1.CC(C)(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CC(C)(C)OC(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(C)(C)C)C=C3)=NC2=C1 SLVRAKUOQYSCEV-KGTIVOESSA-N 0.000 description 1
- TXQGCZAVXNLUCB-NILXTOCOSA-N CC(C)(C)C1=CC=C(CCC2=NC3=CC(C4=CC=C(O)C=C4)=CC=C3N2)C=C1.CC(C)(C)C1=CC=C(CCC2=NC3=CC(C4=CC=CC(O)=C4)=CC=C3N2)C=C1.CSC1=CC=C(/C=C/C2=NC3=CC(C4=C(CO)C=CC=C4)=CC=C3N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(CCC2=NC3=CC(C4=CC=C(O)C=C4)=CC=C3N2)C=C1.CC(C)(C)C1=CC=C(CCC2=NC3=CC(C4=CC=CC(O)=C4)=CC=C3N2)C=C1.CSC1=CC=C(/C=C/C2=NC3=CC(C4=C(CO)C=CC=C4)=CC=C3N2)C=C1 TXQGCZAVXNLUCB-NILXTOCOSA-N 0.000 description 1
- RFMHOELOFWFWDW-UHFFFAOYSA-N CC(C)(C)C1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4O)=CC=C3N2)C=C1.CC1=CC=CC(C2=CC=C3NC(CCCC4=CC=C(C(C)(C)C)C=C4)=NC3=C2)=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(C)(C)C1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4O)=CC=C3N2)C=C1.CC1=CC=CC(C2=CC=C3NC(CCCC4=CC=C(C(C)(C)C)C=C4)=NC3=C2)=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1 RFMHOELOFWFWDW-UHFFFAOYSA-N 0.000 description 1
- UAKYXDYQKALBLV-HKFZPCDBSA-N CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.O=C(CO)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.O=C(CO)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 UAKYXDYQKALBLV-HKFZPCDBSA-N 0.000 description 1
- GMALLCXVWYWBSW-HKFZPCDBSA-N CC(C)(C)OC(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CSC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(C1=CC=C(/C=C/C2=NC3=CC(C4=C(C(F)(F)F)C=CC=C4)=CC=C3N2)C=C1)C(F)(F)F Chemical compound CC(C)(C)OC(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CSC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(C1=CC=C(/C=C/C2=NC3=CC(C4=C(C(F)(F)F)C=CC=C4)=CC=C3N2)C=C1)C(F)(F)F GMALLCXVWYWBSW-HKFZPCDBSA-N 0.000 description 1
- WIYXTVXKGUAFOD-MMYBOGQISA-N CC(C)(O)C1=C(C2=CC=C3NC(/C=C/C4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CC(O)C1=C(C2=CC=C3NC(/C=C/C4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CC(O)C1=C(C2=CC=C3NC(CCC4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 Chemical compound CC(C)(O)C1=C(C2=CC=C3NC(/C=C/C4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CC(O)C1=C(C2=CC=C3NC(/C=C/C4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CC(O)C1=C(C2=CC=C3NC(CCC4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 WIYXTVXKGUAFOD-MMYBOGQISA-N 0.000 description 1
- FZCUGUIGAXUWQD-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1Br.CC1(C)OB(O)C2=CC=CC=C21 Chemical compound CC(C)(O)C1=CC=CC=C1Br.CC1(C)OB(O)C2=CC=CC=C21 FZCUGUIGAXUWQD-UHFFFAOYSA-N 0.000 description 1
- DJJMSYMPSNRCGE-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1Br.COC(=O)C1=CC=CC=C1Br Chemical compound CC(C)(O)C1=CC=CC=C1Br.COC(=O)C1=CC=CC=C1Br DJJMSYMPSNRCGE-UHFFFAOYSA-N 0.000 description 1
- ZGHGFOHUWZLGTJ-PLQUFNPPSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=CC=C3)=NC2=C1.CN(C)CC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.O=CC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=CC=C3)=NC2=C1.CN(C)CC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.O=CC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 ZGHGFOHUWZLGTJ-PLQUFNPPSA-N 0.000 description 1
- XMMCAIORNNBPCK-QBKDXNQMSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC4=C(C=C3)N=CC=C4)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C#N)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(=O)NC(C)C)C=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC4=C(C=C3)N=CC=C4)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C#N)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(=O)NC(C)C)C=C3)=NC2=C1 XMMCAIORNNBPCK-QBKDXNQMSA-N 0.000 description 1
- WMWFUKSPQBGPDU-XKHBQLNCSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.CC1(C)OB(O)C2=CC=CC=C21.FC(F)(F)C1=CC=C(/C=C/C2=NC3=CC(Br)=CC=C3N2)C=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.CC1(C)OB(O)C2=CC=CC=C21.FC(F)(F)C1=CC=C(/C=C/C2=NC3=CC(Br)=CC=C3N2)C=C1 WMWFUKSPQBGPDU-XKHBQLNCSA-N 0.000 description 1
- QTLLBAFKSNDTIA-UTFFCYGFSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(Cl)C=C4)=NC3=C2)C=CC=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Cl)C=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(Cl)C=C4)=NC3=C2)C=CC=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Cl)C=C3)=NC2=C1 QTLLBAFKSNDTIA-UTFFCYGFSA-N 0.000 description 1
- YXFGKLIQLGYKJW-XKSLEERVSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F YXFGKLIQLGYKJW-XKSLEERVSA-N 0.000 description 1
- MYAQKUHVBJIQHS-JIFCMJEASA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 MYAQKUHVBJIQHS-JIFCMJEASA-N 0.000 description 1
- KHURSPFAXFNDKN-LKPGWOPQSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1 KHURSPFAXFNDKN-LKPGWOPQSA-N 0.000 description 1
- CLWDCWOIVCOSAZ-JIFCMJEASA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CS(=O)(=O)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CS(=O)(=O)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 CLWDCWOIVCOSAZ-JIFCMJEASA-N 0.000 description 1
- BKVGSGQTQOAXMD-GIXBJARTSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(C(F)(F)F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(C(F)(F)F)=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(C(F)(F)F)=C3)=NC2=C1)C(F)(F)F Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(C(F)(F)F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(C(F)(F)F)=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(C(F)(F)F)=C3)=NC2=C1)C(F)(F)F BKVGSGQTQOAXMD-GIXBJARTSA-N 0.000 description 1
- NBVQFENNDGZEFC-GIXBJARTSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(Cl)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(Cl)=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(Cl)=C3)=NC2=C1)C(F)(F)F Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(Cl)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(Cl)=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC(Cl)=C3)=NC2=C1)C(F)(F)F NBVQFENNDGZEFC-GIXBJARTSA-N 0.000 description 1
- KQQHRKVTTNIFCD-PSPKVVBTSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC=C3)=NC2=C1.CC1=CC=C(/C=C\C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC=C3)=NC2=C1.CC1=CC=C(/C=C\C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 KQQHRKVTTNIFCD-PSPKVVBTSA-N 0.000 description 1
- OHAGNFMBIOPPMP-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(Cl)=CC=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(Cl)=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(Cl)=CC=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(Cl)=CC=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(Cl)=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC(Cl)=CC=C3)=NC2=C1 OHAGNFMBIOPPMP-UHFFFAOYSA-N 0.000 description 1
- FGOPQQXFIMLFDB-RJBWCFNVSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.COC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.NS(=O)(=O)NCC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.COC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.NS(=O)(=O)NCC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 FGOPQQXFIMLFDB-RJBWCFNVSA-N 0.000 description 1
- FISVIESRCAFSPO-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(Cl)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(Cl)C=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(Cl)C=C3)=NC2=C1)C(F)(F)F Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(Cl)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(Cl)C=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(Cl)C=C3)=NC2=C1)C(F)(F)F FISVIESRCAFSPO-UHFFFAOYSA-N 0.000 description 1
- WBOXZCHXFXAFTE-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 WBOXZCHXFXAFTE-UHFFFAOYSA-N 0.000 description 1
- DAUQYZWBIUPLQL-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 DAUQYZWBIUPLQL-UHFFFAOYSA-N 0.000 description 1
- ZGMFJUGUCSDBJG-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)C1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CS(=O)(=O)C1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)C1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CS(=O)(=O)C1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 ZGMFJUGUCSDBJG-UHFFFAOYSA-N 0.000 description 1
- YHHGCERECACXCQ-MIPMTANYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=CC=C3)=NC2=C1.FC(F)(F)OC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=CC=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=CC=C3)=NC2=C1.FC(F)(F)OC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=CC=C3)=NC2=C1 YHHGCERECACXCQ-MIPMTANYSA-N 0.000 description 1
- QTKBHMKJHLMKDV-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(C(F)(F)F)=CC=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(C(F)(F)F)=CC=C3)=NC2=C1)C(F)(F)F.O=S(=O)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(C(F)(F)F)=CC=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(C(F)(F)F)=CC=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(C(F)(F)F)=CC=C3)=NC2=C1)C(F)(F)F.O=S(=O)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(C(F)(F)F)=CC=C3)=NC2=C1 QTKBHMKJHLMKDV-UHFFFAOYSA-N 0.000 description 1
- DVYPKVDXNVKJEN-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(Cl)=CC=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(Cl)=CC=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(Cl)=CC=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(Cl)=CC=C3)=NC2=C1 DVYPKVDXNVKJEN-UHFFFAOYSA-N 0.000 description 1
- FMZVJWCWYYKGBT-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(Cl)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(Cl)C=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(Cl)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(Cl)C=C3)=NC2=C1 FMZVJWCWYYKGBT-UHFFFAOYSA-N 0.000 description 1
- VUQMHLCHQBONKA-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F VUQMHLCHQBONKA-UHFFFAOYSA-N 0.000 description 1
- OWQOMUZETPFMLG-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 OWQOMUZETPFMLG-UHFFFAOYSA-N 0.000 description 1
- AWINFORAZDFNEY-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4C(N)=O)=CC=C3N2)C=C1.CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4S(=O)(=O)NC(C)(C)C)=CC=C3N2)C=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4C(N)=O)=CC=C3N2)C=C1.CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4S(=O)(=O)NC(C)(C)C)=CC=C3N2)C=C1 AWINFORAZDFNEY-UHFFFAOYSA-N 0.000 description 1
- DWJIENNNHWONED-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F DWJIENNNHWONED-UHFFFAOYSA-N 0.000 description 1
- YPVMXXMATWXCKC-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)F)C=C3)=NC2=C1)C(F)(F)F Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OCC(F)(F)F)C=C3)=NC2=C1)C(F)(F)F YPVMXXMATWXCKC-UHFFFAOYSA-N 0.000 description 1
- UMQODSMVNUNSAW-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)C1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)C1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1 UMQODSMVNUNSAW-UHFFFAOYSA-N 0.000 description 1
- YIUCBUXKILXLHO-ROOCCDHZSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.CCOC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.CCOC(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 YIUCBUXKILXLHO-ROOCCDHZSA-N 0.000 description 1
- NEJBHDLWRUMVQT-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Cl)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Cl)C=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Cl)C=C3)=NC2=C1)C(F)(F)F Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Cl)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Cl)C=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Cl)C=C3)=NC2=C1)C(F)(F)F NEJBHDLWRUMVQT-UHFFFAOYSA-N 0.000 description 1
- YINLAINOMNARAY-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 YINLAINOMNARAY-UHFFFAOYSA-N 0.000 description 1
- ZCAABSAKDBIIBR-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 ZCAABSAKDBIIBR-UHFFFAOYSA-N 0.000 description 1
- LHZNMYYEZOHJNG-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1 LHZNMYYEZOHJNG-UHFFFAOYSA-N 0.000 description 1
- HJOFCQDCULXHOI-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)C1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CS(=O)(=O)C1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1.CS(=O)(=O)C1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CS(=O)(=O)C1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 HJOFCQDCULXHOI-UHFFFAOYSA-N 0.000 description 1
- QMMCUWIFCMKCHW-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(C(F)(F)F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(C(F)(F)F)=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(C(F)(F)F)=C3)=NC2=C1)C(F)(F)F Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(C(F)(F)F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(C(F)(F)F)=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(C(F)(F)F)=C3)=NC2=C1)C(F)(F)F QMMCUWIFCMKCHW-UHFFFAOYSA-N 0.000 description 1
- DHWKCHYEUJUQEQ-UHFFFAOYSA-N CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(Cl)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(Cl)=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(Cl)=C3)=NC2=C1)C(F)(F)F Chemical compound CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(Cl)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(Cl)=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC(Cl)=C3)=NC2=C1)C(F)(F)F DHWKCHYEUJUQEQ-UHFFFAOYSA-N 0.000 description 1
- RVXGWWRJKMNUHD-OUBWWKSTSA-N CC(C)(c(cccc1)c1-c(cc1)cc(C)c1N/C(/C#Cc(cc1)ccc1S(C)(=O)=O)=C\C)O Chemical compound CC(C)(c(cccc1)c1-c(cc1)cc(C)c1N/C(/C#Cc(cc1)ccc1S(C)(=O)=O)=C\C)O RVXGWWRJKMNUHD-OUBWWKSTSA-N 0.000 description 1
- BMMQTAAJXOKXCR-SUMPNEIVSA-N CC(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Br)=C(F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Cl)=C(F)C=C3)=NC2=C1 Chemical compound CC(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Br)=C(F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Cl)=C(F)C=C3)=NC2=C1 BMMQTAAJXOKXCR-SUMPNEIVSA-N 0.000 description 1
- SEVJCIPMCRRGGD-PZRKIACVSA-N CC(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.CC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(Cl)C=C3)=NC2=C1 Chemical compound CC(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.CC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(Cl)C=C3)=NC2=C1 SEVJCIPMCRRGGD-PZRKIACVSA-N 0.000 description 1
- XKQQGDGNYNJJCS-UMHKSRKFSA-N CC(C)C1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.NS(=O)(=O)C1=CC=C(F)C=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(C)C1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.NS(=O)(=O)C1=CC=C(F)C=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 XKQQGDGNYNJJCS-UMHKSRKFSA-N 0.000 description 1
- QZEZCOORWPKYRL-XKLMPIMCSA-N CC(F)(F)COC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC(F)(F)COC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1 QZEZCOORWPKYRL-XKLMPIMCSA-N 0.000 description 1
- LSSNHYQJKVRKHL-UHFFFAOYSA-N CC(F)(F)COC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC(F)(F)COC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC(F)(F)COC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC(F)(F)COC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 LSSNHYQJKVRKHL-UHFFFAOYSA-N 0.000 description 1
- COAVCBLOMBEULW-UHFFFAOYSA-N CC(F)(F)COC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(OCC(C)(F)F)C=C3)=NC2=C1 Chemical compound CC(F)(F)COC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CC(O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(OCC(C)(F)F)C=C3)=NC2=C1 COAVCBLOMBEULW-UHFFFAOYSA-N 0.000 description 1
- UOHZSPOAFFGVLT-JIFCMJEASA-N CC(OC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F Chemical compound CC(OC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F UOHZSPOAFFGVLT-JIFCMJEASA-N 0.000 description 1
- QVHXBWIZXUWAML-UHFFFAOYSA-N CC(OC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F Chemical compound CC(OC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F QVHXBWIZXUWAML-UHFFFAOYSA-N 0.000 description 1
- QEFLAFYNKXNGDG-UHFFFAOYSA-N CC(OC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F.CCOC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4C(C)=O)=CC=C3N2)C=C1 Chemical compound CC(OC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F.CCOC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4C(C)=O)=CC=C3N2)C=C1 QEFLAFYNKXNGDG-UHFFFAOYSA-N 0.000 description 1
- IBWQCEUCSMSUOO-UHFFFAOYSA-N CC(OC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F Chemical compound CC(OC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F IBWQCEUCSMSUOO-UHFFFAOYSA-N 0.000 description 1
- MJIPSYLNQRDRHG-UHFFFAOYSA-N CC(OC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F Chemical compound CC(OC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F.CC(OC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1)C(F)(F)F MJIPSYLNQRDRHG-UHFFFAOYSA-N 0.000 description 1
- ZWBDXFHSBQMDBU-UHFFFAOYSA-N CC(c1ccccc1-c(cc1)cc2c1[nH]c(CCc(cc1)ccc1[U]CC(F)(F)F)n2)O Chemical compound CC(c1ccccc1-c(cc1)cc2c1[nH]c(CCc(cc1)ccc1[U]CC(F)(F)F)n2)O ZWBDXFHSBQMDBU-UHFFFAOYSA-N 0.000 description 1
- CWAVVMIFBXUVFQ-WKSHTIBZSA-N CC.CC.CC(C)(C)NS(=O)(=O)C1=C(Br)C=CC=C1.CCC1=NC2=CC(B3OC(C)(C)C(C)(C)O3)=CC=C2N1C(=O)OC(C)(C)C.CCC1=NC2=CC(C3=C(S(N)(=O)=O)C=CC=C3)=CC=C2N1.[2H][2H][2H].[HH].[HH].[HH] Chemical compound CC.CC.CC(C)(C)NS(=O)(=O)C1=C(Br)C=CC=C1.CCC1=NC2=CC(B3OC(C)(C)C(C)(C)O3)=CC=C2N1C(=O)OC(C)(C)C.CCC1=NC2=CC(C3=C(S(N)(=O)=O)C=CC=C3)=CC=C2N1.[2H][2H][2H].[HH].[HH].[HH] CWAVVMIFBXUVFQ-WKSHTIBZSA-N 0.000 description 1
- SKDURNZLIWOYKT-UHFFFAOYSA-N CC.CC.CC(Cl)=CC1=NC2=CC(Br)=CC=C2N1.NC1=CC=C(Br)C=C1N.[KH].[KH].[K][K].[K][K].[K][K].[K][K].[K][K] Chemical compound CC.CC.CC(Cl)=CC1=NC2=CC(Br)=CC=C2N1.NC1=CC=C(Br)C=C1N.[KH].[KH].[K][K].[K][K].[K][K].[K][K].[K][K] SKDURNZLIWOYKT-UHFFFAOYSA-N 0.000 description 1
- YRTILPMOTFNUKH-UHFFFAOYSA-N CC.CC.CC.CC#CC1=NC2=CC(C3=CC=CC=C3)=CC=C2N1.OB(O)C1=CC=CC=C1.[KH].[K][K].[K][K].[K][K].[K][K].[K][K] Chemical compound CC.CC.CC.CC#CC1=NC2=CC(C3=CC=CC=C3)=CC=C2N1.OB(O)C1=CC=CC=C1.[KH].[K][K].[K][K].[K][K].[K][K].[K][K] YRTILPMOTFNUKH-UHFFFAOYSA-N 0.000 description 1
- KRGRQJSDGSLPTF-UHFFFAOYSA-N CC.CC.CC.CC.CC(C)(C)OC(=O)NC1=CC=C(Br)C=C1NC(=O)OC(C)(C)C.NC1=CC=C(C2=CC=CC=C2)C=C1N Chemical compound CC.CC.CC.CC.CC(C)(C)OC(=O)NC1=CC=C(Br)C=C1NC(=O)OC(C)(C)C.NC1=CC=C(C2=CC=CC=C2)C=C1N KRGRQJSDGSLPTF-UHFFFAOYSA-N 0.000 description 1
- NKRBFJAACDOOSK-HGLRXLPXSA-N CC.CC.CC.CC.CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC=C3)=NC2=C1.CC1(C)OB(O)C2=CC=CC=C21 Chemical compound CC.CC.CC.CC.CC(C)(O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC=C3)=NC2=C1.CC1(C)OB(O)C2=CC=CC=C21 NKRBFJAACDOOSK-HGLRXLPXSA-N 0.000 description 1
- KGLBGYQDRVVNLM-WJCVXNJCSA-N CC.CC.CC.CC.CC.CC.O=C(Cl)/C=C/C1=CC=CC=C1.O=C(O)/C=C/C1=CC=CC=C1.O=CC1=CC=CC=C1 Chemical compound CC.CC.CC.CC.CC.CC.O=C(Cl)/C=C/C1=CC=CC=C1.O=C(O)/C=C/C1=CC=CC=C1.O=CC1=CC=CC=C1 KGLBGYQDRVVNLM-WJCVXNJCSA-N 0.000 description 1
- JUBOJXDTBBDDJF-UHFFFAOYSA-N CC.CC.CC.CC.CC.Cl.ClCC1=NC2=CC(C3=CC=CC=C3)=CC=C2N1.N=C(Cl)CCl.N=N.NC1=CC=C(C2=CC=CC=C2)C=C1N Chemical compound CC.CC.CC.CC.CC.Cl.ClCC1=NC2=CC(C3=CC=CC=C3)=CC=C2N1.N=C(Cl)CCl.N=N.NC1=CC=C(C2=CC=CC=C2)C=C1N JUBOJXDTBBDDJF-UHFFFAOYSA-N 0.000 description 1
- PHBXOCQMMAWXOW-JZCVSEAKSA-N CC.CC.CC.CC.CC/C=C/C1=NC2=CC(C3=CC=CC=C3)=CC=C2N1.CCCCC1=NC2=CC(C3=CC=CC=C3)=CC=C2N1.O=O.[N-]=[N+]=N Chemical compound CC.CC.CC.CC.CC/C=C/C1=NC2=CC(C3=CC=CC=C3)=CC=C2N1.CCCCC1=NC2=CC(C3=CC=CC=C3)=CC=C2N1.O=O.[N-]=[N+]=N PHBXOCQMMAWXOW-JZCVSEAKSA-N 0.000 description 1
- QGQIIZZAFYHBRP-UHFFFAOYSA-N CC.CC.CC.CCC1=NC2=CC(Br)=CC=C2N1.ClCCCl Chemical compound CC.CC.CC.CCC1=NC2=CC(Br)=CC=C2N1.ClCCCl QGQIIZZAFYHBRP-UHFFFAOYSA-N 0.000 description 1
- JGGDNWKIPSWQRJ-FHJHGPAASA-N CC.CC.CC/C=C/C1=NC2=CC(Br)=CC=C2N1.CCOC Chemical compound CC.CC.CC/C=C/C1=NC2=CC(Br)=CC=C2N1.CCOC JGGDNWKIPSWQRJ-FHJHGPAASA-N 0.000 description 1
- CRZGFJSHHYDUKS-LJMUIYSQSA-N CC.CC.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CCC1=NC2=CC(B3OC(C)(C)C(C)(C)O3)=CC=C2N1C(=O)OC(C)(C)C.CCC1=NC2=CC(Br)=CC=C2N1.[2H][2H].[2H][2H][2H] Chemical compound CC.CC.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CCC1=NC2=CC(B3OC(C)(C)C(C)(C)O3)=CC=C2N1C(=O)OC(C)(C)C.CCC1=NC2=CC(Br)=CC=C2N1.[2H][2H].[2H][2H][2H] CRZGFJSHHYDUKS-LJMUIYSQSA-N 0.000 description 1
- WCNDJPXGWDPLQZ-XGEAHXAKSA-N CC.CC.CCC1=NC2=CC(C3=CC=CC=C3)=CC=C2N1.[2H][2H]([2H])[2H].[2H][2H][2H] Chemical compound CC.CC.CCC1=NC2=CC(C3=CC=CC=C3)=CC=C2N1.[2H][2H]([2H])[2H].[2H][2H][2H] WCNDJPXGWDPLQZ-XGEAHXAKSA-N 0.000 description 1
- XEZLYCXUYNXRTE-XJBIRDNESA-O CC/C=C/COC=O.CCC1CC1COC=O.CS(C)(C)(=[OH+])[IH-].FF.FF(F)F.FFF.O=C=O.[H]C1CC1CC Chemical compound CC/C=C/COC=O.CCC1CC1COC=O.CS(C)(C)(=[OH+])[IH-].FF.FF(F)F.FFF.O=C=O.[H]C1CC1CC XEZLYCXUYNXRTE-XJBIRDNESA-O 0.000 description 1
- QEPOSJKOIIUPTH-HTRWEXALSA-N CC1=CC(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)=CC(F)=C1.CC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)F)C=C3)=NC2=C1 Chemical compound CC1=CC(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)=CC(F)=C1.CC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)F)C=C3)=NC2=C1 QEPOSJKOIIUPTH-HTRWEXALSA-N 0.000 description 1
- YAXJTJJTWOGNGK-IOEGSJDLSA-N CC1=CC(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=C(C(F)(F)F)C=C1.CC1=CC(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=CC(C(F)(F)F)=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=CC=C3F)=NC2=C1 Chemical compound CC1=CC(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=C(C(F)(F)F)C=C1.CC1=CC(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=CC(C(F)(F)F)=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=CC=C3F)=NC2=C1 YAXJTJJTWOGNGK-IOEGSJDLSA-N 0.000 description 1
- DUOOMACYWNFMNC-ZHINAZICSA-N CC1=CC(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=CC(F)=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(F)C=C3)=NC2=C1 Chemical compound CC1=CC(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=CC(F)=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(F)C=C3)=NC2=C1 DUOOMACYWNFMNC-ZHINAZICSA-N 0.000 description 1
- FRQVRZIFALYFMI-UHFFFAOYSA-N CC1=CC(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=C(C(F)(F)F)C=C1.CC1=CC(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=CC(C(F)(F)F)=C1.CS(=O)(=O)C1=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=CC(Cl)=C1 Chemical compound CC1=CC(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=C(C(F)(F)F)C=C1.CC1=CC(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=CC(C(F)(F)F)=C1.CS(=O)(=O)C1=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=CC(Cl)=C1 FRQVRZIFALYFMI-UHFFFAOYSA-N 0.000 description 1
- NIQIGNNKXAIJAE-UHFFFAOYSA-N CC1=CC(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=CC(F)=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(F)C=C3)=NC2=C1 Chemical compound CC1=CC(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=CC(F)=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(F)C=C3)=NC2=C1 NIQIGNNKXAIJAE-UHFFFAOYSA-N 0.000 description 1
- FMMNSSZSXXRSCS-RJBWCFNVSA-N CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4O)=CC=C3N2)C=C1.NS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4O)=CC=C3N2)C=C1.NS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1 FMMNSSZSXXRSCS-RJBWCFNVSA-N 0.000 description 1
- SHBYHVODWCMBQT-YWABOPJLSA-N CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4CO)=CC=C3N2)C=C1.CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NC(=O)OC(C)(C)C)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C4=CC=CC=C4)C=C3)=NC2=C1 Chemical compound CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4CO)=CC=C3N2)C=C1.CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4NC(=O)OC(C)(C)C)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C4=CC=CC=C4)C=C3)=NC2=C1 SHBYHVODWCMBQT-YWABOPJLSA-N 0.000 description 1
- OAZMJDKWWPSFKR-CNEOWCJBSA-N CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4S(C)(=O)=O)=CC=C3N2)C=C1.CC1=CC=C([C@@H]2C[C@H]2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C([C@@H]2C[C@H]2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4S(C)(=O)=O)=CC=C3N2)C=C1.CC1=CC=C([C@@H]2C[C@H]2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C([C@@H]2C[C@H]2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 OAZMJDKWWPSFKR-CNEOWCJBSA-N 0.000 description 1
- HXUKCXOBVIOORB-UHFFFAOYSA-N CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 Chemical compound CC1=CC=C(C2CC2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 HXUKCXOBVIOORB-UHFFFAOYSA-N 0.000 description 1
- GCCRJUADKFIEMV-WPQWBADFSA-N CC1=CC=C([C@@H]2C[C@@H]2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C([C@H]2C[C@@H]2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C([C@H]2C[C@@H]2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC1=CC=C([C@@H]2C[C@@H]2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C([C@H]2C[C@@H]2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C([C@H]2C[C@@H]2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 GCCRJUADKFIEMV-WPQWBADFSA-N 0.000 description 1
- MGLLVUGBQPRLLU-VLWDUBJJSA-N CC1=CC=C([C@@H]2C[C@@H]2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.CC1=CC=C([C@H]2C[C@H]2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C([C@H]2C[C@H]2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CC1=CC=C([C@@H]2C[C@@H]2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.CC1=CC=C([C@H]2C[C@H]2C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CC1=CC=C([C@H]2C[C@H]2C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 MGLLVUGBQPRLLU-VLWDUBJJSA-N 0.000 description 1
- RYSGTQQOKRICDE-UHFFFAOYSA-N CC1=CC=CC(C#CC2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)=C1.CC1=CC=CC(C#CC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)=C1.CC1=CC=CC(C#CC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=C1 Chemical compound CC1=CC=CC(C#CC2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)=C1.CC1=CC=CC(C#CC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)=C1.CC1=CC=CC(C#CC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=C1 RYSGTQQOKRICDE-UHFFFAOYSA-N 0.000 description 1
- NCCCEGINQQGBIX-UHFFFAOYSA-O CC=C(C=Cc1cc(F)ccc1F)Nc(cc1)c(C)cc1-c(cccc1)c1S([NH2+]C)(=O)=O Chemical compound CC=C(C=Cc1cc(F)ccc1F)Nc(cc1)c(C)cc1-c(cccc1)c1S([NH2+]C)(=O)=O NCCCEGINQQGBIX-UHFFFAOYSA-O 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- URFVQAOWIFOIDN-UHFFFAOYSA-N CCNc1ccc(CCc2nc(cc(cc3)-c4c(C(C)(C)O)cccc4)c3[nH]2)cc1 Chemical compound CCNc1ccc(CCc2nc(cc(cc3)-c4c(C(C)(C)O)cccc4)c3[nH]2)cc1 URFVQAOWIFOIDN-UHFFFAOYSA-N 0.000 description 1
- GOYWSHVOYQOSET-WBAIRTHOSA-N CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 GOYWSHVOYQOSET-WBAIRTHOSA-N 0.000 description 1
- HGZKMQLVVQBDMX-KHBAIMJNSA-N CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)=O)=CC=C3N2)C=C1.CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)O)=CC=C3N2)C=C1.CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 Chemical compound CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)=O)=CC=C3N2)C=C1.CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(C)O)=CC=C3N2)C=C1.CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 HGZKMQLVVQBDMX-KHBAIMJNSA-N 0.000 description 1
- GMSVLSRUJJNOGI-HNIZIMIRSA-N CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CN(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC4=C(C=CC=C4)C=C3)=NC2=C1 Chemical compound CCOC1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CN(C)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC4=C(C=CC=C4)C=C3)=NC2=C1 GMSVLSRUJJNOGI-HNIZIMIRSA-N 0.000 description 1
- UMDMGYMQCAAETR-UHFFFAOYSA-N CCOC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CCOC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CCOC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CCOC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 UMDMGYMQCAAETR-UHFFFAOYSA-N 0.000 description 1
- UMZFFXGZBGGHNI-UHFFFAOYSA-N CCOC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4C(C)O)=CC=C3N2)C=C1.CCOC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 Chemical compound CCOC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4C(C)O)=CC=C3N2)C=C1.CCOC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 UMZFFXGZBGGHNI-UHFFFAOYSA-N 0.000 description 1
- ZCSXETQEWLWURX-UHFFFAOYSA-N CCOC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CCOC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CCOC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CCOC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4C(C)(C)O)=CC=C3N2)C=C1.CCOC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CCOC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 ZCSXETQEWLWURX-UHFFFAOYSA-N 0.000 description 1
- CSRHMJZLPFMVIX-UHFFFAOYSA-N CCOC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4C(C)=O)=CC=C3N2)C=C1.CCOC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4C(C)O)=CC=C3N2)C=C1.CCOC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 Chemical compound CCOC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4C(C)=O)=CC=C3N2)C=C1.CCOC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4C(C)O)=CC=C3N2)C=C1.CCOC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(C)(=O)=O)=CC=C3N2)C=C1 CSRHMJZLPFMVIX-UHFFFAOYSA-N 0.000 description 1
- NWGVLAKXVOYMDU-SWNPOLSGSA-N CCOC1=CC=CC(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Cl)=C(Cl)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC=C3)=NC2=C1 Chemical compound CCOC1=CC=CC(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Cl)=C(Cl)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=CC=C3)=NC2=C1 NWGVLAKXVOYMDU-SWNPOLSGSA-N 0.000 description 1
- RLSKEOKZYKEZJL-YFJLMHTMSA-N CC[C@@H]1C[C@H]1C(=O)N(C)OC.CNOC.PP(P)P.PPP(P)P Chemical compound CC[C@@H]1C[C@H]1C(=O)N(C)OC.CNOC.PP(P)P.PPP(P)P RLSKEOKZYKEZJL-YFJLMHTMSA-N 0.000 description 1
- TXQLPFMXZTZNBB-DTQAZKPQSA-N CCc1ccc(/C=C/c2nc(ccc(-c(cccc3)c3NS(C)(=O)=O)c3)c3[n]2C)cc1 Chemical compound CCc1ccc(/C=C/c2nc(ccc(-c(cccc3)c3NS(C)(=O)=O)c3)c3[n]2C)cc1 TXQLPFMXZTZNBB-DTQAZKPQSA-N 0.000 description 1
- DSDLEPPQQUHKGV-UHFFFAOYSA-N CN(C(C(C1)C1c1cccc(C(F)(F)F)c1)=CC1)c(cc2)c1cc2-c(cccc1)c1S(O)(=O)=O Chemical compound CN(C(C(C1)C1c1cccc(C(F)(F)F)c1)=CC1)c(cc2)c1cc2-c(cccc1)c1S(O)(=O)=O DSDLEPPQQUHKGV-UHFFFAOYSA-N 0.000 description 1
- KDCHFALLDIPTSD-UHFFFAOYSA-N CN(C)S(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(Cl)C=CC=C3)=NC2=C1 Chemical compound CN(C)S(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(Cl)C=CC=C3)=NC2=C1 KDCHFALLDIPTSD-UHFFFAOYSA-N 0.000 description 1
- NEHLBLPSCZSJQF-UHFFFAOYSA-N CN(C)S(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC(F)=CC(F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC=C3)=NC2=C1 Chemical compound CN(C)S(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC(F)=CC(F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=CC=C3)=NC2=C1 NEHLBLPSCZSJQF-UHFFFAOYSA-N 0.000 description 1
- YTEQCZOFFBOLMJ-GUFGXDRXSA-N CN1C2=CC(C3=CC=CC=C3NS(C)(=O)=O)=CC=C2N=C1/C=C/C1=CC=C(C(F)(F)F)C=C1.NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CN1C2=CC(C3=CC=CC=C3NS(C)(=O)=O)=CC=C2N=C1/C=C/C1=CC=C(C(F)(F)F)C=C1.NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1 YTEQCZOFFBOLMJ-GUFGXDRXSA-N 0.000 description 1
- OYYZRWNGUDTJGN-WVTUODSRSA-N CNCC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.FC(F)(F)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(F)(F)F)=CC=C3N2)C=C1.NCC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CNCC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.FC(F)(F)C1=CC=C(/C=C/C2=NC3=CC(C4=CC=CC=C4C(F)(F)F)=CC=C3N2)C=C1.NCC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1 OYYZRWNGUDTJGN-WVTUODSRSA-N 0.000 description 1
- GESAHTSKFHBLST-BGVSJMHFSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Br)C=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Cl)C=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Cl)C=C3)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Br)C=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Cl)C=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Cl)C=C3)=NC2=C1 GESAHTSKFHBLST-BGVSJMHFSA-N 0.000 description 1
- JGARTEKPIKMCGF-GIZULUQGSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=CC(F)=C3)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=CC(F)=C3)=NC2=C1 JGARTEKPIKMCGF-GIZULUQGSA-N 0.000 description 1
- GFNKPNFKXSXETH-ANZJRFTNSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=CC(C)=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Cl)C=CC=C3F)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(Cl)=CC=C3)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=CC(C)=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Cl)C=CC=C3F)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(Cl)=CC=C3)=NC2=C1 GFNKPNFKXSXETH-ANZJRFTNSA-N 0.000 description 1
- LGFZJTUGMGHMAO-MHXONQOLSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(OC(F)(F)F)=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(OC(F)(F)F)=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1 LGFZJTUGMGHMAO-MHXONQOLSA-N 0.000 description 1
- YQQAMLBBDDBAJQ-OFMODOKRSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Cl)C=C(Cl)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(Cl)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Br)=CC=C3)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Cl)C=C(Cl)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(Cl)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Br)=CC=C3)=NC2=C1 YQQAMLBBDDBAJQ-OFMODOKRSA-N 0.000 description 1
- NANYWNZXVPZAGQ-FSYCTRLZSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(C(F)(F)F)=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(C(F)(F)F)=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(C(F)(F)F)=CC(C)=C3)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(C(F)(F)F)=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(C(F)(F)F)=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(C(F)(F)F)=CC(C)=C3)=NC2=C1 NANYWNZXVPZAGQ-FSYCTRLZSA-N 0.000 description 1
- PIEUJMCQJKIQFF-LBBKVCHMSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(F)=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(F)C(F)=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=CC(C)=C3)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(F)=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(F)C(F)=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=CC(C)=C3)=NC2=C1 PIEUJMCQJKIQFF-LBBKVCHMSA-N 0.000 description 1
- SAJAANFWUHAADM-AKCAHOFXSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(F)=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=CC(F)=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=CC=C3F)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(F)=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=CC(F)=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=CC=C3F)=NC2=C1 SAJAANFWUHAADM-AKCAHOFXSA-N 0.000 description 1
- NCHFIRAQOCBYKM-HOJIEIDUSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(C(F)(F)F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Cl)=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(C(F)(F)F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Cl)=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(C(F)(F)F)C=C3)=NC2=C1 NCHFIRAQOCBYKM-HOJIEIDUSA-N 0.000 description 1
- ZDYNJGOPFTUZNN-TUROWGRJSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(C(F)(F)F)=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(C(F)(F)F)=CC=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(C)(=O)=O)C=C3)=NC2=C1 ZDYNJGOPFTUZNN-TUROWGRJSA-N 0.000 description 1
- AJSUSTDWZLYURP-AQTOZCECSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(S(C)(=O)=O)C=C(Cl)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(SC(F)(F)F)C=C3)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(S(C)(=O)=O)C=C(Cl)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(SC(F)(F)F)C=C3)=NC2=C1 AJSUSTDWZLYURP-AQTOZCECSA-N 0.000 description 1
- BUZMTUBPNJVBJI-SUMPNEIVSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Br)=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Cl)=C(Cl)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(N(C)C)C=C3)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Br)=C(F)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Cl)=C(Cl)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(N(C)C)C=C3)=NC2=C1 BUZMTUBPNJVBJI-SUMPNEIVSA-N 0.000 description 1
- GWDDARPUGNYJPZ-DHFBXMSCSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC4=C(C=CN4)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(=O)O)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NC(C)=O)C=C3)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC4=C(C=CN4)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(=O)O)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(NC(C)=O)C=C3)=NC2=C1 GWDDARPUGNYJPZ-DHFBXMSCSA-N 0.000 description 1
- JEEFBBHAEKAXJT-JVGRRKRSSA-N CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Br)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(F)C=C3)=NC2=C1 Chemical compound CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Br)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C)C=C3)=NC2=C1.CNS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(F)C=C3)=NC2=C1 JEEFBBHAEKAXJT-JVGRRKRSSA-N 0.000 description 1
- OBMBCEIRFGSQKY-MLBSPLJJSA-N CNS(c(cccc1)c1-c(cc1)cc2c1NC(/C=C/c1cc(C(F)(F)F)cc(F)c1)=[I]2)(=O)=[U] Chemical compound CNS(c(cccc1)c1-c(cc1)cc2c1NC(/C=C/c1cc(C(F)(F)F)cc(F)c1)=[I]2)(=O)=[U] OBMBCEIRFGSQKY-MLBSPLJJSA-N 0.000 description 1
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 1
- PJSGUVVOEVKROH-UHFFFAOYSA-N COC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F Chemical compound COC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F PJSGUVVOEVKROH-UHFFFAOYSA-N 0.000 description 1
- RECGSEBTLPMJOL-UHFFFAOYSA-N COC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 Chemical compound COC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 RECGSEBTLPMJOL-UHFFFAOYSA-N 0.000 description 1
- CDUPIIJKSWKIJH-HXMFFAJGSA-N CS(=O)(=O)C1=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=CC(Cl)=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Br)=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(C(F)(F)F)=C(Cl)C=C3)=NC2=C1 Chemical compound CS(=O)(=O)C1=C(/C=C/C2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=CC(Cl)=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Br)=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(C(F)(F)F)=C(Cl)C=C3)=NC2=C1 CDUPIIJKSWKIJH-HXMFFAJGSA-N 0.000 description 1
- SVNCQEFWJCHDTM-FIRVGLBESA-N CS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(C(F)(F)F)C=C3)=NC2=C1 SVNCQEFWJCHDTM-FIRVGLBESA-N 0.000 description 1
- WZJADDSIYMYIOD-WXVXHBNASA-N CS(=O)(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CS(=O)(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(OC(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CS(=O)(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 Chemical compound CS(=O)(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(C(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CS(=O)(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(OC(F)(F)F)C=C4)=NC3=C2)C=CC=C1.CS(=O)(=O)NC1=C(C2=CC=C3NC(/C=C/C4=CC=C(S(=O)(=O)C(F)(F)F)C=C4)=NC3=C2)C=CC=C1 WZJADDSIYMYIOD-WXVXHBNASA-N 0.000 description 1
- MLECOZWWBMPODD-UHFFFAOYSA-N CS(=O)(=O)NC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 Chemical compound CS(=O)(=O)NC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1.CS(=O)(=O)NC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4S(N)(=O)=O)=CC=C3N2)C=C1 MLECOZWWBMPODD-UHFFFAOYSA-N 0.000 description 1
- UKQAATLYCMZRJE-HOJIEIDUSA-N CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Cl)=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(C(F)(F)F)C=C3)=NC2=C1 Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(C(F)(F)F)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Cl)=C(Cl)C=C3)=NC2=C1.CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(C(F)(F)F)C=C3)=NC2=C1 UKQAATLYCMZRJE-HOJIEIDUSA-N 0.000 description 1
- VNNNHFYFYVXRQN-UHFFFAOYSA-N CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Br)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(C(F)(F)F)C=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C(C(F)(F)F)=CC=C3)=NC2=C1 Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(Br)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(C(F)(F)F)C=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C(C(F)(F)F)=CC=C3)=NC2=C1 VNNNHFYFYVXRQN-UHFFFAOYSA-N 0.000 description 1
- PRFUWTYLBPCMGO-RVDQCCQOSA-N CS(Nc(cccc1)c1-c(cc1)cc2c1[nH]c(/C=C/c(cc1Br)ccc1F)n2)(=O)=[U] Chemical compound CS(Nc(cccc1)c1-c(cc1)cc2c1[nH]c(/C=C/c(cc1Br)ccc1F)n2)(=O)=[U] PRFUWTYLBPCMGO-RVDQCCQOSA-N 0.000 description 1
- SKFADUDAIPAPNN-LKPGWOPQSA-N CSC1=CC=C(/C=C/C2=NC3=CC(C4=C(C(N)=O)C=CC=C4)=CC=C3N2)C=C1.CSC1=CC=C(/C=C/C2=NC3=CC(C4=C(NC(C)=O)C=CC=C4)=CC=C3N2)C=C1.CSC1=CC=C(/C=C/C2=NC3=CC(C4=C(O)C=CC=C4)=CC=C3N2)C=C1 Chemical compound CSC1=CC=C(/C=C/C2=NC3=CC(C4=C(C(N)=O)C=CC=C4)=CC=C3N2)C=C1.CSC1=CC=C(/C=C/C2=NC3=CC(C4=C(NC(C)=O)C=CC=C4)=CC=C3N2)C=C1.CSC1=CC=C(/C=C/C2=NC3=CC(C4=C(O)C=CC=C4)=CC=C3N2)C=C1 SKFADUDAIPAPNN-LKPGWOPQSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- OCCJHLZTODGLGO-JQRICITDSA-N FC(F)(F)C1=CC=C(/C=C/C2=NC3=CC(Br)=CC=C3N2)C=C1.NC1=CC=C(Br)C=C1N.O=C(Cl)/C=C/C1=CC=C(C(F)(F)F)C=C1.O=C(O)/C=C/C1=CC=C(C(F)(F)F)C=C1 Chemical compound FC(F)(F)C1=CC=C(/C=C/C2=NC3=CC(Br)=CC=C3N2)C=C1.NC1=CC=C(Br)C=C1N.O=C(Cl)/C=C/C1=CC=C(C(F)(F)F)C=C1.O=C(O)/C=C/C1=CC=C(C(F)(F)F)C=C1 OCCJHLZTODGLGO-JQRICITDSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920004449 Halon® Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 101150042248 Mgmt gene Proteins 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 1
- PCKDICCFFGSFLW-MXGSWVGZSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Br)C=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(C(F)(F)F)=CC=C3)=NC2=C1 Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Br)C=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(C(F)(F)F)=CC=C3)=NC2=C1 PCKDICCFFGSFLW-MXGSWVGZSA-N 0.000 description 1
- QFXWDAFBUNXELP-ZZRDMNOQSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Cl)C=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Br)C=C3)=NC2=C1 Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(C(F)(F)F)C=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Cl)C=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(Br)C=C3)=NC2=C1 QFXWDAFBUNXELP-ZZRDMNOQSA-N 0.000 description 1
- FVIZPZIWXIRIGC-AGVLTFQCSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Cl)C=C(Cl)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=CC=C3Cl)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Br)=C(F)C=C3)=NC2=C1 Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(Cl)C=C(Cl)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=CC=C3Cl)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Br)=C(F)C=C3)=NC2=C1 FVIZPZIWXIRIGC-AGVLTFQCSA-N 0.000 description 1
- JATYJBWWGMHCHH-VCJHQVBUSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(Cl)=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Cl)=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC4=C(C=CC=C4)C=C3)=NC2=C1 Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(Cl)=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(Cl)=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC4=C(C=CC=C4)C=C3)=NC2=C1 JATYJBWWGMHCHH-VCJHQVBUSA-N 0.000 description 1
- NWVPNTSTWWUEQO-OFZXAQRYSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(F)=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(F)C(F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(C(F)(F)F)=C(F)C=C3)=NC2=C1 Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(F)=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(F)C(F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(C(F)(F)F)=C(F)C=C3)=NC2=C1 NWVPNTSTWWUEQO-OFZXAQRYSA-N 0.000 description 1
- YYBILDUIDKNLMO-HFFMTHMQSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(F)=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(F)C=C3)=NC2=C1 Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C(F)=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=C(F)C=C3)=NC2=C1 YYBILDUIDKNLMO-HFFMTHMQSA-N 0.000 description 1
- YAGGEHMFUYFQAH-AWDOSXIXSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=CC(Br)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(SC(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC(C(F)(F)F)=C(F)C=C3)=NC2=C1 Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=CC(Br)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(SC(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC(C(F)(F)F)=C(F)C=C3)=NC2=C1 YAGGEHMFUYFQAH-AWDOSXIXSA-N 0.000 description 1
- HZVZOOROIOISFK-KRVRXFASSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=CC(F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=CC(F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(OC(F)(F)F)=CC=C3)=NC2=C1 Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=C(F)C=CC(F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(F)=CC(F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC(OC(F)(F)F)=CC=C3)=NC2=C1 HZVZOOROIOISFK-KRVRXFASSA-N 0.000 description 1
- VPJKCLXRXWXOPZ-QHTFZSCTSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 VPJKCLXRXWXOPZ-QHTFZSCTSA-N 0.000 description 1
- FWYUXWRHZYAURW-YDXYJDPXSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(/C=C/C3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F FWYUXWRHZYAURW-YDXYJDPXSA-N 0.000 description 1
- NYPNTXAVXCFGHB-UHFFFAOYSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(C(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(OC(F)(F)F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1 NYPNTXAVXCFGHB-UHFFFAOYSA-N 0.000 description 1
- IPGGTGAVUKGGJR-UHFFFAOYSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=C(C#CC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F IPGGTGAVUKGGJR-UHFFFAOYSA-N 0.000 description 1
- OLHBFXBBVFIYFW-UHFFFAOYSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(Cl)=CC=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(Cl)=CC=C3)=NC2=C1)C(F)(F)F Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(Cl)=CC=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C3CC3C3=CC(Cl)=CC=C3)=NC2=C1)C(F)(F)F OLHBFXBBVFIYFW-UHFFFAOYSA-N 0.000 description 1
- GKYSZRBJGXTQJI-UHFFFAOYSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C(F)=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C=C(F)C(F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C=CC=C3F)=NC2=C1 Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C(F)=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C=C(F)C(F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C=CC=C3F)=NC2=C1 GKYSZRBJGXTQJI-UHFFFAOYSA-N 0.000 description 1
- GCYYASNAJQTREM-UHFFFAOYSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C(F)=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C=CC(F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC(F)=C(F)C=C3)=NC2=C1 Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C(F)=CC=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C=CC(F)=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC(F)=C(F)C=C3)=NC2=C1 GCYYASNAJQTREM-UHFFFAOYSA-N 0.000 description 1
- PRRCPAPZCKTMJM-UHFFFAOYSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC(C(F)(F)F)=C(Cl)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC(OC(F)(F)F)=CC=C3)=NC2=C1 Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=C(F)C=C(F)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC(C(F)(F)F)=C(Cl)C=C3)=NC2=C1.NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC(OC(F)(F)F)=CC=C3)=NC2=C1 PRRCPAPZCKTMJM-UHFFFAOYSA-N 0.000 description 1
- BMWIBABFKXAFIA-UHFFFAOYSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(NS(=O)(=O)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=C(CCC2=NC3=CC(C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)=CC=C3N2)C=C1)C(F)(F)F BMWIBABFKXAFIA-UHFFFAOYSA-N 0.000 description 1
- NUKPCELAAUAPET-UHFFFAOYSA-N NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(CCC3=CC=C(OCC(F)(F)C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F NUKPCELAAUAPET-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N Nc(cc1)ccc1Br Chemical compound Nc(cc1)ccc1Br WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- HDTGQDPPKVXGQN-ZIKNSQGESA-N O=C(O)/C=C/C1=CC=C(C(F)(F)F)C=C1.O=CC1=CC=C(C(F)(F)F)C=C1 Chemical compound O=C(O)/C=C/C1=CC=C(C(F)(F)F)C=C1.O=CC1=CC=C(C(F)(F)F)C=C1 HDTGQDPPKVXGQN-ZIKNSQGESA-N 0.000 description 1
- INSZXIZXCQRZSX-UHFFFAOYSA-N O=C=O.[H]C#CC.[H]C#CC.[KH].[K][K].[K][K] Chemical compound O=C=O.[H]C#CC.[H]C#CC.[KH].[K][K].[K][K] INSZXIZXCQRZSX-UHFFFAOYSA-N 0.000 description 1
- DCNYTSXFMCNJBL-UHFFFAOYSA-N O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(OC(F)(F)F)C=C3)=NC2=C1)C(F)(F)F.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F Chemical compound O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(OC(F)(F)F)C=C3)=NC2=C1)C(F)(F)F.O=S(=O)(NC1=CC=CC=C1C1=CC=C2NC(C#CC3=CC=C(S(=O)(=O)C(F)(F)F)C=C3)=NC2=C1)C(F)(F)F DCNYTSXFMCNJBL-UHFFFAOYSA-N 0.000 description 1
- QIAAZIORCYVNFE-UHFFFAOYSA-N O=S(C(F)(F)F)(Nc(cc1)ccc1C#Cc1nc2cc(-c(cccc3)c3NS(C(F)(F)F)(=O)=O)ccc2[nH]1)=O Chemical compound O=S(C(F)(F)F)(Nc(cc1)ccc1C#Cc1nc2cc(-c(cccc3)c3NS(C(F)(F)F)(=O)=O)ccc2[nH]1)=O QIAAZIORCYVNFE-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 238000006959 Williamson synthesis reaction Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- NELWQUQCCZMRPB-UBPLGANQSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-(4-amino-5-ethenyl-2-oxopyrimidin-1-yl)-2-methyloxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](C)O[C@H]1N1C(=O)N=C(N)C(C=C)=C1 NELWQUQCCZMRPB-UBPLGANQSA-N 0.000 description 1
- LFPWGJYISAMLAO-UHFFFAOYSA-N [2-(tert-butylsulfamoyl)-4-(trifluoromethyl)phenyl]boronic acid Chemical compound CC(C)(C)NS(=O)(=O)C1=CC(C(F)(F)F)=CC=C1B(O)O LFPWGJYISAMLAO-UHFFFAOYSA-N 0.000 description 1
- RECUHXGDBHJTGQ-UHFFFAOYSA-N [2-(tert-butylsulfamoyl)-5-(trifluoromethyl)phenyl]boronic acid Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1B(O)O RECUHXGDBHJTGQ-UHFFFAOYSA-N 0.000 description 1
- YKRBAKKINBRIBQ-UHFFFAOYSA-N [2-(tert-butylsulfamoyl)-5-fluorophenyl]boronic acid Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=C(F)C=C1B(O)O YKRBAKKINBRIBQ-UHFFFAOYSA-N 0.000 description 1
- DUSWODNFBUGNKG-UHFFFAOYSA-M [6-[2-(methylsulfamoyl)phenyl]-1h-benzimidazol-2-yl]methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CNS(=O)(=O)C1=CC=CC=C1C1=CC=C(N=C(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)N2)C2=C1 DUSWODNFBUGNKG-UHFFFAOYSA-M 0.000 description 1
- IOUQODXLIXCQHJ-UHFFFAOYSA-N [O-][N+](c1cc(Br)ccc1NC(C(F)(F)F)=O)=O Chemical compound [O-][N+](c1cc(Br)ccc1NC(C(F)(F)F)=O)=O IOUQODXLIXCQHJ-UHFFFAOYSA-N 0.000 description 1
- 125000004062 acenaphthenyl group Chemical group C1(CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 description 1
- ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000007529 anxiety like behavior Effects 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- KHBQMWCZKVMBLN-IDEBNGHGSA-N benzenesulfonamide Chemical group NS(=O)(=O)[13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1 KHBQMWCZKVMBLN-IDEBNGHGSA-N 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- LMQZSIUSHAGOPE-UHFFFAOYSA-N bromobenzene;2-methylpropane-2-sulfonamide Chemical compound BrC1=CC=CC=C1.CC(C)(C)S(N)(=O)=O LMQZSIUSHAGOPE-UHFFFAOYSA-N 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- CHHJDCVKYCVTHD-UHFFFAOYSA-N chloromethyl formate Chemical compound ClCOC=O CHHJDCVKYCVTHD-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- YGNHVMNLOAYHEK-UHFFFAOYSA-M copper(1+);toluene;trifluoromethanesulfonate Chemical compound [Cu+].CC1=CC=CC=C1.[O-]S(=O)(=O)C(F)(F)F YGNHVMNLOAYHEK-UHFFFAOYSA-M 0.000 description 1
- YNYHGRUPNQLZHB-UHFFFAOYSA-M copper(1+);trifluoromethanesulfonate Chemical compound [Cu+].[O-]S(=O)(=O)C(F)(F)F YNYHGRUPNQLZHB-UHFFFAOYSA-M 0.000 description 1
- 230000036757 core body temperature Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000005888 cyclopropanation reaction Methods 0.000 description 1
- HWDVTQAXQJQROO-UHFFFAOYSA-N cyclopropylazanide Chemical compound [NH-]C1CC1 HWDVTQAXQJQROO-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- CVKBMWWNKUWISK-UHFFFAOYSA-L dichloromethane;dichloropalladium Chemical compound ClCCl.Cl[Pd]Cl CVKBMWWNKUWISK-UHFFFAOYSA-L 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- ILIHJUQLUVJLEF-VMPITWQZSA-N ethyl (e)-3-[4-(trifluoromethylsulfanyl)phenyl]prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C(SC(F)(F)F)C=C1 ILIHJUQLUVJLEF-VMPITWQZSA-N 0.000 description 1
- DEBPRNDMJGKCBA-UHFFFAOYSA-N ethyl 1h-pyrazolo[3,4-c]pyridine-3-carboxylate Chemical compound N1=CC=C2C(C(=O)OCC)=NNC2=C1 DEBPRNDMJGKCBA-UHFFFAOYSA-N 0.000 description 1
- BGWMHFKCAUBYJJ-UHFFFAOYSA-N ethyl 2-chloroethanimidate;hydrochloride Chemical compound Cl.CCOC(=N)CCl BGWMHFKCAUBYJJ-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- XLYMOEINVGRTEX-UHFFFAOYSA-N fumaric acid monoethyl ester Natural products CCOC(=O)C=CC(O)=O XLYMOEINVGRTEX-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Chemical group 0.000 description 1
- LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 description 1
- JOLVEJGFWHTTJU-UHFFFAOYSA-N methyl 2-[4-(trifluoromethyl)phenyl]cyclopropane-1-carboxylate Chemical compound COC(=O)C1CC1C1=CC=C(C(F)(F)F)C=C1 JOLVEJGFWHTTJU-UHFFFAOYSA-N 0.000 description 1
- YUEFITCWDISQAO-UHFFFAOYSA-N methyl 3-[4-(trifluoromethyl)phenyl]prop-2-enoate Chemical compound COC(=O)C=CC1=CC=C(C(F)(F)F)C=C1 YUEFITCWDISQAO-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- RMHWQOPWSJKBNU-UHFFFAOYSA-N n-(4-bromo-5-chloro-2-nitrophenyl)-2,2,2-trifluoroacetamide Chemical compound [O-][N+](=O)C1=CC(Br)=C(Cl)C=C1NC(=O)C(F)(F)F RMHWQOPWSJKBNU-UHFFFAOYSA-N 0.000 description 1
- FAARUIOMBUCVOK-UHFFFAOYSA-N n-(4-bromo-5-fluoro-2-nitrophenyl)-2,2,2-trifluoroacetamide Chemical compound [O-][N+](=O)C1=CC(Br)=C(F)C=C1NC(=O)C(F)(F)F FAARUIOMBUCVOK-UHFFFAOYSA-N 0.000 description 1
- JNRJGPWFXHEKTK-UHFFFAOYSA-N n-[2-(3,4-diaminophenyl)phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=CC=C(N)C(N)=C1 JNRJGPWFXHEKTK-UHFFFAOYSA-N 0.000 description 1
- PVDJYCKTHFOWDI-UHFFFAOYSA-N n-[4-bromo-2-nitro-5-(trifluoromethyl)phenyl]-2,2,2-trifluoroacetamide Chemical compound [O-][N+](=O)C1=CC(Br)=C(C(F)(F)F)C=C1NC(=O)C(F)(F)F PVDJYCKTHFOWDI-UHFFFAOYSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- PFGABPIILKDEOG-UHFFFAOYSA-N n-methoxy-n-methyl-3-[4-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound CON(C)C(=O)C=CC1=CC=C(C(F)(F)F)C=C1 PFGABPIILKDEOG-UHFFFAOYSA-N 0.000 description 1
- SVDVKEBISAOWJT-UHFFFAOYSA-N n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1 SVDVKEBISAOWJT-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MLZXGWMHVAQBDF-UHFFFAOYSA-N n-tert-butyl-2-[1-(2-phenylethynyl)benzimidazol-5-yl]benzenesulfonamide Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C(N(C=N2)C#CC=3C=CC=CC=3)C2=C1 MLZXGWMHVAQBDF-UHFFFAOYSA-N 0.000 description 1
- 229940126662 negative allosteric modulator Drugs 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 210000000584 nodose ganglion Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- XNERWVPQCYSMLC-UHFFFAOYSA-N phenylpropiolic acid Chemical compound OC(=O)C#CC1=CC=CC=C1 XNERWVPQCYSMLC-UHFFFAOYSA-N 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- DOICBOHDZGDWQZ-FDOHDBATSA-N sodium;2-[2-[2-[(1s,2s)-2-[4-(trifluoromethyl)phenyl]cyclopropyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound [Na].CC(C)(O)C1=CC=CC=C1C1=CC=C(N=C(N2)[C@@H]3[C@H](C3)C=3C=CC(=CC=3)C(F)(F)F)C2=C1 DOICBOHDZGDWQZ-FDOHDBATSA-N 0.000 description 1
- CRLMFZMERBNONC-KYIGKLDSSA-N sodium;2-[2-[2-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3h-benzimidazol-5-yl]phenyl]propan-2-ol Chemical compound [Na].CC(C)(O)C1=CC=CC=C1C1=CC=C(N=C(\C=C\C=2C=CC(=CC=2)C(F)(F)F)N2)C2=C1 CRLMFZMERBNONC-KYIGKLDSSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- BJAAOPIUUGGGSU-UHFFFAOYSA-N tert-butyl n-[4-[2-(methanesulfonamido)phenyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]carbamate Chemical compound C1=C(NC(=O)OC(C)(C)C)C(NC(=O)OC(C)(C)C)=CC=C1C1=CC=CC=C1NS(C)(=O)=O BJAAOPIUUGGGSU-UHFFFAOYSA-N 0.000 description 1
- LJKCSTXFYRULGQ-UHFFFAOYSA-N tert-butyl n-[4-bromo-2-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(Br)C=C1NC(=O)OC(C)(C)C LJKCSTXFYRULGQ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- AJSTXXYNEIHPMD-UHFFFAOYSA-N triethyl borate Chemical compound CCOB(OCC)OCC AJSTXXYNEIHPMD-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000002827 triflate group Chemical class FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000011706 wistar kyoto rat Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Description
- The present application claims the benefits of the filing of U.S. application Ser. No. 11/734,984 filed Apr. 13, 2007, and U.S. Provisional Application No. 60/797,504 filed May 3, 2006. The complete disclosures of the aforementioned related patent applications are hereby incorporated herein by reference for all purposes.
- Noxious chemical, thermal and mechanical stimuli excite peripheral nerve endings of small diameter sensory neurons (nociceptors) deriving from sensory ganglia (e.g., dorsal root, nodose and trigeminal ganglia) and initiate signals that are perceived as pain. Such nociceptive neurons (i.e., nociceptors) are crucial for the detection of harmful or potentially harmful stimuli (e.g., noxious thermal, chemical, and/or mechanical) that arise from changes in the extracellular environment during inflammatory, ischemic or otherwise traumatic conditions and that cause or have the potential to cause tissue damage (Wall, P. D., and Melzack, R., Textbook of Pain, 1994, New York: Churchill Livingstone).
- Nociceptors transduce noxious stimuli into membrane depolarization that leads to an action potential, its subsequent conduction to the CNS, and ultimately to the perception of pain, discomfort, etc. as well as to certain responses thereto. At the molecular level, nociception is carried out by ion channels and/or receptors. Plant-derived vanilloid compounds (e.g., capsaicin and resiniferatoxin) are known to selectively depolarize nociceptors and elicit sensations of burning pain: the sensation that is typically evoked by capsaicin-containing hot chili peppers. Therefore, capsaicin mimics the action of physiological/endogenous stimuli that activate the “nociceptive pathway”. Recent advances in pain biology have identified a receptor, called VR1 (a.k.a. capsaicin receptor or TRPV1) for vanilloids, protons and noxious heat. Because nociceptors are drivers of unwanted pain and inflammatory conditions in human beings and animals, modulation of their function is a validated strategy for palliative and other analgesic therapies.
- Compounds that are modulators (competitive and non-competitive agonists or antagonists [with respect to capsaicin and/or its recognition site] and allosteric modulators) at VR1 have broad therapeutic potential, as demonstrated by the clinical usefulness of marketed, VR1-targeted pharmaceutical agents or the efficacy of VR1 modulators in animal models of disease. Furthermore, it is recognized that agonist modulators of VR1 may possess clinical utility deriving from their agonist properties, per se, and/or from their ability to produce an agonist-mediated desensitization, which would indirectly manifest as a functional antagonism. Similarly, antagonist modulators could exhibit direct antagonist (competitive or non-competitive) properties and/or indirect antagonist properties via the aforementioned desensitization mechanism. It is further recognized that positive and negative allosteric modulators may produce any or all of the aforementioned functional consequences and, as such, may also have clinical utility. Accordingly, this invention is directed to each of these types of modulators.
- The effective use of VR1 agonists has been demonstrated in inflammatory, neuropathic, and visceral pain states. In an experimental human pain model, dermal capsaicin pretreatment reduced the pain caused by intradermal injection of an acidic solution (Bianco, E. D.; Geppetti, P.; Zippi, P.; Isolani, D.; Magini, B.; Cappugi, P. Brit J of Clin Pharmacol 1996, 41, 1-6), suggesting the benefit of VR1 agonists in the treatment of inflammatory pain. A particular role for VR1 agonists has been shown in inflammation and inflammatory pain: for example, resiniferatoxin prevented inflammatory hypersensitivity and edema induction by carrageenan (Kissin, I.; Bright, C. A.; Bradley, E. L., Jr. Anesth Analg 2002, 94, 1253-1258).
- Additionally, capsaicin-containing creams (for example, Axcain® and Lidocare®) are marketed for dermal relief of pain related to diabetic neuropathy and postherpetic neuralgia, indicative of the usefulness of VR1 agonists in the treatment of neuropathic pain states. Furthermore, such creams have been shown to reduce postsurgical neuropathic pain (Ellison, N., Loprinzi, C. L., Kugler, J., Hatfield, A. K., Miser, A., Sloan, J. A., Wender, D. B., Rowland, K. M., Molina, R., Cascino, T. L., Vukov, A. M., Dhaliwal, H. S. and Ghosh, C. J. Clin. Oncol. 15:2974-2980, 1997). In cancer patients, capsaicin contained in a taffy vehicle, was shown to substantially reduce oral mucositis pain caused by chemotherapy and radiation therapy (Berger, A., Henderson, M., Naadoolman, W., Duffy, V., Cooper, D., Saberski, L. and Bartoshuk, L. J. Pain Sympt. Mgmt 10:243-248, 1995.
- VR1 also plays a role in the physiology of bladder emptying. VR1 is expressed by bladder sensory neurons, where it modulates bladder responsivity to liquid filling. The VR1 agonist resiniferatoxin desensitized bladder afferents in a dose-dependent manner (Avelino, A.; Cruz, F.; Coimbra, A. Eur. J. Pharmacol. 1999, 378, 17-22), supporting its usefulness for the treatment of overactive bladder (Chancellor, M. B.; De Groat, W. C. J. Urol. (Baltimore) 1999, 162, 3-11). Indeed, intravesicular administration of capsaicin or resiniferatoxin inhibited bladder contraction in both normal and spinal cord injured rats (Komiyama, I.; Igawa, Y.; Ishizuka, O.; Nishizawa, O.; Andersson, K.-E. J. Urol. (Baltimore) 1999, 161, 314-319), indicative of the usefulness of VR1 agonists in nerve-injured incontinent patients. The effectiveness of capsaicin or resiniferatoxin treatment on incontinence in spinal cord injured patients was confirmed in a clinical study (de Seze, M.; Wiart, L.; de Seze, M.-P.; Soyeur, L.; Dosque, J.-P.; Blajezewski, S.; Moore, N.; Brochet, B.; Mazaux, J.-M.; Barat, M.; Joseph, P.-A. Journal of Urology (Hagerstown, Md., United States) 2003, 171, 251-255).
- The effectiveness of VR1 agonists in the reduction of elevated blood pressure is suggested by capsaicin reduction in blood pressure in SHR and WKY rats (Li, J.; Kaminski, N. E.; Wang, D. H. Hypertension 2003, 41, 757-762.). Capsaicin was also gastroprotective with respect to gastric antral ulcers (Yamamoto, H.; Horie, S.; Uchida, M.; Tsuchiya, S.; Murayama, T.; Watanabe, K. Eur. J. Pharmacol. 2001, 432, 203-210).
- VR1 antagonists also may be useful in the treatment of inflammatory, neuropathic and visceral pain. For example, the therapeutic utility of VR1 antagonists has been demonstrated in visceral inflammatory conditions. VR1 is elevated in colonic nerve fibers in patients with inflammatory bowel disease, and VR1 antagonists relieved pain and dysmotility (Yiangou, Y.; Facer, P.; Dyer, N. H.; Chan, C. L.; Knowles, C.; Williams, N. S.; Anand, P. Lancet 2001, 357, 1338-1339). Intestinal inflammation induced by toxin A or dextran sulfate sodium in rodents was attenuated by VR1 antagonists (McVey, D. C.; Schmid, P. C.; Schmid, H. H. O.; Vigna, S. R. J. Pharmacol. Exp. Ther. 2003, 304, 713-722). In addition, a synthetic VR1 antagonist reduced colitis disease scores at several important endpoints, including macroscopic damage, microscopic epithelial damage, myeloperoxidase levels, and diarrhea scores, strongly supporting the therapeutic use of VR1 antagonists in inflammatory bowel diseases (Kimball, E. S.; Wallace, N. H.; Schneider, C. R.; D'Andrea, M. R.; Hornby, P. J. Neurogasteroenterology 2004, 16, 811-818). The VR1 antagonists capsazepine and BCTC reversed mechanical hyperalgesia in models of inflammatory and neuropathic pain in guinea pigs (Walker, K. M.; Urban, L.; Medhurst, S. J.; Patel, S.; Panesar, M.; Fox, A. J.; McIntyre, P. J. Pharmacol. Exp. Ther. 2003, 304, 56-62) and rats (Pomonis, J. D.; Harrison, J. E.; Mark, L.; Bristol, D. R.; Valenzano, K. J.; Walker, K. J. Pharmacol. Exp. Ther. 2003, 306, 387-393).
- LPS-induced fever was attenuated in VR1 knock out mice (Lida, T.; Shimizu, I.; Nealen, M. L.; Campbell, A.; Caterina, M. Neurosci. Lett. 2005, 378, 28-33). VR1 agonist-induced rises in core body temperature were suppressed by capsazepine, indicative of the usefulness of VR1 antagonists in the treatment of pyresis (Ohnluki, K.; Haramizu, S.; Watanabe, T.; Yazawa, S.; Fushiki, T. J. Nutr. Sci. Vitaminol. (Tokyo) 2001, 47, 295-298).
- VR1 agonists also modulate body temperature and fever. In ferret, rat and mouse, administration of resiniferatoxin-induced hypothermia (Woods, A. J.; Stock, M. J.; Gupta, A. N.; Wong, T. T. L.; Andrews, P. L. R. Eur. J. Pharmacol. 1994, 264, 125-133). Additionally, phase I of LPS (lipopolysaccharide)-induced fever did not occur in animals desensitized with low intraperitoneal doses of capsaicin (Romanovsky, A. A. Frontiers in Bioscience 2004, 9, 494-504).
- The therapeutic potential of VR1 antagonists in inflammatory bronchial conditions is demonstrated by the finding that they antagonize capsaicin- and acid-induced bronchoconstriction (Nault, M. A.; Vincent, S. G.; Fisher, J. T. J. Physiol. 1999, 515, 567-578). Related findings demonstrate that the VR1 antagonist capsazepine attenuates anandamide-induced cough in guinea pigs (Jia, Y.; McLeod, R. L.; Wang, X.; Parra, L. E.; Egan, R. W.; Hey, J. A. Brit. J. Pharmacol. 2002, 137, 831-836).
- The VR1 antagonist capsazepine was demonstrated to significantly reduce anxiety-like behaviors in rats using the elevated plus maze (Kasckow, J. W.; Mulchahey, J. J.; Geracioti, T. D. Jr. Progress in Neuro-Psychopharmacol. and Biological Psychiatry 2004, 28, 291-295). Thus, VR1 antagonists may have utility in the treatment of anxiety, panic disorders, phobias or other non-adaptive stress responses.
- U.S. Pat. No. 6,299,796B1 discloses electroluminescent elements comprising units of the formula:
- Thus, there is a need for potent modulators of VR1, and in particular, for novel benzimidazole compounds that exhibit potent binding affinity for the human and rat VR1 ion channel. There is also a need for novel benzimidazole compounds that act as potent functional antagonists and/or agonists of the human and rat VR1 ion channel. Finally, there is a need for novel benzimidazoles that bind with high affinity to VR1 and also act as potent functional antagonists of the human and rat VR1 ion channel.
- The present invention is directed to a compound of Formula (I):
- and a form thereof, wherein R1, R2, R3a, R3b, R4, p, q, r, L and A1 are as defined herein, and their use as potent modulators of VR1.
- The present invention is also directed to a method for treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I). The present invention is further directed to a process for making a compound of Formula (I) and salts thereof.
- The present invention is directed to compounds of Formula (I):
- and a form thereof, wherein:
- the dashed lines between positions 1, 2 and 3 in Formula (I) indicate the positions of a tautomeric double bond,
- wherein when a double bond is formed between positions 1 and 2, then R3b is present, and
- wherein, when a double bond is formed between positions 2 and 3, then R3a is present;
- p is 1 or 2;
- q is 0 or 1;
- r is 0, 1, 2 or 3;
- L is C1-3alkyl, C2-3alkenyl, C2-3alkynyl or cyclopropyl;
- A1 is selected from the group consisting of phenyl, biphenyl, naphthyl, pyridinyl, quinolinyl and indole;
- R1 is each selected from the group consisting of hydroxy, cyano, halogen, formyl, carboxy, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylcarbonyl, C1-6alkoxycarbonyl, C1-6alkylthio, C1-6alkylsulfonyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl, C3-8cycloalkyl-C1-4alkoxy, C3-8cycloalkyl-oxy, amino, (C1-6alkyl)1-2amino, (C3-8cycloalkyl)1-2amino, (C3-8cycloalkyl-C1-4alkyl)1-2amino, aminocarbonyl, (C1-6alkyl)1-2aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2aminocarbonylamino, C1-6alkylsulfonylamino, C1-6alkylsulfinylamino, aminosulfonyl, (C1-4alkyl)1-2aminosulfonyl, aminosulfonylamino and (C1-6alkyl)1-2aminosulfonylamino,
- wherein alkyl is optionally substituted with C1-8alkoxy, amino, (C1-4alkyl)1-2amino, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2aminocarbonylamino, C1-6alkylsulfonylamino, aminosulfonylamino, (C1-6alkyl)1-2aminosulfonylamino hydroxy and phenyl,
- wherein phenyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, cyano, nitro, C1-6alkyl, C1-6alkoxy, C1-6alkylthio and C1-6alkylsulfonyl, and
- wherein, each instance of alkyl and alkoxy is optionally perfluorinated;
- R2 is selected from the group consisting of halogen, C1-4alkyl, C1-4alkoxy, C1-4alkylsulfonyl, nitro, amino, (C1-4alkyl)1-2amino and cyano,
- wherein each instance of alkyl and alkoxy is optionally perfluorinated;
- R3a and R3b are each selected from the group consisting of hydrogen and optionally perfluorinated C1-4alkyl; and
- R4 is each selected from the group consisting of halogen, nitro, cyano, carboxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkoxy-C1-6alkyl, C1-6alkylcarbonyl, C1-6alkylthio, haloC1-6alkylthio, C1-6alkylsulfonyl, haloC1-6alkylsulfonyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl, C3-8cycloalkyl-C1-4alkoxy, C3-8cycloalkyl-oxy, amino, (C1-6alkyl)1-2amino, (C3-8cycloalkyl)1-2amino, (C3-8cycloalkyl-C1-4alkyl)1-2amino, aminocarbonyl, (C1-6alkyl)1-2aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2aminocarbonylamino, C1-6alkylsulfonylamino, haloC1-6alkylsulfonylamino, C1-6alkylsulfinylamino, aminosulfonyl and (C1-4alkyl)1-2aminosulfonyl,
- wherein each instance of alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C1-8alkoxy, amino, (C1-4alkyl)1-2amino, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2aminocarbonylamino, C1-6alkylsulfonylamino, oxo and hydroxy, and
- wherein, each instance of alkyl and alkoxy is optionally perfluorinated.
- An example of the present invention includes a compound of Formula (I) or a form thereof, wherein q is 0.
- An example of the present invention includes a compound of Formula (I) or a form thereof, wherein A1 is selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole.
- An example of the present invention includes a compound of Formula (I) or a form thereof, wherein
- R1 is each selected from the group consisting of hydroxy, halogen, formyl, C1-6alkyl, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkylcarbonyl, C1-6alkoxycarbonyl, C1-6alkylthio, C1-6alkylsulfonyl, amino, aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, C1-6alkylsulfonylamino, aminosulfonyl, (C1-4alkyl)1-2aminosulfonyl and aminosulfonylamino,
- wherein alkyl is optionally substituted with amino, (C1-4alkyl)1-2amino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated.
- An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R2 is selected from the group consisting of halogen and C1-4alkyl, wherein alkyl is optionally perfluorinated.
- An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R3a and R3b are each selected from the group consisting of hydrogen and C1-4alkyl.
- An example of the present invention includes a compound of Formula (I) or a form thereof, wherein R4 is each selected from the group consisting of halogen, carboxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkylcarbonyl, haloC1-6alkylthio, C1-6alkylsulfonyl, haloC1-6alkylsulfonyl, (C1-6alkyl)1-2amino, (C1-6alkyl)1-2aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkylsulfonylamino and haloC1-6alkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.
- An example of the present invention includes a compound of Formula (I) or a form thereof, wherein
- p is 1 or 2;
- q is 0;
- r is 0, 1, 2 or 3;
- L is C1-3alkyl, C2-3alkenyl, C2-3alkynyl or cyclopropyl;
- A1 is selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole;
- R1 is each selected from the group consisting of hydroxy, halogen, formyl, C1-6alkyl, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkylcarbonyl, C1-6alkoxycarbonyl, C1-6alkylthio, C1-6alkylsulfonyl, amino, aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, C1-6alkylsulfonylamino, aminosulfonyl, (C1-4alkyl)1-2aminosulfonyl and aminosulfonylamino,
- wherein alkyl is optionally substituted with amino, (C1-4alkyl)1-2amino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated;
- R2 is selected from the group consisting of halogen and C1-4alkyl, wherein alkyl is optionally perfluorinated;
- R3a and R3b are each selected from the group consisting of hydrogen and C1-4alkyl; and
- R4 is each selected from the group consisting of halogen, carboxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkylcarbonyl, haloC1-6alkylthio, C1-6alkylsulfonyl, haloC1-6alkylsulfonyl, (C1-6alkyl)1-2amino, (C1-6alkyl)1-2aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkylsulfonylamino and haloC1-6alkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.
- The present invention is further directed to compounds of Formula Ia or Ib:
- wherein:
- R1 is independently hydroxyl; halogen, C1-6alkanyl; fluorinated C1-6alkanyl; C1-6alkanyloxy; fluorinated C1-6alkanyloxy; C1-6alkanylthio; fluorinated C1-6alkanylthio; C1-6alkanylsulfonyl; fluorinated C1-6alkanylsulfonyl; C3-8cycloalkanyl; C3-8cycloalkanyl; C1-4alkanyl; C3-8cycloalkanyloxy; C3-8cycloalkanyl; C1-4alkanyloxy; amino; (C1-6alkanyl)1-2amino; (C3-8cycloalkanyl)1-2amino; (C3-8cycloalkanyl; C1-4alkanyl)1-2amino; cyano; aminocarbonyl; (C1-6alkanyl)1-2aminocarbonyl; C1-6alkanylcarbonylamino; fluorinated C1-6alkanylcarbonylamino; C1-6alkanyloxycarbonylamino; C0-6alkanylaminocarbonylamino; C1-6alkanylsulfonylamino; fluorinated C1-6alkanylsulfonylamino; aminosulfonyl; (C1-8alkanyl)1-2aminosulfonyl; fluorinated (C1-8alkanyl)1-2aminosulfonyl; wherein the alkanyl in any alkanyl-containing substituent of R1 is optionally substituted with 1 to 3 substituents independently selected from the group consisting of amino, (C1-8alkanyl)1-2amino, C1-6alkanylcarbonylamino; fluorinated C1-6alkanylcarbonylamino; C1-6alkanyloxycarbonylamino; C0-6alkanylaminocarbonylamino; C1-6alkanylsulfonylamino; fluorinated C1-6alkanylsulfonylamino; halogen, oxo, hydroxyl, fluorinated alkanyl, and C1-8alkanyloxy;
- p is 1 or 2;
- R2 is independently selected from the group consisting of halogen; C1-4alkanyl; fluorinated C1-4alkanyl; C1-4alkanyloxy; fluorinated C1-6alkanyloxy; C1-4alkanylsulfonyl; fluorinated C1-4alkanylsulfonyl; nitro; (C1-4alkanyl)1-2amino; cyano;
- n is 0, or 1;
- R3 is independently selected from the group consisting of hydrogen, C1-4alkanyl, and fluorinated C1-4alkanyl;
- L is C2-3alkyldiyl,
- A1 is selected from the group consisting of phenyl and naphthyl;
- R4 is independently halogen, C1-6alkanyl; fluorinated C1-6alkanyl; C1-6alkanyloxy; fluorinated C1-6alkanyloxy; C1-6alkanylthio; fluorinated C1-6alkanylthio; C1-6alkanylsulfonyl; fluorinated C1-6alkanylsulfonyl; C3-8cycloalkanyl; C3-8cycloalkanyl; C1-4alkanyl; C3-8cycloalkanyloxy; C3-8cycloalkanyl; C1-4alkanyloxy; amino; (C1-6alkanyl)1-2amino; (C3-8cycloalkanyl)1-2amino; (C3-8cycloalkanyl; C1-4alkanyl)1-2amino; cyano; aminocarbonyl; (C1-6alkanyl)1-2aminocarbonyl; C0-6alkanylcarbonylamino; fluorinated C1-6alkanylcarbonylamino; C1-6alkanyloxycarbonylamino; C0-6alkanylaminocarbonylamino; C1-6alkanylsulfonylamino; fluorinated C1-6alkanylsulfonylamino; aminosulfonyl; (C1-8alkanyl)1-2aminosulfonyl; fluorinated (C1-8alkanyl)1-2aminosulfonyl; wherein the alkanyl in any alkanyl-containing substituent of R1 is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, oxo, hydroxyl, fluorinated alkanyl, and C1-8alkanyloxy; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen; C1-4alkanyl; fluorinated C1-4alkanyl; C1-4alkanyloxy; fluorinated C1-4alkanyloxy; C1-4alkanylsulfonyl; fluorinated C1-4alkanylsulfonyl; nitro; cyano;
- r is 0, 1 or 2; and
- enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.
- An example of the present invention includes compounds and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof selected from the group consisting of:
- As modulators of the vanilloid VR1 ion channel, the compounds of Formula (I) are useful in methods for treating a VR1 ion channel mediated disease in a subject which disease is affected by the modulation of one or more vanilloid receptors.
- Accordingly, the present invention is directed to a method of treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a salt or solvate thereof.
- The term “form” means, in reference to compounds of the present invention, such may exist as, without limitation, a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form. The present invention encompasses all such compound forms and mixtures thereof.
- The term “isolated form” means, in reference to compounds of the present invention, that such may exist in an essentially pure state such as, without limitation, an enantiomer, a racemic mixture, a geometric isomer (such as a cis or trans stereoisomer), a mixture of geometric isomers, and the like. The present invention encompasses all such isolated forms and mixtures thereof.
- Certain compounds of Formula (I) may exist in various stereoisomeric or tautomeric forms and mixtures thereof. The invention encompasses all such compounds and mixtures thereof.
- The compounds of the present invention may be present in the form of pharmaceutically acceptable salts. For use in medicines, the “pharmaceutically acceptable salts” of the compounds of this invention refer to non-toxic acidic/anionic or basic/cationic salt forms.
- Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- Furthermore when the compounds of the present invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
- Thus, representative pharmaceutically acceptable salts include the following: acetate, adipate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphorsulphonate), carbonate, chloride, choline, clavulanate, citrate, dihydrochloride, disodium, edetate, fumarate, gluconate, glutamate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, salicylate, sodium, stearate, sulfate, succinate, tartrate, tromethane, tosylate, trichloroacetate, trifluoroacetate and the like.
- An example of the present invention includes compounds of Formula (I) and a salt form thereof wherein the salt is selected from the group consisting of disodium, hydrochloride and sodium.
- The invention includes compounds of various isomers and mixtures thereof. The term “isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. Such substances have the same number and kind of atoms but differ in structure. The structural difference may be in constitution (geometric isomers) or in an ability to rotate the plane of polarized light (stereoisomers).
- The term “optical isomer” means isomers of identical constitution that differ only in the spatial arrangement of their groups. Optical isomers rotate the plane of polarized light in different directions. The term “optical activity” means the degree to which an optical isomer rotates the plane of polarized light.
- The term “racemate” or “racemic mixture” means an equimolar mixture of two enantiomeric species, wherein each of the isolated species rotates the plane of polarized light in the opposite direction such that the mixture is devoid of optical activity.
- The term “enantiomer” means an isomer having a nonsuperimposable mirror image. The term “diastereomer” means stereoisomers that are not enantiomers.
- The term “chiral” means a molecule, which in a given configuration, cannot be superimposed on its mirror image. This is in contrast to achiral molecules, which can be superimposed on their mirror images.
- The invention is considered to include the tautomeric forms of all compounds of Formula (I). In addition, for chiral embodiments of the invention, the invention is considered to include pure enantiomers, racemic mixtures, as well as mixtures of enantiomers having 0.001% to 99.99% enantiomeric excess. In addition, some of the compounds represented by Formula (I) may be prodrugs, i.e., derivatives of a drug that possess superior delivery capabilities and therapeutic value as compared to the active drug. Prodrugs are transformed into active drugs by in vivo enzymatic or chemical processes.
- The two distinct mirror image versions of the chiral molecule are also known as levo (left-handed), abbreviated L, or dextro (right handed), abbreviated D, depending on which way they rotate polarized light. The symbols “R” and “S” represent the configuration of groups around a stereogenic carbon atom(s).
- An example of an enantiomerically enriched form isolated from a racemic mixture includes a dextrorotatory enantiomer, wherein the mixture is substantially free of the levorotatory isomer. In this context, substantially free means the levorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10%, less than 5%, less than 2% or less than 1% of the mixture according to the formula:
-
- Similarly, an example of an enantiomerically enriched form isolated from a racemic mixture includes a levorotatory enantiomer, wherein the mixture is substantially free of the dextrorotatory isomer. In this context, substantially free means the dextrorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10%, less than 5%, less than 2% or less than 1% of the mixture according to the formula:
-
- “Geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Substituent atoms (other than hydrogen) on each side of a carbon-carbon double bond may be in an E or Z configuration. In the “E” configuration, the substituents are on opposite sides in relationship to the carbon-carbon double bond. In the “Z” configuration, the substituents are oriented on the same side in relationship to the carbon-carbon double bond. The scope of the present invention is intended to include all such “E” and “Z” isomers.
- Substituent atoms (other than hydrogen) attached to a ring system may be in a cis or trans configuration. In the “cis” configuration, the substituents are on the same side in relationship to the plane of the ring; in the “trans” configuration, the substituents are on opposite sides in relationship to the plane of the ring. Compounds having a mixture of “cis” and “trans” species are designated “cis/trans”. The scope of the present invention is intended to include all such “cis” and “trans” isomers.
- The isomeric descriptors (“R,” “S,” “E,” and “Z”) indicate atom configurations relative to a core molecule and are intended to be used as defined in the literature.
- Furthermore, compounds of the present invention may have at least one crystalline, polymorph or amorphous form. The plurality of such forms is included in the scope of the invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like). The plurality of such solvates is also intended to be encompassed within the scope of this invention.
- Bond lines drawn into a ring system from a substituent variable indicate that the substituent may be attached to any of the substitutable ring atoms.
- As used herein, the following terms are intended to have the following meanings (additional definitions are provided where prophetic throughout the Specification). The definitions herein may specify that a chemical term has an indicated formula. The particular formula provided is not intended to limit the scope of the invention, but is provided as an illustration of the term and is intended to include the plurality of variations expected to be included by one of ordinary skill in the art.
- The term “C1-6alkyl” or “alkyl” means a straight or branched chain hydrocarbon alkyl radical, comprising from 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, tertiary butyl (also referred to as t-butyl or tert-butyl), 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexyl, 3-hexyl and the like. The term further includes alkyl groups in any combination thereof (e.g. C1-2, C1-3, C1-4 and the like). An alkyl radical may be attached to a core molecule where allowed by available valences.
- The terms “C2-3alkenyl” and “C2-3alkynyl” mean straight or branched carbon chains having 2 to 3 carbon atoms, wherein a C2-3alkenyl chain has at least one double bond in the chain and a C2-3alkynyl chain has at least one triple bond in the chain. An alkenyl and alkynyl radical may be attached to a core molecule where allowed by available valences.
- The term “C1-6alkoxy” or “alkoxy” means a straight or branched chain hydrocarbon alkyl radical or alkyldiyl linking group of the formula —O—C1-6alkyl, comprising from 1 to 6 carbon atoms. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like. The term further includes alkoxy groups in any combination thereof (e.g. C1-2, C1-3, C1-4 and the like). An alkoxy radical may be attached to a core molecule where allowed by available valences.
- The term “cycloalkyl” refers to a saturated or partially unsaturated, monocyclic, polycyclic or benzofused hydrocarbon ring system composed of from 3 to 14 carbon atoms. Except when specified, the term includes a C3-8cycloalkyl, C3-10cycloalkyl, C5-6cycloalkyl, C5-8cycloalkyl, C5-12cycloalkyl, C8-10cycloalkyl, C9-13cycloalkyl, C3-14cycloalkyl or benzofused C3-14cycloalkyl ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, 1H-indenyl, indanyl, adamantanyl, 9H-fluorenyl, 1,2,3,4-tetrahydro-naphthalenyl, acenaphthenyl, bicyclo[2.2.1]heptenyl and the like. C3-14cycloalkyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
- The term “benzofused,” used as a prefix for a ring system, means a radical formed by any ring system radical fused with a benzene ring. The benzofused radical may be attached to a core molecule via either ring of the bicyclic system and further substituted on any atom where allowed by available valences.
- The term “aryl” refers to monocyclic or bicyclic aromatic ring systems containing from 6 to 12 carbons in the ring. Examples include phenyl, biphenyl, naphthalene, azulenyl, anthracenyl and the like. Aryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
- The term “aromatic” refers to a cycloalkylic hydrocarbon ring system having an unsaturated, conjugated π electron system.
- The term “hetero,” used as a prefix for a ring system, refers to the replacement of at least one ring carbon atom with one or more heteroatoms independently selected from a nitrogen, oxygen or sulfur atom, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state. Examples include rings wherein 1, 2, 3 or 4 ring members are a nitrogen atom; or, 0, 1, 2 or 3 ring members are nitrogen atoms and 1 member is an oxygen or sulfur atom. When allowed by available valences, up to two adjacent ring members may be heteroatoms; wherein one heteroatom is nitrogen and the other is one heteroatom selected from N, S or O.
- The term “heterocyclyl” refers to a nonaromatic (i.e. saturated or partially unsaturated) monocyclic, polycyclic or benzofused ring system radical. Heteroatom ring members are selected from at least one of N, O, S, S(O) or SO2, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state. Examples include 2H-pyrrole, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 2-imidazolinyl (also referred to as 4,5-dihydro-1H-imidazolyl), imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, oxazolidinyl, tetrazolinyl, tetrazolidinyl, piperidinyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, piperazinyl, azetidinyl, azepanyl, dihydro-pyranyl, tetrahydro-furanyl, tetrahydro-thienyl, tetrahydro-pyranyl, tetrahydro-pyridazinyl, hexahydro-1,4-diazepinyl, hexahydro-1,4-oxazepanyl, 1,3-dioxolanyl, 1,4-dioxanyl, 1,3-benzodioxolyl (also referred to as benzo[1,3]dioxolyl), 2,3-dihydro-1,4-benzodioxinyl (also referred to as 2,3-dihydro-benzo[1,4]dioxinyl) and the like. Heterocyclyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
- The term “heteroaryl” means an aromatic monocyclic, polycyclic or benzofused ring system radical. Heteroatom ring members are selected from at least one of N, O, S, S(O) or SO2, wherein the nitrogen and sulfur atoms can exist in any allowed oxidation state.
- Examples include furanyl, thienyl, pyrrolyl, pyrazolyl, 1H-imidazolyl, isothiazolyl, isoxazolyl, oxazolyl, thiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, 1H-tetrazolyl, 2H-tetrazolyl, 1H-[1,2,3]triazolyl, 2H-[1,2,3]triazolyl, 4H-[1,2,4]triazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, indolyl, azaindolyl, indazolyl, azaindazolyl, isoindolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzoisoxazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalzinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl and the like. Heteroaryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
- The term “C1-6alkoxy-C1-6alkyl” means a radical of the formula: —C1-6alkyl-O—C1-6alkyl.
- The term “C1-6alkoxycarbonyl” means a radical of the formula: —C(O)—O—C1-6alkyl. Examples include C1-4alkoxycarbonyl.
- The term “C1-6alkoxycarbonylamino” means a radical of the formula: —NH—C(O)—O—C1-6alkyl. Examples include C1-4alkylcarbonylamino.
- The term “(C1-6alkyl)1-2amino” means a radical of the formula: —NH—C1-6alkyl or —N(C1-6alkyl)2. Examples include (C1-4alkyl)1-2amino.
- The term “(C1-6alkyl)1-2amino-C1-6alkyl” means a radical of the formula: —C1-6alkyl-NH—C1-6alkyl or —C1-6alkyl-N(C1-6alkyl)2. Examples include (C1-4alkyl)1-2amino-C1-6alkyl.
- The term “(C1-6alkyl)1-2aminocarbonyl” means a radical of the formula: —C(O)—NH—C1-6alkyl or —C(O)—N(C1-6alkyl)2. Examples include (C1-4alkyl)1-2aminocarbonyl.
- The term “(C1-6alkyl)1-2aminocarbonylamino” means a radical of the formula: —NH—C(O)—NH—C1-6alkyl or —NH—C(O)—N(C1-6alkyl)2. Examples include (C1-4alkyl)1-2aminocarbonylamino.
- The term “(C1-4alkyl)1-2aminosulfonyl” means a radical of the formula: —SO2—NH—C1-4alkyl or —SO2—N(C1-4alkyl)2.
- The term “C1-6alkylcarbonyl” means a radical of the formula: —C(O)—C1-6alkyl. Examples include C1-4alkylcarbonyl.
- The term “C1-6alkylcarbonylamino” means a radical of the formula: —NH—C(O)—C1-6alkyl. Examples include C1-4alkylcarbonylamino.
- The term “C1-6alkylsulfonyl” means a radical of the formula: —SO2—C1-6alkyl. Examples include C1-4alkylsulfonyl.
- The term “C1-6alkylsulfinylamino” means a radical of the formula: —NH—S(O)—C1-6alkyl.
- The term “C1-6alkylsulfonylamino” means a radical of the formula: —NH—SO2—C1-6alkyl.
- The term “C1-6alkylthio” means a radical of the formula: —S—C1-6alkyl. Examples include C1-4alkylthio.
- The term “amino” means a radical of the formula: —NH2.
- The term “amino-C1-6alkyl” means a radical of the formula: —C1-6alkyl-NH2.
- The term “aminocarbonyl” means a radical of the formula: —C(O)—NH2.
- The term “aminocarbonylamino” means a radical of the formula: —NH—C(O)—NH2.
- The term “aminosulfonyl” means a radical of the formula: —SO2—NH2.
- The term “aminosulfonylamino” means a radical of the formula: —NH—SO2—NH2.
- The term “(C1-6alkyl)1-2aminosulfonylamino” means a radical of the formula: —NH—SO2—NH—C1-6alkyl or —NH—SO2—N(C1-6alkyl)2. Examples include (C1-4alkyl)1-2aminosulfonylamino.
- The term “aminosulfonylamino-C1-6alkyl” means a radical of the formula: —C1-6alkyl-NH—SO2—NH2.
- The term “(C1-6alkyl)1-2aminosulfonylamino-C1-6alkyl” means a radical of the formula: —C1-6alkyl-NH—SO2—NH—C1-6alkyl or —C1-6alkyl-NH—SO2—N(C1-6alkyl)2.
- The term “carboxy” means a radical of the formula: —C(O)OH.
- The term “C3-8cycloalkyl-C1-6alkyl” means a radical of the formula: —C1-6alkyl-C3-8cycloalkyl. Examples include C3-8cycloalkyl-C1-4alkyl.
- The term “C3-8cycloalkyl-C1-6alkoxy” means a radical of the formula: —O—C1-6alkyl-C3-8cycloalkyl. Examples include C3-8cycloalkyl-C1-4alkoxy.
- The term “C3-8cycloalkyl-oxy” means a radical of the formula: —O—C3-8cycloalkyl.
- The term “(C3-8cycloalkyl)1-2amino” means a radical of the formula: —NH—(C3-8cycloalkyl) or —N(C3-8cycloalkyl)2.
- The term “(C3-8cycloalkyl-C1-4alkyl)1-2amino” means a radical of the formula: —NH—C1-4alkyl-C3-8cycloalkyl or —N(C1-4alkyl-C3-8cycloalkyl)2.
- The term “formyl” means a radical of the formula: —C(O)H.
- The term “oxo” means a radical of the formula: ═O.
- The term “halogen” or “halo” means the group chloro, bromo, fluoro or iodo.
- The term “haloC1-6alkyl” means a radical of the formula: —C1-6alkyl(halo)n, wherein “n” represents that amount of available valences on C1-6alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include difluoromethyl, trifluoromethyl, trifluoroethyl, chloromethyl and the like.
- The term “haloC1-6alkoxy” means a radical of the formula: —O—C1-6alkyl(halo)n, wherein “n” represents that amount of available valences on C1-6alkoxy, which may be substituted with one or more halogen atoms while remaining stable. Examples include difluoromethoxy, trifluoromethoxy, trifluoroethoxy, chloromethoxy and the like.
- The term “haloC1-6alkylsulfonyl” means a radical of the formula: —SO2—C1-6alkyl(halo)n, wherein “n” represents that amount of available valences on C1-6alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.
- The term “haloC1-6alkylsulfonylamino” means a radical of the formula: —NH—SO2—C1-6alkyl(halo)n, wherein “n” represents that amount of available valences on C1-6alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.
- The term “haloC1-6alkylthio” means a radical of the formula: —S—C1-6alkyl(halon, wherein “n” represents that amount of available valences on C1-6alkyl, which may be substituted with one or more halogen atoms while remaining stable. Examples include trifluoromethylsulfonyl and the like.
- The term “perfluorinated” means a radical that is substituted with fluoro atoms to the extent allowed by available valences while remaining stable.
- The term “substituted,” refers to a core molecule on which one or more hydrogen atoms have been replaced with one or more functional radical moieties. The number that is allowed by available valences limits the amount of substituents. Substitution is not limited to the core molecule, but may also occur on a substituent radical, whereby the substituent radical becomes a linking group.
- As modulators of the vanilloid VR1 ion channel, the compounds of Formula (I) are useful in methods for treating a VR1 ion channel mediated disease in a subject which disease is affected by the modulation of one or more vanilloid receptors.
- Accordingly, the present invention is directed to a method of treating a VR1 ion channel mediated disease in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) or a salt or solvate thereof.
- The term “VR1 ion channel mediated disease” refers to chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.
- An example of a use of the compound of Formula (I) or a salt or solvate thereof includes use in the manufacture of a medicament for treating a VR1 ion channel mediated disease, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.
- An example of a use of the compound of Formula (I) or a salt or solvate thereof includes use as a medicine for treating a VR1 ion channel mediated disease, wherein the VR1 ion channel mediated disease is chronic or acute pain due to disease that causes inflammatory pain, burning pain or post-operative pain.
- The term “prodrug” means a compound of Formula (I) or a form thereof that is converted in vivo into a functional derivative form that may contribute to therapeutic biological activity, wherein the converted form may be: 1) a relatively active form; 2) a relatively inactive form; 3) a relatively less active form; or, 4) any form which results, directly or indirectly, from such in vivo conversions.
- Prodrugs are useful when said compound may be either too toxic to administer systemically, absorbed poorly by the digestive tract or broken down by the body before it reaches its target. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
- The term “metabolite” means a form of a compound of Formula (I) or a form thereof converted by in vivo metabolism or a metabolic process to a derivative of said compound.
- The term “subject” as used herein, refers to a patient, such as an animal, a mammal or a human, who has been the object of treatment, observation or experiment and is at risk of (or susceptible to) developing a disease that has or will result in VR1 ion channel mediated chronic or acute pain, wherein the pain caused by the disease is inflammatory pain, burning pain or post-operative pain.
- The term “effective amount” refers to that amount of a compound of Formula (I) or a form, pharmaceutical composition, medicine or medicament thereof that elicits the biological or medicinal response (such as inhibiting, preventing or ameliorating VR1 ion channel mediated chronic or acute pain) in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the inflammatory pain, burning pain or post-operative pain being treated.
- The effective amount of a compound of Formula (I) or a form thereof is from about 0.001 mg/kg/day to about 300 mg/kg/day.
- The term “pharmaceutical composition” refers to a product containing a compound of Formula (I) or a form thereof, such as a product comprising the specified ingredients in the specified amounts, as well as any product that results, directly or indirectly, from such combinations of the specified ingredients in the specified amounts.
- The term “medicament” or “medicine” refers to a product containing a compound of Formula (I) or a form thereof. The present invention includes use of such a medicament for treating VR1 ion channel mediated chronic or acute pain.
- The term “pharmaceutically acceptable” refers to molecular entities and compositions that are of sufficient purity and quality for use in the formulation of a pharmaceutical composition, medicine or medicament of the present invention. Since both human use (clinical and over-the-counter) and veterinary use are equally included within the scope of the present invention, a pharmaceutically acceptable formulation would include a pharmaceutical composition, medicine or medicament for either human or veterinary use.
- The term “treating” refers, without limitation, inhibiting, ameliorating, facilitating the eradication of, inhibiting the progression of or promoting the stasis of VR1 ion channel mediated chronic or acute pain.
- For oral administration, the pharmaceutical composition, medicine or medicament is preferably in the form of a tablet containing, e.g., 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of a compound of formula (I) or a form thereof for the symptomatic adjustment of the dosage to the patient to be treated. Optimal dosages will vary depending on factors associated with the particular patient being treated (e.g., age, weight, diet and time of administration), the severity of the condition being treated, the particular compound being used, the mode of administration and the strength of the preparation. The use of either daily administration or post-periodic dosing may be employed.
- A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
-
Cpd Name 1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 3 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol, 4 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 6 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 7 (E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 8 (E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 10 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- carbamic acid tert-butyl ester, 11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine, 12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanol, 13 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 14 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol, 15 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 19 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 20 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 21 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 23 (E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 24 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 25 (E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 26 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 27 (E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 28 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 29 2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol, 30 2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole, 31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 32 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 33 3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 34 4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 35 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 36 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol, 37 (E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-acetamide, 38 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 39 (E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 40 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 41 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol, 42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 43 (E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-acetamide, 44 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzamide, 45 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanol, 46 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-phenyl)-ethanol, 47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-propan-2-ol, 48 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-phenol, 49 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-phenol, 50 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-acetamide, 51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-methanol, 52 (E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl- 1H-benzimidazole, 53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-benzamide, 54 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-carbamic acid tert-butyl ester, 55 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 56 (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-acetamide, 57 (E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanol, 59 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol, 60 (E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol, 61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 62 (E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 63 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 64 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-acetamide, 65 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 66 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 67 (E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 68 (E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol, 69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 72 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 73 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 74 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 75 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 76 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 80 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 81 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 82 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 83 (E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 85 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 86 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 87 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 88 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 89 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 90 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 91 (E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 92 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 93 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-ethanone, 94 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-ethanol, 95 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-methanesulfonamide, 96 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-propan-2-ol, 97 (E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)- benzenesulfonamide, 98 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 99 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 100 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 101 (E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 102 (E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 103 (E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 104 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 105 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 106 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 107 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 108 (E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 109 (E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 110 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 111 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 112 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 113 (E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 115 (E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 116 (E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 117 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)- methanesulfonamide, 118 (E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)- phenyl]-methanesulfonamide, 119 (E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 120 (E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2- yl}-vinyl)-phenyl]-methanesulfonamide, 121 (E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 122 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 123 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 124 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H- benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, 125 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide, 126 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, 127 (E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 128 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)- 1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide, 129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 132 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 133 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 134 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 135 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 136 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol, 137 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 138 2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan- 2-ol, 139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 140 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 141 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 142 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 143 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 144 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 145 2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 146 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 147 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 148 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 149 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 150 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 151 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 152 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 153 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-ethanone, 154 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-ethanol, 155 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-methanesulfonamide, 156 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-propan-2-ol, 157 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- benzenesulfonamide, 158 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 159 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 160 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 161 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 162 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 163 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol- 5-yl)-benzenesulfonamide, 164 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 165 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 166 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol, 167 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 168 2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol, 169 2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 170 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 171 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 172 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 173 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 174 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 176 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 177 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)- methanesulfonamide, 178 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)- phenyl]-methanesulfonamide, 179 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 180 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- ethyl)-phenyl]-methanesulfonamide, 181 2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 182 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 183 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 184 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2- yl}-ethyl)-phenyl]-methanesulfonamide, 185 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide, 186 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide, 187 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 188 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 189 2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 190 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 191 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 192 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 193 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 194 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 195 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 196 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 197 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 199 2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 200 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 201 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 202 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 203 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 204 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 205 2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 206 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 207 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanone, 208 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanol, 209 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 210 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 211 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-benzenesulfonamide, 212 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 213 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol- 5-yl)-phenyl]-ethanone, 214 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol- 5-yl)-phenyl]-ethanol, 215 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 216 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol- 5-yl)-phenyl]-propan-2-ol, 217 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5- yl)-benzenesulfonamide, 218 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 219 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 220 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 221 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 222 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 223 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 224 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 225 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 226 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 227 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 228 2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 229 2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 230 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 231 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 232 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 233 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 234 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 235 2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 236 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 237 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)- methanesulfonamide, 238 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)- phenyl]-methanesulfonamide, 239 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 240 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- cyclopropyl)-phenyl]-methanesulfonamide, 241 2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 242 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 243 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 244 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2- yl}-cyclopropyl)-phenyl]-methanesulfonamide, 245 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide, 246 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide, 247 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 248 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)- cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 249 2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 251 2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 252 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 253 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol- 5-yl]-phenyl}-methanesulfonamide, 254 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 255 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone, 256 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol, 257 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 258 2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 259 2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 260 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 261 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanone, 262 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanol, 263 N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 264 2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 265 2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 266 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 267 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 268 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanol, 269 N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 270 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 271 2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 272 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 273 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 274 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 275 N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 276 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 277 2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 278 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 279 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 280 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanol, 281 N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 282 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 283 2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 284 C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 285 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone, 286 2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 287 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 288 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol, 289 2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 290 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 291 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanone, 292 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanol, 293 N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 296 C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol- 5-yl]-phenyl}-methanesulfonamide, 297 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}- methanesulfonamide, 298 N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}- phenyl)-methanesulfonamide, 299 N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]- phenyl}-methanesulfonamide, 300 N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl- ethynyl}-phenyl)-methanesulfonamide, 301 2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 302 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 303 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 304 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl- ethynyl}-phenyl)-methanesulfonamide, 305 C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide, 306 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide, 307 2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5- yl]-benzenesulfonamide, 308 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)- 1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide, 309 (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 311 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 325 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 326 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 327 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 330 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 334 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 336 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 338 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide, 341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 343 (E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 346 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 348 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 350 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 351 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 375 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 380 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 389 2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 400 N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 406 (E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 408 (E)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 409 (E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 410 (E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 411 (E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 412 (E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 413 (E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 414 (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 415 (E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 416 (E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 425 (E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide, 427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 440 (E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 441 (E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 443 (E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide, 444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 447 5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- vinyl)-phenyl]-ethanone, 449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 450 (E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]- vinyl}-benzamide, 451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 452 (E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}- phenyl)-acetamide, 453 (E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}- benzoic acid, 454 (E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 457 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 458 (E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-acetamide, 459 (E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)- vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide, 460 (E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-propionamide, 461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-amide, 462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid methyl ester, 463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 465 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenylamine, 466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester, 467 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 470 (E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]- 1H-benzimidazole, 471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 472 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenol, 473 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid tert-butyl ester, 474 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 477 (E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide, 478 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-acetamide, 479 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid tert-butyl ester, 480 (E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 481 (E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl- phenyl)-1H-benzimidazole, 482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 483 (E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzyl)-amine, 484 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzaldehyde, 485 (E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzyl)-amine, 486 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzylamine, 487 (E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 488 (E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 490 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 491 (E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl- phenyl)-vinyl]-1H-benzimidazole, 492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzamide, 499 N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]- 1H-benzimidazole, 501 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 502 2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 505 2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 506 2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 507 2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, and 508 2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide. - A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
-
Cpd Name 1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 3 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol, 4 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 6 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 7 (E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 8 (E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 10 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- carbamic acid tert-butyl ester, 11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine, 12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanol, 13 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 14 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol, 15 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 19 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 20 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 21 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 23 (E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 24 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 25 (E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 26 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 27 (E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 28 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 29 2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol, 30 2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole, 31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 32 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 33 3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 34 4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 35 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 36 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol, 37 (E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-acetamide, 38 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 39 (E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 40 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 41 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol, 42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 43 (E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-acetamide, 44 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzamide, 45 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanol, 46 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-phenyl)-ethanol, 47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-propan-2-ol, 48 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-phenol, 49 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-phenol, 50 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-acetamide, 51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-methanol, 52 (E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl- 1H-benzimidazole, 53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-benzamide, 54 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-carbamic acid tert-butyl ester, 55 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 56 (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-acetamide, 57 (E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanol, 59 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol, 60 (E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol, 61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 62 (E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 63 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 64 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-acetamide, 65 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 66 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 67 (E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 68 (E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol, 69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 83 (E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 85 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 95 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-methanesulfonamide, 101 (E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 113 (E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 145 2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 190 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 234 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 309 (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 311 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 325 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 326 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 327 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 330 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 334 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 336 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 338 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide, 341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 343 (E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide 345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 346 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 348 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 350 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 351 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 375 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 380 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 389 2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 400 N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 406 (E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 408 (E)-N-(2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 409 (E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 410 (E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 411 (E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 412 (E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 413 (E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 414 (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 415 (E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 416 (E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 425 (E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide, 427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 440 (E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 441 (E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 443 (E)-N-(2-{3-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-3H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide, 444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 447 5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- vinyl)-phenyl]-ethanone, 449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 450 (E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]- vinyl}-benzamide, 451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 452 (E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}- phenyl)-acetamide, 453 (E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}- benzoic acid, 454 (E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 457 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 458 (E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-acetamide, 459 (E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)- vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide, 460 (E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-propionamide, 461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-amide, 462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid methyl ester, 463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 465 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenylamine, 466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester, 467 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 470 (E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]- 1H-benzimidazole, 471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 472 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenol, 473 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid tert-butyl ester, 474 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 477 (E)-N-(2-{1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide, 478 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-acetamide, 479 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid tert-butyl ester, 480 (E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 481 (E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl- phenyl)-1H-benzimidazole, 482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 483 (E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzyl)-amine, 484 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzaldehyde, 485 (E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzyl)-amine, 486 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzylamine, 487 (E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 488 (E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 490 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 491 (E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl- phenyl)-vinyl]-1H-benzimidazole, 492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzamide, 499 N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]- 1H-benzimidazole, 501 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 502 2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 505 2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 506 2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 507 2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, and 508 2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide. - A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
-
Cpd Name 1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 3 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol, 4 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide, 5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 10 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- carbamic acid tert-butyl ester, 11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine, 12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanol, 13 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 15 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 27 (E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 28 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 32 2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 34 4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol, 35 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 38 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 39 (E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 40 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 41 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol, 42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 44 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzamide, 45 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanol, 46 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-phenyl)-ethanol, 47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-propan-2-ol, 50 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-acetamide, 51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-methanol, 53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-benzamide, 56 (E)-N-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-acetamide, 58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanol, 59 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol, 61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 62 (E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 63 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide, 66 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 67 (E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 68 (E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol, 69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 95 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-methanesulfonamide, 114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 190 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 309 (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 311 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 325 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 326 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 327 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 330 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 334 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 336 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 338 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide, 341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 343 (E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 346 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 348 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 350 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 375 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 380 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 406 (E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 410 (E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 411 (E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 412 (E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 413 (E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 414 (E)-N-(2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 415 (E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 416 (E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide, 427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 440 (E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 447 5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- vinyl)-phenyl]-ethanone, 449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-amide, 462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid methyl ester, 463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 465 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenylamine, 466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester, 467 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 470 (E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]- 1H-benzimidazole, 471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 490 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 491 (E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl- phenyl)-vinyl]-1H-benzimidazole, 492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzamide, 500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]- 1H-benzimidazole, 501 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 502 2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, and 504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide. - A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
-
Cpd Name 1 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 2 (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide, 9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanol, 16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 35 (E)-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 40 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 45 (E)-1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanol, 46 1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-phenyl)-ethanol, 47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-propan-2-ol, 51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-methanol, 53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol-5- yl}-benzamide, 58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanol, 61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 66 (E)-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol, 69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 190 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 311 (E)-2-hydroxy-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone, 312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide, 341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 350 N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 380 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide, 427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 440 (E)-2-{2-[2-(4-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 447 5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- vinyl)-phenyl]-ethanone, 449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide, 456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-amide, 462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid methyl ester, 463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester, 468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 470 (E)-5-(2-aminosulfonylamino-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]- 1H-benzimidazole, 471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol, 482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 490 2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide, 491 (E)-5-(2-aminosulfonylamino-methylphenyl)-2-[2-(4-trifluoromethyl- phenyl)-vinyl]-1H-benzimidazole, 492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzamide, 500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]- 1H-benzimidazole, 501 2-(2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, and 504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide. - A representative compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
-
Cpd Name 9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanol, 17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 18 (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 69 (E)-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 70 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 310 (E)-N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide, 319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- N-methyl-benzenesulfonamide, 341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 422 (E)-5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole, 428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 442 2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 449 (E)-2-{2-[2-(2-quinolin-6-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-amide, 464 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 469 (Z)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 471 2-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 489 2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, and 503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol. - A representative prophetic compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
-
Cpd Name 72 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 73 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 74 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 75 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 76 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 80 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 81 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 82 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 86 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 87 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 88 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 89 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 90 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 91 (E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 92 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 93 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-ethanone, 94 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-ethanol, 96 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-propan-2-ol, 97 (E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)- benzenesulfonamide, 98 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 99 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 100 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 102 (E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 103 (E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 104 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 105 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 106 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 107 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 108 (E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 109 (E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 110 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 111 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 112 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 115 (E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 116 (E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 117 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)- methanesulfonamide, 118 (E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)- phenyl]-methanesulfonamide, 119 (E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 120 (E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2- yl}-vinyl)-phenyl]-methanesulfonamide, 121 (E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 122 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 123 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 124 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H- benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, 125 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide, 126 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, 127 (E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 128 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)- 1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide, 132 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 133 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 134 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 135 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 136 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol, 137 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 138 2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan- 2-ol, 140 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 141 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 142 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 143 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 144 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 146 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 147 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 148 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 149 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 150 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 151 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 152 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 153 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-ethanone, 154 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-ethanol, 155 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-methanesulfonamide, 156 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-propan-2-ol, 157 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- benzenesulfonamide, 158 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 159 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 160 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 161 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 162 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 163 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol- 5-yl)-benzenesulfonamide, 164 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 165 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 166 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol, 167 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 168 2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan- 2-ol, 169 2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 170 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 171 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 172 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 173 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 174 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 176 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 177 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)- methanesulfonamide, 178 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)- phenyl]-methanesulfonamide, 179 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 180 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- ethyl)-phenyl]-methanesulfonamide, 181 2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 182 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 183 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 184 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2- yl}-ethyl)-phenyl]-methanesulfonamide, 185 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide, 186 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide, 187 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 188 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 189 2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 191 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 192 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 193 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 194 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 195 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 196 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 197 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 199 2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 200 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 201 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 202 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 203 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 204 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 205 2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 206 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 207 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanone, 208 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanol, 209 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 210 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 211 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-benzenesulfonamide, 212 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 213 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol- 5-yl)-phenyl]-ethanone, 214 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol- 5-yl)-phenyl]-ethanol, 215 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 216 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol- 5-yl)-phenyl]-propan-2-ol, 217 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5- yl)-benzenesulfonamide, 218 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 219 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 220 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 221 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 222 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 223 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 224 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 225 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 226 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 227 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 228 2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 229 2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 230 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 231 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 232 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 233 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 235 2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 236 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 237 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)- methanesulfonamide, 238 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-cyclopropyl)- phenyl]-methanesulfonamide, 239 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 240 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- cyclopropyl)-phenyl]-methanesulfonamide, 241 2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 242 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 243 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 244 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2- yl}-cyclopropyl)-phenyl]-methanesulfonamide, 245 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide, 246 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide, 247 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 248 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)- cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 249 2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 251 2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 252 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 253 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol- 5-yl]-phenyl}-methanesulfonamide, 254 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 255 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone, 256 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol, 257 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 258 2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 259 2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 260 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 261 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanone, 262 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanol, 263 N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 264 2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 265 2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 266 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 267 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 268 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanol, 269 N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 270 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 271 2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 272 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 273 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 274 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 275 N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 276 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 277 2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 278 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 279 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 280 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanol, 281 N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 282 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 283 2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 284 C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 285 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone, 286 2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 287 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 288 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol, 289 2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-benzenesulfonamide, 290 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 291 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanone, 292 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanol, 293 N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 296 C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol- 5-yl]-phenyl}-methanesulfonamide, 297 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}- methanesulfonamide, 298 N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}- phenyl)-methanesulfonamide, 299 N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]- phenyl}-methanesulfonamide, 300 N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl- ethynyl}-phenyl)-methanesulfonamide, 301 2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 302 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 303 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 304 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl- ethynyl}-phenyl)-methanesulfonamide, 305 C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide, 306 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide, 307 2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5- yl]-benzenesulfonamide, and 308 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)- 1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide. - Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated in the schemes that follows. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.
- Compounds of the present invention can be synthesized using the methods described in the schemes that follow.
- The terms used in describing the invention are commonly used and known to those skilled in the art. As used herein, the following abbreviations and formulas have the indicated meanings:
-
Abbreviation Meaning Boc tert-butoxycarbonyl BOP benzotriazol-1-yloxy- tris(dimethylamino)phosphonium hexafluorophosphate AcOH acetic acid Cpd compound DBU 1,8-diazabicyclo[5.4.0]undec-7-ene DCM dichloromethane DIEA N,N-diisopropyl ethyl amine DME ethylene glycol dimethyl ether DMF N,N-dimethylformamide DMSO dimethyl sulfoxide EtOAc ethyl acetate EtOH ethanol HPLC high performance liquid chromatography LiOH lithium hydroxide min minute(s) n-BuLi n-butyl lithium h/hr/hrs hour(s) mCPBA m-chloroperbenzoic acid MeOH methanol MTBE methyl-t-butyl ether PdCl2(dppf) or [1,1′-bis-(diphenylphosphino)ferroceno] Pd(dppf)Cl2CH2Cl2 dichloropalladium (II) dichloromethane complex Pd(PPh3)4 palladium tetrakistriphenylphosphine RT or rt room temperature TBAB tetrabutylammonium bromide TBSOTf t-butyldimethylsilyl trifluoromethane sulfonate Et3N triethylamine TFA trifluoroacetic acid THF tetrahydrofuran TLC thin layer chromatography - Reaction Scheme AA
- Scheme AA illustrates a general synthesis of benzimidazoles of formula AA5, representative of a compound of Formula (I).
- Typically, a solution of 4-bromobenzene-1,2-diamine AA1 and a suitable carboxylic acid AA2 in phosphorous oxychloride (POCl3) is heated at reflux to obtain bromobenzimidazole AA3.
- Alternatively, the acid can be converted to an acid chloride using oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride.
- The acid chloride AA2 is heated with 4-bromobenzene-1,2-diamine AA1 in acetic acid to give AA3. A suitably substituted phenyl group can be appended to AA3 by a variety of coupling reactions (Suzuki, Stille) that are well known to those versed in the art. A particularly useful substitution method employs a palladium catalyzed cross-coupling Suzuki reaction (Huff, B. et. al. Org. Syn. 1997, 75: 53-60; and, Goodson, F. E. et. al. Org. Synth. 1997, 75: 61-68).
- As an example, a mixture of bromobenzimidazole AA3 is reacted with a suitable phenyl boronic acid AA4 in the presence of a reagent such as cesium carbonate and a catalytic amount of a palladium catalyst such as PdCl2dppf in a solvent such as a mixture of dioxane and ethanol at elevated temperatures to give AA5. The reaction times can be reduced by carrying out this procedure at similar (about 100° C.) or lower temperatures in a microwave synthesizer. Other palladium catalysts suitable for this type of reaction include Pd(PPh3)4.
- Reaction Scheme BB
- Cinnamic acids, as required, can be synthesized via procedures described in reaction Scheme BB.
- A solution of arylaldehyde BB1 and (carbethoxymethylene)triphenyl phosphorane in a solvent such as toluene or benzene in the presence of a base such as NaOH is stirred usually at elevated temperatures to give the corresponding cinnamate ester. The ester is hydrolyzed under standard conditions to provide the corresponding cinnamic acid BB2.
- Phenylpropionic acid BB3, as required, can be synthesized from cinnamic acid BB2 by hydrogenation using a variety of standard procedures. As shown above, a mixture of BB2 in ethanol with a catalytic amount of palladium on carbon (10%) is stirred at room temperature in an atmosphere of hydrogen (50 psi) to provide acid BB3.
- Reaction Scheme BB′
- Reaction Scheme BB′ is a variation of Reaction Scheme BB.
- Reaction of aldehyde BB1 with malonic acid and a catalytic amount of piperidine in pyridine at elevated temperatures produces cinnamic acid BB2 in high yield.
- Acid BB2 is converted to the acid chloride by reaction with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride. The acid chloride is then heated with AA1 in acetic acid to give BB′1, which is further elaborated in place of AA3 as described in reaction Scheme AA.
- Reaction Scheme CC
- Reaction Scheme CC provides a method to prepare substituted 4-bromobenzene-1,2-diamine intermediates.
- As an example, to a solution of a suitably substituted 4-bromoaniline CC1 in trifluoroacetic anhydride is added KNO3 portionwise at a suitable temperature. The reaction mixture may then be warmed to room temperature for optimal conversion to nitroamide CC2.
- Sequentially, using standard procedures, the amide is hydrolyzed and the nitro group is reduced to give bromodiamine CC3. Intermediate CC3 is further elaborated as described in reaction Scheme AA.
- Reaction Scheme DD
- An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme DD.
- A substituted bromobenzimidazole DD1 (representative of AA3 in Scheme AA) is protected (using a protecting group such as Boc), then converted to a pinicolboronate ester DD2 under standard Suzuki coupling conditions (Prieto, M. et. al., J. Org. Chem. 2004, 69: 6812-6820; McDonald, D. et. al., Bioorg. Med. Chem. Lett. 2005, 15: 5241-5246; and, Poon, S. F. et. al. Bioorg. Med. Chem. Lett. 2004, 14, 5477-5480).
- In a typical procedure, a mixture of bromo-benzimidazole DD1, bis-(pinacolato)diboron, potassium carbonate and a catalytic amount of a palladium catalyst such as PdCl2dppf in DMF is heated at elevated temperatures to give boronate ester DD2. Frequently, the reaction durations can be reduced by carrying out this procedure at similar or lower temperatures in a microwave irradiation apparatus.
- Boronate ester DD2 can be converted to compounds of the present invention (Boc protected DD3) by Suzuki coupling with a phenyl halide, mesylate or triflate (R1)pPh-X. In this instance, borane DD2 is reacted with a suitable aryl halide, tetrakis (triphenylphosphine) palladium (0) and tri-tert-butylphosphonium tetrafluoroborate in 2M aqueous potassium carbonate in toluene at 100° C. to give the protected form of DD3. Deprotection with an acid such as TFA gives DD3.
- Reaction Scheme EE
- Reaction Scheme EE describes methods to prepare representative compounds of the present invention.
- Aniline EE1 can be converted to a variety of amides, carbamates or ureas EE2 by utilizing any number of acylation methods that are commonly used by persons versed in the art. As an example, reaction of EE1 in a solvent such as THF with a substituted acid chloride and a base such as triethylamine gives the corresponding amide of EE2. As a further example, reaction of EE1 in THF with a substituted chloroformate and triethylamine gives the corresponding substituted carbamate of EE2.
- EE1 can be converted to sulfonamides by utilizing various sulfonylation conditions. For instance, reaction of EE1 in a solvent such as THF with an alkylsulfonyl chloride and triethylamine gives the alkylsulfonamide EE3. EE1 can be selectively, and successively substituted to give EE3. An efficient method of achieving this is via reductive alkylation with aldehydes or ketones (see Mattson, R. J. et. al. J. Org. Chem. 1990, 55, 2552-2554) and references cited therein]. In this procedure, equal amounts of EE1 and an aldehyde or ketone are stirred with titanium (IV) isopropoxide, followed the addition of sodium cyanoborohydride in a solvent such as ethanol to give substituted amine EE3.
- Reaction Scheme FF
- A synthetic sequence to produce compounds of the present invention wherein L is cyclopropyl is described in reaction Scheme FF.
- Reaction of cinnamate ester FF1, in this case a methyl ester, with trimethylsulfonium iodide methylide in a solvent such as DMSO and sodium hydride (as exemplified by Burger, A. et. al. J. Med. Chem. 1970, 13, 33-35), gives cyclopropyl ester FF2. Hydrolysis of FF2 gives acid FF3, which is further elaborated into the benzimidazoles described in Scheme AA.
- Reaction Scheme GG
- Reaction Scheme GG describes an alternative method to prepare cyclopropyl acid intermediates.
- Cinnamic acids are converted to the corresponding Weinreb amide, by conversion to the acid chloride as described in Reaction Scheme AA and BB′. The acid chloride is reacted with N,N-dimethylhydroxylamine hydrochloride and a base such as triethylamine in methylene chloride to give amide GG2.
- Amide GG2 is converted to cyclopropyl amide GG3 as described in Scheme FF. The amide GG3 is then hydrolyzed to give acid GG4, typically by reaction with potassium tertiary butoxide in THF.
- Reaction Scheme HH
- A synthetic sequence to produce compounds of the present invention wherein R1Ar is benzenesulfonamide is described in reaction Scheme HH.
- Coupling by Suzuki reaction of boronate ester DD2 from reaction Scheme DD and bromobenzene-t-butylsulfonamide HH1 followed by deprotection with TFA gives the product HH2.
- Reaction Scheme II
- A synthetic sequence to produce compounds of the present invention wherein R is an ether group is described in reaction Scheme II.
- An ester of commercially available 4-hydroxycinnamic acid II1 can be converted to ether analogs by a number of routes including the Williamson reaction. In this well-known procedure, II1 and an alkyl halide is reacted with a base such as cesium carbonate in a solvent such as acetonitrile to give the product II2.
- More effective electrophiles can be derivatives of alcohols such as mesylates, p-toluene sulfonates or trifluoromethanesulfonates (triflates). An effective alternative method is the conversion of II1 to ether analogs II2 via the Mitsunobu reaction (as reviewed by Mitsunobu, O., Synthesis, 1981, 1-28).
- Ether analogs II2 can be further reduced to acid II3 using standard techniques.
- Reaction Scheme JJ
- Reaction Scheme JJ describes methods to prepare cinnamic acids that contain substituted amino groups.
- Cinnamate ester JJ1 can be converted to a variety of amides, carbamates or ureas JJ2 by utilizing any number of acylation methods that are commonly used by persons versed in the art. As an example, reaction of JJ1 in a solvent such as THF with a substituted acid chloride and a base such as triethylamine gives the corresponding amide of JJ2. As a further example, reaction of JJ1 in THF with a substituted chloroformate and triethylamine gives the corresponding substituted carbamate of JJ2. JJ1 can be converted to sulfonamides by utilizing various sulfonylation conditions.
- For instance, reaction of JJ1 in a solvent such as THF with an alkylsulfonyl chloride and triethylamine gives the alkylsulfonamide JJ3. JJ1 can be selectively, and successively substituted to give JJ4. An efficient method of substitution is via reductive alkylation with aldehydes or ketones (see Mattson, R. J. et. al. J. Org. Chem., 1990, 55, 2552-2554 and references cited therein). In this procedure, equal amounts of JJ1 and an aldehyde or ketone are stirred with titanium (IV) isopropoxide, followed the addition of sodium cyanoborohydride in a solvent such as ethanol to give substituted amine JJ4.
- Reaction Scheme KK
- A synthetic sequence to prepare compounds of the present invention wherein L is acetylene is described in Reaction Scheme KK.
- When not commercially available, propiolic acids KK2 are prepared by reaction of acetylenes KK1 with n-butyl lithium in THF at −78° C. warming to 0° C. for 30 min. The mixture is cooled to −78° C., and transferred to a saturated solution of carbon dioxide in THF at −78° C. The reaction is slowly warmed to rt to give the corresponding propiolic acid KK2.
- Reaction of the propiolic acid KK2 with 4-bromobenzene-1,2-diamine dihydrochloride KK3 in refluxing ethylene glycol gives chlorovinylbenzimidazole KK4.
- Reaction of KK3 with a phenyl boronic acid under Suzuki conditions in a microwave synthesizer and thermal conditions as described in Reaction Scheme AA gives acetylene compounds KK4.
- Reaction Scheme LL
- An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme LL.
- Protected bromodiamine LL1 is coupled with a suitable boronic acid via Suzuki coupling as described in previous reaction schemes to give the diamine LL2.
- LL2 is then reacted with an acid or acid chloride to give LL3 (as described in reaction Schemes AA or BB′).
- Reaction Scheme MM
- A synthetic sequence to produce compounds of the present invention wherein L is vinyl or ethyl that may be used as an alternative to Scheme BB′ is described in reaction Scheme MM.
- A solution of AA1 and dichloroimine MM1 (as described in McElvain, S. M. et. al. J. Am. Chem. Soc. 1942, 64, 1825) in ethanol is heated to give chloromethyl benzimidazole MM2 (as described in Komoriya et. al. Bioorg. Med. Chem., 2004, 12, 2099-2114).
- Heating in dichloroethane with triphenylphosphine converts MM2 to the phosphonium salt MM3.
- Reaction of MM3 with various aldehydes or ketones in a solution of anhydrous THF and EtOH with a base such as DBU (1,8-diazabicyclo[4.5.0]undec-7-ene) gives bromobenzimidazole BB′1, which is further elaborated as described in reaction Scheme AA.
- Reaction Scheme NN
- An alternative synthetic sequence to produce compounds of the present invention is described in reaction Scheme NN.
- The biaryldiamine LL2 is reacted with dichloroimine MM1 as described in reaction Scheme MM to give NN1.
- As described in reaction Scheme MM, NN1 is carried forward to give NN2.
- Reaction Scheme OO
- Compounds of the present invention wherein L is ethylene can be prepared by the alternate route described in Reaction Scheme OO.
- Compounds of the present invention such as NN3, wherein L is vinyl, are dissolved in a solvent such as methanol, and are hydrogenated using a catalyst such as 10% Pd on carbon to give OO1.
- Reaction Scheme PP
- A synthetic sequence to produce compounds of the present invention wherein L is cyclopropyl is described in reaction Scheme PP.
- Reaction of olefin PP1 with an alkyl diazoacetate, such as ethyl diazoacetate, in the presence of a catalyst, such as copper(I)trifluoromethane sulfonate and Evans' chiral ligand (Evans, D. A.; Woerpel, K. A.; Hinman, M. M.; Faul, M. M. J. Am. Chem. Soc. 1991, 113, 726-728) in a solvent such as chloroform, gives a cyclopropyl ester enantiomer PP2.
- The (R,R)-cyclopropyl ester PP2 enantiomer is obtained when a chiral ligand such as 2,2-bis-[2-((4S)-(1,1-dimethylethyl)-1,3-oxazolinyl)]propane Compound 38b is used. The (S,S)-cyclopropyl ester enantiomer is obtained when the chiral ligand 2,2-bis-[2-((4R)-(1,1-dimethylethyl)-1,3-oxazolinyl)]propane Compound 38a is used. The configurations of the cyclopropyl moiety were predicted based on Evans' J. Am. Chem. Soc. 1991 report. Hydrolysis of the ester PP2 gives acid PP3, which is further elaborated into the benzimidazoles of Scheme AA.
- To determine the enantiomeric excess of the asymmetric cyclopropanation products PP2, acid PP3 is reacted with N,O-dimethylhydroxyl amine in the presence of a base such as diisopropylethylamine, and an amide coupling reagent such as BOP, in a solvent such as DMF to produce the methoxy methyl amide PP4.
- The resulting 1H NMR of amide PP4 in the presence of an appropriate amount of chiral shifting agent, such as (R)-(−)-2,2,2-trifluoro-1-(9-anthryl)ethanol, gives base line resolution of the resulting methoxy singlets. The ratio of the integration of the methoxy singlets gives the ee value. Thus, the NMR showed methoxy singlets around 3.47 and 3.45 ppm. The integration of the singlets was 1 and 99, respectively; thus providing an ee value of 99%.
- Reaction Scheme QQ
- A synthetic sequence to produce compounds of the present invention wherein R1 is an alcohol is described in reaction Scheme QQ.
- As elaborated in Scheme BB′, the aldehyde QQ1 is reacted with malonic acid and a catalytic amount of piperidine in pyridine at elevated temperatures to provide an acid QQ2. Acid QQ2 is converted to an acid chloride QQ3 by reaction with oxalyl chloride and a catalytic amount of DMF in a solvent such as methylene chloride.
- As elaborated in Scheme AA, the acid chloride QQ3 is heated with 4-bromobenzene-1,2-diamine AA1 in acetic acid to give a bromobenzimidazole QQ4.
- As elaborated in Scheme AA, a suitably substituted phenyl boronic acid is reacted with benzimidazole QQ4 in the presence of a reagent and a catalytic amount of a palladium catalyst in a solvent to give an alcohol substituted benzimidazole QQ5, representative of a compound of Formula (I).
- To a solution of 3-(4-tert-butyl-phenyl)-acrylic acid (12 g, 58.7 mmol) in POCl3 (200 mL), was slowly added 4-bromo-benzene-1,2-diamine (10 g, 53.4 mmol). The solution was heated at reflux for 18 h. The solution was concentrated, and the residual POCl3 was azeotropically removed with toluene. The residue was partitioned between EtOAc and 10% Na2CO3. The organic layer was washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated. The residue was purified by chromatography (silica, EtOAc:hexanes, 3:7) to give the title Compound 1a (7.1 g, 31% yield). 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.64 (d, 1H, J=13.9 Hz) 7.62 (s, 1H) 7.41 (d, 2H, J=8.4 Hz) 7.36 (d, 1H, J=8.5 Hz) 7.33 (d, 2H, J=8.4 Hz) 7.28 (s, 1H) 7.22 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.02 (d, 1H, J=16.5 Hz) 1.25 (s, 9H).
- A solution of Compound 1a (0.106 g, 0.30 mmol), 2-acetylbenzeneboronic acid (136 mg; 0.76 mmol), PdCl2dppf (0.06 mmol) and Cs2CO3 (0.244 g, 0.75 mmol) in 1,4-dioxane:EtOH 5:1 was heated to 115° C. After 18 h, the solution was cooled and concentrated. The residue was purified using preparative TLC plates (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 3:7) to give the title Compound 1 (0.0146 g). 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.54 (m, 11H) 7.23 (dd, 1H, J=1.6 Hz, J=8.3 Hz) 7.15 (d, 1H, J=16.5 Hz) 2.02 (s, 3H) 1.36 (s, 9H). MS (ESI, pos. ion) m/z: 395.3 (M+1).
- Using the procedures described in Example 1 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 3 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.0048 g) was prepared from 2-hydroxybenzeneboronic acid (0.0345 g, 0.25 mmol) and Compound 1a (0.029 g, 0.1 mmol). 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.56 (s, 1H) 7.31 (dd, 2H, J = 12.2 Hz, J = 24.1 Hz) 7.10 (m, 8H) 6.86 (t, 1H, J = 7.3 Hz) 6.78 (d, 1H, J = 16.4 Hz) 1.19 (s, 9H). MS (ESI, pos. ion) m/z: 368.3 (M + 1). 4 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide The title compound (0.001 g) was prepared from 2-N-acetyl-benzeneboronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.44 (m, 4H) 7.24 (m, 6H) 6.91 (d, 1H, J = 12.4 Hz) 6.47 (d, 1H, J = 12.4 Hz) 1.86 (s, 1H) 1.20 (s, 9H). MS (ESI, pos. ion) m/z: 410.2 (M + 1). 5 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.001 g) was prepared from 2-aminocarbonyl benzeneboronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.48 (m, 6H) 7.37 (m, 5H) 7.26 (dd, 1H, J = 1.6 Hz, J = 8.3 Hz) 7.04 (d, 1H, J = 16.5 Hz) 1.26 (s, 9H). MS (ESI, pos. ion) m/z: 396.1 (M + 1). 6 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.001 g) was prepared from 3-aminocarbonylbenzene boronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). 1H- NMR (400 MHz, CD3OD) δ (ppm) 8.22 (t, 1H, J = 1.7 Hz) 7.88 (m, 3H) 7.62 (m, 6H) 7.51 (m, 2H) 7.17 (d, 1H, J = 16.5 Hz) 1.38 (s, 9H). MS (ESI, pos. ion) m/z: 396.1 (M + 1). 7 (E)-4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.002 g) was prepared from 4-aminocarbonylbenzene boronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). 1H- NMR (400 MHz, CD3OD) δ (ppm) 7.97 (m, 2H) 7.77 (m, 4H) 7.60 (m, 4H) 7.47 (d, 2H, J = 8.4 Hz) 7.13 (d, 1H, J = 16.5 Hz) 1.36 (s, 9H). MS (ESI, pos. ion) m/z: 410.2 (M + 1). 8 (E)-N-(4-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide The title compound 0.0038 g) was prepared from 4-N-acetylbenzeneboronic acid (0.136 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol) to give the title compound (0.0038 g). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.73 (m, 2H) 7.61 (m, 7H) 7.49 (m, 3H) 7.12 (d, 1H, J = 16.5 Hz) 2.17 (s, 3H) 1.36 (s, 9H). MS (ESI, pos. ion) m/z: 410.2 (M + 1). 9 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide The title compound (0.0045 g) was prepared from 2-methanesulfonamide benzeneboronic acid (0.163 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.62 (m, 6H) 7.50 (d, 2H, J = 8.5 Hz) 7.41 (m, 2H) 7.34 (m, 2H) 7.17 (d, 1H, J = 16.5 Hz) 2.75 (s, 3H) 1.37 (s, 9H). MS (ESI, pos. ion) m/z: 446.2 (M + 1). 10 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- carbamic acid tert-butyl ester The title compound (0.0016 g) was prepared from 2-N-Boc-benzeneboronic acid (0.180 g, 0.76 mmol) and (E)-5-bromo-2-[2-(4-tert-butyl-phenyl)-vinyl]-1H- aminobenzimidazole Compound 1b (0.106 g, 0.3 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.62 (m, 5H) 7.50 (m, 2H) 7.33 (dd, 1H, J = 1.6 Hz, J = 8.3 Hz) 7.14 (m, 3H) 6.83 (m, 2H) 3.37 (s, 9H) 1.37 (s, 9H). MS (ESI, pos. ion) m/z: 468.1 (M + 1). 11 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenylamine A solution of (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid tert-butyl ester (0.005 g, 0.01 mmol) in methylene chloride (1 mL) was treated with trifluoroacetic acid (0.5 mL). The solution was stirred at room temperature for 4 h, then concentrated to give the title compound (0.003 g). 1H-NMR (400 MHz, CD3OD) δ (ppm) 8.03 (d, 1H, J = 16.5 Hz) 7.90 (d, 1H, J = 8.5 Hz) 7.85 (s, 1H) 7.74 (d, 2H, J = 8.4 Hz) 7.65 (dd, 1H, J = 1.5 Hz, J = 8.5 Hz) 7.59 (d, 2H, J = 8.4 Hz) 7.43 (m, 5H) 1.39 (s, 9H). MS (ESI, pos. ion) m/z: 368.1 (M + 1). 12 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanol The title compound (0.0046 g) was prepared from 2-hydroxymethylbenzene boronic acid (0.102 g, 0.76 mmol) and Compound 1a (0.106 g, 0.3 mmol). 1H- NMR (400 MHz, CD3OD) δ (ppm) 7.59 (m, 5H) 7.49 (d, 2H, J = 8.4 Hz) 7.40 (m, 2H) 7.34 (m, 2H) 7.27 (dd, 1H, J = 1.6 Hz, J = 8.3 Hz) 7.16 (d, 1H, J = 16.6 Hz) 4.58 (s, 2H) 1.37 (s, 9H). MS (ESI, pos. ion) m/z: 383.2 (M + 1). 24 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide Using the procedure of Example 1, Step B, the title compound (0.001 g) was prepared from 2-N-acetylbenzeneboronic acid (0.136 g, 0.76 mmol) and (E)-5- bromo-2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazole Compound 1c (0.10 g, 0.30 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.61 (m, 5H) 7.39 (m, 6H) 7.18 (d, 1H, J = 16.5 Hz) 1.99 (s, 3H). MS (ESI, pos. ion) m/z: 390.2 (M + 1). 25 (E)-N-(3-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- acetamide The title compound (0.0102 g) was prepared from 3-N-acetylbenzeneboronic acid (0.136 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.78 (d, 1H, J = 0.9 Hz) 7.63 (s, 1H) 7.44 (m, 5H) 7.26 (m, 4H) 7.01 (d, 1H, J = 16.5 Hz) 2.06 (s, 3H). MS (ESI, pos. ion) m/z: 390.1 (M + 1). 26 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzamide The title compound (0.0031 g) was prepared from 2-aminocarbonylbenzene boronic acid (0.125 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). 1H- NMR (400 MHz, CDCl3 + CD3OD) δ (ppm) 7.62 (s, 1H) 7.40 (m, 9H) 7.18 (td, 1H, J = 8.4 Hz, J = 10.1 Hz) 7.01 (d, 1H, J = 16.5 Hz). MS (ESI, pos. ion) m/z: 376.2 (M + 1). 27 (E)-1-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone The title compound (0.001 g) was prepared from 2-acetylbenzeneboronic acid (0.125 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.49 (m, 5H) 7.37 (m, 4H) 7.23 (td, 1H, J = 8.4 Hz, J = 10.3 Hz) 7.14 (dd, 1H, J = 1.7 Hz, J = 8.3 Hz) 7.06 (d, 1H, J = 16.5 Hz) 1.91 (s, 3H). MS (ESI, pos. ion) m/z: 375.2 (M + 1). 28 (E)-N-(2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide The title compound (0.0021 g) was prepared from 2-methylsulfonylamino benzeneboronic acid (0.163 g, 0.76 mmol) and Compound 1c (0.10 g, 0.30 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.50 (m, 5H) 7.36 (m, 1H) 7.26 (m, 5H) 7.07 (d, 1H, J = 16.5 Hz) 2.64 (s, 3H). MS (ESI, pos. ion) m/z: 426.1 (M + 1). 30 (E)-2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole The title compound (0.0182 g) was prepared from 3-methylphenylbenzene boronic acid (0.052 g, 0.38 mmol) and 5-bromo-2-[3-(4-tert-butyl-phenyl)- propyl]-1H-benzimidazole Compound 5a (0.055 g, 0.15 mmol). 1H-NMR (400 MHz, CDCl3) δ (ppm) 7.33 (m, 3H) 7.18 (m, 5H) 7.03 (d, 1H, J = 7.4 Hz) 6.95 (d, 2H, J = 8.3 Hz) 2.85 (m, 2H) 2.57 (t, 2H, J = 7.5 Hz) 2.30 (s, 3H) 2.06 (m, 2H) 1.17 (s, 9H). MS (ESI, pos. ion) m/z: 383.2 (M + 1). - A solution of (E)-1-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone Cpd 1 (0.005 g, 0.01 mmol) in ethanol (0.5 mL) was treated with NaBH4 (0.003 g, 0.08 mmol). After 3 h, the reaction mixture was applied to a preparative TLC plate (2000 microns, silica gel, 20×20) and developed using EtOAc: hexanes, 1:1. The desired band was extracted and concentrated to give the title compound (0.002 g). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.69 (m, 1H) 7.62 (m, 3H) 7.50 (m, 3H) 7.41 (ddd, 2H, J=2.5 Hz, J=10.1 Hz, J=14.1 Hz) 7.32 (dt, 1H, J=1.4 Hz, J=7.5 Hz) 7.23 (m, 2H) 7.17 (d, 1H, J=16.5 Hz) 4.99 (q, 1H, J=6.3 Hz) 1.38 (s, 9H) 1.35 (d, 1.5H, J=6.1 Hz) 1.33 (d, 1.5H, J=6.1 Hz). MS (ESI, pos. ion) m/z: 397.2 (M+1).
- Using the procedure of Example 1, Step A, the title Compound 10c (0.910 g) was prepared from 3-(4-trifluoromethyl-phenyl)-acrylic acid Compound 10a (1.5 g, 6.9 mmol) and 4-bromo-benzene-1,2-diamine (1.3 g, 6.9 mmol). 1H-NMR (400 MHz, CDCl3+DMSO(d6)) δ (ppm) 7.78 (d, 1H, J=16.5 Hz) 7.73 (d, 1H, J=1.7 Hz) 7.66 (m, 4H) 7.48 (d, 2H, J=8.0 Hz) 7.33 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.23 (d, 1H, J=16.5 Hz).
- Using the procedure of Example 1, Step B, the title compound (0.001 g) was prepared from 2-carboxamidophenylbenzeneboronic acid (0.120 g, 0.76 mmol) and Compound 10c (0.110 g, 0.30 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.74 (d, 2H, J=8.2 Hz) 7.63 (m, 3H) 7.57 (s, 1H) 7.40 (m, 6H) 7.22 (d, 1H, J=16.5 Hz). MS (ESI, pos. ion) m/z: 408.1 (M+1).
- Using the procedures described in Example 3 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 14 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.001 g) was prepared from 2-hydroxybenzeneboronic acid (0.105 g, 0.38 mmol) and Compound 10c (0.110 g, 0.30 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.74 (d, 2H, J = 8.3 Hz) 7.63 (dd, 3H, J = 8.7 Hz, J = 17.1 Hz) 7.56 (s, 1H) 7.50 (d, 1H, J = 8.3 Hz) 7.38 (dd, 1H, J = 1.5 Hz, J = 8.4 Hz) 7.22 (m, 2H) 7.06 (m, 1H) 6.82 (m, 2H). MS (ESI, pos. ion) m/z: 381.3 (M + 1). 15 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone The title compound (0.001 g) was prepared from 2-acetylbenzeneboronic acid (0.125 g, 0.76 mmol) and Compound 10c (0.110 g, 0.30 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.75 (d, 2H, J = 8.2 Hz) 7.60 (m, 4H) 7.48 (m, 2H) 7.38 (m, 3H) 7.23 (d, 1H, J = 16.6 Hz) 7.16 (dd, 1H, J = 1.7 Hz, J = 8.3 Hz) 1.92 (s, 3H). MS (ESI, pos. ion) m/z: 407.3 (M + 1). 16 (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol A solution of (E)-1-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone Compound 15 (0.005 g, 0.01 mmol) in ethanol (0.5 mL) was treated with NaBH4 (0.003 g, 0.08 mmol). After 3 h, the solution was applied to a preparative TLC plate (2000 microns, silica gel, 20 × 20) and developed using EtOAc: hexanes, 1:1. The desired band was extracted and concentrated to give the title compound (0.001 g). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.87 (d, 1H, J = 8.2 Hz) 7.76 (d, 1H, J = 8.0 Hz) 7.67 (m, 1H) 7.51 (s, 1H) 7.42 (m, 1H) 7.32 (m, 1H) 7.25 (m, 1H) 4.98 (q, 1H, J = 6.4 Hz) 1.35 (d, 1H, J = 6.4 Hz). MS (ESI, pos. ion) m/z: 409.2 (M + 1). 17 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide The title compound (0094 g) was prepared from 2-methylsulfonyl aminobenzeneboronic acid (0.163 g, 0.76 mmol) and Compound 10c (0.110 g, 0.30 mmol). 1H-NMR (400 MHz, DMSO(d6)) δ (ppm) 12.82 (s, 1H) 8.89 (s, 1H) 7.91 (d, 2H, J = 8.1 Hz) 7.80 (m, 2H) 7.75 (s, 1H) 7.70 (m, 1H) 7.58 (d, 1H, J = 6.9 Hz) 7.37 (m, 6H) 2.73 (d, 3H, J = 28.8 Hz). MS (ESI, pos. ion) m/z: 458.2 (M + 1). 31 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide Using the procedure of Example 1, Step A., 5-bromo-2-[2-(4-trifluoroethyl- phenyl)-ethyl]-1H-benzimidazole Compound 3b was prepared from 3-(4- trifluoromethyl-phenyl)-propionic acid (1.04 g, 5.04 mmol) and 4-bromo- benzene-1,2-diamine (0.946 g, 5.06 mmol). Using the procedure of Example 1, Step B., the title compound was prepared from 2-methylsulfonylaminobenzeneboronic acid (0.367 g, 1.7 mmol) and Compound 3b (0.188 g, 0.51 mmol). 1H-NMR (400 MHz, (CD3OD) δ (ppm) 7.64-7.50 (m, 5H), 7.47-7.34 (m, 4H), 7.34-7.27 (m, 2H), 3.27 (s, 4H), 2.71 (s, 3H). MS (ESI, pos. ion) m/z: 460.16 (M + 1). - A solution of 4-trifluoromethoxybenzaldehyde (26.3 mmol), malonic acid (5.6 g, 53.8 mmol) and piperidine (0.265 mL, 2.7 mmol) in pyridine (15 mL) was heated to 70° C. for 18 h. Water (200 mL) was added to the reaction solution. The mixture was acidified to pH 4 using concentrated hydrochloric acid. The solution was filtered. The solid was washed with water. The solid was dried in vacuo to give the title Compound 4a (1.2 g). 1H-NMR (d6-DMSO) δ (ppm): 6.80 (d, J=16.02 Hz, 1H), 6.72 (m, 2H), 6.38 (m, 2H), 5.55 (d, J=16.00 Hz, 1H).
- A solution of Compound 4a (1.2 g, 5.2 mmol) in methylene chloride (20 mL) was treated with oxalyl chloride (7.8 mL, 3.6 mmol). To the solution was added DMF (0.02 mL). The reaction solution was stirred at room temperature for 2 h. The reaction solution was concentrated. The residue was dried in vacuo to provide Compound 4b, which was used without further purification in the next step.
- A solution of Compound 4b (1 g, 4 mmol) in acetic acid (10 mL) was added slowly to a solution of 4-bromo-benzene-1,2-diamine (0.744 g, 4 mmol) in acetic acid (10 mL). The solution was heated to 100° C. for 18 h. The solution was cooled to room temperature. To the solution was added ethyl acetate:hexanes 3:7 (100 mL). The solution was filtered. The solid was dried in vacuo to give the title Compound 4c (1.1 g). 1H-NMR (400 MHz, DMSO d6) ppm 8.12 (d, J=16.60 Hz, 1H), 7.98 (m, 1H), 7.87 (m, 2H), 7.82-7.68 (m, 1H), 7.67-7.37 (m, 4H), 7.34 (d, J=16.58 Hz, 1H). MS (ESI pos. ion) m/z: 383.2 and 385.2.
- Using the procedure of Example 1, Step B, the title Compound 19 was prepared from 2-carboxamido-phenylbenzene boronic acid and Compound 4c.
- Using the procedures described in Example 4 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 20 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone The title compound (0.001 g) was prepared from 2-acetylbenzeneboronic acid (0.280 g, 1.7 mmol) and Compound 4c (0.195 g, 0.51 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.66 (d, J = 8.72 Hz, 2H), 7.61-7.43 (m, 4H), 7.43-7.32 (m, 3H), 7.24 (d, J = 8.19 Hz, 2H), 7.19-7.06 (m, 2H), 1.96-1.86 (m, 3H). MS (ESI, pos. ion) m/z: 423.14 (M + 1). 21 (E)-1-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol Using the procedure of Example 2, the title compound was prepared from Compound 20. 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.76-7.80 (d, J = 8.84 Hz, 2H) 7.60-7.70 (m, 3H) 7.50 (bs, 1H) 7.40-7.44 (ddd, J = 1.26, 7.32 Hz, 1H) 7.29-7.37 (m, 3H) 7.20-7.25 (m, 3H) 4.96-5.02 (q, J = 6.57 Hz, 1H) 1.34-1.36 (d, J = 6.32 Hz, 3H). MS (ESI, pos. ion) m/z: 425.2 (M + 1). 22 (E)-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide The title compound (0.05 g) was prepared from 2-methylsulfonyl aminobenzeneboronic acid (0.521 g, 2.4 mmol) and Compound 4c (0.463 g, 1.2 mmol). 1H-NMR (400 MHz, DMSO(d6)) δ (ppm) 12.76 (d, J = 5.43 Hz, 1H), 8.90 (d, J = 4.68 Hz, 1H), 7.83 (d, J = 8.72 Hz, 2H), 7.65 (m, 1H), 7.50-7.22 (m, 8H), 2.76 (s, 1.5H), 2.69 (s, 1.5H). MS (ESI, pos. ion) m/z: 474.2 (M + 1). - Using the procedure of Example 1, Step A, the title Compound 5a (0.512 g) was prepared from 4-(4-tert-butyl-phenyl)-butyric acid (2.0 g, 10.7 mmol) and 4-bromo-benzene-1,2-diamine (2.0 g, 10.7 mmol). 1H-NMR (400 MHz, CDCl3) δ(ppm) 7.73 (d, 1H, J=1.6 Hz) 7.45 (d, 1H, J=8.5 Hz) 7.38 (dd, 1H, J=1.8 Hz, J=8.5 Hz) 7.32 (m, 3H) 7.12 (d, 2H, J=8.3 Hz) 2.97 (m, 2H) 2.73 (t, 2H, J=7.4 Hz) 2.23 (m, 2H) 1.33 (s, 9H).
- Using the procedure outlined in Example 1, Step B, the title Compound 29 (0.0083 g) was prepared from 2-hydroxybenzeneboronic acid (0.07 g, 0.5 mmol) and Compound 5a (0.074 g, 0.2 mmol). 1H-NMR (400 MHz, CDCl3) δ (ppm) 7.51 (s, 1H) 7.39 (d, 1H, J=8.1 Hz) 7.16 (m, 6H) 6.95 (d, 3H, J=8.2 Hz) 6.88 (t, 1H, J=7.4 Hz) 2.73 (t, 2H, J=7.5 Hz) 2.52 (t, 2H, J=7.3 Hz) 2.00 (m, 2H) 1.20 (s, 9H). MS (ESI, pos. ion) m/z: 385.3 (M+1).
- A mixture of 3-(4-tert-butyl-phenyl)-acrylic acid (12.28 g, 60.1 mmol) and 10% palladium on carbon (0.6 g) in ethanol was hydrogenated at 50 psi hydrogen for 2 hours. The reaction mixture was filtered over a pad of celite, a nylon disk, and the solvents were removed in vacuo to yield the title Compound 6a (12.36 g, 59.9 mmol) as a white crystalline powder. 1H-NMR (d6-DMSO) δ (ppm): 12.10 (s, 1H), 7.29 (d, 2H), 7.12 (d, 2H), 2.88 (t, 2H), 2.50 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion) m/z: 228.9 (M+Na+).
- To a solution of Compound 6a (1.04 g, 5.04 mmol), in 25 mL of POCl3 was added 4-bromo-benzene-1,2-diamine (0.946 g, 5.06 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 2.5 h then concentrated in vacuo. The residue was treated with 25 mL benzene and evaporated in vacuo. The residue was partitioned between 50 mL EtOAc and 50 mL saturated NaHCO3. The organic fractions were washed with 50 mL of saturated NaHCO3 and with 50 mL brine. The organic fraction was dried with Na2SO4, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel, EtOAc:Heptane, 2:8-4:6)) to yield the title Compound 6b (0.726 g, 2.03 mmol) as a tan powder. 1H-NMR (d6-DMSO) δ (ppm): 12.48-12.32 (m, 1H), 7.74-7.58 (m, 1H), 7.51-7.38 (m, 1H), 7.33-7.22 (m, 3H), 7.17 (d, 2H), 3.10 (m, 4H), 1.27 (s, 9H). MS (ESI pos. ion) m/z: 357.1/359.1 (M+H+).
- A mixture of Compound 6b, (0.036 g, 0.10 mmol), 2-hydroxy phenyl boronic acid (0.022 g, 0.16 mmol), Cs2CO3 (0.074 g, 0.23 mmol), and PdCl2(dppf) (0.008 g, 0.01 mmol) in 2 mL 5:1 dioxane/EtOH in a sealed tube was heated at 100° C. for 15 minutes in a microwave synthesizer. More 2-hydroxy phenyl boronic acid (0.024 g, 0.17 mmol) and more PdCl2(dppf) (0.010 g, 0.01 mmol) were added and the reaction was heated at 120° C. for 20 minutes. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fraction was evaporated, and the residue was purified by chromatography. (reverse-phase, acetonitrile:water+0.1% TFA, 25:75-95:5). The relevant fractions were frozen and lyophilized to give the product Compound 32 (0.013 g, 0.04 mmol) as a tan powder. 1H-NMR (d6-DMSO) δ (ppm): 14.55 (br s, 1H), 9.69 (s, 1H), 7.87 (s, 1H), 7.77 (d, 1H), 7.65 (d, 1H), 7.36-7.30 (m, 3H), 7.24-7.15 (m, 3H), 6.98 (d, 1H), 6.92 (t, 1H), 3.40 (t, 2H), 3.17 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion) m/z: 371.2 (M+H+).
- Using the procedures described in Example 6 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 33 3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.016 g) was prepared from 3-hydroxy phenyl boronic acid (0.037 g) and Compound 6b (0.036 g). 1H-NMR (d6-DMSO) δ (ppm): 14.62 (br s, 1H), 9.62 (s, 1H), 7.88 (s, 1H), 7.81 (d, 1H), 7.71 (dd, 1H), 7.36-7.27 (m, 3H), 7.18 (d, 2H), 7.13 (d, 1H), 7.08 (t, 1H), 6.82 (dd, 1H), 3.40 (t, 2H), 3.16 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion): 371.2 (M + H+). 34 4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol The title compound (0.022 g) was prepared from 4-hydroxy phenyl boronic acid (0.032 g) and Compound 6b (0.036 g). 1H-NMR (d6-DMSO) δ (ppm): 14.61 (br s, 1H), 9.65 (s, 1H), 7.85 (s, 1H), 7.78 (d, 1H), 7.71 (dd, 1H), 7.56 (d, 2H), 7.33 (d, 2H), 7.18 (d, 2H), 6.89 (d, 2H), 3.39 (t, 2H), 3.16 (t, 2H), 1.25 (s, 9H). MS (ESI pos. ion) m/z: 371.2 (M + H+). - To a solution of 4-trifluoromethylsulfanyl-benzaldehyde (15.46 g, 75.0 mmol) in 350 mL of benzene was added (carbethoxymethylene)triphenyl-phosphorane (26.14 g, 75.0 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 6 hours. The solvents were removed in vacuo and the resulting material was triturated with 350 mL of diethyl ether and filtered. The filtrate was concentrated in vacuo and triturated once more with 50 mL diethyl ether and filtered. The filtrate was evaporated in vacuo and purified by chromatography (silica, EtOAc:heptane, 0:10-1:9) to obtain the title Compound 7a (15.8 g, 57.3 mmol) as a white solid. 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 7.89 (d, 2H), 7.75 (d, 2H), 7.70 (d, 1H), 6.77 (d, 1H), 4.21 (q, 2H), 1.27 (t, 3H). MS (ESI pos. ion) m/z: 277.0 (M+H+).
- To a solution of Compound 7a (10.31 g, 37.3 mmol), in 300 mL of ethanol was added 3N aqueous NaOH solution (13.0 mL, 39.0 mmol). The reaction mixture was stirred for 21 hours, then evaporated in vacuo. The residue was dissolved in 250 mL water, and to it was added 1N aqueous HCl (45 mL, 45 mmol). The resulting precipitate was filtered, rinsed with water and dried under a stream of air to yield the title Compound 7b (8.967 g, 36.1 mmol) as a white powder. 1H-NMR (400M Hz, d6-DMSO) δ (ppm): 12.58 (s, 1H), 7.85 (d, 2H), 7.74 (d, 2H), 7.63 (d, 1H), 6.66 (d, 1H).
- To a suspension of Compound 7b (1.240 g, 5.00 mmol) in 100 mL of CH3CN was added POCl3 (2.3 mL, 25.1 mmol) and 4-bromo-benzene-1,2-diamine (0.938 g, 5.01 mmol). The reaction mixture was heated at reflux under a nitrogen atmosphere for 18 hours, cooled slightly then additional 4-bromo-benzene-1,2-diamine (0.468 g, 2.50 mmol) was added. Refluxing was continued for 6 hours, then a final amount of 4-bromo-benzene-1,2-diamine (0.468 g, 2.50 mmol) was added. After heating for an additional 15 hours, the reaction mixture was concentrated in vacuo. The residue was purified by chromatography (silica, NH3 in MeOH (2M):CH2Cl2, 1:99-5:95) then a second time (EtOAc:heptane, 1:9-1:1)) to afford the title Compound 7c (1.255 g, 3.14 mmol) as a tan powder. 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 12.96-12.83 (br d, 1H), 7.87-7.68 (m, 6H), 7.60-7.45 (m, 1H), 7.39-7.29 (m, 2H). MS (ESI pos. ion) m/z: 398.9/400.9 (M+H+).
- To a solution of Compound 7c (0.040 g, 0.10 mmol) and 2-hydroxymethyl phenyl boronic acid (0.029 g, 0.19 mmol) in 3 mL dioxane in a small pressure tube was added aqueous Na2CO3 solution (0.13 mL, 2M, 0.26 mmol) followed by PdCl2(dppf) (0.008 g, 0.01 mmol). The vessel was flushed with argon, capped and heated in an oil bath at 120° C. for 1 hour. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fractions were dried with Na2SO4, filtered and the filtrate was evaporated. The residue was purified by chromatography (reverse-phase, acetonitrile:water+0.1% TFA, 1:3-95:5). The relevant fractions were mixed with poly(vinylpyridine), filtered, frozen and lyophilized to give the title Compound 35 (0.027 g, 0.063 mmol) as a yellow powder. 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 7.89-7.78 (m, 5H), 7.71-7.57 (m, 3H), 7.44-7.28 (m, 5H), 4.44 (s, 2H). MS (ESI pos. ion) m/z: 426.7 (M+H+).
- Using the procedures described in Example 7 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 36 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenol The title compound (0.029 g) was prepared from 2-hydroxy phenyl boronic acid (0.028 g) and Compound 7c (0.040 g). 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 9.61 (s, 1H), 7.90-7.79 (m, 6H), 7.70 (d, 1H), 7.54 (d, 1H), 7.42 (d, 1H), 7.33 (dd, 1H), 7.19 (dt, 1H), 6.98 (d, 1H), 6.91 (dt, 1H). MS (ESI pos. ion) m/z: 412.8 (M + H+). 37 (E)-N-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-acetamide The title compound (0.016 g) was prepared from N-[2-(4,4,5,5-tetramethyl- [1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (0.052 g) and Compound 7c (0.040 g). 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 9.24 (s, 1H), 7.86 (d, 2H), 7.82-7.75 (m, 3H), 7.67 (d, 1H), 7.57 (s, 1H), 7.51 (d, 1H), 7.44-7.24 (m, 5H), 1.89 (s, 3H). MS (ESI pos. ion) m/z: 453.8 (M + H+). 38 (E)-2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzamide The title compound (0.031 g) was prepared from 2-benzamido boronic acid (0.034 g) and Compound 7c (0.040 g). 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 7.91-7.79 (m, 5H), 7.73-7.66 (m, 3H), 7.54-7.38 (m, 6H), 7.31 (s, 1H). MS (ESI pos. ion) m/z: 439.8 (M + H+). 39 (E)-1-(2-{2-[2-(4-trifluoromethylsulfanyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone The title compound (0.027 g) was prepared from 2-acetyl phenyl boronic acid (0.034 g) and Compound 7c (0.040 g). 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 7.87 (d, 2H), 7.84-7.77 (m, 3H), 7.69 (d, 1H), 7.55-7.47 (m, 2H), 7.64-7.58 (m, 3H), 7.40 (d, 1H), 7.21 (dd, 1H), 2.09 (s, 3H). MS (ESI pos. ion) m/z: 438.7 (M + H+). - To a suspension of Compound 7b (2.483 g, 10.01 mmol), in 50 mL of TFA was added 30% H2O2 solution (8 mL, 83 mmol). The reaction mixture was stirred for 21 h, then poured into 250 mL of ice water. The resulting precipitate was filtered off, rinsed with water and dried under vacuum at 50° C. to yield the title Compound 8a (2.281 g, 8.14 mmol) as a white powder. 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 12.80 (s, 1H), 8.15 (s, 4H), 7.73 (d, 1H), 6.83 (d, 1H). MS (ESI pos. ion) m/z: 278.9 (M−H+).
- To a suspension of Compound 8a (1.405 g, 5.01 mmol) in 100 mL of acetonitrile was added POCl3 (2.3 mL, 25.1 mmol). The reaction mixture was refluxed under a nitrogen atmosphere for 30 minutes, then cooled slightly. To this reaction mixture was added 4-bromo-benzene-1,2-diamine (0.946 g, 5.06 mmol) and the reaction was refluxed for 2 h before additional 4-bromo-benzene-1,2-diamine (0.942 g, 5.04 mmol) was added. After an hour of heating, the reaction mixture was cooled and filtered over a pad of celite. The filter cake was rinsed with acetonitrile, ethyl acetate, and methanol. The filtrate was stirred with aqueous NaHCO3/EtOAc. The organic fraction was evaporated, and partitioned between 100 mL EtOAc and 100 mL saturated NaHCO3. The organic fraction was dried with Na2SO4, filtered, and the filtrate was evaporated. The residue was purified by chromatography (silica gel, EtOAc:heptane, 1:4-1:1)) to yield the title Compound 8b (1.595 g, 3.70 mmol) as a tan powder. 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 13.00 (d, 1H), 8.14 (q, 4H), 7.87-7.73 (m, 2H), 7.63-7.50 (m, 2H), 7.40-7.33 (m, 1H). MS (ESI pos. ion) m/z: 430.8/432.8 (M+H+).
- A solution of Compound 8b (0.043 g, 0.10 mmol), and 2-acetyl phenyl boronic acid (0.035 g, 0.21 mmol) in 3 mL dioxane was stirred in a small pressure tube. Aqueous Na2CO3 solution (0.13 mL, 2M, 0.26 mmol) was added followed by PdCl2(dppf) (0.007 g, 0.01 mmol). The vessel was flushed with argon, capped and heated in an oil bath at 120° C. for 1 h. The reaction mixture was partitioned between 20 mL EtOAc, 20 mL water, and 2 mL brine. The organic fraction was dried with Na2SO4, filtered, and the filtrate was evaporated. The residue was flushed over a plug of silica gel with 100% EtOAc then evaporated. The crude material was purified by chromatography (reverse-phase, acetonitrile/water+0.1% TFA, 1:3-95:5). The appropriate fractions were mixed with poly(vinylpyridine), filtered, frozen and lyophilized to give the title Compound 40 (0.022 g, 0.047 mmol) as a yellow powder. 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 8.16 (q, 4H), 7.87 (d, 1H), 7.70 (d, 1H), 7.64-7.56 (m, 3H), 7.55-7.47 (m, 3H), 7.21 (d, 1H), 2.09 (s, 3H). MS (ESI pos. ion): 471.0 (M+H+).
- Using the procedures described in Example 8 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 41 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol The title compound (0.024 g) was prepared from 2-hydroxy phenyl boronic acid (0.029 g) and Compound 8b (0.043 g). 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 9.53 (s, 1H), 8.16 (q, 4H), 7.85 (d, 1H), 7.77 (s, 1H), 7.65 (d, 1H), 7.58 (d, 1H), 7.47 (d, 1H), 7.33 (d, 1H), 7.17 (dt, 1H), 6.97 (d, 1H), 6.90 (dt, 1H). MS (ESI pos. ion) m/z: 445.0 (M + H+). 42 (E)-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol The title compound (0.030 g) was prepared from 2-hydroxymethyl phenyl boronic acid (0.027 g) and Compound 8b (0.043 g). 1H-NMR (400 MHz, d6- DMSO) δ (ppm): 8.16 (q, 4H), 7.89 (d, 1H), 7.69 (d, 1H), 7.62 (d, 2H), 7.58 (d, 1H), 7.43-7.33 (m, 2H), 7.30 (dd, 2H), 4.44 (s, 2H). MS (ESI pos. ion) m/z: 459.0 (M + H+). 43 (E)-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-acetamide The title compound (0.011 g) was prepared from N-[2-(4,4,5,5-tetramethyl- [1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (0.053 g) and Compound 8b (0.043 g). 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 9.23 (s, 1H), 8.15 (q, 4H), 7.85 (d, 1H), 7.67 (d, 1H), 7.62-7.55 (m, 2H), 7.51 (d, 1H), 7.42-7.23 (m, 4H), 1.89 (s, 3H). MS (ESI pos. ion) m/z: 486.1 (M + H+). 44 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzamide The title compound (0.018 g) was prepared from 2-benzamido boronic acid (0.034 g) and Compound 8b (0.043 g). 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 8.16 (q, 4H), 7.88 (d, 1H), 7.70-7.64 (m, 3H), 7.59 (d, 1H), 7.54-7.39 (m, 4H), 7.36 (dd, 1H), 7.30 (s, 1H). MS (ESI pos. ion) m/z: 472.0 (M + H+). - To a solution of Compound 40 (0.047 g, 0.10 mmol) in 5 mL EtOH was added NaBH4 (0.028 g, 0.74 mmol). After 1 h, an additional amount of NaBH4 (0.024 g, 0.63 mmol) was added. After an additional 4.5 h, the reaction was diluted into 25 mL EtOAc and washed twice with 25 mL water/brine. The organic fractions were dried with Na2SO4, filtered and the filtrate was evaporated. The residue was purified by chromatography (reverse-phase (acetonitrile/water with 0.1% TFA, 1:3-95:5). The two products were isolated, frozen and lyophilized to give the products Compound 45 (0.024 g, 0.051 mmol) as a yellow powder and Compound 46 (0.020 g, 0.042 mmol) as a white powder.
- Compound 45: 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 8.18 (dd, 4H), 7.93 (d, 1H), 7.74 (d, 1H), 7.67 (d, 1H), 7.64-7.57 (m, 2H), 7.43 (dt, 1H), 7.35-7.27 (m, 2H), 7.21 (dd, 1H), 4.80 (q, 1H), 1.22 (d, 3H). MS (ESI pos. ion) m/z: 472.8 (M+H+).
- Compound 46: 1H-NMR (400 MHz, d6-DMSO) δ (ppm): 8.12 (d, 2H), 7.82-7.74 (m, 3H), 7.70-7.63 (m, 2H), 7.47-7.37 (m, 2H), 7.32 (dt, 1H), 7.18 (dd, 1H), 4.72 (q, 1H), 3.47 (t, 2H), 3.40 (t, 2H), 1.19 (d, 3H). MS (ESI pos. ion) m/z: 474.8 (M+H+).
-
- A solution of 4-trifluoromethylbenzaldehyde (7.7 mL, 57.7 mmol), malonic acid (12.0 g, 115.4 mmol), 0.567 μL piperidine (5.75 mmol) in 30 mL of pyridine was stirred at 70° C. for 18 h. The reaction solution was cooled to room temperature. Water (300 mL) was added and the resulting mixture was acidified to pH 4 (litmus) using concentrated hydrochloric acid to give a precipitate. The solid was filtered, and washed with water until the filtrate was neutral. The solid product was dried in vacuo to give the title Compound 10a as a white powder (11.2 g, 90%). 1HNMR (400 MHz, DMSO-d6) δ (ppm): 12.60 (bs, 1H), 7.92 (d, 2H, J=8.2 Hz), 7.77 (d, 2H, J=8.2 Hz), 7.66 (d, 1H, J=16.0 Hz), 6.70 (d, 1H, J=16.0 Hz).
- A solution of Compound 10a (20.6 g, 95.4 mmol) in anhydrous methylene chloride (200 mL) was treated with oxalyl chloride (16.6 mL, 190 mmol) and “3 drops” of anhydrous dimethylformamide. The resulting solution was stirred at room temperature under an argon atmosphere for 18 h. The solvent was concentrated to give 3-(4-trifluoromethyl-phenyl)-acryloyl chloride Compound 10b as a solid, which was used without further purification in the next step.
- To a solution of 4-bromo-benzene-1,2-diamine (16.1 g, 86.7 mmol) in acetic acid (100 mL) was added dropwise a solution of Compound 10b (assumed 95.4 mmol) in acetic acid (100 mL). The reaction mixture was stirred at 100° C. for 18 h. The reaction mixture was cooled to room temperature, and a mixture of ethyl acetate and hexanes 3:7 (500 mL) was added. The mixture was triturated at room temperature for 3 h to give a precipitate. The solid was filtered, and dried in vacuo to give the title Compound 10c (23.2 g, 73%). 1H NMR (400 MHz, DMSO-d6/CDCl3) δ (ppm): 8.45 (d, 1H, J=16.7 Hz), 7.84-7.90 (m, 1H), 7.74 (d, 2H, J=8.3
- Hz), 7.56-7.62 (m, 3H), 7.50-7.52 (m, 1H), 7.34 (d, 1H, 16.7 Hz).
- To a solution of methyl 2-bromobenzoate (20.76 g, 96 mmol) in 120 mL of anhydrous ether under Argon at 0° C. was slowly added methylmagnesium bromide (77 mL, 3.26 M) at a rate that the internal temperature of the mixture was below 20° C. A white suspension resulted, and the mixture was stirred at room temperature for 2 h. The mixture was cooled in an ice-water bath. To the reaction mixture was very slowly added hydrochloric acid (400 mL, 0.5 M). The pH of the final mixture was adjusted to less than about 6 with few drops of 2M hydrochloric acid. The layers were separated, and the aqueous layer was extracted twice with ether. The organic layers were combined and dried over magnesium sulfate. The organic fraction was filtered, and the filtrate was concentrated to yield the title compound as a pale yellow liquid, which was distilled under vacuum to afford the title Compound 10d as a colorless liquid (16.9 g, 82%, b.p. about 65-70° C./0.3 mmHg). 1H NMR (400 MHz, CDCl3) δ (ppm): 7.67 (dd, 1H, J=1.7, 7.9 Hz), 7.58 (dd, 1H, J=1.3, 7.9 Hz), 7.30 (ddd, 1H, J=1.4, 7.4, 7.9 Hz), 7.10 (ddd, 1H, J=1.7, 7.4, 7.8 Hz), 2.77 (br s, 1H), 1.76 (s, 6H).
- To a solution of n-BuLi (166 mL, 2.6 M, 432 mmol) in 200 mL of THF at −78° C. under argon was slowly added a solution of Compound 10d (42.2 g, 196 mmol) in 60 mL of THF at a rate that the internal temperature remained below −70° C. The mixture was stirred at −75° C. for 2 h. To the reaction mixture was then added triisopropylborate (59 mL, 255 mmol) in three portions. The mixture was allowed to warm slowly to room temperature overnight. The mixture was then cooled to 0° C., and was carefully quenched with dilute hydrochloric acid (250 mL, 2N). The mixture was then stirred at room temperature for 1 h. The pH of the mixture was checked and adjusted to acidic using additional 2N HCl if prophetic. The two layers were separated, and the aqueous layer was extracted twice with ether. The organic layers were combined, and dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to yield a pale yellow oil. The residue was then diluted with ethyl acetate (400 mL) and, washed with 1N sodium hydroxide solution (150 mL×3). The basic aqueous layers were combined and acidified with 2N HCl. The clear solution turned cloudy when the acid was added. The mixture was extracted with ether (150 mL×3). The organic layers were combined and dried with magnesium sulfate. The solution was filtered, and the filtrate was concentrated under reduced pressure to yield the title Compound 10e as a colorless oil (26.2 g, 82%) which was used without further purification in the next step. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.00 (s, 1H), 7.66 (dm, 1H, J=7.3 Hz), 7.45 (dt, 1H, J=1.1, 7.7 Hz), 7.40 (dm, 1H, J=7.6 Hz), 7.31 (dt, 1H, J=1.2, 7.1 Hz), 1.44 (s, 6H).
- To a mixture of Compound 10e (11.7 g, 71 mmol), Compound 10c (19.9 g, 54 mmol), sodium carbonate (46 g, 435 mmol) and PdCl2(dppf).CH2Cl2 (8.9 g, 11 mmol) in a 1 L round bottom flask equipped with water condenser was added 400 mL of anhydrous DME and 200 mL of water. The mixture was evacuated and filled with Argon three times. The mixture was heated to 100° C. for 20 h. The mixture was then cooled to room temperature. The biphasic system was transferred to a 1 L separatory funnel and the two layers were separated. The organic layer was washed with brine (2×300 mL). The aqueous layers were combined and extracted with ethyl acetate once (about 300 mL). The organic layers were combined, dried with sodium sulfate, and filtered. The volume of the filtrate was reduced to about 170 mL under reduced pressure. The mixture was then filtered through a pad of silica gel and the pad was washed with ethyl acetate until the filtrate did not contain any product. After concentration, a light pink/beige solid was obtained. The solid was triturated with 50 mL ethyl acetate, and the mixture was heated to 85° C. for 5 min. The mixture was slowly cooled to r.t., then cooled at 0° C. for 0.5 h. The mixture was filtered, and the solid was washed with cold ethyl acetate twice, and dried under vacuum at 40° C. to yield the title Compound 18 as a light beige solid (7.58 g, 33%). RP-HPLC 95% pure. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 12.73 (m, 1H,), 7.90 (d, 2H, J=8.2 Hz), 7.85 (dd, 1H, J=8.0, 0.6 Hz), 7.78 (d, 2H, J=8.4 Hz), 7.74 (d, 1H, J=16.8 Hz), 7.59-7.47 (m, 1H), 7.41 (s, 1H), 7.37-7.32 (m, 2H), 7.21 (dt, 1H, J=1.2, 7.4 Hz), 7.06 (s, 1H), 7.02 (d, 1H, J=7.4 Hz), 4.85 (s, 1H), 1.21 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C25H21F3N2O: 423.2 (M+H). Found 423.3. m.p. (uncorr.) 250-251° C.
- Using the procedures described in Example 10 and corresponding reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 23 (E)-2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol 1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.84 (dd, J = 1.26, 8.084 Hz, 1H) 7.75-7.85 (m, 2H) 7.66 (d, J = 16.4 Hz) 7.53-7.58 (m, 1H) 7.45 (bs, 1H) 7.34-7.38 (m, 3H) 7.17-7.26 (m, 3H) 7.09 (dd, J = 1.58, 7.58 Hz, 1H) 1.36 (s, 6H). MS (ESI, pos. ion) m/z: 439.2 (M + 1). 47 (E)-2-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-propan-2-ol 1H NMR (400 MHz, CD3OD) δ (ppm): 8.07 (d, 2H, J = 8.6 Hz), 7.98 (d, 2H, J = 8.6 Hz), 7.78 (dd, 1H, J = 1.1, 8.1 Hz), 7.69 (d, 1H, J = 16.5 Hz), 7.54 (d, 1H, J = 8.2 Hz), 7.44 (d, 1H, J = 16.5 Hz), 7.42 (br s, 1H), 7.31 (ddd, 1H, J = 1.5, 7.8, 8.1 Hz), 7.18 (dt, 1H, J = 1.3, 7.4 Hz), 7.16 (dd, 1H, J = 1.5, 8.3 Hz), 7.03 (dd, 1H, J = 1.4, 7.5 Hz), 1.31 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C25H21F3N2O3S: 487.1 (M + H), Found 487.1. 78 (E)-2-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol 1H NMR (400 MHz, CD3OD) δ (ppm): 7.79 (dd, 1H, J = 8.1, 1.1 Hz), 7.63-7.54 (m, 3H), 7.51 (br d, 1H, J = 9.7, 7.4 Hz), 7.40-7.38 (m, 3H), 7.31 (m, 1H), 7.19 (dt, 1H, J = 1.4, 7.4 Hz), 7.15 (d, 1H, J = 16.5 Hz), 7.13 (dd, 1H, J = 7.9, 1.8 Hz), 7.04 (dd, 1H, J = 7.5, 1.4 Hz), 1.30 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C24H21ClN2O: 389.1 (M + H), Found 389.3. 84 (E)-2-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.00 (d, J = 8 Hz, 2H), 7.91 (d, J = 8 Hz, 2H), 7.82 (dd, J = 1.6, 8 Hz, 1H), 7.70 (d, J = 16.4 Hz, 2H), 7.41 (s, 1H), 7.36 (dt, J = 1.6, 8 Hz, 1H), 7.34 (s, 1H), 7.23 (dt, J = 1.6, 8 Hz, 1H), 7.19 (dd, J = 1.6, 8 Hz, 1H), 7.07 (dd, J = 1.6, 8 Hz, 1H), 3.16 (s, 3H), 1.26 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C25H24N2O3S: 433.1 (M + H), Found 433.4. 114 (E)-2-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol 1H NMR (400 MHz, CD3OD) δ (ppm): 7.89-7.87 (m, 2H), 7.79 (dd, 1H, J = 8.1, 1.1 Hz), 7.67-7.56 (m, 3H), 7.52 (m, 1H), 7.40 (br s, 1H), 7.31 (m, 1H), 7.27 (d, 1H, J = 16.6 Hz), 7.18 (dt, 1H, J = 1.3, 7.4 Hz), 7.14 (dd, 1H, J = 8.3, 1.4 Hz, 1H), 7.04 (dd, 1H, J = 7.52, 1.38 Hz), 1.31 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C25H21F3N2O: 423.2 (M + H), Found 423.3. 458 (E)-2,2,2-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-acetamide. The title compound (0.0195 g) was prepared from Compound 465 (0.10 g, 0.26 mmol) and trifluoroacetylimidazolide (0.047 g, 0.29 mmol). 1H-NMR (400 MHz, DMSO d6) δ (ppm): 12.7-12.9 (bs, 1H) 11.0 (s, 1H) 7.90-7.94 (d, J = 8.59 Hz, 2H)) 7.78-7.81 (d, J = 8.59 Hz, 2H) 7.37-7.76 (m, 7H) 7.20 (d, J = 9.34 Hz, 1H) MS (ESI, pos. ion) m/z: 476.2 (M + 1). 459 (E)-2,2,2-trifluoro-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)- vinyl]-1H-benzimidazol-5-yl}-phenyl)-amide The title compound (0.0015 g) was prepared from Compound 465 (0.034 g, 0.09 mmol) and trifluoromethylsulfonylchloride (0.018 g, 0.10 mmol). 1H-NMR (400 MHz, DMSO d6) δ (ppm) 12.75-12.82 (bs, 1H) 9.70-9.80 (bs, 1H) 7.90-7.96 (d, J = 8.08 Hz, 2H) 7.78-7.84 (m, 3H) 7.54-7.77 (m, 2H) 7.40-7.50 (m, 2H) 7.24-7.40 (m, 6H) 4.0 (bs, 2H)MS (ESI, pos. ion) m/z: 526.1 (M + 1). 460 (E)-2,2-dimethyl-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-propionamide The title compound (0.0014 g) was prepared from Compound 465 (0.034 g, 0.09 mmol) and trimethylacetylchloride (0.012 mL, 0.036 mmol). 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.80-7.84 (m, 3H) 7.58-7.78 (m, 6H) 7.38-7.42 (m, 2H) 7.24-7.35 (m, 3H) 1.20 (s, 9H) MS (ESI, pos. ion) m/z: 464.3 (M + 1). 461 (E)-ethanesulfonic acid (2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-amide The title compound (0.0018 g) was prepared from Compound 465 (0.10 g, 0.26 mmol) and ethylsulfonyl chloride (0.027 mL, 0.29 mmol). 1H-NMR (400 MHz, DMSO d6) δ (ppm) 12.88 (d, J = 9.1 Hz, 1H) 8.92 (d, J = 7.3 Hz, 1H) 7.78 (d, J = 8.08 Hz, 2H)) 7.85 (d, J = 8.08 Hz, 2H) 7.72-7.82 (m, 3H) 7.63-7.68 (m, 1H) 7.30-7.53 (m, 6H) 2.78-2.92 (qq, J = 7.33 Hz, 2H) 1.00 (tt, J = 7.33 Hz, 3H). MS (ESI, pos. ion) m/z: 472.1 (M + 1). 462 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid methyl ester The title compound (0.0056 g) was prepared from Compound 465 (0.10 g, 0.26 mmol) and chloromethylformate (0.022 mL, 0.29 mmol). 1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.82-7.84 (d, J = 8.59 Hz, 2H) 7.76-7.78 (d, J = 8.59 Hz, 2H) 7.62-7.70 (m, 3H) 7.59 (bs, 1H) 7.36-7.41 (m, 3H) 7.24-7.34 (m, 3H). MS (ESI, pos. ion) m/z: 438.4 (M + 1). 463 (E)-2-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol 1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.82-7.84 (m, 1H) 7.35-7.64 (m, 8H) 7.10-7.30 (m, 4H) 1.38 (s, 15H). MS (ESI, pos. ion) m/z: 411.3 (M + 1). 465 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenylamine The title compound was prepared from Compound 479 by stirring in TFA with heating. 1H-NMR (400 MHz, DMSO d6) δ (ppm) 12.78 (s, 0.5H) 12.75 (s, 0.5H) 7.91 (d, J = 8.08 Hz, 2H) 7.78-7.81 (m, 3H) 7.74 (d, J = 4.55 Hz, 1H) 7.68 (d, J = 8.08 Hz, 1H) 7.56-7.62 (m, 1H) 7.52 (bs, 1H) 7.41 (d, J = 16.4 Hz, 1H) 7.20-7.29 (m, 1H) 7.05 (t, J = 7.6 Hz, 2H) 6.78 (d, J = 8.34 Hz, 1H) 6.65 (t, J = 6.8 Hz, 1H) 4.81 (s, 1H) 4.74 (s, 1H)MS (ESI, pos. ion) m/z: 526.1 (M + 1). 466 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzoic acid ethyl ester 1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.82-7.84 (d, J = 8.59 Hz, 2H) 7.76-7.78 (d, J = 8.59 Hz, 2H) 7.62-7.70 (m, 3H) 7.59 (bs, 1H) 7.36-7.41 (m, 3H) 7.24-7.34 (m, 3H). MS (ESI, pos. ion) m/z: 438.4 (M + 1). 468 (E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol 1H-NMR (400 MHz, CD3OD) δ (ppm) 8.18 (bs, 2H) 7.70 (m, 3H) 7.44 (m, 3H) 7.30 (m, 3H) 7.22 (m, 2H) 7.19 (m, 1H) 1.28 (s, 9H). MS (ESI, pos. ion) m/z: 412.2 (M + 1). 470 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)sulfamide The title compound (0.0023 g) was prepared from Compound 465 (0.0175 g, 0.046 mmol) and sulfamide (0.5 g, 5.2 mmol). 1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.86 (d, J = 8.61 Hz, 2H) 7.62-7.78 (m, 6H) 7.31-7.41 (m, 4H) 7.21-7.25 (m, 1H). MS (ESI, pos. ion) m/z: 459.2 (M + 1). 476 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanol 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.83 (d, J = 8.59 Hz, 2H) 7.77 (d, J = 8.34 Hz, 2H)7.56-7.74 (m, 5H)7.24-7.42 (m, 5H) 4.56 (s, 2H)MS (ESI, pos. ion) m/z: 395.1 (M + 1). 478 (E)-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-acetamide 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.80-7.84 (m, 3H) 7.56-7.78 (m, 5H) 7.30-7.44 (m, 5H) 1.97 (s, 3H). MS (ESI, pos. ion) m/z: 422.3 (M + 1). 479 (E)-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-carbamic acid tert-butyl ester 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.76-8.00 (d, J = 8.1 Hz, 2H) 7.82-7.90 (d, J = 8.8 Hz, 2H) 7.68-7.79 (m, 4H) 7.36-7.48 (5H) 1.44 (s, 9H). MS (ESI, pos. ion) m/z: 480.2 (M + 1). 480 (E)-5-(2-methylsulfanyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.84-7.87 (d, J = 8.1 Hz, 2H) 7.56-7.78 (m, 5H) 7.20-7.40 (m, 6H). MS (ESI, pos. ion) m/z: 411.2 (M + 1). 481 (E)-2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-5-(2-trifluoromethyl- phenyl)-1H-benzimidazole 1H NMR (400 MHz, CD3OD) δ (ppm): 8.10 (d, 2H, J = 8.5 Hz, 1H), 8.02 (d, 2H, J = 8.5 Hz), 7.77 (d, 1H, J = 7.8 Hz, 1H), 7.73 (d, 1H, J = 16.5 Hz), 7.64 (d, 1H, J = 7.4 Hz), 7.60 (d, 1H, J = 8.4 Hz), 7.54 (d, 1H, J = 7.7 Hz), 7.50 (s, 1H), 7.46 (d, 1H, J = 16.5 Hz), 7.42 (d, 1H, J = 7.6 Hz), 7.22 (dd, 1H, J = 8.4, 1.0 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For C23H14F6N2O2S: 497.1 (M + H), Found 497.1. 482 (E)-2-(2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol 1H NMR (400 MHz, CD3OD) δ (ppm): 8.00-7.94 (m, 2H), 7.79 (dd, 1H, J = 8.1, 1.1 Hz), 7.73 (d, 1H, J = 7.9 Hz), 7.66 (t, 1H, J = 7.7 Hz), 7.53 (br s, 1H), 7.50 (t, 1H, J = 7.67, 7.67 Hz), 7.41 (br s, 1H), 7.31 (m, 1H), 7.21-7.13 (m, 3H), 7.04 (dd, 1H, J = 7.5, 1.4 Hz), 1.31 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C25H21F3N2O: 423.2 (M + H), Found 423.3. 483 (E)-dimethyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzyl)-amine To a solution of Compound 484 (20.7 mg, 0.053 mmol) in DMF (10 mL) was added dimethylamine 2.0 M in THF (66 μL, 0.132 mmol). The mixture was stirred for 45 min and sodium triacetoxyborohydride (17 mg, 0.080 mmol) was added. The mixture was stirred at rt for 2.5 d and then concentrated under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20 × 20 cm, 2000 microns, EtOAc:hexanes:methanol 5:5:1) to give the title compound (18.2 mg, 81%). 1H NMR (400 MHz, CD3OD) δ (ppm): 7.81 (d, 2H, J = 8.2 Hz), 7.70 (d, 2H, J = 8.0 Hz), 7.67 (d, 1H, J = 16.3 Hz), 7.60 (d, 1H, J = 8.2 Hz), 7.55-7.47 (m, 2H), 7.40-7.26 (m, 4H), 7.19 (dd, 1H, J = 8.3, 1.5 Hz), 3.58 (s, 2H), 2.14 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C25H22F3N3: 422.2 (M + H), Found 422.1. 484 (E)-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzaldehyde 1H NMR (400 MHz, DMSO-d6) δ (ppm): 12.93 (d, 1H, J = 12.5 Hz), 9.93 (s, 1H), 7.93 (d, 3H, J = 8.4 Hz), 7.82-7.56 (m, 8H), 7.44 (d, 1H, J = 16.5 Hz), 7.28 (dd, 1H, J = 10.1, 9.3 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For C23H15F3N2O: 393.1 (M + H), Found 393.3. 485 (E)-methyl-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzyl)-amine The title compound was prepared according to the procedure used for Compound 483, with the exception that methylamine was used. 1H NMR (400 MHz, CD3OD) δ (ppm): 7.82 (d, 2H, J = 8.3 Hz, 1H), 7.71 (d, 2H, J = 8.3 Hz), 7.69 (d, 1H, J = 16.6 Hz), 7.63 (d, 1H, J = 8.1 Hz), 7.52-7.47 (m, 2H), 7.39 (tdd, 2H, J = 9.1, 7.2, 3.6, 3.6 Hz), 7.35-7.29 (m, 2H), 7.23 (dd, 1H, J = 8.3, 1.6 Hz), 3.86 (s, 2H), 2.30 (s, 3H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C24H20F3N3: 408.2 (M + H), Found 408.1. 487 (E)-5-(2-trifluoromethyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole 1H NMR (400 MHz, CD3OD) δ (ppm): 7.80 (d, 2H, J = 8.2 Hz), 7.76 (d, 1H, J = 7.9 Hz), 7.70-7.60 (m, 4H), 7.57 (d, 1H, J = 8.3 Hz), 7.52 (t, 1H, J = 7.7 Hz), 7.47 (s, 1H), 7.40 (d, 1H, J = 7.6 Hz), 7.29 (d, 1H, J = 16.6 Hz), 7.19 (dd, 1H, J = 8.3, 1.0 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For C23H14F6N2: 433.1 (M + H), Found 433.3. 488 (E)-5-(2-trifluoromethoxy-phenyl)-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazole 1H NMR (400 MHz, CD3OD) δ (ppm): 7.78 (d, 2H, J = 8.3 Hz), 7.68-7.66 (m, 3H), 7.63-7.58 (m, 2H), 7.50 (m, 1H), 7.43-7.35 (m, 3H), 7.33 (dd, 1H, J = 8.4, 1.6 Hz), 7.27 (d, 1H, J = 16.6 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For C23H14F6N2O: 449.1 (M + H), Found 449.3. - A 2-L 4-neck round bottom flask equipped with an air condenser/argon inlet, mechanical stirrer, thermocouple and a stopper was charged with 4-(trifluoromethyl)benzaldehyde (250 g, 196.2 mL, 1.44 mol), malonic acid (302.6 g, 2.87 mol), and pyridine (750 mL). An exotherm developed (about 38-40° C.), which was maintained for 30 min. Piperidine (14.202 mL, 143.58 mmol) was then added to the reaction and a second exotherm developed (Tmax about 42° C. after about 10 min.). The reaction was stirred for 30 min and then heated to 60° C. for 18 h (overnight). The reaction appeared to be complete by TLC, and was cooled to about 40° C., diluted into water (2 L; done to prevent reaction freezing), cooled to room temperature, and further diluted with water (4 L, 6 L total). The slurry was acidified to pH=2.0-3.0 with concentrated hydrochloric acid (about 675-700 mL). The material was stirred for 30 min., and a white solid was collected by filtration. The filter cake was washed with water until the filtrate was neutral (pH about 5.5-6, 2.5 L), air-dried in a Buchner funnel for 2 h, and then further dried in a vacuum oven at 60° C. overnight to provide 300.5 g (96%) of the title Compound 10a as a white solid.
- To a 5-L 4-neck round bottom flask equipped with a magnetic stirrer, argon inlet-argon outlet to a carbonate scrub, two stoppers, and a room temperature water bath was charged with 4-(trifluoromethyl)cinnamic acid (315 g, 1.46 mol) and dichloromethane (3.15 L) to give a slurry. To the slurry was added oxalyl chloride (151.71 mL, 1.75 mol) and DMF (1.13 mL, 14.57 mmol). Upon addition of DMF, gas evolution commenced, and the reaction was continued for about 3 h during which time a solution developed. When the reaction was complete (LC-MS), it was concentrated to dryness to give 342.4 g of 3-(4-trifluoromethyl-phenyl)-acryloyl chloride Compound 10b (>100%) as a yellow oily solid.
- A 5-L 4-neck round bottom flask equipped with mechanical stirrer, thermocouple, air condenser with argon inlet, and a stopper was charged with 4-bromo-benzene-1,2-diamine (244 g, 1.27 mol) and acetic acid (2.13 L). To this solution was added a solution of Compound 10b (327 g, 1.39 mol) in toluene (237 mL). After this addition, the temperature spiked to 45° C. in about 30 seconds and then subsided. The reaction was then heated to 90° C. for 16 h (overnight). The reaction was cooled to 40° C., and poured into a mixed solution of EtOAc and heptane (about 1:3, 5.75 L) and a precipitate occurred. The resulting slurry was stirred for 3 h, and the solid was collected by filtration, washed with EtOAc:heptane (1:3, 3 L), and then dried in a vacuum oven (60° C.) to give 324.3 g (65%) of the title Compound 10c as a partial acetate salt.
- A 12-Liter 4-neck flask equipped with a thermocouple, condenser, septum, addition funnel and overhead mechanical stirrer under argon was charged with methyl-2-bromobenzoate (226.5 g, 1.05 mol) and THF (1.6 L, 19.66 mol). The mixture was cooled to a temperature between 2 and 5° C. with stirring and held for 30 min. To the solution was slowly added methyl magnesium bromide in diethyl ether (3M, 1.05 L; 3.15 mol) via the addition funnel at a rate to maintain the reaction temperature below 15° C. An exotherm was observed during the addition, the reaction temperature warmed from 3 to 15° C. The addition of 1.05 L Grignard was complete in 4 h (approximate feed rate was 4.17 mL/min). The reaction mixture appeared to be off-white/yellow slurry. The reaction was allowed to warm to room temperature and stirred overnight (15 h). The reaction was sampled by HPLC/TLC and showed no starting material present. The ice bath was again applied to the reaction flask and a 0.5 M HCl solution (4.5 L; 2.25 mol) was slowly added over a period of 2 h. The temperature increased dramatically from 0 to 15° C. After the quench was complete, the reaction was stirred at room temperature for 30 min. Additional 2 N HCl (500 mL; 1.00 mol) was slowly added to maintain a pH less than 6. MTBE (1 L) was added to help with the phase split. The reaction was stirred at room temperature for 1 to 2 h to dissolve the solid material into the aqueous phase (most likely Mg(OH)2 which is very basic). The pH must be checked and adjusted with additional acid when necessary. The phases were separated and the aqueous layer was washed with an additional 1 L MTBE (2×500 mL). The organic phases were combined, washed with NaHCO3 solution (2×300 mL), dried over MgSO4, filtered and the filtrate was concentrated under vacuum to yield the title Compound 10d (220.83 g, 97.48% yield) as a clear yellow oil.
- A 12-Liter 4-neck round bottom flask equipped with a thermocouple, condenser, addition funnel and overhead mechanical stirrer under dry Argon was charged with anhydrous THF, (3 L) and chilled to −70 to −78° C. via a dry ice/acetone bath. n-Butyl lithium (2.5N in hexanes, 860 mL, 2.15 mol) was slowly added via addition funnel. An exotherm was observed as the temperature rose from −78 to −70° C. To the addition funnel was added a solution of Compound 10d (220 g, 979.97 mmol) in anhydrous THF (1 L). The 2-(2-bromophenyl)propan-2-ol solution was slowly added to the n-BuLi solution. The addition took 90 min in order to maintain a reaction temperature below −70° C. After the addition was complete, the reaction mixture was stirred at −70 to −75° C. for 30 min. The triethylborate (230 mL, 1.35 mol) was quickly added in 3 portions at −70° C. An exotherm was observed, the batch temperature rose from −70 to −64° C. The reaction was stirred at −70° C. and slowly warmed to room temperature over night. After the reaction was cooled to 0-5° C., the reaction was slowly quenched with 2 M HCl (1 L, 2.00 mol) added via the addition funnel while maintaining the batch temperature 0-5° C. The reaction mixture was stirred for 1 h. The aqueous phase pH was 9-10. The pH was then adjusted to acidic (4-5) with 2 M HCl (200 mL). The two phases were separated and the aqueous layer was extracted with MTBE (2×500 mL). The combined organic phases were dried with anhydrous magnesium sulfate. The solution was filtered and concentrated to yield a yellow oil. The yellow oil was diluted with MTBE (1.5 L) and washed with 1M NaOH (3×500 mL). The product containing basic aqueous phases were combined and acidified with 2 M HCl (800 mL) (the clear solution turns turbid with the addition of acid). After stirring the turbid solution for 15 min (pH=4-5) (Note 1), it was extracted with MTBE (2×500 mL). The organic phases were combined and dried over MgSO4. The solution was filtered and the filtrate was concentrated to yield the title Compound 10e as a clear yellow oil (121.78 grams, 77% yield).
- A 5-L 4-neck flask equipped with a thermocouple controller, condenser, overhead mechanical stirrer, Firestone Valve® and a nitrogen inlet/outlet was charged with dimethoxyethane (2 L), DI water (1 L) and sodium carbonate (230.9 g, 2.18 mol). The solution was degassed and purged with N2 three times. Compound 10e (71.7 g, 0.35 mol) and Compound 10c (100.0 g, 0.27 mol) were added to the degassed solution. The solution was degassed and purged with N2 three times. PdCl2(dppf) (44.48 g, 54.4 mmol) was added to the solution, and the solution was degassed and purged with N2 three times. The resulting two-phase suspension was heated to reflux for 18 h, and then cooled to room temperature. The reaction mixture was transferred to a 12-L separatory funnel, and the layers were separated. The organic layer was washed with brine (1 L). The two aqueous layers were combined and extracted with EtOAc (1 L). The combined organic layers were dried (Na2SO4), filtered, and the filtrate was concentrated to an oil. Two separate 100 g coupling reactions were combined and purified by chromatography in 10 successive chromatography runs on an ISCO preparative chromatography system (10×1.5 Kg SiO2, 5 column volumes of EtOAc, 250 mL/min flow rate). The combined fractions were transferred to two 22 L 4-neck round bottom flasks, and Silicycle Si-thiol functionalized silica gel (2 g) was added to each solution. The solutions were warmed to 40° C. and aged for 1 h. The solutions were filtered thru a medium glass funnel and washed with EtOAc (4 L) and combined. The filtrate was evaporated to a semi solid, which was transferred to a 2 L round bottom flask, to which EtOAc (0.4 L) was added. The resulting white precipitate slurry was cooled to −5° C. and stirred for 1 h. The slurry was filtered and washed twice with cold EtOAc (100 mL). The solids were dried in a vacuum oven at 40° C. for 40 h to afford 84.0 g (36.5% yield, 98.8 area % purity) of the title Compound 18 as a white solid. Anal. Calcd for C25H21N2OF3.0.04% H2O.0.15 mol MeOH: C, 70.48; H, 5.14: N, 6.42; F, 13.06 Found: C, 70.54; H, 4.83: N, 6.18; F, 13.33
- A 5-L 4-neck flask equipped with a thermocouple controller, an overhead mechanical stirrer, and a nitrogen inlet/outlet was charged with (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol. Compound 18 (125.0 g, 0.510 mol) and MeOH (1.25 L). A solution of sodium methoxide in methanol (0.5 M, 592 mL, 0.3 mol) was added. The reaction was heated to 65° C. for 30 min and all solids dissolved. The solution was cooled and evaporated to dryness. The foam was collected by scraping it out of the flask. The solids were placed in vacuum oven for 24 h at 40° C. to afford 139 g (about 100% isolated yield) of the title Compound 18 monosodium salt as a yellowish solid. 1H NMR (400 MHz, DMSO-d6) δ 7.80-7.84 (m, 3H), 7.74 (d, 2H, J=8.59 Hz), 7.65 (d, 1H, J=16.4 Hz), 7.40-7.44 (m, 2H), 7.25-7.37 (m, 2H), 7.16-7.20 (m, 1H), 7.01-7.05 (m, 1H), 6.84-6.87 (m, 1H), 1.23 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C25H21F3N2O: 423.2 (M+H). Found 423.3. m.p. (uncorr.) 258-259° C.
- A 250-mL separatory funnel was charged with (E)-2-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol. Compound 18 (1.0 g, 2.4 mmol) and EtOAc (20 mL). Aqueous HCl (1M, 20 mL) was added to the white slurry, and the separatory funnel was shaken. The solid product quickly dissolved, and a white precipitate started to form. The organic layer was transferred to a 100 mL round bottom flask equipped with a magnetic stir bar, and was stirred for 2 h. The thick slurry was filtered, rinsed with EtOAc (2×5 mL), and put into a vacuum oven at 40° C. for 36 h to afford 0.95 g (87.5%) of the title Compound 18 hydrochloride salt.
- 4-bromo-3-trifluoromethyl aniline (4.8 g, 0.02 mol) was added in portions to a stirred ice-cold trifluoroacetic anhydride (50 mL). To the resulting solution was added KNO3 (2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0° C. for 1 h, and then allowed to warm to room temperature overnight. The reaction mixture was diluted with ice water (150 mL), and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried in vacuo to provide the title Compound 11a as a bright yellow solid (6.4 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 9.19 (s, 1H) 8.64 (s, 1H) MS (ESI, pos. ion) m/z: 381.4 (M+1).
- Compound 11a (5.7 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) and saturated aqueous K2CO3 (15 mL). The reaction mixture was then stirred at room temperature for 10 h. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound 11b as a yellow solid (2.99 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.44 (s, 1H) 7.21 (s, 1H), 6.21 (bs, 2H). MS (ESI, pos. ion) m/z: 285.0 (M+1).
- Compound 11b (2.85 g, 0.01 mol) was dissolved in 30 mL of ethanol. Zinc powder (5.9 g, 0.09 mol) was added in portions followed by the addition of ammonium chloride (1.07 g, 0.02 mol, 2 eq). The reaction mixture was stirred at room temperature overnight (16 h). The reaction mixture was filtered over a pad of celite and the solvent was evaporated in vacuo. The residue was taken up in ethyl acetate (40 mL), washed with 35 mL of brine, dried over Na2SO4, and evaporated in vacuo. The residue was purified by chromatography (silica gel, CH2Cl2: MeOH, 96:4-94:6)) to provide the title Compound 11c as a bright yellow solid (1.53 g), which was used without further purification in the next step. 1H-NMR (400 MHz, CD3OD) δ (ppm): 6.99 (s, 1H) 6.92 (s, 1H) MS (ESI, pos. ion) m/z: 254.7 (M+1).
- 4-t-butyl acrylic acid (1.02 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl3. To this was added Compound 11c (1.27 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h. (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was taken up in 50 mL of ethyl acetate, washed with 50 mL of brine, dried over Na2SO4, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel, hexanes: EtOAc, 1:3-2:3) to provide the title Compound 11d as a light brown solid (0.84 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.91 (d, 2H, J=18.5 Hz) 7.69 (d, 1H, J=16.4 Hz), 7.32 (m, 4H) 7.09 (d, 1H, J=16.5 Hz) 1.28 (s, 9H). MS (ESI, pos. ion) m/z: 423.7 (M+1).
- Compound 11d (0.00026 mol, 0.10 g) was dissolved in 5 mL of dioxane. 2-hydroxyphenyl boronic acid (0.00052 mol, 0.072 g, 2.0 equiv) was added followed by aqueous Na2CO3 (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110° C. for 20 minutes. The reaction mixture was cooled and the solvent was concentrated in vacuo. The residue was taken up in 10 mL of CH2Cl2, and washed sequentially with 10 mL of saturated aqueous NaHCO3 and 10 mL of brine. The organic fractions were dried over Na2SO4, filtered, and the filtrate was concentrated in vacuo. The residue purified by chromatography (silica gel, CH2Cl2: MeOH, 98:2-95:5) to provide the title Compound 48 as a white solid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.29-7.56 (m, 8H) 7.15 (d, 1H, J=6.7 Hz) 6.89-7.05 (m, 3H)) 1.34 (s, 9H). MS (ESI, pos. ion) m/z: 437.1 (M+1).
- Using the procedures described in Example 11 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 49 (E)-3-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenol The title compound was prepared from 3-hydroxyphenyl boronic acid (0.00052 mol, 0.072 g) and Compound 1a (0.00026 mol, 0.10 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.25-7.61 (m, 8H) 7.19 (d, 1H, J = 7.0 Hz) 6.90-7.11 (m, 3H)) 1.28 (s, 9H). MS (ESI, pos. ion) m/z: 437.1 (M + 1). 50 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-acetamide The title compound was prepared from 2-acetamidophenyl boronic acid (0.00052 mol, 0.093 g) and Compound 1a (0.00026 mol, 0.10 g) to give the product as an off-white solid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.15 (d, 2H, J = 8.1 Hz) 7.73-7.76 (m, 2H) 7.35-7.52 (m, 4H) 7.0-7.14 (m, 3H) 6.77 (s, 1H) 1.45 (s, 9H) 1.35 (s, 3H). MS (ESI, pos. ion) m/z: 478.2 (M + 1). 51 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-methanol The title compound was prepared from 2-hydroxymethyl phenylboronic acid (0.00052 mol, 0.070 g) and Compound 1a (0.00026 mol, 0.10 g) to give the product as a white solid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 6.9-7.5 (m, 12H) 4.39 (m, 2H) MS (ESI, pos. ion) m/z: 451.2 (M + 1). 52 (E)-2-[2-(4-tert-butyl-phenyl)-vinyl]-5-(2-fluoro-phenyl)-6-trifluoromethyl- 1H-benzimidazole The title compound was prepared from 2-fluorophenylboronic acid (0.00052 mol, 0.073 g) and Compound 1a (0.00026 mol, 0.10 g) to give the product as a beige solid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.1 (m, 2H) 7.72 (d, 2H, J = 16.5 Hz) 7.42-7.53 (m, 4H) 7.05-7.20 (m, 4H) 1.34 (s, 9H). MS (ESI, pos. ion) m/z: 440.1 (M + 1). 53 (E)-2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-benzamide The title compound was prepared from 2-aminocarbonyl phenylboronic acid (0.00052 mol, 0.086 g) and Compound 1a (0.00026 mol, 0.10 g) to give the product as a yellow solid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.2-7.8 (m, 9H) 6.91 (d, 2H, J = 5.4 Hz) 6.68 (d, 1H, J = 19.5 Hz) 1.32 (s, 9H). MS (ESI, pos. ion) m/z: 465.25 (M + 1). 54 (E)-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H-benzimidazol- 5-yl}-phenyl)-carbamic acid tert-butyl ester The title compound was prepared from t-butyl-N-[2-4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl) phenylcarbamate (0.00052 mol, 0.166 g) and Compound 1a (0.00026 mol, 0.10 g) to give the product as a beige solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.0 (s, 1H), 7.89 (s, 1H), 7.62-7.79 (m, 4H), 7.42-7.55 (m, 3H), 7.36-7.41 (m, 2H), 7.15-7.30 (m, 2H))) 1.32 (s, 18H) MS (ESI, pos. ion) m/z: 536.2 (M + 1). 55 (E)-N-(2-{2-[2-(4-tert-butyl-phenyl)-vinyl]-6-trifluoromethyl-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide The title compound was prepared from 2-methylsulfonylaminophenyl boronic acid (0.00052 mol, 0.111 g) and Compound 1a (0.00026 mol, 0.10 g) to give the product as a bright yellow solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.0 (s, 1H) 7.79 (d, 1H, J = 16.5 Hz) 7.65 (d, 2H, J = 8.4 Hz) 7.5 (m, 3H) 7.41 (t, 1H, J = 7.7 Hz) 7.23-7.28 (m, 3H) 7.10 (d, 1H, J = 12.1 Hz) 2.5 (s, 3H) 1.31 (s, 9H). MS (ESI, pos. ion) m/z: 514.2 (M + 1). - Using the procedure of Example 11, Step D, 4-trifluoromethyl acrylic acid (1.19 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl3. To this solution was added Compound 11c (1.27 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and then concentrated in vacuo. The residue was taken up in 50 mL of ethyl acetate, washed with 50 mL of brine, dried over Na2SO4, filtered, and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel, hexanes:EtOAc, 3:1-3:2) to provide the title Compound 12a as a light yellow solid (1.02 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.92 (d, 2H, J=14.1 Hz) 6.67-7.76 (m, 5H) 7.21 (d, 1H, J=16.5 Hz) MS (ESI, pos. ion) m/z: 368.3 (M+1).
- Compound 12a (0.00025 mol, 0.10 g) was dissolved in 5 mL of dioxane. 2-acetamidophenyl boronic acid (0.0005 mol, 0.089 g, 2.0 equiv) was added followed by aqueous Na2CO3 (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110° C. for 20 minutes. The reaction mixture was cooled and the reaction mixture was concentrated in vacuo. The residue was taken up in 10 mL of CH2Cl2, and washed sequentially with 10 mL of saturated aqueous NaHCO3 and 10 mL of brine. The organic fractions were dried over Na2SO4, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel CH2Cl2: MeOH, 98:2-95:5) to provide the title Compound 56 as a white solid. 1H-NMR (400M Hz, DMSO-d6) δ (ppm): 8.68 (s, 1H) 8.03 (s, 1H) 7.80-7.96 (m, 6H) 7.35-7.50 (m, 3H) 7.20 (d, 2H, J=4.1 Hz) 1.8 (s, 3H) MS (ESI, pos. ion) m/z: 490.0 (M+1).
- Using the procedures described in Example 12 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 57 (E)-1-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]- 1H-benzimidazol-5-yl}-phenyl)-ethanone The title compound was prepared from 2-acetylphenyl boronic acid (0.0005 mol, 0.082 g) and Compound 12a (0.00025 mol, 0.10 g) to give the product as a whitish-yellow solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.81-8.0 (m, 8H) 7.42-7.62 (m, 3H) 7.30 (d, 1H, J = 6.8 Hz) 2.49 (s, 3H) MS (ESI, pos. ion) m/z: 475.0 (M + 1). 58 (E)-(2-{6-trifluoromethyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]- 1H-benzimidazol-5-yl}-phenyl)-methanol The title compound was prepared from 2-hydroxymethyl phenylboronic acid (0.0005 mol, 0.067 g) and Compound 12a (0.00025 mol, 0.10 g) to give the product as a light yellow powder. 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.0 (d, 2H, J = 8.1 Hz) 7.8 (d, 2H, J = 8.2 Hz) 7.0-7.59 (m, 8H) 4.91-5.07 (m, 1H) 4.09-4.22 (m, 2H) (s, 9H). MS (ESI, pos. ion) m/z: 463.0 (M + 1). - 4-bromo-3-fluoromethyl aniline (3.8 g, 0.02 mol) was added in portions to a stirred ice-cold trifluoroacetic anhydride (50 mL). To the solution was added KNO3 (2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0° C. for 1 h and then allowed to warm to room temperature overnight. The reaction mixture was diluted with ice water (150 mL) and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried in vacuo to provide the title Compound 13a as a bright yellow solid (5.42 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.66 (d, 1H, J=10.0 Hz) 8.60 (d, 1H, J=11.3 Hz). MS (ESI, pos. ion) m/z: 402.0 (M+Na).
- Compound 13a (5.0 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) and saturated aqueous K2CO3 (15 mL) and the mixture was stirred at room temperature for 10 h. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound 13b as a yellow solid (2.5 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.39 (d, 1H, J=7.1 Hz) 6.75 (d, 1H, J=9.6 Hz) 6.19 (bs, 2H). MS (ESI, pos. ion) m/z: 236.9 (M+1).
- Compound 13b (1.88 g, 0.008 mol) was dissolved in 20 mL of ethanol. Zinc powder (4.71 g, 0.072 mol) was added in portions followed by the addition of the ammonium chloride (0.86 g, 0.016 mol). The reaction mixture was stirred at room temperature overnight (16 h). The reaction mixture was filtered over a pad of celite and the solvent was evaporated in vacuo. The residue was taken up in ethyl acetate (30 mL) and washed with 25 mL of brine. The organic fractions were dried over Na2SO4, filtered and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (silica gel, CH2Cl2: MeOH, 96:4-94:6)) to provide the title Compound 13c as a dark yellow solid (1.02 g) that was used immediately in the next reaction. MS (ESI, pos. ion) m/z: 235.7 (M+1).
- 4-trifluoromethyl cinnamic acid (1.2 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl3. To the solution was added Compound 13c (1.02 g, 0.005 mol), and the reaction mixture was heated at reflux for 6 h. The reaction mixture was cooled to room temperature and then evaporated in vacuo. The residue was taken up in 50 mL of ethyl acetate, and washed with 50 mL of brine. The organic fractions were dried over Na2SO4 and concentrated in vacuo. The residue was purified by chromatography (silica gel, hexanes:EtOAc, 3:1-3:2) to provide the title Compound 13d as a light brown solid (0.80 g). 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.63-8.09 (m, 4H) 7.4 (d, 1H, J=20.7 Hz) 6.69 (d, 1H, J=20.7 Hz) MS (ESI, pos. ion) m/z: 386.0 (M+1).
- Compound 13d (0.00025 mol, 0.096 g) was dissolved in 5 mL of dioxane. 2-hydroxyphenyl boronic acid (0.0005 mol, 0.069 g) was added followed by aqueous Na2CO3 (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave synthesizer at 110° C. for 20 minutes. The reaction mixture was cooled and the solvent was evaporated in vacuo. The residue was taken up in 10 mL of CH2Cl2, and washed sequentially with 10 mL of saturated aqueous NaHCO3 and 10 mL of brine. The organic fractions were dried over Na2SO4, filtered and the filtrate was concentrated in vacuo. The residue was purified by chromatography (silica gel (CH2Cl2: MeOH, 98:2-95:5) to provide the title Compound 59 as a tan solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.90 (d, 2H, J=8.0 Hz) 7.79 (d, 2H, J=7.8 Hz) 7.22-7.53 (m, 4H) 6.88-6.96 (m, 4H) MS (ESI, pos. ion) m/z: 399.1 (M+1).
- Using the procedures described in Example 13 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 60 (E)-3-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenol The title compound was prepared from 3-hydroxyphenyl boronic acid (0.0005 mol, 0.069 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as an off-white solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.76-8.0 (m, 4H) 7.24-7.64 (m, 5H) 6.96-7.03 (m, 1H) 6.75-6.8 (m, 2H) MS (ESI, pos. ion) m/z: 399.3 (M + 1). 61 (E)-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-phenyl)-methanol The title compound was prepared from 2-hydroxymethyl phenylboronic acid (0.0005 mol, 0.067 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as a yellowish solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.83 (d, 2H, J = 8.2 Hz) 7.70-7.73 (m, 2H) 7.64 (t, 2H, J = 7.9, 7.5 Hz)) 7.55 (d, 1H, J = 7.2 Hz) 7.25-7.46 (m, 4H) 7.10 (dd, 1H, J = 1.2 Hz) 4.29 (d, 2H, J = 0.85 Hz) MS (ESI, pos. ion) m/z: 413.1 (M + 1). 62 (E)-1-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-ethanone The title compound was prepared from 2-acetylphenyl boronic acid (0.0005 mol, 0.082 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as a bright yellow solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.75-7.91 (m, 5 H) 7.55-7.68 (m, 4H) 7.41-7.47 (m, 3H) 2.46 (s, 3H) MS (ESI, pos. ion) m/z: 425.1 (M + 1). 63 (E)-2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzamide The title compound was prepared from 2-aminocarbonyl phenylboronic acid (0.0005 mol, 0.083 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as a sticky tan solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.93 (d, 2H, J = 8.6 Hz) 7.83 (d, 2H, J = 8.6 Hz) 7.40-7.71 (m, 8H) MS (ESI, pos. ion) m/z: 426.0 (M + 1). 64 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-acetamide The title compound was prepared from 2-acetamidophenyl boronic acid (0.0005 mol, 0.089 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as an off-white solid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.68 (s, 1H) 8.03 (s, 1H) 7.80-7.96 (m, 6H) 7.35-7.50 (m, 3H) 7.20 (d, 2H, J = 4.1 Hz) 1.8 (s, 3H) MS (ESI, pos. ion) m/z: 440.1 (M + 1). 65 (E)-N-(2-{6-fluoro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide The title compound was prepared from 2 methylsulfonylaminophenyl boronic acid (0.0005 mol, 0.108 g) and Compound 13d (0.00025 mol, 0.096 g) to give the product as an off-white solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.65 (s, 1 H) 7.59 (d, 1H, J = 6.7 Hz) 7.26-7.48 (m, 10 H) 2.95 (s, 3H) MS (ESI, pos. ion) m/z: 476.1 (M + 1). - 4-Bromo-3-chloromethyl aniline (4.1 g, 0.02 mol) was added in portions to a stirred ice cold trifluoroacetic anhydride (50 mL). To the resulting solution was added KNO3 (2.22 g, 0.022 mol, 1.1 eq) in portions. The reaction mixture was stirred at 0° C. for 1 hour and then allowed to warm to room temperature overnight. The reaction mixture was diluted with ice water (150 mL) and the solid was collected by vacuum filtration. The solid was washed with water (50 mL) and dried in vacuo to provide the title Compound 14a as a pale yellow solid (5.55 g).
- Compound 14a (5.2 g, 0.015 mol) was dissolved in a mixture of methanol (25 mL) saturated aqueous K2CO3 (15 mL). The reaction mixture was stirred at room temperature for 10 hours. The reaction mixture was diluted with water (25 mL) and the product was collected by vacuum filtration to provide the title Compound 14b as a yellow solid (2.71 g). 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.39 (s, 1H) 6.98 (s, 1H) 6.08 (bs, 2H). MS (ESI, pos. ion) m/z: 250.9 (Br, Cl pattern).
- Compound 14b (2.0 g, 0.008 mol) was dissolved in 20 mL of ethanol. Zinc powder (4.7 g, 0.072 mol) was added in portions followed by the addition of the ammonium chloride (0.88 g, 0.016 mol, 2 eq). The reaction mixture was stirred at room temperature overnight (16 hours). The reaction mixture was filtered over a pad of celite and the solvent was evaporated in vacuo. The residue was taken up in ethyl acetate (30 mL) and washed with 25 mL of brine. The organic fractions were dried over Na2SO4, filtered and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (silica gel, CH2Cl2: MeOH, 96:4-94:6) to provide the title Compound 14c as a dark yellowish-brown solid (1.08 g) and was used immediately in the next reaction. MS (ESI, pos. ion) m/z: 220.9 (Br, Cl pattern).
- 4-trifluoromethyl cinnamic acid (1.2 g, 0.0055, 1.1 eq) was dissolved in 30 mL of POCl3. To this solution was added Compound 14c (1.08 g, 0.005 mol), and the reaction mixture was heated to reflux for 6 hours (The reaction mixture was quite dark). The reaction mixture was cooled to room temperature and the evaporated in vacuo. The residue was taken up in 50 mL of ethyl acetate, and washed with 50 mL of brine. The organic fractions were dried over Na2SO4, filtered and the filtrate was evaporated in vacuo. The residue was purified by chromatography (silica gel hexanes:EtOAc, 3:1-3:2) to provide the title Compound 14d as a light brown solid (0.80 g). 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.57-8.21 (m, 4H) 7.35 (d, 1H, J=19 Hz) 6.72 (d, 1H, J=18.5 Hz). MS (ESI, pos. ion) m/z: 401.0.
- Compound 14d (0.00025 mol, 0.100 g) was dissolved in 5 mL of dioxane. 2-hydroxymethyl phenylboronic acid (0.0005 mol, 0.067 g, 2.0 equiv) was added followed by aqueous Na2CO3 (0.00055 mol, 0.28 mL of 2M solution) and dichlorobis(tricyclohexylphosphine)-palladium(II) (0.011 g, 6 mol %). The reaction mixture was heated in a microwave at 110° C. for 20 minutes. The reaction mixture was cooled and the solvent was evaporated in vacuo. The residue was taken up in 10 mL of CH2Cl2, and washed sequentially with 10 mL of saturated aqueous NaHCO3 and 10 mL of brine. The organic fractions were dried over Na2SO4, filtered and the solvent was evaporated in vacuo. The residue was purified by chromatography (silica gel, CH2Cl2: MeOH, 98:2-95:5) to provide the title Compound 66 as a yellow sticky solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.82-7.85 (d, 2H, J=8.4 Hz) 7.72-7.74 (d, 2H, J=8.3 Hz) 7.56-7.66 (m, 3H) 7.26-7.43 (m, 5H) 5.05 (s, 1H) 4.58 (s, 2H). MS (ESI, pos. ion) m/z: 395.3 (—CH2OH).
- Using the procedures described in Example 14 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 67 (E)-1-(2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone The title compound was prepared from 2-acetylphenyl boronic acid (0.0005 mol, 0.082 g) and Compound 14d (0.00025 mol, 0.100 g) to give the product as a pale yellow solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.80-7.84 (m, 2H) 7.70-7.74 (m, 2H) 7.67 (s, 1H), 7.50-7.7.64 (m, 2H) 7.27-7.43 (m, 5H), 1.36 (s, 9H). MS (ESI, pos. ion) m/z: 441.1 (M + 1). 68 (E)-2-{6-chloro-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenol The title compound was prepared from 2-hydroxyphenyl boronic acid (0.0005 mol, 0.108 g) and Compound 14d (0.00025 mol, 0.069 g) to give the product as a dark yellow solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 6.2-6.6 (m, 5H) 5.99-6.05 (m, 5H) 5.59-5.66 (2H) 7.80-7.84 (m, 2H). MS (ESI, pos. ion) m/z: 415.0 (M + 1). - (E)-N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide (Cpd 309)
- A mixture of 2-(t-butylamino)sulfonylphenyl boronic acid (12.4 g, 0.048 mol), Compound 10c (13.6 g, 0.037 mol), Pd(dppf)Cl2CH2Cl2 (3.00 g, 3.70 mmol), TBAB (11.9 g, 0.037 mmol), and Na2CO3 (31.4, 0.296 mol) in 750 mL of mixed solvent (DME:water, 4:1) was heated at 90° C. for 12 hours. The reaction mixture was concentrated, and the residue was purified by chromatography (silica gel, hexanes:EtOAc, 1:1) to provide the title Compound 309 as a yellow oil. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J=1.6 and 7.6 Hz) 7.84 (d, 2H, J=8.4 Hz) 7.73 (d, 2H, J=8.4 Hz) 7.70-7.62 (m, 4H) 7.54 (dt, 1H, J=1.6 and 8.6 Hz) 7.41 (dd, 1H, J=1.2 and 7.6 Hz) 7.37-7.31 (m, 2H) 1.00 (s, 9H) MS (ESI, pos. ion) m/z: 490.3 (M+1).
- A solution of Compound 309 in 60 mL TFA was heated at 70° C. for 2 hours.
- The reaction was concentrated, the residue was dissolved in EtOAc, and washed with sat'd NaHCO3. The organic layer was dried over Na2SO4, filtered, and the residue was concentrated. The residue was purified by chromatography (silica gel, hexanes:EtOAc, 1:2) to provide the title Compound 70 as a light brown solid. M.p. 168-170° C. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.16 (dd, 1H, J=1.2 and 8.0 Hz) 7.95-7.91 (m, 3H) 7.82-7.76 (m, 4H) 7.70-7.56 (m, 3H) 7.44 (s, 1H) 7.16 (d, 1H, J=9.6 Hz) MS (ESI, pos. ion) m/z: 444.3 (M+1).
- Using the procedures described in Example 15 and reagents, starting materials and conditions known to those skilled in the art, the following compound representative of the present invention was prepared:
-
Cpd Name and Data 71 (E)-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 8.10 (d, 2H, J = 8.4 Hz) 8.01 (d, 2H, J = 8.4 Hz) 7.71-7.53 (m, 5H) 7.44 (d, 1H, J = 16.4 Hz) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.35 (dd, 1H, J = 1.2 and 8.4 Hz) MS (ESI, pos. ion) m/z: 508.3 (M + 1). 398 (E)-N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared from 2-N,N-dimethylaminosulfonylphenyl boronic acid and Compound 10c. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.08 (dd, 1H, J = 1.2 and 8.4 Hz) 7.84 (d, 2H, J = 8.4 Hz) 7.73 (d, 2H, J = 8.8 Hz) 7.69-7.56 (m, 5H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.33 (d, 1H, J = 16.4 Hz) 7.28 (dd, 1H, J = 1.6 and 8.4 Hz) 2.34 (s, 6H) MS (ESI, pos. ion) m/z: 472.5 (M + 1). 441 (E)-4-fluoro-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide The title compound was prepared from 2-tert-butylaminosulfonyl-5- fluorophenylboronic acid and Compound 10c. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.18 (dd, J = 5.6, 8 Hz, 1H), 7.94 (d, J = 5.6, 8 Hz, 1H), 7.84 (d, J = 8 Hz, 2H), 7.73 (s, 1H), 7.71-7.69 (m, 2H), 7.63 (d, J = 8 Hz, 1H), 7.35-7.32 (m, 1H), 7.28-7.22 (m, 2H), 7.14 (dd, J = 2, 9 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H15F4N3O2S: 462.4 (M + H), Found 462.2. 444 (E)-4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared from 2-tert-butylaminosulfonyl-5- trifluoromethylphenyl boronic acid and Compound 10c. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.33 (d, J = 8 Hz, 1H), 7.88 (s, 1H), 7.85 (d, J = 8 Hz, 2H), 7.74-7.68 (m, 6H), 7.36-7.32 (m, 1H), 7.34 (d, J = 16.4 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H15F6N3O2S: 512.5 (M + H), Found 512.3. 446 (E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared from 2-tert-butylaminosulfonyl-4- trifluoromethylphenyl boronic acid and Compound 10c. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.42 (s, 1H), 7.94 (d, J = 8 Hz, 1H), 7.85 (d, J = 8 Hz, 2H), 7.73 (d, J = 8 Hz, 2H), 7.71 (d, J = 8 Hz, 2H), 7.64 (d, J = 8 Hz, 2H), 7.34 (d, J = 16.4 Hz, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H15F6N3O2S: 512.1 (M + H), Found 512.2. - 4-bromo-phenylenediamine (25 g, 0.134 mol) was added portionwise to di-t-butyl dicarbonate (175 g, 0.802 mol) at 25° C., and the reaction mixture was stirred for 10 hours. The mixture was purified by chromatography (silica gel, hexanes to hexanes:EtOAc, 1:1) to provide the title Compound 16a as a light brown solid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.76 (brs, 1H) 7.32 (brs, 1H) 7.22 (dd, 1H, J=2.0 and 8.8 Hz) 6.72 (brs, 1H) 6.53 (brs, 1H).
- A mixture of 2-(t-butylamino)sulfonylphenyl boronic acid (4.7 g, 0.018 mmol), Compound 16a (4.7 g, 0.012 mmol), Pd(dppf)Cl2.CH2Cl2 (0.99 g, 0.0012 mmol), TBAB (3.90 g, 0.012 mmol), and 20 mL of 1M Na2CO3 (aq) in 100 mL of DME was heated at 100° C. for 12 hours. The reaction mixture was concentrated, and the residue was purified by chromatography (silica gel, hexanes:EtOAc, 2:1) to provide the title Compound 16b as a yellow oil.
- A mixture of Compound 16b in 20 mL of 4M HCl in dioxane was stirred for 3 hours. The reaction mixture was concentrated, diluted with EtOAc and washed with sat'd NaHCO3 (aq), then dried over Na2SO4 and filtered. The filtrate was concentrated to provide the title Compound 16c as a brown oil. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.04 (dd, 1H, J=1.2 and 7.6 Hz) 7.56 (dt, 1H, J=1.2 and 8.2 Hz) 7.44 (dt, 1H, J=1.2 and 8.4 Hz) 7.33 (dd, 1H, J=1.2 and 7.6 Hz) 6.86 (d, 1H, J=1.6 Hz) 6.77 (d, 1H, J=7.6 Hz) 6.73 (dd, 1H, J=2.0 and 8.0 Hz) 0.97 (s, 9H). MS (ESI, pos. ion) m/z: 319.9 (M+1).
- A mixture of Compound 16c (0.120 g, 0.376 mmol), trans 4-(trifluoromethoxy)-cinnamic acid (0.105 g, 0.451 mmol), and 0.4 mL of 4N HCl (aq) in 4 mL of ethylene glycol was heated at 180° C. for 1 hour. The reaction mixture was purified directly by HPLC (YMC ODS-A, H2O:MeCN, 90:10 to 40:60, over 10 min) to provide the title Compound 69 as an off-white solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J=1.2 and 8.0 Hz) 7.75 (d, 2H, J=8.4 Hz) 7.68-7.53 (m, 5H) 7.41 (dd, 1H, J=1.2 and 7.6 Hz) 7.37-7.33 (m, 3H) 7.19 (d, 1H, J=16.8 Hz) MS (ESI, pos. ion) m/z: 460.3 (M+1).
- Using the procedures described in Example 16 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 79 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.68-7.54 (m, 7H) 7.46-7.40 (m, 3H) 7.38 (dd, 1H, J = 1.2 and 8.4 Hz) 7.19 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) m/z: 410.4 (M + 1). 85 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.99 (d, 2H, J = 8.4 Hz) 7.89 (d, 2H, J = 8.4 Hz) 7.71-7.53 (m, 5H) 7.41 (dd, 1H, J = 1.6 and 7.6 Hz) 7.36 (d, 1H, J = 16.4 Hz) 7.34 (dd, 1H, J = 1.6 and 8.4 Hz) MS (ESI, pos. ion) m/z: 453.4 (M + 1). 357 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (d, 1H, J = 8.0 Hz) 7.83-7.75 (m, 2H) 7.67-7.53 (m, 4H) 7.38 (t, 2H, J = 9.2 Hz) 7.22 (d, 1H, J = 16.8 Hz) 7.08-7.03 (m, 2H) MS (ESI, pos. ion) m/z: 412.4 (M + 1). 358 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.72-7.55 (m, 6H) 7.48-7.35 (m, 4H) 7.20 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 412.4 (M + 1). 359 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.84 (d, 1H, J = 16.8 Hz) 7.70-7.54 (m, 5H) 7.41 (dd, 2H, J = 1.6 and 8.4 Hz) 7.33 (d, 1H, J = 16.8 Hz) 7.29-7.23 (m, 2H) MS (ESI, pos. ion) m/z: 412.4 (M + 1). 360 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.81 (d, 1H, J = 16.8 Hz) 7.69-7.54 (m, 5H) 7.46-7.38 (m, 2H) 7.33 (d, 1H, J = 16.8 Hz) 7.26-7.14 (m, 2H) MS (ESI, pos. ion) m/z: 412.4 (M + 1). 361 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.6 and 8.0 Hz) 7.71-7.55 (m, 5H) 7.42 (td, 2H, J = 1.4 and 8.4 Hz) 7.34-7.28 (m, 3H) 7.04-6.99 (m, 1H) MS (ESI, pos. ion) m/z: 412.4 (M + 1). 362 (E)-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.37-7.51 (m, 8H) 7.41 (dd, 1H, J = 1.2 and 8.0 Hz) 7.35 (dd, 1H, J = 1.6 and 8.0 Hz) 7.29 (d, 1H, J = 8.8 Hz) 7.25 (d, 1H, J = 16.8 Hz) 7.34 (dd, 1H, J = 1.6 and 8.4 Hz) MS (ESI, pos. ion) m/z: 460.4 (M + 1). 363 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, 1H, J = 1.2 and 7.6 Hz) 7.93 (d, 1H, J = 1.2 and 7.6 Hz) 7.65-7.47 (m, 6H) 7.42-7.29 (m, 4H) 7.22 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) m/z: 454.3 (M + 1). 364 (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 8.10 (dd, 1H, J = 2.0 and 16.4 Hz) 8.01 (d, 1H, J = 7.6 Hz) 7.80 (d, 1H, J = 7.6 Hz) 7.75-7.55 (m, 6H) 7.42 (dd, 2H, J = 1.2 and 8.4 Hz) 7.25 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 444.3 (M + 1). 365 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.16 (d, 1H, J = 7.6 Hz) 8.13 (s, 1H) 7.90 (d, 1H, J = 9.2 Hz) 7.68 (d, 1H, J = 14.4 Hz) 7.65-7.49 (m, 4H) 7.43-7.38 (m, 4H) 7.25 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 410.3 (M + 1). 366 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.35 (d, 1H, J = 16.4 Hz) 8.16 (dd, 1H, J = 1.6 and 8.0 Hz) 7.97 (dd, 1H, J = 1.6 and 7.6 Hz) 7.84 (s, 1H) 7.80 (d, 1H, J = 9.2 Hz) 7.76 (dd, 1H, J = 1.2 and 8.0 Hz) 7.70-7.60 (m, 3H) 7.52 (dt, 1H, J = 1.2 and 8.2 Hz) 7.45-7.39 (m, 2H) 7.32 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 454.3 (M + 1). 367 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 7.6 Hz) 8.12-8.08 (m, 2H) 7.76-7.41 (m, 8H) 7.25 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 461.4 (M + 1). 368 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 8.10 (t, 1H, 7.0 Hz) 7.91 (d, 1H, J = 16.4 Hz) 7.75-7.54 (m, 5H) 7.46-7.34 (m, 4H) MS (ESI, pos. ion) m/z: 461.4 (M + 1). 369 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.16 (dd, 1H, J = 1.6 and 8.0 Hz) 8.12-8.10 (m, 2H) 7.94 (d, 1H, J = 16.8 Hz) 7.85 (dd, 1H, J = 0.8 and 1.6 Hz) 7.80 (dd, 1H, J = 0.8 and 8.8 Hz) 7.70-7.59 (m, 3H) 7.52 (t, 1H, J = 9.8 Hz) 7.43 (dd, 1H, J = 1.6 and 7.6 Hz) 7.39 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) m/z: 462.3 (M + 1). 370 (E)-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (d, 1H, J = 8.0 Hz) 7.79 (d, 1H, J = 16.8 Hz) 7.68 (d, 1H, J = 16.0 Hz) 7.64-7.55 (m, 4H) 7.43-7.40 (m, 2H) 7.31 (d, 1H, J = 16.8 Hz) 7.23 (q, 1H, J = 8.1 Hz) MS (ESI, pos. ion) m/z: 430.4 (M + 1). 371 (E)-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.84-7.79 (m, 1H) 7.75 (d, 1H, J = 15.6 Hz) 7.68-7.53 (m, 4H) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.37 (dd, 1H, J = 1.6 and 8.4 Hz) 7.33-7.25 (m, 2H) MS (ESI, pos. ion) m/z: 430.3 (M + 1). 372 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 0.8 and 7.6 Hz) 7.85 (d, 1H, J = 16.8 Hz) 7.70-7.54 (m, 4H) 7.49 (d, 1H, J = 16.8 Hz) 7.46-7.40 (m, 3H) 7.10 (t, 2H, J = 8.8 Hz) MS (ESI, pos. ion) m/z: 412.3 (M + 1). 373 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.25 (s, 2H) 8.14 (dd, 1H, J = 1.2 and 7.6 Hz) 7.95 (s, 1H) 7.71 (d, 1H, J = 16.8 Hz) 7.68-7.53 (m, 4H) 7.44 (d, 1H, J = 16.8 Hz) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.35 (dd, 1H, J = 1.6 and 8.0 Hz) MS (ESI, pos. ion) m/z: 512.4 (M + 1). 374 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.36 (s, 1H) 8.24 (dd, 1H, J = 2.0 and 16.4 Hz) 8.16 (dd, 1H, J = 1.2 and 8.0 Hz) 8.06 (d, 1H, J = 8.4 Hz) 7.84 (d, 1H, J = 8.4 Hz) 7.83 (s, 1H) 7.79 (d, 1H, J = 8.8 Hz) 7.69-7.57 (m, 3H) 7.48-7.42 (m, 2H) MS (ESI, pos. ion) m/z: 512.4 (M + 1). 375 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.51 (d, 1H, J = 16.0 Hz) 8.16-8.10 (m, 2H) 8.03 (d, 1H, J = 8.4 Hz) 7.82 (dd, 1H, J = 1.6 and 8.0 Hz) 7.75-7.55 (m, 4H) 7.49-7.36 (m, 2H) 7.28 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 488.1 (M + 1). 376 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (d, 1H, J = 7.6 Hz) 7.89 (s, 1H) 7.74-7.58 (m, 7H) 7.48-7.37 (m, 3H) 7.27 (d, 1H, J = 16.4 Hz) MS (ESI, pos. ion) m/z: 454.3 (M). 378 (E)-2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.6 and 8.0 Hz) 8.04 (d, 1H, J = 2.0 Hz) 7.93 (dd, 1H, J = 2.0 and 8.4 Hz) 7.71-7.54 (m, 6H) 7.43-7.38 (m, 2H) 7.32 (d, 1H, J = 16.8 Hz) MS (ESI, pos. ion) m/z: 478.4 (M + 1). 379 (E)-2-{2-[2-(5-bromo-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 8.0 Hz) 8.00 (dd, 1H, J = 2.4 and 6.4 Hz) 7.88 (d, 1H, J = 16.4 Hz) 7.76-7.57 (m, 5H) 7.51 (dd, 1H, J = 1.6 and 8.8 Hz) 7.42 (dd, 1H, J = 1.2 and 8.0 Hz) 7.38 (d, 1H, J = 16.4 Hz) 7.20 (dd, 1H, J = 8.8 and 10.4 Hz) MS (ESI, pos. ion) m/z: 472.3 (M + 1). 423 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, J = 1.2, 8.2 Hz, 1H), 7.74-7.62 (m, 7H), 7.43-7.34 (m, 3H), 6.64 (d, J = 16.0 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H15F4N3O2S: 462.1 (M + H), Found 462.2. 424 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8.0 Hz, 1H), 7.99 (t, J = 7.2 Hz, 1H), 7.83 (d, J = 16.8 Hz, 1H), 7.67-7.52 (m, 4H), 7.45 (s, 1H), 7.43-7.40 (m, 3H), 7.34 (dd, J = 1.6, 7.6 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H15F4N3O2S: 462.1 (M + H), Found 462.2. 425 (E)-2-{2-[2-(3-ethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8.0 Hz, 1H), 7.99 (t, J = 7.2 Hz, 1H), 7.57 (d, J = 16 Hz, 1H), 7.67-7.60 (m, 2H), 7.45 (s, 1H), 7.43-7.40 (m, 2H), 7.25 (t, J = 4 Hz, 1H), 7.11 (d, J = 8 Hz, 1H), 7.07-7.08 (m, 1H), 6.92-6.89 (m, 1H), 6.45 (d, J = 16 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H21N3O3S: 420.1 (M + H), Found 420.2. 426 (E)-2-(2-styryl-1H-benzimidazol-5-yl)-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 7.8 Hz, 1H), 7.66-7.58 (m, 6H), 7.54 (dt, J = 1.6, 7.6 Hz, 1H), 7.44-7.40 (m, 3H), 7.38-7.34 (m, 1H), 7.31 (dd, J = 1.6, 8 Hz, 1H), 7.18 (d, J = 16.4 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H17N3O2S: 376.1 (M + H), Found 376.3. 427 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.82 (s, 1H), 7.65-7.61 (m, 3H), 7.60-7.54 (m, 3H), 7.52 (s, 1H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.32 (dd, J = 1.6, 8 Hz, 1H), 7.22 (d, J = 16.4 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H15Cl2N3O2S: 444.0 (M + H), Found 444.1. 428 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.78 (d, J = 8 Hz, 1H), 7.75 (d, J = 8 Hz, 1H), 7.72 (s, 1H), 7.55-7.54 (m, 1H), 7.62 (dd, J = 1.6, 8 Hz, 1H), 7.54 (dt, J = 1.6, 8 Hz, 1H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.34-7.26 (m, 4H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H15ClFN3O2S: 428.9 (M + H), Found 430.2. 429 (E)-2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.65-7.60 (m, 4H), 7.58-7.52 (m, 3H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.32-7.29 (m, 3H), 7.13 (d, J = 16.8 Hz, 1H), 2.94 (h, J = 2.4 Hz, 1H), 1.27 (d, J = 8 Hz, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C24H23N3O2S: 418.1 (M + H), Found 418.4. 430 (E)-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.65-7.58 (m, 5H), 7.53 (d, J = 7.6 Hz, 2H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.30 (dd, J = 1.6, 8 Hz, 1H), 7.23 (d, J = 8 Hz, 2H), 7.11 (d, J = 16.8 Hz, 1H), 2.36 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H19N3O2S: 390.1 (M + H), Found 390.5. 431 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.80 (d, J = 16 Hz, 1H), 7.73 (t, J = 7.2 Hz, 1H), 7.66-7.60 (m, 4H), 7.57-7.52 (m, 1H), 7.51-7.46 (m, 1H), 7.42 (dd, J = 1.6, 8 Hz, 1H), 7.33 (dd, J = 1.6, 8 Hz, 1H), 7.22 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H15ClFN3O2S: 428.9 (M + H), Found 428.3. 432 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.80 (dd, J = 2, 7.2 Hz, 1H), 7.65-7.52 (m, 6H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.33-7.28 (m, 2H), 7.16 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H15ClFN3O2S: 428.9 (M + H), Found 428.3. 433 (E)-2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-benzene sulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 8.01 (s, 1H), 7.91-7.82 (m, 4H), 7.80 (d, J = 16.8 Hz, 1H), 7.66-7.59 (m, 3H), 7.55 (dd, J = 1.6, 8 Hz, 1H), 7.52-7.48 (m, 2H), 7.42 (dd, J = 2, 7.6 Hz, 1H), 7.32 (dd, J = 1.6, 8 Hz, 1H), 7.30 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C25H19N3O2S: 426.5 (M + H), Found 426.3. 434 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.69-7.66 (m, 2H), 7.65-7.52 (m, 5H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.31 (dd, J = 1.6, 8 Hz, 1H), 7.18-7.10 (m, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H16FN3O2S: 394.4 (M + H), Found 394.3. 435 (E)-2-{2-[2-(4-difluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.70 (d, J = 8 Hz, 2H), 7.66-7.61 (m, 4H), 7.54 (dt, J = 1.6, 8 Hz, 1H), 7.42 (dd, J = 1.6, 8 Hz, 1H), 7.32 (d, J = 8 Hz, 1H), 7.20 (d, J = 8 Hz, 2H), 7.15 (d, J = 16 Hz, 1H), 6.89 (s, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H17F2N3O2S: 426.5 (M + H), Found 426.3. 436 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.78 (s, 1H), 7.73 (dd, J = 1.6, 8 Hz, 1H), 7.66-7.61 (m, 4H), 7.54 (dt, J = 1.6, 8 Hz, 1H), 7.44 (d, J = 8 Hz, 1H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.33 (d, J = 8 Hz, 1H), 7.34 (d, J = 16 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H15F4N3O2S: 461.4 (M + H), Found 462.2. 437 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzene sulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.97 (d, J = 16.8 Hz, 1H), 7.84 (d, J = 8 Hz, 1H), 7.66-7.51 (m, 5H), 7.41-7.37 (m, 2H), 7.32 (dd, J = 1.6, 8 Hz, 1H), 7.20 (d, J = 16 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H15Cl2N3O2S: 445.3 (M + H), Found 446.1. 438 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzene sulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.89 (d, J = 16.8 Hz, 1H), 7.66-7.60 (m, 3H), 7.54 (dt, J = 1.6, 8 Hz, 1H), 7.45 (d, J = 16 Hz, 1H), 7.43 (s, 1H), 7.41-7.32 (m, 3H), 7.24-7.18 (m, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H15ClFN3O2S: 428.9 (M + H), Found 428.3. 439 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.94 (dd, J = 1.6, 8 Hz, 1H), 7.68-7.62 (m, 6H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.32 (d, J = 1.6, 8 Hz, 1H), 7.28 (t, J = 8 Hz, 1H), 7.16 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H15BrFN3O2S: 473.3 (M + H), Found 473.2. 440 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, J = 1.6, 8 Hz, 1H), 7.94 (dd, J = 1.6, 8 Hz, 1H), 7.68-7.62 (m, 6H), 7.41 (dd, J = 1.6, 8 Hz, 1H), 7.32 (d, J = 1.6, 8 Hz, 1H), 7.28 (t, J = 8 Hz, 1H), 7.16 (d, J = 16.8 Hz, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H15BrFN3O2S: 473.3 (M + H), Found 473.2. - Using the procedures described in Example 15 or 16 and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:
-
Cpd Name and Data 91 (E)-2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]- vinyl}-1H-benzimidazol-5-yl)-benzenesulfonamide, 97 (E)-2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 103 (E)-2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 109 (E)-2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 115 (E)-2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide, 121 (E)-2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, and 127 (E)-2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide. - To a solution of N-methylbenzenesulfonamide (2.00 g, 0.0117 mmol) in 20 mL THF at 0° C. was added dropwise n-butyl lithium (1.6 M in hexanes, 14.6 mL, 0.0234 mmol). After 30 min., triisopropyl borate (3.1 mL, 0.0164 mmol) was added, and the mixture was stirred at 0° C. for 2 hours. The reaction was quenched by addition of 20 mL of 1M HCl (aq). The mixture was extracted with EtOAc, and the organic fractions were washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated to provide the title Compound 18a as a yellow oil. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.81 (d, 1H) 7.62-7.56 (m, 2H) 2.52 (s, 3H).
- A mixture of the freshly prepared Compound 18a (9.3 g, 0.0434 mol), Compound 16a (11.2 g, 0.289 mol), Pd(dppf)Cl2CH2Cl2 (4.7 g, 6.42 mmol), TBAB (9.3 g, 0.0289 mol), in 120 mL of 1M Na2CO3 (aq) and 600 mL DME was heated at 85° C. for 10 hours. The reaction mixture was cooled, and concentrated. The residue was purified by chromatography (silica gel, hexanes:EtOAc, 2:1) to provide the title Compound 18b as a yellow oil. 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.12 (d, 1H) 7.86 (d, 1H) 7.62-7.46 (m, 3H) 7.22 (d, 1H) 7.14 (d, 1H) 2.62 (d, 3H) 1.55 (s, 9H) 1.44 (s, 9H).
- A solution of Compound 18b (21.4 g, 0.0995 mol) in 210 mL of 4M HCl in dioxane was stirred for 4 hours. The reaction mixture was concentrated, made basic with 1M NaOH (aq), and extracted with EtOAc. The organic fraction was dried over Na2SO4, filtered, and the filtrate was concentrated to provide the title Compound 18c as a brown oil. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.00 (dd, 1H, J=1.6 and 8.0 Hz) 7.59 (dt, 1H, J=1.6 and 8.4 Hz) 7.48 (dt, 1H, J=1.2 and 8.4 Hz) 7.33 (dd, 1H, J=1.2 and 8.0 Hz) 6.79 (d, 1H, J=2.0 Hz) 6.75 (d, 1H, J=8.4 Hz) 6.68 (d, 1H, J=2.0 and 7.6 Hz) 2.93 (s, 3H) MS (ESI, pos. ion) m/z: 277.9 (M+1).
- A mixture of Compound 18c (0.100 g, 0.361 mmol) and 4-trifluoromethyl cinnamic acid (0.324 mmol) in 2 mL of POCl3 was heated to 100° C. for 14 hours. Evaporation of the reaction mixture provided a residue, which was then purified by HPLC (H2O:MeCN, 90:10 to 30:70, over 15 min) to provide the title Compound 310 as a white solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.07 (dd, 1H, J=1.2 and 8.4 Hz) 7.85 (d, 2H, J=8.4 Hz) 7.73 (d, 2H, J=8 Hz) 7.69-7.63 (m, 3H) 7.58 (dt, 2H, J=1.6 and 7.2 Hz) 7.44 (dd, 1H, J=1.2 and 7.2 Hz) 7.34 (d, J=16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 499.2 (M+MeCN+1).
- Using the procedures described in Example 18 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 312 (E)-2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.68-7.60 (m, 3H) 7.59-7.55 (m, 6H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.30 (dd, 1H, J = 1.6 and 8.0 Hz) 7.21 (d, 1H, J = 16.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 509.2 (M + MeCN). 314 (E)-N-methyl-2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-benzene sulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.04 (dd, 1H, J = 1.2 and 8.0 Hz) 7.77 (d, 1H, J = 16.4 Hz) 7.70 (d, 1H, J = 15.2 Hz) 7.66-7.64 (m, 2H) 7.61-7.55 (m, 3H) 7.46 (dd, 1H, J = 1.6 and 8.4 Hz) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.26 (d, 2H, J = 7.6 Hz) 7.15 (d, 1H, J = 16.8 Hz) 2.42 (s, 3H) 2.36 (s, 3H) MS (ESI, pos. ion) m/z: 404.2 (M + 1). 315 (E)-2-{2-[2-(4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 7.6 Hz) 7.82-7.73 (m, 4H) 7.70-7.66 (m, 2H) 7.61 (dd, 1H, J = 1.2 and 7.6 Hz) 7.45 (dd, 1H, J = 1.2 and 8.0 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.22 (d, 1H, J = 8.4 Hz) 7.21 (s, 2H) 7.18 (d, 1H, J = 7.6 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) m/z: 408.3 (M + 1). 316 (E)-2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 7.6 Hz) 7.84 (s, 1H) 7.70-7.66 (m, 2H) 7.64 (d, 1H) 7.60 (d, 2H, J = 7.6 Hz) 7.59 (s, 2H) 7.42 (dt, 2H, J = 1.6 and 9.2 Hz) 7.25 (d, 1H, J = 16.4 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) m/z: 408.3 (M + 1). 317 (E)-2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 7.6 Hz) 7.96 (dd, 1H, J = 2 and 5 Hz) 7.69-7.62 (m, 4H) 7.61-7.57 (m, 2H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.39 (dd, 1H, J = 1.6 and 8.0 Hz) 7.29 (t, 1H, J = 8.4 Hz) 7.18 (d, 1H, J = 16.4 Hz) 2.40 (s, 3H) MS (ESI, pos. ion) m/z: 486.2 (M). 318 (E)-2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 7.6 Hz) 7.96 (d, 1H, J = 16.4 Hz) 7.73-7.67 (m, 3H) 7.63 (dd, 1H, J = 1.2 and 8.0 Hz) 7.59 (d, 2H, J = 9.2 Hz) 7.52 (dd, 1H, J = 1.6 and 8.4 Hz) 7.44 (dd, 1H, J = 1.6 and 7.6 Hz) 6.90 (d, 1H, J = 16 Hz) 6.81 (d, 2H, J = 8.8 Hz) 3.06 (s, 6H) 2.45 (s, 3H) MS (ESI, pos. ion) m/z: 433.4 (M + 1). 319 (E)-2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 6.4 Hz) 7.77 (q, 1H, J = 5.3 Hz) 7.73-7.63 (m, 5H) 7.60 (dt, 1H, J = 1.6 and 8.4 Hz) 7.51 (dd, 1H, J = 1.6 and 6.4 Hz) 7.43 (d, 2H, J = 8.4 Hz) 7.39 (d, 1H, J = 16.8 Hz) 2.41 (s, 3H) MS (ESI, pos. ion) m/z: 476.3 (M + 1). 320 (E)-2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 6.4 Hz) 8.01 (t, 1H, J = 7.8 Hz) 7.90 (d, 1H, J = 16.4 Hz) 7.70-7.65 (m, 3H) 7.61-7.56 (m, 3H) 7.45 (d, 1H, J = 16.8 Hz) 7.28 (dd, 1H, J = 1.2 and 7.2 Hz) 7.40 (d, 1H, J = 1.2 and 7.2 Hz) 2.40 (s, 3H) MS (ESI, pos. ion) m/z: 476.3 (M + 1). 321 (E)-2-{2-[2-(3-chloro-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 6.0 Hz) 7.86 (t, 1H, J = 2.0 and 6.2 Hz) 7.73-7.65 (m, 5H) 7.61 (dd, 1H, J = 1.6 and 7.6 Hz) 7.46 (dd, 1H, J = 1.6 and 8.8 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.34 (t, 1H, J = 8.8 Hz) 7.22 (d, 1H, J = 16.4 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) m/z: 442.3 (M + 1). 322 (E)-2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.6 and 6.0 Hz) 7.86 (t, 1H, J = 2.0 and 6.2 Hz) 7.73-7.65 (m, 5H) 7.61 (dd, 1H, J = 1.6 and 7.6 Hz) 7.46 (dd, 1H, J = 1.6 and 8.8 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.34 (t, 1H, J = 8.8 Hz) 7.22 (d, 1H, J = 16.4 Hz) 2.42 (s, 3H) MS (ESI, pos. ion) m/z: 442.3 (M + 1). 323 (E)-N-methyl-2-{2-[2-(2,3,4-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (d, 1H, J = 7.6 Hz) 7.75 (d, 1H, J = 16.8 Hz) 7.68-7.56 (m, 5H) 7.43 (d, 1H, J = 3.2 Hz) 7.34 (d, 1H, J = 1.2 and 8.0 Hz) 7.33 (d, 1H, J = 4.0 Hz) 7.22 (q, 1H, J = 8.8 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 444.4 (M + 1). 324 (E)-N-methyl-2-{2-[2-(2,4,5-trifluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 8.0 Hz) 7.87-7.82 (m, 2H) 7.72-7.58 (m, 5H) 7.46-7.42 (m, 2H) 7.31 (d, 1H, J = 16.4 Hz) 2.41 (s, 3H) MS (ESI, pos. ion) m/z: 444.4 (M + 1). 325 (E)-2-{2-[2-(2,3-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.95 (d, 1H, J = 16.8 Hz) 7.74-7.66 (m, 3H) 7.63-7.59 (m, 2H) 7.47 (dd, 1H, J = 1.6 and 8.0 Hz) 7.44 (dd, 1H, J = 1.6 and 8.0 Hz) 7.39 (d, 1H, J = 16.8 Hz) 7.34-7.70 (m, 2H) 2.42 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1). 326 (E)-2-{2-[2-(2,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.82 (d, 1H, J = 16.4 Hz) 7.69-7.64 (m, 3H) 7.61-7.55 (m, 2H) 7.43 (dd, 1H, J = 1.6 and 7.6 Hz) 7.37 (dd, 1H, J = 1.6 and 8.8 Hz) 7.33 (d, 1H, J = 16.8 Hz) 7.26-7.15 (m, 2H) 2.39 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1). 327 (E)-2-{2-[2-(2,6-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.90 (d, 1H, J = 16.8 Hz) 7.71-7.58 (m, 4H) 7.51 (d, 1H, J = 16.8 Hz) 7.46-7.43 (m, 3H) 7.12 (t, 2H, J = 9.0 Hz) 2.41 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1). 328 (E)-2-{2-[2-(3,5-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 8.0 Hz) 7.68-7.56 (m, 5H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.36 (dd, 1H, J = 1.6 and 8.8 Hz) 7.31-7.25 (m, 3H) 6.99-6.96 (m, 1H) 2.39 (s, 3H) MS (ESI, pos. ion) m/z: 426.3 (M + 1). 329 (E)-2-{2-[2-(3,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.66-7.56 (m, 6H) 7.48-7.42 (m, 2H) 7.36-7.32 (m, 2H) 7.17 (d, 1H, J = 16.8 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1). 330 (E)-2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.25 (dd, 1H, J = 1.6 and 16.4 Hz) 8.16 (dd, 1H, J = 1.2 and 9.2 Hz) 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 8.4 (d, 1H, J = 1.2 Hz) 8.25 (dd, 1H, J = 0.8 and 8.0 Hz) 7.73-7.56 (m, 5H) 7.46 (dd, 1H, J = 1.6 and 8.0 Hz) 7.65 (d, 1H, J = 16.4 Hz) 2.46 (s, 3H) MS (ESI, pos. ion) m/z: 476.4 (M + 1). 331 (E)-2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02-7.98 (m, 2H) 7.18-7.56 (m, 4H) 7.45-7.40 (m, 2H) 7.38 (dd, 1H, J = 1.6 and 8.4 Hz) 7.26 (d, 1H, J = 16.8 Hz) 2.39 (s, 3H) MS (ESI, pos. ion) m/z: 476.4 (M + 1). 332 (E)-2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-N-methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.10-8.05 (m, 2H) 7.84 (d, 1H, J = 16.8 Hz) 7.71-7.55 (m, 5H) 7.43 (dd, 1H, J = 1.6 and 7.2 Hz) 7.37 (d, 1H, J = 16.8 Hz) 7.32 (dd, 1H, J = 1.2 and 8.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 476.5 (M + 1). 333 (E)-2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.24 (s, 2H) 7.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.94 (s, 1H) 7.73-7.55 (m, 5H) 7.45-7.40 (m, 2H) 7.32 (dd, 1H, J = 1.6 and 8.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 526.4 (M + 1). 334 (E)-2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.27 (s, 1H) 8.08-7.92 (m, 3H) 8.87 (d, 1H, J = 8.4 Hz) 7.69-7.56 (m, 4H) 7.44 (dd, 1H, J = 1.6 and 8.0 Hz) 7.36-7.32 (m, 2H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 526.4 (M + 1). 335 (E)-2-{2-[2-(3-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (d, 1H, J = 8.4 Hz) 7.93 (d, 1H, J = 8.0 Hz) 7.81 (d, 1H, J = 16.4 Hz) 7.74-7.56 (m, 4H) 7.50-7.23 (m, 5H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 442.4 (M + 1). 336 (E)-2-{2-[2-(2-chloro-6-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.89 (d, 1H, J = 16.8 Hz) 7.68-7.55 (m, 4H) 7.45 (d, 1H, J = 16.8 Hz) 7.43 (dd, 1H, J = 1.2 and 7.6 Hz) 7.38-7.31 (m, 3H) 7.23-7.18 (m, 1H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 442.4 (M + 1). 337 (E)-2-{2-[2-(2,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J = 1.2 and 8.0 Hz) 8.51 (d, 1H, J = 16.8 Hz) 7.88 (d, 1H, J = 8.0 Hz) 7.68-7.56 (m, 5H) 7.45-7.41 (m, 2H) 7.32 (dd, 1H, J = 1.6 and 8.4 Hz) 7.24 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 458.3 (M + 1). 338 (E)-2-{2-[2-(3-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.82 (t, 1H, J = 1.8 Hz) 7.68-7.49 (m, 7H) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.35 (d, 1H, J = 7.6 Hz) 7.30 (dd, 1H, J = 0.8 and 8.0 Hz) 7.21 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 468.3 (M + 1). 339 (E)-2-{2-[2-(4-chloro-2-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.40 (d, 1H, J = 16.4 Hz) 8.08-8.06 (m, 2H) 8.01 (d, 1H, J = 8.4 Hz) 7.89 (dd, 1H, J = 2.4 and 8.4 Hz) 7.80-7.56 (m, 4H) 7.44 (dd, 1H, J = 1.2 and 7.2 Hz) 7.33 (dd, 1H, J = 1.6 and 7.2 Hz) 7.26 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 442.3 (M + 1). 340 (E)-2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-N-methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.76-7.72 (m, 2H) 7.66-7.54 (m, 4H) 7.42 (dd, 1H, J = 0.8 and 7.2 Hz) 7.32-7.26 (m, 4H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 502.3 (M + 1). 341 (E)-N-methyl-2-{2-[2-(4-trifluoromethylthio-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (d, 2H, J = 8.8 Hz) 8.06 (dd, 1H, J = 1.2 and 8.4 Hz) 8.06 (d, 2H, J = 8.8 Hz) 7.75-7.56 (m, 5H) 7.47 (d, 1H, J = 16.4 Hz) 7.44 (dd, 1H, J = 1.2 and 7.2 Hz) 7.34 (dd, 1H, J = 1.2 and 8.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 522.3 (M + 1). 342 (E)-N-methyl-2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.4 Hz) 7.75 (q, 4H, J = 10.6 Hz) 7.44-7.55 (m, 5H) 7.43 (dd, 1H, J = 1.2 and 7.6 Hz) 7.33-7.28 (m, 2H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 490.3 (M + 1). 343 (E)-N-methyl-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5- yl}-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02 (dd, 1H, J = 12.0 and 16.0 Hz) 7.98 (d, 1H, J = 8.0 Hz) 7.77 (d, 1H, J = 8.4 Hz) 7.72-7.62 (m, 4H) 7.57 (dt, 1H, J = 1.6 and 8.4 Hz) 7.54 (t, 1H, J = 7.6 Hz) 7.44 (dd, 1H, J = 1.2 and 7.2 Hz) 7.32 (dd, 1H, J = 1.6 and 8.4 Hz) 7.21 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 458.4 (M + 1). 344 (E)-N-methyl-2-{2-[2-(3-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.66-7.62 (m, 4H) 7.60-7.54 (m, 3H) 7.51 (d, 1H, J = 8.0 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.31 (dd, 1H, J = 1.2 and 8.0 Hz) 7.28 (d, 1H, J = 8.4 Hz) 7.25 (d, 1H, J = 16.8 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 474.4 (M + 1). 345 (E)-N-methyl-2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 7.6 Hz) 7.75 (d, 2H, J = 8.4 Hz) 7.69-7.64 (m, 3H) 7.61 (d, 1H, J = 8.0 Hz) 7.57 (dt, 1H, J = 1.2 and 8.4 Hz) 7.42 (dd, 1H, J = 1.6 and 8.4 Hz) 7.33 (d, 3H, J = 10.0 Hz) 7.20 (d, 1H, J = 16.4 Hz) 2.38 (s, 3H) MS (ESI, pos. ion) m/z: 474.4 (M + 1). 346 (E)-2-{2-[2-(2-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.03-8.05 (m, 2H) 7.87 (dd, 2H, J = 1.68 and 7.6 Hz) 7.66-7.55 (m, 4H) 7.45 (dd, 1H, J = 1.6 and 7.6 Hz) 7.43 (dd, 1H, J = 1.2 and 7.2 Hz) 7.38-7.30 (m, 3H) 7.22 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 425.3 (M + 1). 347 (E)-2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.36-7.63 (m, 4H) 7.62-7.55 (m, 3H) 7.44 (d, 3H, J = 8.0 Hz) 7.31 (dd, 1H, J = 1.6 and 8.0 Hz) 7.19 (d, 1H, J = 16.4 Hz) 2.36 (s, 3H) MS (ESI, pos. ion) m/z: 425.3 (M + 1). 348 (E)-2-{2-[2-(2-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02 (d, 1H, J = 16.4 Hz) 7.84 (dd, 1H, J = 1.6 and 8.4 Hz) 7.68-7.55 (m, 5H) 7.44-7.40 (m, 2H) 7.31 (dd, 1H, J = 1.2 and 6.8 Hz) 7.02 (dt, 1H, J = 1.6 and 8.4 Hz) 7.17 (d, 1H, J = 16.4 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 469.5 (M + 1). 349 (E)-2-{2-[2-(2,4-difluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 1.2 and 8.0 Hz) 7.80 (q, 1H, J = 8.0 Hz) 7.74 (d, 1H, J = 16.8 Hz) 7.67-7.54 (m, 5H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.30 (dd, 1H, J = 1.6 and 8.4 Hz) 7.23 (d, 1H, J = 16.8 Hz) 7.05 (t, 1H, J = 8.8 Hz) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 426.4 (M + 1). 351 (E)-2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 8.01 (d, 2H, J = 8.4 Hz) 7.90 (d, 2H, J = 8.8 Hz) 7.72 (d, 1H, J = 16.4 Hz) 7.67-7.56 (m, 4H) 7.44 (dd, 1H, J = 1.6 and 7.2 Hz) 7.38 (d, 1H, J = 16.4 Hz) 7.33 (dd, 1H, J = 1.6 and 8.4 Hz) 3.15 (s, 3H) 2.37 (s, 3H) MS (ESI, pos. ion) m/z: 468.4 (M + 1). - To a solution of Compound 16a (2.0 g, 5.1 mmol), 2-methylsulfonylphenyl boronic acid (1.1 g, 5.1 mmol), and K2CO3 (2.1 g, 15.3 mmol) in 1,4-dioxane:water (4:1, 120 mL), was added Pd(dppf)Cl2CH2Cl2 (0.42 g, 0.51 mmol) under an argon atmosphere. The mixture was heated at 95° C. for 12 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by chromatography (silica, EtOAc:hexanes, 3:7) to provide the title Compound 19a as a yellow solid (1.7 g, 70% yield). 1H NMR (400 MHz, CDCl3) δ (ppm): 7.64 (d, J=8.4 Hz, 1H), 7.57 (d, J=14.4 Hz, 1H), 7.34 (t, J=8.4 Hz, 1H), 7.26-7.15 (m, 3H), 7.07 (s, 1H), 7.04 (d, J=8 Hz, 1H), 6.87 (s, 1H), 6.63 (s, 1H), 2.90 (s, 3H), 1.51 (s, 9H), 1.49 (s, 9H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H31N3O6S: 478.19 (M+H). Found 478.0.
- A solution of Compound 19a (1.0 g, 2.1 mmol) in a mixture of 4M HCl in 1,4-dioxane (10 mL) was heated at 70° C. for 2 h. After concentration of the reaction, the residue was dissolved in dichloromethane (20 mL), and to the solution was added K2CO3 (0.5 g) and the mixture was stirred at room temperature for 20 min. After filtration and removal of solvents, the residue was dried to provide the title Compound 19b as a brown solid (0.58 g, quantitative yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 7.47 (d, J=8.4 Hz, 1H), 7.40-7.35 (m, 1H), 7.32-7.29 (m, 2H), 7.16-7.09 (m, 3H), 2.80 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C13H15N3O2S: 278.09 (M+H). Found 278.1.
- A solution of Compound 19b (50 mg, 0.18 mmol) and commercially available 3-(4-ethoxy-phenyl)-acrylic acid (34.6 mg, 0.18 mmol) in POCl3 (1.5 mL) was heated to 100° C. for 12 h. The reaction was cooled, the excess POCl3 was removed under reduced pressure, and the residue was purified by HPLC (Gilson, C-18 column, CH3CN:H2O (gradient of CH3CN: 5%-80%)) to provide the title Compound 414 as an off-white solid (25 mg, 32% yield). 1H NMR (400 MHz, CD3OD) δ (ppm):7.62-7.59 (m, 4H), 7.54-7.52 (m, 1H), 7.41-7.37 (m, 2H), 7.35-7.30 (m, 2H), 7.03 (d, J=16.8 Hz, 2H), 6.97 (d, J=12 Hz, 2H), 4.09 (q, J=7.2 Hz, 2H), 2.72 (s, 3H), 1.41 (t, J=7.2 Hz, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C24H23N3O3S: 434.1 (M+H). Found 434.1.
- Using the procedures described in Example 19 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 77 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.40-7.56 (m, 6H) 7.24-7.33 (m, 4H) 7.19-7.22 (m, 2H) 7.05 (d, J = 16.4 Hz, 1H) 2.61 (s, 3H). MS (ESI, pos. ion) m/z: 424.1 (M + 1)., 83 (E)-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.99-7.96 (m, 2H), 7.89-7.86 (m, 4H), 7.78 (dd, J = 6.4, 15.8 Hz, 2H), 7.60 (dd, J = 1.2, 8.2 Hz, 1H), 7.46-7.39 (m, 2H), 7.33 (dt, J = 1.6, 8.2 Hz, 2H), 6.99 (dd, J = 6.4, 15.8 Hz, 2H), 3.10 (s, 3H), 3.09 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H21N3O4S2: 468.1 (M + H), Found 468.0., 95 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5- yl)-phenyl]-methanesulfonamide 1H NMR (400 MHz, CD3OD) δ (ppm): 7.67-7.62 (m, 5H), 7.54-7.52, (m, 1H), 7.42-7.33 (m, 4H), 7.09 (d, J = 16.4 Hz, 2H), 7.08 (d, J = 12 Hz, 1H), 4.60 (q, J = 8.4 Hz, 2H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C24H20F3N3O3S: 488.1 (M + H), Found 488.3, 101 (E)-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.65-7.60 (m, 5H), 7.54-7.52 (m, 1H), 7.41-7.37 (m, 2H), 7.34-7.30 (m, 2H), 7.10-7.06 (m, 3H), 4.68 (t, J = 12.8 Hz, 2H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C25H20F5N3O3S: 538.1 (M + H), Found 538.2., 113 (E)-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.90-7.96 (m, 2H) 7.54-7.76 (m, 6H) 7.26-7.42 (m, 5H) 2.76 (s, 3H). MS (ESI, pos. ion) m/z: 458.1 (M + 1)., 406 (E)-N-(2-{2-[2-(4-bromo-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.87-7.80 (m, 2H), 7.58-7.30 (m, 9H), 2.85 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H18BrN3O2S: 468.0 (M + H), Found 469.1., 407 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.67-7.52) (m, 6H), 7.14 (d, J = 16.4 Hz, 1H), 3.13-3.12 (m, 1H), 2.72 (s, 3H), 1.27 (d, J = 6.8 Hz, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C25H25N3O2S: 432.2 (M + H), Found 432.2., 408 (E)-N-(2-{2-[2-(4-isopropyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.82 (dd, J = 2.4, 7.2 Hz, 1H) 7.66-7.60 (m, 4H), 7.56-7.52 (m, 2H), 7.41-7.39 (m, 6H), 7.18 (d, J = 16.4 Hz, 1H), 2.73 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H17ClFN3O2S: 442.1 (M + H), Found 442.3., 409 (E)-N-(2-{2-[2-(3-bromo-4-fluoro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.95 (dd, J-2.4, 6.8 Hz, 1H), 7.69-7.68 (m, 1H), 7.67-7.63 (m, 2H), 7.58 (d, J = 16.4 Hz, 1H), 7.53-7.51 (m, 1H), 7.40-7.26 (m, 5H), 7.18 (d, J = 16.4 Hz, 1H), 2.72 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H17BrFN3O2S: 486.0 (M + H), Found 486.3., 410 (E)-N-(2-{2-[2-(4-difluoromethoxy-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.73 (d, J = 12.8 Hz, 2H), 7.54-7.52 (m, 1H), 7.48-7.45 (m, 1H), 7.41-7.39 (m, 2H), 7.34-7.30 (m, 2H), 7.21 (d, J = 8.8 Hz, 2H), 7.16 (d, J = 17.2 Hz, 1H), 6.90 (s, 1H), 2.73 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H19F2N3O3S: 456.1 (M + H), Found 456.1., 411 (E)-N-(2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.77 (s, 1H), 7.75 (d, J = 12 Hz, 1H), 7.68 (s, 1H), 7.67-7.64 (m, 2H), 7.52 (d, J = 12 Hz, 1H), 7.46 (d, J = 12 Hz, 1H), 7.40-7.25 (m, 5H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H17F4N3O2S: 476.1 (M + H), Found 476.2, 412 (E)-N-{2-[2-(2-p-tolyl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.65-7.60 (m, 3H), 7.41-7.36 (m, 3H), 7.41-7.36 (m, 2H), 7.33-7.30 (m, 2H), 7.26 (d, J = 10 Hz, 2H), 7.18 (d, J = 20 Hz, 1H), 2.74 (s, 3H), 2.39 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H21N3O2S: 404.1 (M + H), Found 404.3, 413 (E)-N-(2-{2-[2-(4-dimethylamino-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.69-7.61 (m, 2H) 7.57-7.51 (m, 2H), 7.46-7.39 (m, 3H), 7.29 (d, J = 16.2 Hz, 2H), 7.05 (d, J = 12 Hz, 1H), 6.67 (d, J = 16.2 Hz, 2H), 6.33 (d, J = 12 Hz, 1H), 3.01 (s, 3H), 2.97 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C24H24N4O2S: 433.2 (M + H), Found 433.3, 415 (E)-N-{2-[2-(2-naphthalen-2-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.09 (s, 1H), 7.96-7.88, (m, 4H), 7.74-7.72 (m, 2H), 7.57-7.52 (m, 3H), 7.51-7.33 (m, 6H), 2.80 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C26H21N3O2S: 440.1 (M + H), Found 440.3, 416 (E)-N-(2-{2-[2-(3,4-dichloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.03-8.00 (m, 1H), 7.93 (s, 1H), 7.77 (s, 1H), 7.74 (d, J = 11.2 Hz, 1H), 7.69 (s, 1H), 7.57-7.52 (m, 2H), 7.47 (d, J = 8 Hz, 1H), 7.44 (d, J = 7.6 Hz, 2H), 7.40-7.36 (m, 1H), 7.32 (d, J = 17.2 Hz, 1H), 2.84 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H17Cl2N3O2S: 458.0 (M + H), Found 458.2., 417 (E)-N-(2-{2-[2-(3-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.03-8.00 (m, 1H), 7.76 (t, J = 8.0 Hz, 1H), 7.71-7.67 (m, 3H), 7.63 (d, J = 8.4 Hz, 1H), 7.54-7.52 (m, 1H), 7.78-7.44 (m, 1H), 7.43-7.38 (m, 3H), 7.38-7.32 (m, 1H), 2.77 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H17F4N3O2S: 476.1 (M + H), Found 476.2., 418 (E)-N-(2-{2-[2-(2-fluoro-4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol- 5-yl}-phenyl)-methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.00 (t, J = 8.4 Hz, 1H), 7.84 (d, J = 17.2 Hz, 1H), 7.62-7.58 (m, 2H), 7.55-7.52 (m, 2H), 7.46 (s, 1H), 7.44-7.38 (m, 3H), 7.38-7.32 (m, 2H), 2.74 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H17F4N3O2S: 476.1 (M + H), Found 476.2, 475 (E)-N-{2-[2-(2-biphenyl-4-yl-vinyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide 1H-NMR (400 MHz, CDCl3) δ (ppm) 7.44-7.65 (m, 10H) 7.22-7.40 (m, 5H) 7.10-7.20 (m, 3H) 2.76 (s, 3H). MS (ESI, pos. ion) m/z: 466.2 (M + 1)., - Using the procedures described in Example 19, or using the procedures in Example 1 and the corresponding bromobenzimidazole and boronic acid or boronate ester, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:
-
Cpd Name and Data 89 (E)-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]- methanesulfonamide, 107 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 119 (E)-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 125 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)- 1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide, - Using the procedures described in Example 1 or Example 19 and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared:
-
Cpd Name and Data 72 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 73 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 74 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide. 75 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 76 (E)-1-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 80 (E)-N-(2-{2-[2-(4-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide. 81 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 82 (E)-1-(2-{2-[2-(4-methanesulfonyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 87 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanone, 88 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanol, 90 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-vinyl}- 1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 92 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 93 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)- phenyl]-ethanone, 94 (E)-1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)- phenyl]-ethanol, 96 (E)-2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H-benzimidazol-5-yl)- phenyl]-propan-2-ol, 98 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 99 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 100 (E)-1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 102 (E)-2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-vinyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, and 104 (E)-C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- vinyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide. 105 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 106 (E)-1-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 108 (E)-2-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 110 (E)-N-(2-{2-[2-(3-chloro-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 111 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 112 (E)-1-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 116 (E)-C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide. 117 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)- methanesulfonamide, 118 (E)-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)- phenyl]-methanesulfonamide, 120 (E)-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2- yl}-vinyl)-phenyl]-methanesulfonamide, 122 (E)-C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-vinyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 123 (E)-N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 124 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H- benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, 126 (E)-C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-vinyl)-phenyl]-methanesulfonamide, and 128 (E)-C,C,C-trifluoro-N-(4-{2-[5-(2-trifluoromethanesulfonylamino-phenyl)- 1H-benzimidazol-2-yl]-vinyl}-phenyl)-methanesulfonamide. - A mixture of (E)-2-{2-[2-(2-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide Cpd 364 (0.020 g, 0.045 mmol) and 10% palladium on charcoal (0.005 g, 0.0045 mmol) in 2 mL MeOH was hydrogenated under H2 gas (1 atm) for 1 hour. The catalyst was removed by filtration, the filtrate was concentrated to dryness, and the residue was purified by chromatography (silica gel, MeOH:CH2Cl2=10:1) to give the title compound as a white solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J=1.2 and 7.6 Hz) 7.74-7.53 (m, 4H) 7.60-7.56 (m, 2H) 7.51-7.40 (m, 4H) 3.41 (m, 4H) MS (ESI, pos. ion) m/z: 446.5 (M+1).
- Using the procedures described in Example 22 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:
-
Cpd Name and Data 129 2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, 1.2 and 8.0 Hz) 7.65-7.54 (m, 4H) 7.44-7.31 (m, 4H) 7.20 (d, 2H, J = 8.8 Hz) 3.26-3.23 (m, 4H) MS (ESI, pos. ion) m/z: 462.4 (M + 1). 130 2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (dd, 1H, J = 1.2 and 8.4 Hz) 7.64-7.51 (m, 6H) 7.42 (d, 2H, J = 8.0 Hz) 7.39 (dd, 1H, J = 1.2 and 7.6 Hz) 7.27 (dd, 1H, J = 1.6 and 8.4 Hz) 3.24 (m, 4H) MS (ESI, pos. ion) m/z: 446.4 (M + 1). 131 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 8.0 Hz) 8.02 (d, 2H, J = 8.8 Hz) 7.70-7.55 (m, 7H) 7.42 (dd, 1H, J = 1.6 and 7.2 Hz) 7.36 (dd, 1H, J = 1.6 and 8.4 Hz) 3.41-3.48 (m, 4H) MS (ESI, pos. ion) m/z: 510.2 (M + 1). 139 2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzene sulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (dd, 1H, 1.6 and 8.0 Hz) 7.64-7.59 (m, 2H) 7.55-7.51 (m, 2H) 7.39 (dd, 1H, J = 0.8 and 7.6 Hz) 7.32-7.14 (m, 5H) 3.20-3.13 (m, 4H) MS (ESI, pos. ion) m/z: 412.3 (M + 1). 145 2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, 1.2 and 7.6 Hz) 7.87 (d, 2H, J = 8.4 Hz) 7.66-7.50 (m, 6H) 7.41 (dd, 1H, J = 1.2 and 8.0 Hz) 7.30 (dd, 1H, J = 1.6 and 8.4 Hz) 3.10 (m, 4H) MS (ESI, pos. ion) m/z: 456.3 (M + 1). 175 2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.13 (dd, 1H, J = 1.2 and 7.6 Hz) 7.70-7.48 (m, 8H) 7.44 (dd, 1H, J = 1.6 and 8.0 Hz) 7.39 (dd, 1H, J = 1.2 and 7.2 Hz) 3.40-3.30 (m, 4H) MS (ESI, pos. ion) m/z: 446.4 (M + 1). 383 2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.02 (dd, 1H, J = 1.2 and 8.0 Hz) 7.52-7.49 (m, 2H) 7.45-7.41 (m, 4H) 7.31-7.26 (m, 1H) 7.18 (dd, 1H, J = 1.2 and 8.0 Hz) 7.13 (t, 1H, J = 7.2 Hz) 3.20-3.15 (m, 4H) MS (ESI, pos. ion) m/z: 446.4 (M + 1). 384 2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.66-7.53 (m, 4H) 7.42 (dd, 1H, J = 1.6 and 7.6 Hz) 7.29 (dd, 1H, J = 1.6 and 8.4 Hz) 7.04-6.99 (m, 2H) 3.24 (m, 4H) MS (ESI, pos. ion) m/z: 432.5 (M + 1). 385 2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.4 Hz) 7.67-7.53 (m, 4H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.30 (dd, 1H, J = 1.6 and 8.4 Hz) 7.26-7.10 (m, 2H) 3.23-3.20 (m, 4H) MS (ESI, pos. ion) m/z: 432.3 (M + 1). 386 2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J = 1.2 and 8.0 Hz) 7.67-7.53 (m, 4H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.31-7.25 (m, 2H) 6.97-6.93 (m, 2H) 3.26-3.19 (m, 4H) MS (ESI, pos. ion) m/z: 414.3 (M + 1). 387 2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (dd, 1H, 1.6 and 8.0 Hz) 7.92 (dd, 1H, 1.2 and 8.4 Hz) 7.80 (s, 1H) 7.64-7.51 (m, 4H) 7.40-7.33 (m, 2H) 7.28 (dd, 1H, J = 1.6 and 8.0 Hz) 3.38-3.25 (m, 4H) MS (ESI, pos. ion) m/z: 514.4 (M + 1). 388 2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 7.6 Hz) 7.94 (d, 1H, J = 8.0 Hz) 7.76-7.72 (m, 2H) 7.67-7.54 (m, 4H) 7.42 (dd, 1H, J = 1.2 and 7.6 Hz) 7.33 (dd, 1H, J = 1.6 and 8.4 Hz) 3.50-3.45 (m, 2H) 3.31-3.26 (m, 2H) MS (ESI, pos. ion) m/z: 514.5 (M + 1). 390 2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (dd, 1H, 1.6 and 8.0 Hz) 7.54-7.60 (m, 3H) 7.54 (dd, 1H, J = 1.2 and 8.0 Hz) 7.52-7.48 (m, 2H) 7.43 (dd, 1H, J = 2.0 and 8.4 Hz) 7.39 (dd, 1H, J = 1.6 and 7.2 Hz) 7.27 (d, 1H, J = 8.0 Hz) 3.23 (m, 4H) MS (ESI, pos. ion) m/z: 480.4 (M + 1). 391 2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, 1.2 and 8.0 Hz) 7.65-7.54 (m, 4H) 7.43-7.37 (m, 2H) 7.33 (dd, 1H, J = 2.0 and 8.0 Hz) 7.26 (d, 1H, J = 8.8 Hz) 7.17 (s, 1H) 7.13 (d, 1H, J = 9.6 Hz) 3.26 (m, 4H) MS (ESI, pos. ion) m/z: 462.4 (M + 1). 392 2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, 1.6 and 6.4 Hz) 7.67-7.53 (m, 4H) 7.42 (dd, 1H, 1.6 and 8.0 Hz) 7.30 (dd, 1H, J = 1.2 and 6.8 Hz) 7.28-7.23 (m, 1H) 6.96-6.85 (m, 2H) 3.22 (m, 4H) MS (ESI, pos. ion) m/z: 414.2 (M + 1). 393 2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, 1.2 and 7.6 Hz) 7.65-7.53 (m, 4H) 7.42 (dd, 1H, 1.2 and 7.2 Hz) 7.32 (dd, 1H, J = 1.2 and 8.4 Hz) 7.22-7.13 (m, 2H) 7.04-7.01 (m, 1H) 3.22 (m, 4H) MS (ESI, pos. ion) m/z: 414.4 (M + 1). 394 2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, 1.6 and 8.0 Hz) 7.68-7.53 (m, 4H) 7.42 (dd, 1H, 1.6 and 7.6 Hz) 7.32 (dd, 1H, J = 1.6 and 8.0 Hz) 7.15-7.01 (m, 3H) 3.28 (m, 4H) MS (ESI, pos. ion) m/z: 414.3 (M + 1). 395 2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, 2.4 and 7.6 Hz) 7.67-7.53 (m, 4H) 7.43-7.39 (m, 1H) 7.33-7.29 (m, 1H) 7.12-6.94 (m, 3H) 3.26 (m, 4H) MS (ESI, pos. ion) m/z: 414.4 (M + 1). 396 2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzene sulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, 2.0 and 8.0 Hz) 7.67-7.54 (m, 4H) 7.42 (dd, 1H, 1.6 and 7.6 Hz) 7.36 (dd, 1H, 1.6 and 8.4 Hz) 6.91-6.77 (m, 3H) 3.26-3.20 (m, 4H) MS (ESI, pos. ion) m/z: 414.6 (M + 1). 397 2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, 1.6 and 7.6 Hz) 7.67-7.54 (m, 4H) 7.42 (dd, 1H, 1.6 and 7.6 Hz) 7.30-7.17 (m, 7H) 3.25-3.06 (m, 4H) MS (ESI, pos. ion) m/z: 378.3 (M + 1). 399 N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5- yl}-benzenesulfonamide The title compound was prepared by hydrogenation using Compound 398. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.07 (dd, 1H, J = 1.2 and 8.0 Hz) 7.65 (dt, 1H, J = 1.6 and 8.2 Hz) 7.58-7.53 (m, 5H) 7.41-7.38 (m, 3H) 7.20 (dd, 1H, J = 1.6 and 8.4 Hz) 3.25 (m, 4H) 2.27 (s, 6H) MS (ESI, pos. ion) m/z: 474.4 (M + 1). 402 2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (d, 1H) 7.64-7.52 (m, 4H) 7.41-7.38 (m, 2H) 7.26-7.19 (m, 4H) 3.22-3.18 (m, 4H) MS (ESI, pos. ion) m/z: 412.3 (M + 1). 404 2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (dd, 1H, J = 1.6 and 8.0 Hz) 7.64-7.60 (m, 2H) 7.56-7.51 (m, 2H) 7.46-7.38 (m, 3H) 7.30-7.27 (m, 2H) 3.33-3.30 (m, 2H) 3.35-3.32 (m, 2H) MS (ESI, pos. ion) m/z: 464.4 (M + 1). 405 2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.15 (dd, 1H, J = 1.2 and 8.0 Hz) 7.66-7.62 (m, 2H) 7.59-7.50 (m, 4H) 7.41 (dd, 1H, J = 1.2 and 7.6 Hz) 7.31 (dd, 1H, J = 1.6 and 8.0 Hz) 7.26-7.21 (m, 1H) 3.26 (m, 4H) MS (ESI, pos. ion) m/z: 464.3 (M + 1). 419 2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzene sulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (d, J = 8.0 Hz, 1H), 7.71 (s, 1H), 7.68-7.64 (m, 2H), 7.60-7.57 (m, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.29-7.24 (m, 2H), 7.12-7.06 (m, 2H), 3.41 (t, J = 8.0 Hz, 2H), 3.28 (t, J = 8.0 Hz, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H18FN3O2S: 396.1 (M + H), Found 396.3. 420 2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, J = 1.6, 8.0 Hz, 1H), 7.73 (s, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.65 (dd, J = 1.6, 8.0 Hz, 1H), 7.58 (dt, J = 1.6, 8.0 Hz, 1H), 7.51 (d, J = 1.6, 8.0 Hz, 1H), 7.40 (dd, J = 1.2, 7.2 Hz, 1H), 7.27-7.24 (m, 2H), 7.04-7.00 (m, 2H), 3.42 (t, J = 8.0 Hz, 2H), 3.23 (t, J = 8.0 Hz, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H18FN3O2S: 396.1 (M + H), Found 396.3. 421 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (d, J = 8.0 Hz, 1H), 7.64-7.60 (m, 2H), 7.56-7.51 (m, 2H), 7.40-7.36 (m, 2H), 7.32-7.29 (m, 3H), 3.27-3.25 (m, 4H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H17F4N3O2S: 464.1 (M + H), Found 464.3. 442 2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.12 (dd, J = 1.6, 8 Hz, 1H), 8.01 (d, J = 1.6, 8 Hz, 1H), 7.65-7.60 (m, 3H), 7.58-7.53 (m, 3H), 7.48-7.44 (m, 1H), 7.40 (dd, J = 1.6, 8 Hz, 1H), 7.33 (dd, J = 1.6, 8 Hz, 1H), 3.13 (m, 1H), 2.86 (t, J = 7.6 Hz, 2H), 2.83 (t, J = 7.6 Hz, 2H), 1.21 (d, J = 7.6 Hz, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C24H25N3O2S: 420.5 (M + H), Found 420.4. 445 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared by hydrogenation using Compound 444. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.33 (d, J = 8 Hz, 1H), 7.83 (dd, J = 2, 8 Hz, 1H), 7.63 (d, J = 8 Hz, 2H), 7.58-7.54 (m, 3H), 7.42 (d, J = 8 Hz, 2H), 7.29 (dd, J = 2, 8 Hz, 1H), 3.28-3.24 (m, 4H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H17F6N3O2S: 514.5 (M + H), Found 514.3. 447 4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-benzenesulfonamide The title compound was prepared by hydrogenation using Compound 446. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.42 (s, 1H), 7.94 (d, J = 8 Hz, 1H), 7.63-7.56 (m, 5H), 7.42 (d, J = 8 Hz, 2H), 7.29 (d, J = 1.6, 8 Hz, 1H), 3.27-3.25 (m, 4H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H17F6N3O2S: 514.1 (M + H), Found 514.2. - Using the procedure of Example 18, the title compound was prepared from Compound 18c and 4-trifluoromethylphenyl propionic acid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.04 (dd, 1H, J=1.2 and 8.0 Hz) 7.66-7.53 (m, 6H) 7.42-7.38 (m, 3H) 7.29 (dd, 1H, J=1.6 and 8.4 Hz) 3.27 (m, 4H) MS (ESI, pos. ion) m/z: 460.4 (M+1).
- Using the procedure of Example 18, the title compound was prepared from Compound 18c and 3-trifluoromethylphenyl propionic acid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.05 (dd, 1H, J=1.2 and 7.6 Hz) 7.64 (td, 1H, 1.2 and 8.2 Hz) 7.58-7.53 (m, 4H) 7.50-7.44 (m, 3H) 7.40 (dd, 1H, J=1.2 and 7.2 Hz) 7.25 (dd, 1H, J=1.6 and 8.0 Hz) 3.26-3.22 (m, 4H) MS (ESI, pos. ion) m/z: 460.4 (M+1).
- Using the procedure of Example 10, the title Compound 464 (0.013 g) was prepared from 5-bromo-2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazole Compound 25a (0.048 g, 0.13 mmol) and Compound 10e (0.032 g, 0.20 mmol). 1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.71 (dd, J=1.26, 8.08 Hz, 1H) 7.45 (d, J=7.8 Hz, 2H) 7.37 (d, J=8.34 Hz, 1H) 7.31 (d, J=8.08 Hz, 2H) 7.20-7.26 (m, 2H) 7.10 (ddd, J=1.51, 7.33, 7.58 Hz, 1H) 6.93-7.20 (m, 2H) 3.14 (m, 4H) 1.21 (s, 6H). MS (ESI, pos. ion) m/z: 425.1 (M+1).
- Using the procedures described in Example 25 and Compound 25a, and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:
-
Cpd Name and Data 457 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-phenyl)-acetamide 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.50-7.60 (m, 5H) 7.32-7.44 (m, 5H) 7.22-7.26 (d, J = 8.6 Hz, 1H) 3.24-3.30 (s, 4H) 1.96 (s, 3H). MS (ESI, pos. ion) m/z: 424.2 (M + 1). - Using the procedures of Examples 22, 23, 24 or 25, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared.
-
Cpd Name and Data 133 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 134 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 135 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 136 1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol, 137 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 138 2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol, 140 N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 141 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 142 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 143 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 144 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 146 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 147 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 148 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 149 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 150 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 151 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 152 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 153 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-ethanone, 154 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-ethanol, 155 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-methanesulfonamide, 156 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- phenyl]-propan-2-ol, 157 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)- benzenesulfonamide, 158 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 159 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 160 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 161 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 162 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 163 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 164 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 165 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 166 1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol, 167 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 168 2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan- 2-ol, 169 2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 170 N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 171 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 172 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 173 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 174 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 176 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 177 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)- methanesulfonamide, 178 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)- phenyl]-methanesulfonamide, 179 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 180 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- ethyl)-phenyl]-methanesulfonamide, 181 2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 182 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 183 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C- trifluoro-methanesulfonamide, 184 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol- 2-yl}-ethyl)-phenyl]-methanesulfonamide, 185 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide, 186 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide, 187 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, and 188 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)- ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide. - To a solution of trimethylsulfonium iodide (0.53 g, 2.39 mmol) in 8 mL of DMSO was added sodium hydride (0.06 g, 2.39 mmol) at 25° C. After stirring for one hour, a solution of methyl 4-trifluoromethylcinnamate (0.50 g, 2.17 mmol) in 4 mL DMSO was added. The reaction mixture was stirred for six hours, when it was quenched by sat'd NH4Cl solution. The resulting mixture was extracted with CH2Cl2, the organic layer was dried over Na2SO4, filtered and the filtrate was concentrated. The residue was purified by chromatography (silica gel, hexanes:EtOAc, 2:1) to provide the title Compound 27a as a solid.
- A solution of Compound 27a in 10 mL MeOH and 4 mL of 1N LiOH (aq) was heated at 70° C. for 4 h. The mixture was then acidified by 4N HCl (aq) and extracted with EtOAc. The organic layer was washed with brine, dried over Na2SO4, filtered, and filtrate was concentrated to provide the title Compound 27b. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.56 (d, 2H) 7.25 (d, 2H) 2.39 (m, 1H) 1.80 (m, 1H) 1.47 (m, 1H) 1.18 (m, 1H).
- To a solution of Compound 16c (0.140 g, 0.438 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride Compound 27c (0.060 g, 0.313 mmol) in 4 mL acetonitrile at rt was slowly added a solution of Compound 27b (0.072 g, 0.313 mmol) in 2 mL of acetonitrile. After stirring for 2 hours, the mixture was passed through a short column (silica gel, hexanes:EtOAc, 2:1). The collected eluent was concentrated, and the residue was dissolved in AcOH. The reaction was heated at 80° C. for 3 h. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes:EtOAc, 2:1). This material was dissolved in TFA, and the mixture was heated at 60° C. for 2 h. The reaction was concentrated, and the residue was purified by chromatography (silica gel, hexanes:EtOAc, 1:1) to provide the title Compound 190 as a solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.14 (dd, 1H, J=1.2 and 7.6 Hz) 7.74-7.63 (m, 6H) 7.60-7.47 (m, 5H) 7.40 (dd, 1H, J=1.6 and 7.2 Hz) 2.97-2.92 (m, 1H) 2.76-2.71 (m, 1H) 2.12-2.00 (m, 2H) MS (ESI, pos. ion) m/z: 458.3 (M+1).
- To a solution of 4-trifluoromethyl cinnamic acid (3.6 g, 16.7 mmol) in anhydrous methylene chloride (40 mL) was slowly added oxalyl chloride (1.7 mL, 19.5 mmol). To the solution was added anhydrous dimethylformamide (10 μL) and the reaction was stirred at room temperature under an argon atmosphere. After 18 h, the reaction was concentrated. A solution of the residue Compound 10b (16.7 mmol) in methylene chloride (40 mL) was added dropwise to a solution of N,N-dimethylhydroxylamine hydrochloride (1.6 g, 16.7 mmol) and triethylamine (5.8 mL, 41.7 mmol) in methylene chloride (40 mL) at 0° C. The reaction mixture was stirred at 0° C. for 30 min, then warmed to room temperature. After 6 h, the reaction was successively washed with sodium carbonate (10% in water), water and brine. The organic fraction was dried over magnesium sulfate, filtered and the filtrate was concentrated. The compound was purified by chromatography (silica, EtOAc:hexanes, 1:1) to provide the title Compound 28a (2.2 g, 50% over two steps) 1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.96 (d, J=8.3 Hz, 2H) 7.78 (d, J=8.08 Hz, 2H) 7.64 (d, J=15.9 Hz, 1H) 7.24 (d, J=15.9 Hz, 1H) 3.77 (s, 3H) 3.23 (s, 3H).
- Anhydrous dimethylsulfoxide (8 mL) was added dropwise under an argon atmosphere to a mixture of sodium hydride (60% suspension in oil, 0.369 g, 9.2 mmol) and trimethylsulfoxonium iodide (2 g, 9.1 mmol). To the solution was added dropwise Compound 28a (1.2 g, 4.6 mmol) in DMSO (8 mL). The reaction mixture was stirred at room temperature for 18 h. The reaction was poured into ethyl ether:water (1:1, 50 mL). The organic layer was separated and washed successively with water and brine. The organic fraction was dried over magnesium sulfate, filtered and the filtrate was concentrated to provide the title Compound 28b (1.9 g, 90%). 1H-NMR (400 MHz, CDCl3) δ (ppm) 7.55 (d, J=8.08 Hz, 2H) 7.25 (d, J=8.3 Hz, 2H) 3.72 (s, 3H) 3.26 (s, 3H) 2.54-2.59 (m, 1H) 2.43-2.52 (m, 1H) 1.68-1.74 (m, 1H) 1.33-1.38 (m, 1H).
- To a solution of Compound 28b (3.6 g, 13.2 mmol) in tetrahydrofuran (45 mL) was added a solution of potassium-t-butoxide (1M in tetrahydrofuran, 50 mL, 50 mmol). To the reaction was added water (1.5 mL, 83.3 mmol), and the reaction was stirred at room temperature under an argon atmosphere. After 18 h, ice was added to the reaction until it became homogeneous. To the solution was added ethyl ether, and the layers were separated. The aqueous layer was cooled and acidified with 1 M HCl until the pH was 4. The aqueous layer was extracted with ethyl acetate. The ethyl acetate layer was washed successively with water and brine. The organic layer was dried over magnesium sulfate, filtered and the filtrate was concentrated to provide the title Compound 28c (2.2 g, 73%). 1H-NMR (400 MHz, DMSO d6) δ (ppm) 12.4 (s, 1H) 7.62 (d, J=8.08 Hz, 2H) 7.40 (d, J=8.08 Hz, 2H) 2.46-2.54 (m, 1H) 1.88-1.96 (m, 1H) 1.46-1.52 (m, 1H) 1.38-1.44 (m, 1H).
- Using the procedure of Example 1, the title Compound 28d was prepared from Compound 28c and 4-bromobenzene-1,2-diamine. 1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.96 (s, 1H) 7.68-7.75 (m, 3H) 7.60-7.64 (dd, J=1.5, 8.6 Hz, 1H) 7.46-7.56 (m, 4H) 7.10-7.14 (d, J=8.4 Hz, 2H) 2.96-3.02 (m, 1H) 2.70-2.78 (m, 1H) 2.10-2.16 (m, 1H) 2.00-2.08 (m, 1H).
- Using the procedure of Example 10, the title Compound 471 was prepared from Compound 28d and Compound 10e. 1H-NMR (400 MHz, CD3OD) δ (ppm) 12.4 (s, 0.5H) 12.32 (s, 0.5H) 7.88 (m, 1H) 7.65 (d, 2H, J=8.084 Hz) 7.46 (m, 2H) 7.35 (m, 2H) 7.20 (m, 1H) 6.95 (m, 2H) 4.85 (s, 1H) 2.70 (m, 1H) 2.46 (m, 1H) 1.90 (m, 1H) 1.70 (m, 1H) 1.20 (d, 6H). MS (ESI, pos. ion) m/z: 437.2 (M+1).
- Using the procedures described in Example 28 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:
-
Cpd Name and Data 198 2-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.83-7.86 (m, 1H) 7.44-7.49 (bs, 1H) 7.31-7.36 (m, 4H) 7.21-7.26 (m, 3H) 7.055-7.13 (m, 2H) 2.60-2.65 (m, 1H) 2.40-2.44 (m, 1H) 1.84-1.90 (m, 1H) 1.62-1.70 (m, 1H) 1.32 (s, 6H). MS (ESI, pos. ion) m/z: 403.2 (M + 1). 234 2-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-propan-2-ol 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.71-7.74 (dd, J = 1.01, 8.08 Hz, 1H) 7.40-7.45 (m, 4H) 7.33-7.38 (d, J = 8.34 Hz) 7.21-7.26 (m, 2H) 7.08-7.13 (ddd, J = 1.52, 7.58 Hz, 1H) 6.99-7.02 (dd, J = 1.52, 8.34 Hz) 6.93-6.97 (dd, J = 1.52, 7.58 Hz, 1H) 2.60-2.66 (m, 1H) 2.37-2.42 (m, 1H) 1.78-1.84 (m, 1H) 1.59-1.65 (m, 1H) 1.22 (s, 6H). MS (ESI, pos. ion) m/z: 437.3 (M + 1). 467 N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.52-7.62 (m, 5H) 7.33-7.41 (m, 4H) 7.24-7.32 (m, 2H) 2.70 (m, 4H) 2.48-2.53 (m, 1H) 1.90-1.96 (m, 1H) 1.69-1.75 (m, 1H). MS (ESI, pos. ion) m/z: 472.2 (M + 1), 472 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenol 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.70 (bs, 1H) 7.61 (d, 2H, J = 8.34 Hz) 7.51 (m, 3H) 7.42 (m, 3H) 7.30 (m, 1H) 7.15 (m, 1H) 6.93 (m, 2H) 2.72 (m, 1H) 2.50 (m, 1H) 1.93 (m, 1H) 1.74 (m, 1H). MS (ESI, pos. ion) m/z: 395.2 (M + 1), 474 (2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanol 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.62 (m, 3H) 7.50 (m, 4H) 7.35 (m, 3H) 7.20 (m, 1H) 4.50 (s, 2H) 2.73 (m, 1H) 2.52 (m, 1H) 1.95 (m, 1H) 1.78 (m, 1H). MS (ESI, pos. ion) m/z: 409.1 (M + 1). 494 2-(2-{2-[2-(4-methoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.83-7.86 (m, 1H) 7.44-7.49 (d, J = 8.08 Hz, 1H) 7.34-7.40 (m, 2H) 7.14-7.28 (m, 3H) 7.12-7.18 (m, 2H) 3.80 (s, 3H) 2.60-2.65 (m, 1H) 2.31-2.35 (m, 1H) 1.78-1.82 (m, 1H) 1.62-1.70 (m, 1H) 1.34 (s, 6H). MS (ESI, pos. ion) m/z: 399.1 (M + 1). 497 2-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-propan-2-ol 1H-NMR (400 MHz, DMSO d6) δ (ppm) 12.30-12.40 (d, 1H) 7.84-7.87 (d, J = 7.83 Hz, 1H) 7.45-7.48 (d, J = 7.83 Hz, 1H) 7.29-7.40 (m, 6H) 7.17-7.23 (m, 1H) 6.96-7.10 (m, 2H) 2.60-2.67 (m, 1H) 2.38-2.43 (m, 1H) 1.81-1.86 (m, 1H) 1.62-1.68 (m, 1H) 1.20 (s, 6H). MS (ESI, pos. ion) m/z: 453.3 (M + 1). 498 2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzamide 1H-NMR (400 MHz, DMSO d6) δ (ppm) 12.5 (bs, 1H) 7.68-7.72 (d, J = 8.08 Hz, 2H) 7.40-7.60 (m, 7H) 7.28 (s, 1H) 7.21-7.25 (dd, J = 1.77, 8.34 Hz, 1H) 2.70-2.78 (m, 1H) 2.44-2.53 (m, 1H) 1.90-1.99 (m, 1H) 1.70-1.80 (m, 1H). MS (ESI, pos. ion) m/z: 422.2 (M + 1). 499 N-tert-butyl-2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-benzenesulfonamide 1H-NMR (400 MHz, DMSO d6) δ (ppm) 12.40 (s, 1H) 8.2-8.3 (d, J = 9.34 Hz, 1H) 7.30-7.70 (m, 9H) 7.10-7.15 (m, 1H) 6.28-6.32 (m, 1H) 2.64-2.72 (m, 1H) 1.90-1.94 (m, 1H) 1.70-1.75 (m, 1H) 0.90 (s, 9H). MS (ESI, pos. ion) m/z: 514.2 (M + 1). 500 5-(2-methanesulfonyl-phenyl)-2-[2-(4-trifluoromethyl-phenyl)- cyclopropyl]-1H-benzimidazole 1H-NMR (400 MHz, DMSO d6) δ (ppm) 8.12-8.15 (dd, J = 1.26, 7.83 Hz, 1H) 7.70-7.83 (m, 6H) 7.53-7.57 (d, J = 8.08 Hz, 2H) 7.42-7.47 (ddd, J = 1.26, 7.32 Hz, 2H) 2.93-3.00 (m, 1H) 2.66-2.74 (m, 1H) 2.06-2.13 (m, 1H) 1.97-2.03 (m, 1H). MS (ESI, pos. ion) m/z: 457.1 (M + 1). - Using the procedures of Examples 27 or 28, and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared.
-
Cpd Name and Data 189 2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 191 2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 192 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 193 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 194 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)- cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 195 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 196 1-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 197 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 199 2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 200 N-(2-{2-[2-(4-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 201 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-ethanone, 202 1-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-ethanol, 203 N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-methanesulfonamide, 204 2-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5- yl}-phenyl)-propan-2-ol, 205 2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 206 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 207 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanone, 208 1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-ethanol, 209 N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]- cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 210 2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-propan-2-ol, 211 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-benzenesulfonamide, 212 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenyl]-cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 213 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 214 1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 215 N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 216 2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 217 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}-1H-benzimidazol-5- yl)-benzenesulfonamide, 218 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-cyclopropyl}- 1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 219 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanone, 220 1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-ethanol, 221 N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-methanesulfonamide, 222 2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-phenyl]-propan-2-ol, 223 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-cyclopropyl}-1H- benzimidazol-5-yl)-benzenesulfonamide, 224 C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]- cyclopropyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide, 225 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanone, 226 1-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- ethanol, 227 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- methanesulfonamide, 228 2-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- propan-2-ol, 229 2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 230 N-(2-{2-[2-(3-chloro-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 231 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 232 1-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 233 N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 235 2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 236 C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 237 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)- methanesulfonamide, 238 N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}- cyclopropyl)-phenyl]-methanesulfonamide, 239 N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 240 N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}- cyclopropyl)-phenyl]-methanesulfonamide, 241 2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 242 C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-cyclopropyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 243 N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-cyclopropyl}-phenyl)- C,C,C-trifluoro-methanesulfonamide, 244 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol- 2-yl}-cyclopropyl)-phenyl]-methanesulfonamide, 245 C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl]-cyclopropyl}-phenyl)-methanesulfonamide, 246 C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl}-cyclopropyl)-phenyl]-methanesulfonamide, 247 2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, and 248 C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)- cyclopropyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide. - A mixture of 4-bromo-benzene-1,2-diamine dihydrochloride (1.3 g, 5 mmol), phenylpropiolic acid (0.73 g, 5 mmol) in 4 mL of ethylene glycol was heated to reflux for 5 h. The mixture was cooled to rt and poured into water. The mixture was neutralized with 2N sodium hydroxide and filtered. The solid was suspended in water and extracted with ethyl acetate. The organic layers were combined, dried with anhydrous sodium sulfate, and filtered. The filtrate was concentrated to yield a red oil. The residue was purified using preparative TLC plates twice (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 3:7 and silica gel, 20×20 cm, 2000 microns, EtOAc:dichloromethane 3:97) to provide a mixture of cis and trans isomers of the title Compound 30a (0.345 g). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 12.59 (m, 1H), 7.86-7.78 (m, 3H), 7.64-7.56 (m, 1H), 7.54-7.49 (m, 3H), 7.46 (s, 1H), 7.40-7.34 (m, 1H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C15H10BrClN2: 333.0 (M+H). Found 333.1.
- A mixture of Compound 30a (25 mg, 0.075 mmol), Compound 10e (18 mg, 0.113 mmol) and Pd(dppf)Cl2CH2Cl2 (12 mg, 0.015 mmol) in 3 mL of DME and sodium carbonate solution (1.0 M, 0.6 mL) was heated at 150° C. for 1 h in a Biotage Initiator™ microwave synthesizer. The mixture was filtered through a pad of silica gel. The reaction was repeated total three times. The residues were combined and purified using preparative TLC plates twice (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 3:7 and then silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes:methanol 2:8:1) to provide the title Compound 489 (8.4 mg). 1H NMR (400 MHz, CD3OD) δ (ppm): 7.78 (dd, 1H, J=8.1, 1.1 Hz, 1H), 7.62-7.60 (m, 2H), 7.52 (d, 1H, J=8.3 Hz), 7.46-7.38 (m, 4H), 7.31 (dt, 1H, J=1.5, 8.0 Hz), 7.21-7.17 (m, 2H), 7.02 (dd, J=7.5, 1.3 Hz, 1H), 1.30 (s, 6H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C24H20N2O: 353.2 (M+H). Found 353.3.
- A mixture of Compound 30a (25 mg, 0.075 mmol), 2-(tert-butylamino)sulfonylphenyl boronic acid (29 mg, 0.113 mmol), and Pd(dppf)Cl2.CH2Cl2 (12 mg, 0.015 mmol) in 3 mL of DME and sodium carbonate solution (1.0 M, 0.6 mL) was heated at 150° C. for 1 h in a Biotage Initiator™ microwave synthesizer. The mixture was filtered through a pad silica gel. The residue was purified by preparative TLC (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 3:7) to provide the title Compound 31a (12.8 mg). Mass Spectrum (LCMS, APCI pos.) Calcd. For C25H23N3O2S: 430.2 (M+H). Found 430.3.
- A mixture of Compound 31a (14.9 mg, 0.034 mmol) in trifluoroacetic acid and 1,2-dichloroethane (2 mL, 1:1) was heated at 90° C. for 3 h. The reaction was cooled to rt, and concentrated under reduced pressure. The residue was dissolved in dichloromethane, and washed with saturated sodium bicarbonate solution. The aqueous layer was extracted twice with ethyl acetate. The organic layers were combined, dried with anhydrous magnesium sulfate, filtered, and the filtrate was removed under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes:methanol 5:5:1) to provide the title Compound 490 (12.1 mg). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.11 (dd, 1H, J=8.0, 1.2 Hz), 7.67-7.56 (m, 5H), 7.52 (ddd, 1H, J=7.6, 6.4, 1.4 Hz), 7.48-7.33 (m, 5H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C21H15N3O2S: 374.1 (M+H). Found 374.2.
- Using the procedures described in Examples 30 and 31, and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared from the corresponding vinyl derivatives:
-
Cpd Name and Data 250 2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide 1H NMR (400 MHz, CD3OD) δ (ppm): 8.04 (dd, 1H, J = 8.0, 1.2 Hz), 7.76 (d, J2H, = 8.2 Hz), 7.69 (d, 2H, J = 8.2 Hz), 7.58-7.53 (m, 2H), 7.54 (dt, 1H, J = 1.4, 7.5 Hz), 7.46 (dt, 1H, J = 1.4, 7.7 Hz), 7.31 (dd, 1H, J = 7.5, 1.3 Hz), 7.30 (dd, 1H, J = 8.4, 0.9 Hz). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H14F3N3O2S: 442.1 (M + H), Found 442.2. 294 2-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol 1H NMR (400 MHz, CD3OD) δ (ppm): 7.94 (s, 1H), 7.89 (d, 1H, J = 7.7 Hz), 7.80-7.74 (m, 2H), 7.66 (t, 1H, J = 7.8 Hz, 1H), 7.60-7.39 (m, 2H), 7.33 (m, 1H), 7.28-7.18 (m, 2H), 7.04 (dd, 1H, J = 7.5, 1.4 Hz, 1H), 1.32 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C25H19F3N2O: 421.1 (M + H), Found 421.3. 295 2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide 1H NMR (400 MHz, CD3OD) δ (ppm): 8.11 (dd, 1H, J = 8.0, 1.2 Hz), 7.94 (s, 1H), 7.89 (dm, 1H, J = 7.6 Hz), 7.77 (dm, 1H, J = 7.9 Hz), 7.67-7.58 (m, 4H), 7.52 (m, 1H), 7.38 (dd, J = 7.5, 1.3 Hz, 1H), 7.37 (br s, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C22H14F3N3O2S: 442.1 (M + H), Found 442.2 492 2-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol 1H NMR (400 MHz, CD3OD) δ (ppm): 7.83 (d, 2H, J = 8.2 Hz), 7.79 (dd, 1H, J = 8.2 1.1 Hz, 1H), 7.76 (d, 2H, J = 8.3 Hz), 7.64-7.37 (m, 2H), 7.33 (m, 1H), 7.22 (br d, 1H, J = 7.2 Hz), 7.20 (dt, 1H, J = 1.3, 7.4 Hz), 7.04 (dd, 1H, J = 7.5, 1.4 Hz), 1.32 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C25H19F3N2O: 421.1 (M + H), Found 421.3. Preparation of (4-trifluoromethylphenyl)propynoic acid. To a solution of 4- ethynyl-α,α,α-trifluorotoluene (5 g, 29 mmol) in anhydrous THF (25 mL), was slowly added n-butyllithium 2.6M in hexanes (14.5 mL, 47 mmol). The mixture was stirred at −78° C. for 30 min and then at 0° C. for an additional 30 min. The mixture was cooled to −78° C. and transferred via a cannula to a saturated solution of carbon dioxide in anhydrous THF (25 mL) at −78° C. The mixture was stirred and allowed to warm to rt over 18 h. The mixture was quenched with saturated sodium chloride solution, and the two layers were separated. The aqueous layer was washed with hexanes and then acidified with 2N hydrochloric acid. The aqueous layer was extracted twice with ethyl acetate. The organic layers were combined and dried with anhydrous sodium sulfate and magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure to yield the title Compound 31b as a white solid (5.4 g, 87%). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 7.81 (s, 4H). Compound 31b was carried forward using the procedure of Example 31 to provide the title Compound 492. - Using the procedures of Examples 30 or 31, the corresponding bromobenzimidazole and, when not commercially available, the arylacetylenic acid precursors prepared as described in Reaction Scheme KK and reagents, starting materials and conditions known to those skilled in the art, the following prophetic compounds representative of the present invention may be prepared. Alternatively, the following compounds may be prepared from their corresponding vinyl compounds by hydrogenation:
-
Cpd Name and Data 249 2-[2-(4-trifluoromethoxy-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 251 2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 252 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethoxy-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 253 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethyl-phenylethynyl)-1H-benzimidazol- 5-yl]-phenyl}-methanesulfonamide, 254 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonyl-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 255 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone, 256 1-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol, 257 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 258 2-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2-ol, 259 2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 260 N-{2-[2-(4-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 261 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanone, 262 1-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanol, 263 N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- phenyl}-methanesulfonamide, 264 2-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- propan-2-ol, 265 2-[2-(4-methanesulfonyl-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 266 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonyl-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 267 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 268 1-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanol, 269 N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 270 2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 271 2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-benzenesulfonamide, 272 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)- phenylethynyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 273 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-ethanone, 274 1-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-ethanol, 275 N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-methanesulfonamide, 276 2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- phenyl)-propan-2-ol, 277 2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H-benzimidazol-5-yl}- benzenesulfonamide, 278 C,C,C-trifluoro-N-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 279 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanone, 280 1-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-ethanol, 281 N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-methanesulfonamide, 282 2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol, 283 2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide, 284 C,C,C-trifluoro-N-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenylethynyl]- 1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide, 285 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanone, 286 2-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-propan-2- ol, 287 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 288 1-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-ethanol, 289 2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 290 N-{2-[2-(3-chloro-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 291 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanone, 292 1-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- ethanol, 293 N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol-5-yl]-phenyl}- methanesulfonamide, 296 C,C,C-trifluoro-N-{2-[2-(3-trifluoromethyl-phenylethynyl)-1H-benzimidazol- 5-yl]-phenyl}-methanesulfonamide, 297 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}- methanesulfonamide, 298 N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl-ethynyl}- phenyl)-methanesulfonamide, 299 N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]- phenyl}-methanesulfonamide, 300 N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl- ethynyl}-phenyl)-methanesulfonamide, 301 2-[2-(4-methanesulfonylamino-phenylethynyl)-1H-benzimidazol-5-yl]- benzenesulfonamide, 302 C,C,C-trifluoro-N-{2-[2-(4-methanesulfonylamino-phenylethynyl)-1H- benzimidazol-5-yl]-phenyl}-methanesulfonamide, 303 N-{4-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl-ethynyl]-phenyl}-C,C,C- trifluoro-methanesulfonamide, 304 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl- ethynyl}-phenyl)-methanesulfonamide, 305 C,C,C-trifluoro-N-{4-[5-(2-methanesulfonylamino-phenyl)-1H- benzimidazol-2-yl-ethynyl]-phenyl}-methanesulfonamide, 306 C,C,C-trifluoro-N-(4-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H- benzimidazol-2-yl-ethynyl}-phenyl)-methanesulfonamide, 307 2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)-1H-benzimidazol-5- yl]-benzenesulfonamide, and 308 C,C,C-trifluoro-N-{2-[2-(4-trifluoromethanesulfonylamino-phenylethynyl)- 1H-benzimidazol-5-yl]-phenyl}-methanesulfonamide. - A mixture of 4-bromo-benzene-1,2-diamine (200 mg, 1.07 mmol) and 2-chloroacetimidic acid ethyl ester hydrochloride salt (168 mg, 1.07 mmol; prepared according to the procedure described in J. Med. Chem. 1986, 29, 2280) in anhydrous ethanol (200 proof, 5 mL) was stirred at room temperature for 4 h. The reaction mixture was concentrated under reduced pressure and extracted with ethyl acetate and water. The organic layer was dried over Na2SO4, filtered, and the filtrate was concentrated in vacuo to provide the title Compound 33a as an off-white solid (240 mg, 92% yield). 1H NMR (400 MHz, CDCl3) δ (ppm): 7.75 (d, 1H, J=1.4 Hz), 7.47 (d, 1H, J=8.6 Hz), 7.42 (dd, 1H, J=8.6 Hz, J=1.3 Hz), 4.84 (s, 2H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C18H20ClN3O2S: 247.50 (M+H). Found 247.0.
- A mixture of Compound 33a (240 mg, 0.98 mmol) and triphenylphosphine (385 mg, 1.47 mmol), in 1,2-dichloroethane (10 mL) was heated at 140° C. for 1 h. The reaction mixture was concentrated under reduced pressure to provide the title Compound 33b, which was used in the next step without further purification.
- A mixture of Compound 33b (100 mg, 0.204 mmol), 6-quinolinecarboxaldehyde (32 mg, 0.29 mmol) and DBU (39.6 uL, 0.265 mmol) in ethanol:tetrahydrofuran (1:1, 2 mL) was stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure, and the residue was purified by reverse phase preparative HPLC (10-100% gradient acetonitrile/water over 10 min) to provide the title Compound 33c as an off-white solid (50 mg, 72 yield). Calcd. For C18H12BrN3: 350.21 (M+H). Found 350.2.
- A mixture of Compound 33c (50.0 mg, 0.143 mmol), Compound 10e (46 mg, 0.29 mmol), PdCl2(dppf) (23.4 mg, 0.029 mmol) and 1M sodium bicarbonate solution (1.15 mL, 1.15 mmol) in 1,2-dimethoxyethane (1 mL) was heated at reflux for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography (silica, EtOAc) to provide the title Compound 449 as an off-white solid (11.8 mg, 20% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 9.01 (br s, 1H), 8.68 (d, 1H, J=8.1 Hz), 8.35 (m, 2H), 8.12-8.21 (m, 2H), 7.76 (m, 3H), 7.67 (s, 1H), 7.53 (m, 2H), 7.38-7.43 (m, 1H), 7.28 (m, 1H), 7.09 (m, 1H), 1.42 (s, 6H). Calcd. For C27H23N3O: 406.5 (M+H). Found 406.3.
- Using the procedures described in Example 33 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 448 (E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2- yl}-vinyl)-phenyl]-ethanone The title compound was prepared from Compound 33b (100 mg, 0.204 mmol) and 4-acetylbenzaldehyde (30.2 mg, 0.204 mmol) as an off-white solid (3.75 mg, 10% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.06 (d, 1H, J = 8.8 Hz), 7.96 (m, 1H), 7.80 (m, 3H), 7.68 (m, 1H), 7.55 (m, 1H), 7.43 (m, 1H), 7.34 (m, 2H), 7.17-7.24 (m, 2H), 7.07 (m, 1H), 2.63 (s, 3H), 1.35 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C26H24N2O2: 397.5 (M + H), Found 397.3. 450 (E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2- yl]-vinyl}-benzamide The title compound was prepared from [5-(2-methylsulfamoyl-phenyl)-1H- benzimidazol-2-ylmethyl]-triphenyl-phosphonium chloride Compound 33c (90 mg, 0.15 mmol) and 4-carboxyaldehyde-N-isopropylbenzamide (24.3 mg, 0.15 mmol) as an off-white solid (10.5 mg, 15% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.06 (dd, 1H, J = 8.1, Hz, J = 1.5 Hz), 7.87 (m, 2H), 7.55-7.74 (m, 7H), 7.43 (dd, 1H, J = 8.1 Hz, J = 1.5 Hz), 7.29 (m, 2H), 4.22 (m, 1H), 2.37 (s, 3H), 1.26 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C26H26N4O3S: 475.5 (M + H), Found 475.2. 451 (E)-2-{2-[2-(4-cyano-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and 4-cyanobenzaldehyde (19.6 mg, 0.15 mmol) as an off-white solid (7.4 mg, 12% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.07 (dd, 1H, J = 8.0 Hz, J = 1.0 Hz), 7.49-7.69 (m. 8H), 7.37 (m, 2H), 7.20 (m, 2H), 2.32 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H18N4O2S: 415.5 (M + H), Found 415.2. 452 (E)-N-(4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}- phenyl)-acetamide The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and 4-acetamidobenzaldehyde (24.3 mg, 0.15 mmol) as an off-white solid (11.3 mg, 17% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.04 (dd, 1H, J = 8.0 Hz, J = 1.3 Hz), 7.63 (td, 1H, J = 7.4 Hz, J = 1.4 Hz), 7.55 (m, 5H), 7.26-7.39 (m, 5H), 7.19 (dd, 1H, J = 8.1 Hz, J = 1.5 Hz), 2.22 (s, 3H), 2.03 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C24H22N4O3S: 447.5 (M + H), Found 447.2. 453 (E)-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}- benzoic acid The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and 4-carboxybenzaldehyde (22.4 mg, 0.15 mmol) as an off-white solid (3.4 mg, 5% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.02 (m, 2H), 7.53-7.77 (m, 6H), 7.18-7.45 (m, 5H), 2.36 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C23H19N3O4S: 434.5 (M + H), Found 434.2. 454 (E)-2-{2-[2-(1H-indol-6-yl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and indole-6-carboxaldehyde (21.6 mg, 0.15 mmol) as an off-white solid (6.5 mg, 10% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.06 (m, 1H), 7.05-7.73 (m, 11H), 6.48 (m, 2H), 2.36 (m, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C24H20N4O2S: 429.5 (M + H), Found 429.2. 455 (E)-2-{2-[2-(2,4-bis-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N- methyl-benzenesulfonamide The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and 2,4-bis(trifluoromethyl)benzaldehyde (24.4 uL, 0.15 mmol) as an off-white solid (8.62 mg, 11% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 7.14-8.17 (m, 12H), 2.44 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C24H17F6N3O2S: 526.5 (M + H), Found 526.3. 456 (E)-2-{2-[2-(4-acetyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-N-methyl- benzenesulfonamide The title compound was prepared from Compound 33c (90 mg, 0.15 mmol) and 4-acetylbenzaldehyde (22.1 mg, 0.15 mmol) as an off-white solid (8.32 mg, 13% yield). 1H NMR (400 MHz, CD3OD) δ (ppm): 8.06 (m, 3H), 7.56-7.79 (m, 9H), 7.44 (m, 1H), 2.62 (s, 3H), 2.37 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd. For C24H21N3O3S: 432.5 (M + H), Found 432.2. - A mixture of Compound 10c (52 mg, 0.14 mmol), 2-cyanophenylboronic acid (38 mg, 0.26 mmol), Pd(dppf)Cl2CH2Cl2 (36 mg, 0.044 mmol), tetrabutylammonium bromide (55 mg, 0.17 mmol), and sodium carbonate (1 mL, 1.0 M) in DME (5 mL) was heated at 90° C. for 18 h. The mixture was cooled to rt, filtered through a pad of Celite and concentrated under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20×20 cm, 2000 microns, EtOAc:hexanes 1:1 and hexanes:dichloromethane:methanol 6:14:1) to provide the title Compound 34a (20 mg, 37%). 1H NMR (400 MHz, CD3OD+CDCl3) δ (ppm): 7.72-7.47 (m, 10H), 7.40-7.30 (m, 3H), 7.14 (d, 1H, J=16.55 Hz). Mass Spectrum (LCMS, APCI pos.) Calcd. For C23H14F3N3:.390.1 (M+H). Found 390.3.
- A mixture of Compound 34a (20 mg, 0.051 mmol), Raney®-Nickel, ammonium hydroxide (0.1 mL) in ethanol was hydrogenated under 50 psi for 18 h. The mixture was filtered through a pad of Celite and washed with ethanol. The filtrate was concentrated under reduced pressure. The residue was purified using preparative TLC plates (silica gel, 20×20 cm, 2000 microns, NH3 in methanol:EtOAc 1:9) to provide the title Compound 486 (6.3 mg, 31%). 1H NMR (400 MHz, CD3OD) δ (ppm): 7.57-7.52 (m, 4H), 7.46-7.34 (m, 6H), 7.14 (dd, J=8.2, 1.5 Hz, 1H), 4.05 (s, 2H), 3.24 (s, 4H). Mass Spectrum (LCMS, APCI pos.) Calcd. For C23H20F3N3: 396.2 (M+H). Found 396.2.
- A solution of Compound 18 (0.030 g, 0.07 mmol) in DMSO (5 mL) was stirred at room temperature for 5 days under a 60 W light bulb. The reaction was then applied to a 2000 micron prep TLC plate (20×20 cm) and developed using ethyl acetate:hexanes 4:6. The desired band was extracted with MeOH, filtered and concentrated to provide the title Compound 469 (0.001 g). 1H-NMR (400 MHz, DMSO d6) δ (ppm) 7.71 (dd, J=1.01, 8.34 Hz, 1H) 7.53 (s, 4H) 7.37-7.41 (m, 1H) 7.21-7.28 (m, 2H) 7.11 (dt, J=1.26, 7.33 Hz, 1H) 7.05 (dd, J=1.52, 8.34 Hz, 1H), 6.94-7.10 (m, 4H) 6.67 (d, 12.6 Hz, 1H) 1.23 (s, 6H). MS (ESI, pos. ion) m/z: 423.2 (M+1).
- To a solution of sodium hydride (60% suspension in oil, 0.131 g, 3.2 mmol) in anhydrous tetrahydrofuran (10 mL) was added Compound 10c (1 g, 2.7 mmol). The solution was stirred at room temperature under an argon atmosphere. After five minutes methyl iodide was added (0.205 mL, 3.2 mmol), and the solution was stirred at room temperature for 3 h. The reaction mixture was partitioned between ethyl acetate (10 mL) and ice water (20 mL). The organic fraction was washed with brine, dried over magnesium sulfate, then filtered and concentrated to give a 1:1 mixture of the title Compound 36a and 36b (0.38 g).
- Using the procedure of Example 1, Step B, the title compounds were prepared from a mixture of (E)-5-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and (E)-6-bromo-1-methyl-2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazole and 2-methylsulfonylaminophenyl boronic acid.
- Cpd 443: 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.82-7.80 (m, 3H) 7.75 (d, J=8.1 Hz, 3H) 7.52-7.62 (m, 3H) 7.34-7.42 (m, 4H) 4.00 (s, 3H) 2.76 (s, 3H). MS (ESI, pos. ion) m/z: 472.1 (M+1).
- Cpd 477: 1H-NMR (400 MHz, CD3OD) δ (ppm) 7.88-7.95 (m, 3H) 7.72-7.77 (m, 3H) 7.56-7.67 (m, 4H) 7.40-7.44 (m, 3H) 4.10 (s, 3H) 2.73 (s, 3H). MS (ESI, pos. ion) m/z: 472.1 (M+1).
- To a solution of Compound 15 (0.20 g, 0.492 mmol) in 16 mL 1,2-dichloroethane was added TBSOTf (0.19 mL, 1.08 mmol) and Et3N (0.27 mL, 1.97 mmol) at 0° C. After 5 min., the mixture was warmed to 25° C. and stirred for 8 hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes:EtOAc, 4:1) to provide the title Compound 37a as a colorless oil.
- A mixture of Compound 37a (0.124 g, 0.238 mmol) and mCPBA (0.053 g, 0.238 mmol) in 10 mL CH2Cl2 was stirred for two hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes:EtOAc, 4:1) to provide the title Compound 37b as a yellow oil.
- A mixture of Compound 37b (0.026 g, 0.048 mmol) and p-toluenesulfonic acid monohydrate (p-TsOHH2O, 0.018 g, 0.0968 mmol) in 4 mL THF was stirred for four hours. The reaction was concentrated and the residue was purified by chromatography (silica gel, hexanes:EtOAc, 1:2) to provide the title Compound 311 as a brown solid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.85 (d, 2H, J=8.8 Hz) 7.74 (d, 2H, J=7.6 Hz) 7.71 (d, 1H, J=16.4 Hz) 7.63-7.47 (m, 6H) 7.33 (d, 1H, J=16.0 Hz) 7.25 (dd, 1H, J=1.6 and 8.4 Hz) 4.08 (s, 2H) MS (ESI, pos. ion) m/z: 423.3 (M+1).
- To a suspension of copper(I) trifluoromethanesulfonate toluene complex (31.0 mg, 0.12 mmol) in anhydrous CHCl3 (3.0 mL) was added a solution of 2,2-bis-[(4S)-(1,1-dimethylethyl)-1,3-oxazolin-2-yl]propane (35 mg, 0.12 mmol) in chloroform (1.2 mL). After stirring at ambient temperature for 1 h, the resulting green solution was filtered through glass wool under argon atmosphere into a flask previously charged with a solution of 4-(trifluoromethyl)-styrene (0.887 mL, 6.00 mmol) in chloroform (0.9 mL). To this solution was added a solution of ethyl diazoacetate (1.56 mL, 15.0 mmol) in chloroform (12.0 mL) at ambient temperature through a dropping funnel over a period of 6 h. The resulting mixture was stirred for 24 h, concentrated to dryness, and purified by flash chromatography on a silica gel column (45 mm×140 mm silica gel), eluting with ethyl acetate/hexane (1, 1.5, 2%) to provide the title Compound 38a (892 mg, 58% yield, 98% ee) as a colorless liquid, and cis isomer (1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester Compound 38b (128 mg, 5% yield calculated based on 34 wt % contamination of ethyl fumarate as analyzed by 1 NMR). The enantiomeric excess of the product was determined as described in Step E below.
- 1H-NMR of Compound 38a (400 MHz, CDCl3) δ (ppm): 7.53 (d, 2H, J=8.3 Hz), 7.23 (d, 2H, J=8.1 Hz), 4.18 (q, 2H, J=7.1 Hz), 2.55 (dd, 1H, J=2.6, 4.3, & 6.6 Hz), 1.94 (ddd, 1H, J=4.3, 5.6, & 9.6 Hz), 1.68-1.53 (m, 1H), 1.34 (1H, ddd, 4.8, 6.7, & 1.1 Hz), 1.29 (t, 2H, J=7.0 Hz).
- 1H-NMR of Compound 38b (400 MHz, CDCl3) δ (ppm): 7.51 (d, 2H, J=7.9 Hz), 7.37 (d, 2H, J=7.8 Hz), 3.92-3.86 (m, 2H), 2.62-2.56 (m, 1H), 2.14 (ddd, 1H, J=5.8, 8.1 & 9.3 Hz), 1.73 (td, 1H, J=5.3 & 7.6 Hz), 1.39 (ddd, 1H, J=5.1, 7.8 & 8.6 Hz), 0.99 (t, 3H, J=7.1 Hz).
- To a solution of Compound 38a (750 mg, 2.91 mmol) in ethanol (7.27 mL) was added a 1M aqueous solution of NaOH (7.27 mL). The resulting mixture was stirred at ambient temperature for 16 h, concentrated to about 4 g, acidified with 2M HCl to pH 3, and extracted with ethyl acetate (15 mL×2). The extracts were combined, washed with brine, dried over Na2SO4, concentrated to provide the title Compound 38c (611 mg, 91% yield) as a white solid. 1H-NMR (400 MHz, CDCl3 with a drop of CD3OD) δ (ppm): 7.51 (d, 2H, J=8.3 Hz), 7.18 (d, 2H, J=8.1 Hz), 2.57 (ddd, 1H, J=4.2, 6.6, & 10.3 Hz), 1.90 (ddd, 1H, J=4.0, 5.3, & 8.3 Hz), 1.65 (dt, 1H, J=4.9 & 9.3 Hz), 1.35 (ddd, 1H, J=4.9, 6.4, & 11.1 Hz).
- Using the procedure of Example 10, Steps B and E, the title Compound 501 was prepared from Compound 38c. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 12.40 (s, 0.5H), 12.32 (s, 0.5H), 7.87-7.84 (m, 1H), 7.66 (d, 2H, J=8.0 Hz), 7.49-7.17 (m, 6H), 7.00-6.96 (m, 2H), 4.84 (s, 1H), 2.72-2.67 (m, 1H), 2.50-2.46 (m, 1H), 1.92-1.86 (m, 1H), 1.74-1.68 (m, 1H), 1.19 (s, 3H), 1.18 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd for C26H24F3N2O: 437.2. Found 437.3.
- To a mixture of Compound 38c (50 mg, 0.216 mmol), N,O-dimethylhydroxylamine hydrochloride (30 mg, 0.30 mmol), BOP (134 mg, 0.30 mmol), and DMF (0.4 mL) was added DIEA (0.15 mL). The resulting mixture was stirred at ambient temperature for 48 h, concentrated to dryness, and partitioned between saturated NaHCO3 (2 mL) and ethyl acetate (4 mL). The ethyl acetate layer was separated, and the aqueous layer was extracted with ethyl acetate (5 mL×2). All ethyl acetate layers were combined, washed with brine, dried over Na2SO4, concentrated, and purified by prep-TLC, developed with 10% ethyl acetate/DCM to provide Compound 38d (46 mg, 78% yield) as a white solid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.52 (d, 2H, J=8.4 Hz), 7.23 (d, 2H, J=8.1 Hz), 3.70 (s, 3H), 3.24 (s, 3H), 2.56-2.52 (m, 1H), 2.45 (bs, 1H), 2.17-1.67 (m, 1H), 1.34 (ddd, 1H, J=4.6, 6.3, & 8.7 Hz).
- To a solution of Compound 38d (0.8 mg) in CDCl3 (0.6 mL) was added (R)-(+2,2,2-trifluoro-1-(9-anthryl)ethanol portion-wise and the amount of addition was monitored by 1HNMR until base line resolution of the resulting methoxy singlets was achieved. Thus, the enantiomer methoxy singlets were around 3.47 and 3.45 ppm. The integration of these singlets was 99 and 1, respectively; thus providing an ee value of 99%.
- Using the procedure described in Example 38 and reagents, starting materials and conditions known to those skilled in the art, the following compounds representative of the present invention were prepared:
-
Cpd Name and Data 502 2-{2-[(1R,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide Using the procedure of Example 38, the title compound was prepared from Compound 38c and 2-(t-butylamino)sulfonylphenyl boronic acid. 1H-NMR (400 MHz, CDCl3) δ (ppm): 12.42 (s, 0.5H), 12.40 (s, 0.5H), 8.04 (dd, 1H, J = 1.3 & 7.8 Hz), 7.66 (d, 2H, J = 8.3 Hz), 7.63-7.34 (m, 7H), 7.17-7.11 (m, 1H), 7.06 (s, 1H), 7.03 (s, 1H), 2.71-2.65 (m, 1H), 2.50-2.46 (m, 1H), 1.92-1.87 (m, 1H), 1.75-1.70 (m, 1H). Mass Spectrum (LCMS, ESI pos.) Calcd for C23H19F3N3O2S: 458.1 (M + 1). Found 458.2. 503 2-(2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol monosodium salt Using the procedure of Example 38, the title compound was prepared from 2,2- bis-[(4R)-(1,1-dimethylethyl)-1,3-oxazolin-2-yl]propane and 4-(trifluoromethyl)- styrene. To a suspension of N,N′-bis-[(2R)-3,3-dimethyl-1-hydroxybutyl]-2,2-dimethyl- 1,3-propanediamide (83 mg, 0.25 mmol, prepared according to the procedure described in J. Am. Chem. Soc. 1991, 113, 726) in DCM (2.5 mL) was added (diethylamino)sulfur trifluoride (0.066 mL, 0.50 mmol, as described in J. Org. Chem. 2002, 67, 8566 for the formation of oxazoline from hydroxyamide) dropwise at ambient temperature. The resulting mixture was stirred at ambient temperature for 16 h, and poured into saturated NaHCO3 (4.0 mL). The mixture was extracted with DCM (3 × 5 mL). The extracts were combined and dried over Na2SO4, then concentrated and flash chromatographed with ethyl acetate/ DCM (0, 5, 10, and 20%) to provide 2,2-bis-[2-((4R)-(1,1-dimethylethyl)-1,3- oxazolinyl)]propane (53 mg, 72% yield) as a white solid. 1H-NMR was identical to the literature as reported by Evans. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.82 (dd, 1H, J = 1.5 & 8.1 Hz), 7.61 (d, 2H, J = 8.1 Hz), 7.37 (d, 2H, J = 8.1 Hz), 7.24 (dt, 1H, J = 1.8 & 7.3 Hz), 7.15-7.11 (m, 2H), 7.00 (d, 1H, J = 1.5 Hz), 6.98 (dd, 1H, J = 1.5 & 7.3 Hz), 6.52 (d, 1H, J = 7.8 Hz), 4.63 (bs, 1H), 2.52-2.47 (m, 1H), 2.33 (ddd, 1H, J = 4.1, 5.8 & 8.8 Hz), 1.75 (ddd, 1H, J = 3.7, 5.8, & 8.8 Hz), 1.45-1.40 (m, 1H), 1.22 (s, 6H). Mass Spectrum (LCMS, ESI pos.) Calcd for C26H24F3N2O: 437.2. Found 437.2. Analogous to Example 38, step A, both the trans isomer (1S,2S)-2-(4- trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester Compound 38e and the cis isomer (1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid ethyl ester Compound 38f were isolated. 504 2-{2-[(1S,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide Using the procedure described for Compound 503, the title compound was prepared from Compound 38e, 4-(trifluoromethyl)-styrene and 2-(t- butylamino)sulfonylphenyl boronic acid. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 12.41 (s, 0.5H), 12.40 (s, 0.5H), 8.04 (dd, 1H, J = 1.3 & 7.8 Hz), 7.66 (d, 2H, J = 8.3 Hz), 7.63-7.34 (m, 7H), 7.17-7.11 (m, 1H), 7.06 (s, 1H), 7.03 (s, 1H), 2.71-2.65 (m, 1H), 2.50-2.46 (m, 1H), 1.92-1.87 (m, 1H), 1.75-1.70 (m, 1H). MS (ESI, pos. ion) m/z: 458.2 (M + 1). Mass Spectrum (LCMS, ESI pos.) Calcd for C23H19F3N3O2S: 458.1 (M + 1). Found 458.2. 505 2-(2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol Using the procedure described for Compound 503, the title compound was prepared from Compound 38f. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.79 (dd, 1H, J = 1.0 & 8.1 Hz), 7.36-7.15 (m, 8H), 7.01 (t, 1H, J = 1.5 Hz), 6.99 (d, 1H, J = 1.5 Hz), 2.83-2.73 (m, 2H), 2.08-2.03 (m, 1H), 1.71 (td, 1H, J = 8.6 & 5.6 Hz), 1.23 (s, 3H), 1.22 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd for C26H24F3N2O: 437.2. Found 437.3. Determination of ee: To a mixture of (1S,2R)-2-(4-trifluoromethyl-phenyl)- cyclopropanecarboxylic acid (14 mg, 0.0.061 mmol), (S)-(−)-α- methylbenzylamine (10.0 mg, 0.0609 mmol), BOP (27 mg, 0.0609 mmol), and DMF (0.2 mL) was added DIEA (0.023 mL, 0.13 mmol). The resulting solution was stirred at room temperature for 48 h, concentrated to dryness, and partitioned between saturated NaHCO3 (1 mL) and ethyl acetate (3 mL). Ethyl acetate layer was separated, and aqueous was extracted with ethyl acetate (5 mL × 2). All ethyl acetate layers were combined, washed with brine, dried over Na2SO4, concentrated, and purified by prep-TLC, developed with 10% ethyl acetate/DCM to give the title compound (10.1 mg, 70% yield) as a white solid. 1H-NMR (400 MHz, C6D6) δ (ppm): 7.26 (d, 2H, J = 8.1 Hz), 7.03-6.95 (m, 5H), 6.68-6.65 (m, 2H), 4.96-4.89 (m, 1H), 4.79 (bd, 1H, J = 7.6 Hz), 1.80-1.73 (m, 2H), 1.23-1.17 (m, 1H), 1.00 (d, 3H, J = 6.8 Hz), 0.82-0.79 (m, 1H).). In the 1H-NMR doublet of the Me in (1R, 2S, 1′S)-N-(1′-phenethyl)-2-(4-trifluoromethyl- phenyl)-cyclopropanecarboxamide appeared at 0.85 ppm. Integration of this methyl doublet and that of the title compound was 2.5 and 97.5, respectively. 506 2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide Using the procedure of Example 38, the title compound was prepared from Compound 38b and 2-(t-butylamino)sulfonylphenyl boronic acid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.09 (dd, 1H, J = 1.3 & 7.9 Hz), 7.59 (dt, 1H, J = 1.6 & 7.6 Hz), 7.51 (dt, 1H, J = 1.5 & 7.8 Hz), 7.47 (bs, 1H), 7.42-7.29 (m, 6H), 7.19 (dd, 1H, J = 1.7 & 8.3 Hz), 2.84-2.74 (m, 2H), 2.05 (q, 1H, J = 6.3 Hz), 1.72 (td, 1H, J = 8.5 & 5.7 Hz). Mass Spectrum (LCMS, ESI pos.) Calcd for C23H19F3N3O2S: 458.1 (M + 1). Found 458.2. 507 2-(2-{2-[(1R,2S)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H- benzimidazol-5-yl}-phenyl)-propan-2-ol Using the procedure of Example 38, the title compound was prepared using Compound 38b. 1H-NMR (400 MHz, CD3OD) δ (ppm): 7.79 (dd, 1H, J = 1.0 & 8.1 Hz), 7.36-7.15 (m, 8H), 7.01 (t, 1H, J = 1.5 Hz), 6.99 (d, 1H, J = 1.5 Hz), 2.83-2.73 (m, 2H), 2.08-2.03 (m, 1H), 1.71 (td, 1H, J = 8.6 & 5.6 Hz), 1.23 (s, 3H), 1.22 (s, 3H). Mass Spectrum (LCMS, ESI pos.) Calcd for C26H24F3N2O: 437.2. Found 437.3. Determination of ee: Using the procedure described for Compound 506, the amide intermediate of Compound 507 was prepared from (1R,2S)-2-(4- trifluoromethyl-phenyl)-cyclopropanecarboxylic acid Compound 38 g and (S)-(−)- α-methylbenzylamine. 1H-NMR (400 MHz, C6D6) δ (ppm): 7.37 (d, 2H, J = 8.1 Hz), 7.35-7.02 (m, 5H), 6.97-6.95 (m, 2H), 4.95-4.88 (m, 1H), 4.82 (bd, 1H, J = 7.8 Hz), 1.81-1.75 (m, 1H), 1.70 (ddd, 1H, J = 4.8, 5.8 & 7.3 Hz), 1.14 (ddd, 1H, J = 5.6, 7.8 & 9.0 Hz), 0.85 (d, 3H, J = 6.6 Hz), 0.80-0.75 (m, 1H). In the 1H-NMR doublet of the Me in (1S, 2R, 1′S)-N-(1′-phenethyl)-2-(4- trifluoromethyl-phenyl)-cyclopropanecarboxamide appeared at 1.00 ppm. Integration of this methyl doublet and that of the title compound was 3 and 97, respectively. 508 2-{2-[(1S,2R)-2-(4-trifluoromethyl-phenyl)-cyclopropyl]-1H-benzimidazol- 5-yl}-benzenesulfonamide Using the procedure described for Compound 503, the title compound was prepared from Compound 38f and 2-(t-butylamino)sulfonylphenyl boronic acid. 1H-NMR (400 MHz, CD3OD) δ (ppm): 8.09 (dd, 1H, J = 1.3 & 7.9 Hz), 7.59 (dt, 1H, J = 1.6 & 7.6 Hz), 7.51 (dt, 1H, J = 1.5 & 7.8 Hz), 7.47 (bs, 1H), 7.42-7.29 (m, 6H), 7.19 (dd, 1H, J = 1.7 & 8.3 Hz), 2.84-2.74 (m, 2H), 2.05 (q, 1H, J = 6.3 Hz), 1.72 (td, 1H, J = 8.5 & 5.7 Hz). Mass Spectrum (LCMS, ESI pos.) Calcd for C23H19F3N3O2S: 458.1 (M + 1). Found 458.2. - Compounds of the present invention were tested for their ability to inhibit the binding of [3H] RTX to hVR1 receptors in a [3H] RTX binding assay as previously described (Zhang, Sui-Po. Improved ligand binding assays for vanilloid receptors. PCT Int. Appl. (2002), WO 0233411 A1 20020425 AN 2002:315209, and Elfrida G. R. et al., J. Pharmacol. Exp. Ther., 2002, 300(1): 9-17.)
- HEK293 cells were transfected with hVR1 vanilloid receptors and washed with Hank's balanced Salt Solution, dissociated with cell dissociation buffer (Sigma), and then centrifuged at 1000×g for 5 min. Cell pellets were homogenized in cold 20 mM HEPES buffer (pH=7.4), containing 5.8 mM NaCl, 320 mM sucrose, 2 mM MgCl2, 0.75 CaCl2 and 5 mM KCl and centrifuged at 1000×g for 15 min. The resultant supernatant was then centrifuged at 40,000×g for 15 min. The pelleted membranes were stored in a freezer at −80° C.
- Approximately 120 μg protein/ml from membranes were incubated with indicated concentrations of [3H]RTX in 0.5 ml of the HEPES buffer (pH 7.4) containing 0.25 mg/mL fatty acid-free bovine serum albumin at 37° C. for 60 min. The reaction mixture was then cooled to 4° C., and 0.1 mg of αl-acid glycoprotein was added to each sample, which was then incubated at 4° C. for 15 min. The samples were centrifuged at 18,500×g for 15 min. The tip of the microcentrifuge tube containing the pellet was cut off. Bound radioactivity was quantified by scintillation counting. Non-specific binding was measured in the presence of 200 nM unlabeled RTX.
- Data were calculated according to the equation:
-
% inhibition=100%×[(total binding-binding)/(total binding-non specific binding)] - Ki values were calculated using a Prism program.
-
TABLE 1 Cpd Ki (nM) 1 9.7 3 20 4 31 5 17 9 0.9 14 380 15 41 17 8.7 18 6.5 27 1800 32 100 36 820 40 81 50 16 51 6.4 56 120 69 6 70 8.6 71 22 78 6.4 79 18 310 10 312 19 319 6 407 5.7 434 39 - The functional activity of the test compounds was determined by measuring changes in intracellular calcium concentration using a Ca++-sensitive fluorescent dye and FLIPR™ technology. Increases in Ca++ concentration were readily detected upon challenge with capsaicin.
- HEK293 cells expressing hVR1 were grown on poly-D-lysine coated 384 well black-walled plates (BD 354663) and 1 day later loaded with Calcium 3 Dye for 35 min at 37° C., 5% CO2 and then for 25 min at room temperature, and subsequently tested for agonist-induced increases in intracellular Ca2+ levels using FLIPR™ technology. Cells were challenged with test compounds (at varying concentrations) and intracellular Ca2+ was measured for 5 min prior to the addition of capsaicin to all wells to achieve a final concentration of 0.030 μM eliciting about 80% maximal response. IC50 values were determined from concentration-response studies, which were generated using the average of quadruplicate wells for each data point.
- For those compounds tested, an IC50 (nM) value and percent inhibition value is shown in Table 2. Except where indicated, the percent inhibition values were obtained at a test concentration of 1 μM; otherwise: (1)the test concentration was 5 μM. The percent inhibition value is provided for those compounds where an IC50 value was not obtained. The term “NA” means that the data is “not available” because it was not obtained for a particular compound.
-
TABLE 2 Cpd % Inh IC50 1 100 27 2 100 12 3 NA 140 4 78 400 5 100 71 6 12 NA 7 10 NA 8 10 NA 9 99 2 10 94 280 11 100 210 12 100 10 13 82 310 14 49 1000 15 100 120 16 100 45 17 100 8 18 100 4 19 32 NA 20 NA 320 22 NA 18 24 8 NA 25 4 NA 26 6 NA 27 100 260 28 96 250 29 6 NA 30 10 NA 31 NA 13 32 77 380 33 NA 1700 34 (1)75 NA 35 100 41 36 44 NA 37 18 NA 38 89 270 39 98 200 40 99 54 41 90 280 42 100 22 43 58 890 44 95 300 45 100 16 46 100 46 47 100 20 48 33 NA 49 16 NA 50 100 100 51 100 66 52 28 NA 53 98 47 54 20 NA 55 14 NA 56 100 110 57 15 NA 58 87 95 59 80 440 60 7 NA 61 100 75 62 100 200 63 97 260 64 41 NA 65 0 NA 66 98 48 67 98 130 68 NA 329 69 98 6 70 100 7 71 99 22 77 100 76 78 99 5 79 100 7 83 NA >500 84 100 40 85 16 NA 95 81 301 101 NA >500 113 48 NA 114 99 3 129 96 34 130 100 6 131 96 31 139 98 31 145 19 NA 175 100 16 190 94 38 198 95 10 234 7 NA 250 98 19 294 101 9.1 295 100 16 309 73 NA 310 100 6 311 99 54 312 100 6 314 100 18 315 100 11 316 101 12 317 101 11 318 100 50 319 100 10 320 100 13 321 100 18 322 101 14 323 97 40 324 98 33 325 73 NA 326 89 157 327 77 343 328 99 35 329 98 27 330 85 131 331 97 43 332 98 49 333 98 27 334 94 178 335 100 47 336 89 240 337 96 14 338 96 104 339 99 27 340 98 62 341 99 6 342 98 24 343 82 243 344 101 24 345 101 13 346 87 264 347 100 44 348 86 162 349 99 59 350 100 33 351 NA >500 357 100 8 358 99 9 359 98 24 360 98 46 361 97 27 362 99 8 363 98 12 364 97 65 365 99 17 366 99 35 367 98 53 368 99 15 369 99 8 370 98 13 371 98 18 372 97 71 373 99 20 374 99 34 375 97 139 376 100 28 378 100 12 379 99 40 380 99 12 383 96 11 384 98 7 385 97 21 386 96 43 387 98 41 388 99 54 389 23 NA 390 96 7 391 95 8 392 97 10 393 98 10 394 98 6 395 99 15 396 99 13 397 99 23 398 97 3 399 97 3 402 93 38 404 94 47 405 95 20 406 97 170 407 96 9 408 64 NA 409 43 NA 410 91 156 411 85 350 412 86 190 413 82 240 414 98 140 415 95 150 416 96 120 417 100 11 418 100 18 419 93 32 420 93 15 421 95 10 422 98 7 423 99 11 424 99 11 425 2 NA 426 99 22 427 98 13 428 100 7 429 98 6 430 100 9 431 97 35 432 98 15 433 98 10 434 98 7 435 97 20 436 96 10 437 97 24 438 96 71 439 97 23 440 98 40 441 40 NA 442 96 4 444 98 28 445 96 20 446 97 76 447 98 44 448 99 17 449 100 9 450 27 NA 451 101 28 452 5 NA 453 22 NA 454 36 NA 455 100 17 456 100 45 457 22 NA 458 15 NA 459 0 NA 460 21 NA 461 99 5 462 98 97 463 100 14 464 100 3 465 75 363 466 98 71 467 86 182 468 97 8 469 99 7 470 97 45 471 100 10 472 NA >500 473 NA >500 474 NA >500 475 NA 77 476 NA 68 477 44 NA 478 NA >500 479 12 NA 480 NA >500 481 42 NA 482 100 13 483 21 NA 484 NA >500 485 NA >500 486 NA >500 487 20 NA 488 4 NA 489 96 2 490 99 26 491 NA 77 492 99 5 494 93 52 497 94 39 498 100 19 499 7 NA 500 97 19 501 99 85 502 82 190 503 93 10 504 95 22 - Compounds of the present invention were tested in animal models of inflammation and inflammatory pain. To assess the ability of test compounds to reverse thermal hyperalgesia, baseline response latencies on a radiant heat (RH) paw stimulator were obtained before an intraplantar injection of 100 μL (1 μg/μL) CFA (1:1 CFA:saline) in male Sprague-Dawley rats. Only withdrawal responses that were quick hind paw movements (with or without licking of the hind paw) were recorded. Paw movements associated with locomotion or a shifting of weight were not considered a withdrawal response. The stimulus intensity that produced 10-15 sec baseline withdrawal latencies was used and a maximum cutoff of 20 sec was imposed. Hypersensitivity was evaluated 24 hr after CFA. Only rats that exhibited at least a 25% reduction in response latency from baseline (i.e. hyperalgesia) were included in further analysis.
- Following the post-inflammogen latency assessment, rats were orally dosed (2.5 mL/kg) with test compound (10 mg/kg) or vehicle (20% hydroxypropyl beta cyclodextran). To determine the time of peak effect, latencies were redetermined 30, 60, 100, 180 and 300 min after compound administration.
- Data are presented as the maximal percent reversal of hypersensitivity obtained during the 300 min test, which was calculated for each animal according to the formula:
-
% reversal=100%×(treatment response−post-inflammogen response)/(pre-inflammogen response−post-inflammogen response) -
TABLE 3 Cpd % Reversal 17 104 18 133 22 18 23 31 31 72 47 58 70 76 78 19 114 56 310 23 464 65 - Compounds of the present invention were tested in animal models of postoperative surgery, as previously described (Brennan, T. J. et al., Pain, 1996, 64: 493-501). Male Sprague-Dawley rats were anaesthetized with 2-3 isoflurane and the plantar surface of the hindpaw was sterilized using three alternating betadine and alcohol scrubs. A 1 cm longitudinal incision through the skin of the plantar paw was made using a number 10 scalpel beginning 0.5 cm from the proximal heel and extending toward the toes. The plantaris muscle was excised using a forcep and incised longitudinally. The skin was then sutured in two locations using 5-0 silk. The wound site was then covered with antibiotic ointment and the animals were returned to their individual home cages. Changes in thermal sensitivity were evaluated before surgery and 24 hr after surgery. Vehicle (20% HPβCD) or test compound was orally administered and thermal sensitivity was re-assessed 30, 60, 100, 180 and 300 min later.
- Data are presented as the maximal percent reversal of hypersensitivity obtained during the 300 min test, which was calculated for each animal according to the formula:
-
% reversal=100% (treatment response−post-inflammogen response)/(pre-inflammogen response−post-inflammogen response) -
TABLE 4 Cpd % Reversal 18 132 - While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.
- All publications disclosed in the above specification are hereby incorporated by reference in full.
Claims (15)
1. A compound of Formula (I):
and a salt, stereoisomer, tautomer or ester thereof, wherein:
the dashed lines between positions 1, 2 and 3 in Formula (I) indicate the positions of a tautomeric double bond,
wherein when a double bond is formed between positions 1 and 2, then R3b is present, and
wherein, when a double bond is formed between positions 2 and 3, then R3a is present;
p is 1 or 2;
q is 0 or 1;
r is 0, 1, 2 or 3;
L is C1-3alkyl;
A1 is selected from the group consisting of phenyl, biphenyl, naphthyl, pyridinyl, quinolinyl and indole;
R1 is each selected from the group consisting of hydroxy, cyano, halogen, formyl, carboxy, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylcarbonyl, C1-6alkoxycarbonyl, C1-6alkylthio, C1-6alkylsulfonyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl, C3-8cycloalkyl-C1-4alkoxy, C3-8cycloalkyl-oxy, amino, (C1-6alkyl)1-2amino, (C3-8cycloalkyl)1-2amino, (C3-8cycloalkyl-C1-4alkyl)1-2-amino, aminocarbonyl, (C1-6alkyl)1-2-aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2-aminocarbonylamino, C1-6alkylsulfonylamino, C1-6alkylsulfinylamino, aminosulfonyl, (C1-4alkyl)1-2-aminosulfonyl, aminosulfonylamino and (C1-6alkyl)1-2-aminosulfonylamino,
wherein alkyl is optionally substituted with C1-8alkoxy, amino, (C1-4alkyl)1-2amino, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2-aminocarbonylamino, C1-6alkylsulfonylamino, aminosulfonylamino, (C1-6alkyl)1-2aminosulfonylamino hydroxy and phenyl,
wherein phenyl is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, cyano, nitro, C1-6alkyl, C1-6alkoxy, C1-6alkylthio and C1-6alkylsulfonyl, and
wherein, each instance of alkyl and alkoxy is optionally perfluorinated;
R2 is selected from the group consisting of halogen, C1-4alkyl, C1-4alkoxy, C1-4alkylsulfonyl, nitro, amino, (C1-4alkyl)1-2amino and cyano,
wherein each instance of alkyl and alkoxy is optionally perfluorinated;
R3a and R3b are each selected from the group consisting of hydrogen and optionally perfluorinated C1-4alkyl; and
R4 is each selected from the group consisting of halogen, nitro, cyano, carboxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkoxy-C1-6alkyl, C1-6alkylcarbonyl, C1-6alkylthio, haloC1-6alkylthio, C1-6alkylsulfonyl, haloC1-6alkylsulfonyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-4alkyl, C3-8cycloalkyl-C1-4alkoxy, C3-8cycloalkyl-oxy, amino, (C1-6alkyl)1-2amino, (C3-8cycloalkyl)1-2amino, (C3-8cycloalkyl-C1-4alkyl)1-2amino, aminocarbonyl, (C1-6alkyl)1-2aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2aminocarbonylamino, C1-6alkylsulfonylamino, haloC1-6alkylsulfonylamino, C1-6alkylsulfinylamino, aminosulfonyl and (C1-4alkyl)1-2aminosulfonyl,
wherein each instance of alkyl is optionally substituted with one, two or three substituents independently selected from the group consisting of C1-8alkoxy, amino, (C1-4alkyl)1-2amino, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, aminocarbonylamino, (C1-6alkyl)1-2aminocarbonylamino, C1-6alkylsulfonylamino, oxo and hydroxy, and
wherein, each instance of alkyl and alkoxy is optionally perfluorinated.
2. The compound of claim 1 , wherein q is 0.
3. The compound of claim 1 , wherein A1 is selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole.
4. The compound of claim 1 , wherein
R1 is each selected from the group consisting of hydroxy, halogen, formyl, C1-6alkyl, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkylcarbonyl, C1-6alkoxycarbonyl, C1-6alkylthio, C1-6alkylsulfonyl, amino, aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, C1-6alkylsulfonylamino, aminosulfonyl, (C1-4alkyl)1-2aminosulfonyl and aminosulfonylamino,
wherein alkyl is optionally substituted with amino, (C1-4alkyl)1-2amino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated.
5. The compound of claim 1 , wherein R2 is selected from the group consisting of halogen and C1-4alkyl, wherein alkyl is optionally perfluorinated.
6. The compound of claim 1 , wherein R3a and R3b are each selected from the group consisting of hydrogen and C1-4alkyl.
7. The compound of claim 1 , wherein R4 is each selected from the group consisting of halogen, carboxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkylcarbonyl, haloC1-6alkylthio, C1-6alkylsulfonyl, haloC1-6alkylsulfonyl, (C1-6alkyl)1-2amino, (C1-6alkyl)1-2aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkylsulfonylamino and haloC1-6alkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.
8. The compound of claim 1 , wherein
p is 1 or 2;
q is 0;
r is 0, 1, 2 or 3;
L is C1-3alkyl;
A1 is selected from the group consisting of phenyl, biphenyl, naphthyl, quinolinyl and indole;
R1 is each selected from the group consisting of hydroxy, halogen, formyl, C1-6alkyl, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkylcarbonyl, C1-6alkoxycarbonyl, C1-6alkylthio, C1-6alkylsulfonyl, amino, aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkoxycarbonylamino, C1-6alkylsulfonylamino, aminosulfonyl, (C1-4alkyl)1-2aminosulfonyl and aminosulfonylamino,
wherein alkyl is optionally substituted with amino, (C1-4alkyl)1-2amino, aminosulfonylamino or hydroxy, and wherein, alkyl is optionally perfluorinated;
R2 is selected from the group consisting of halogen and C1-4alkyl, wherein alkyl is optionally perfluorinated;
R3a and R3b are each selected from the group consisting of hydrogen and C1-4alkyl; and
R4 is each selected from the group consisting of halogen, carboxy, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylcarbonyl, haloC1-6alkylthio, C1-6alkylsulfonyl, haloC1-6alkylsulfonyl, (C1-6alkyl)1-2amino, (C1-6alkyl)1-2aminocarbonyl, C1-6alkylcarbonylamino, C1-6alkylsulfonylamino and haloC1-6alkylsulfonylamino, wherein alkyl and alkoxy are optionally perfluorinated.
9. A compound selected from the group consisting of:
2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol,
2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole,
N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)ethanol,
N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,
N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,
C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
(E)-5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
(E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-ethanone,
N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzylamine.
10. The compound of claim 9 , wherein the compound is selected from the group consisting of:
2-{2-[3-(4-tert-butyl-phenyl)-propyl]-1H-benzimidazol-5-yl}-phenol,
2-[3-(4-tert-butyl-phenyl)-propyl]-5-m-tolyl-1H-benzimidazole,
N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
2-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
3-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
4-{2-[2-(4-tert-butyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenol,
1-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
N-methyl-2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,3,4-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,4,5-trifluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,6-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,5-bis-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-chloro-2-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(3-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(3,4-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,3-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(3,5-difluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-(2-phenethyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
N,N-dimethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
N-methyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2-fluoro-3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(2-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-fluoro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
2-{2-[2-(4-isopropyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
4-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
5-trifluoromethyl-2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
(E)-1-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-vinyl)-phenyl]-ethanone,
(E)-N-isopropyl-4-{2-[5-(2-methylsulfamoyl-phenyl)-1H-benzimidazol-2-yl]-vinyl}-benzamide,
N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-acetamide,
2-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
(E)-2-[2-(2-styryl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzylamine,
2-[2-(2-phenylethynyl-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
2-(2-phenylethynyl-1H-benzimidazol-5-yl)-benzenesulfonamide,
11. The compound of claim 9 , wherein the compound is selected from the group consisting of:
C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethoxy-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
1-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
2-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
N-(2-{2-[2-(4-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
1-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
2-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
1-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
2-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
1-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
2-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanone,
1-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-ethanol,
N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
2-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-propan-2-ol,
2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-benzenesulfonamide,
C,C,C-trifluoro-N-[2-(2-{2-[4-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-ethyl}-1H-benzimidazol-5-yl)-phenyl]-methanesulfonamide,
1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
1-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)ethanol,
N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
2-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
N-(2-{2-[2-(3-chloro-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanone,
1-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-ethanol,
N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
2-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol,
C,C,C-trifluoro-N-(2-{2-[2-(3-trifluoromethyl-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,
N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
C,C,C-trifluoro-N-(2-{2-[2-(4-methanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide,
N-(4-{2-[5-(2-acetyl-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-C,C,C-trifluoro-methanesulfonamide,
C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
C,C,C-trifluoro-N-(4-{2-[5-(2-methanesulfonylamino-phenyl)-1H-benzimidazol-2-yl]-ethyl}-phenyl)-methanesulfonamide,
C,C,C-trifluoro-N-[4-(2-{5-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-1H-benzimidazol-2-yl}-ethyl)-phenyl]-methanesulfonamide,
2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-benzenesulfonamide,
C,C,C-trifluoro-N-(2-{2-[2-(4-trifluoromethanesulfonylamino-phenyl)-ethyl]-1H-benzimidazol-5-yl}-phenyl)-methanesulfonamide.
12. A salt of the compound of claim 1 selected from the group consisting of acetate, adipate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphorsulphonate), carbonate, chloride, choline, clavulanate, citrate, dihydrochloride, disodium, edetate, fumarate, gluconate, glutamate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, salicylate, sodium, stearate, sulfate, succinate, tartrate, tromethane, tosylate, trichloroacetate and trifluoroacetate.
13. The salt of claim 12 , wherein the salt is selected from the group consisting of disodium, hydrochloride and sodium.
14. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable carriers, excipients or diluents.
15.-20. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/084,705 US20110190344A1 (en) | 2006-05-03 | 2011-04-12 | Benzimidazole modulators of vr1 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79750406P | 2006-05-03 | 2006-05-03 | |
US11/734,984 US7951829B2 (en) | 2006-05-03 | 2007-04-13 | Benzimidazole modulators of VR1 |
US13/084,705 US20110190344A1 (en) | 2006-05-03 | 2011-04-12 | Benzimidazole modulators of vr1 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/734,984 Division US7951829B2 (en) | 2006-05-03 | 2007-04-13 | Benzimidazole modulators of VR1 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110190344A1 true US20110190344A1 (en) | 2011-08-04 |
Family
ID=38566108
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/734,984 Active 2028-12-02 US7951829B2 (en) | 2006-05-03 | 2007-04-13 | Benzimidazole modulators of VR1 |
US13/084,705 Abandoned US20110190344A1 (en) | 2006-05-03 | 2011-04-12 | Benzimidazole modulators of vr1 |
US13/084,718 Abandoned US20110190364A1 (en) | 2006-05-03 | 2011-04-12 | Benzimidazole modulators of vr1 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/734,984 Active 2028-12-02 US7951829B2 (en) | 2006-05-03 | 2007-04-13 | Benzimidazole modulators of VR1 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/084,718 Abandoned US20110190364A1 (en) | 2006-05-03 | 2011-04-12 | Benzimidazole modulators of vr1 |
Country Status (37)
Country | Link |
---|---|
US (3) | US7951829B2 (en) |
EP (1) | EP2021330B1 (en) |
JP (1) | JP5302884B2 (en) |
KR (1) | KR101434883B1 (en) |
CN (1) | CN101511797B (en) |
AR (1) | AR060840A1 (en) |
AT (1) | ATE482201T1 (en) |
AU (1) | AU2007248341C1 (en) |
BR (1) | BRPI0709803B8 (en) |
CA (1) | CA2651128C (en) |
CO (1) | CO6160329A2 (en) |
CR (1) | CR10479A (en) |
CY (1) | CY1111269T1 (en) |
DE (1) | DE602007009378D1 (en) |
DK (1) | DK2021330T3 (en) |
EA (1) | EA019386B1 (en) |
EC (1) | ECSP088854A (en) |
ES (1) | ES2350959T3 (en) |
HK (1) | HK1131971A1 (en) |
HR (1) | HRP20100700T1 (en) |
IL (1) | IL194916A (en) |
JO (1) | JO3602B1 (en) |
MX (1) | MX2008014108A (en) |
MY (1) | MY154595A (en) |
NI (1) | NI200800290A (en) |
NO (1) | NO341965B1 (en) |
NZ (1) | NZ572251A (en) |
PE (1) | PE20080065A1 (en) |
PL (1) | PL2021330T3 (en) |
PT (1) | PT2021330E (en) |
RS (1) | RS51473B (en) |
SI (1) | SI2021330T1 (en) |
TW (1) | TWI419882B (en) |
UA (1) | UA94749C2 (en) |
UY (1) | UY30322A1 (en) |
WO (1) | WO2007130780A2 (en) |
ZA (1) | ZA200810234B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9457027B2 (en) * | 2011-05-16 | 2016-10-04 | Cellceutix Corporation | Compounds for use in treatment of mucostis |
US10166232B2 (en) | 2006-12-29 | 2019-01-01 | Innovation Pharmaceuticals Inc. | Arylamide compounds and compositions and uses thereof |
US11771694B2 (en) | 2020-06-05 | 2023-10-03 | Innovation Pharmaceuticals Inc. | Arylamide compounds for treatment and prevention of viral infections |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ598485A (en) * | 2006-12-15 | 2013-08-30 | Janssen Pharmaceutica Nv | Benzimidazole trpv1 inhibitors |
PE20091102A1 (en) * | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 |
WO2009079000A1 (en) * | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica N.V. | Imidazolopyrimidine modulators of trpv1 |
CA2719515C (en) * | 2008-04-18 | 2013-11-05 | Daewoong Pharmaceutical Co., Ltd. | A novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof |
US8232409B2 (en) | 2008-10-15 | 2012-07-31 | Janssen Pharmaceutica N.V. | Heterocyclic benzimidazoles as TRPM8 modulators |
US8217060B2 (en) * | 2009-05-15 | 2012-07-10 | Janssen Pharmaceutica, Nv | Benzimidazole derivatives useful as TRP M8 receptor modulators |
US8323805B2 (en) * | 2009-06-04 | 2012-12-04 | Nitto Denko Corporation | Emissive aryl-heteroaryl acetylenes |
CN102002010A (en) * | 2009-08-31 | 2011-04-06 | 住友化学株式会社 | Method for refining bioxazoline alkane compound |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
WO2014143638A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases |
CN105517999B (en) | 2013-07-11 | 2019-06-28 | 百时美施贵宝公司 | IDO inhibitor |
US9676728B2 (en) | 2013-10-30 | 2017-06-13 | Novartis Ag | 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof |
CN108026071A (en) * | 2015-09-08 | 2018-05-11 | 住友化学株式会社 | The method for preparing triazole compounds |
EP3534888B1 (en) * | 2016-11-01 | 2022-04-06 | Merck Sharp & Dohme Corp. | Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors |
ES2949366T3 (en) * | 2018-05-03 | 2023-09-28 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Benzimidazole derivatives as modulators of the retinoid-related orphan gamma receptor (rory) and pharmaceutical uses thereof |
CN108997398B (en) * | 2018-07-23 | 2020-12-15 | 被忽略疾病药物研发组织 | Preparation method of 3, 3-dimethylbenzo [ C ] [1,2] oxapentaborane-1 (3H) -alcohol |
CN112745268B (en) * | 2019-10-31 | 2022-09-16 | 江苏恒瑞医药股份有限公司 | Crystal form of benzimidazole derivative and preparation method thereof |
CA3156332A1 (en) * | 2019-10-31 | 2021-05-06 | Jiangsu Hengrui Medicine Co., Ltd. | Acid addition salt of ror.gamma. regulator |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6299796B1 (en) | 1997-12-18 | 2001-10-09 | Fuji Photo Film Co., Ltd. | Styryl compound, method for the preparation thereof and electroluminescent element employing the same |
US6748803B1 (en) * | 2000-02-22 | 2004-06-15 | Simmonds Precison Products, Inc. | Liquid measurement system and shared interface apparatus for use therein |
JP2006505570A (en) * | 2002-10-17 | 2006-02-16 | アムジエン・インコーポレーテツド | Benzimidazole derivatives and their use as vanilloid receptor ligands |
TW200418806A (en) * | 2003-01-13 | 2004-10-01 | Fujisawa Pharmaceutical Co | HDAC inhibitor |
SG130192A1 (en) * | 2003-07-28 | 2007-03-20 | Janssen Pharmaceutica Nv | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators |
CA2543918A1 (en) * | 2003-10-28 | 2005-05-12 | Dean Wilson | Benzimidazoles useful as modulators of ion channels |
WO2006058338A2 (en) * | 2004-11-29 | 2006-06-01 | Janssen Pharmaceutica N.V. | 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor |
SI2081572T1 (en) * | 2006-07-04 | 2010-06-30 | Janssen Pharmaceutica Nv | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
NZ598485A (en) * | 2006-12-15 | 2013-08-30 | Janssen Pharmaceutica Nv | Benzimidazole trpv1 inhibitors |
-
2007
- 2007-04-13 US US11/734,984 patent/US7951829B2/en active Active
- 2007-04-17 PL PL07760746T patent/PL2021330T3/en unknown
- 2007-04-17 AT AT07760746T patent/ATE482201T1/en active
- 2007-04-17 AU AU2007248341A patent/AU2007248341C1/en active Active
- 2007-04-17 KR KR1020087029196A patent/KR101434883B1/en active IP Right Grant
- 2007-04-17 CN CN2007800247619A patent/CN101511797B/en active Active
- 2007-04-17 SI SI200730410T patent/SI2021330T1/en unknown
- 2007-04-17 DE DE602007009378T patent/DE602007009378D1/en active Active
- 2007-04-17 BR BRPI0709803A patent/BRPI0709803B8/en active IP Right Grant
- 2007-04-17 ES ES07760746T patent/ES2350959T3/en active Active
- 2007-04-17 RS RSP-2010/0493A patent/RS51473B/en unknown
- 2007-04-17 WO PCT/US2007/066748 patent/WO2007130780A2/en active Application Filing
- 2007-04-17 PT PT07760746T patent/PT2021330E/en unknown
- 2007-04-17 NZ NZ572251A patent/NZ572251A/en unknown
- 2007-04-17 JP JP2009509920A patent/JP5302884B2/en active Active
- 2007-04-17 EA EA200870497A patent/EA019386B1/en unknown
- 2007-04-17 UA UAA200813889A patent/UA94749C2/en unknown
- 2007-04-17 MX MX2008014108A patent/MX2008014108A/en active IP Right Grant
- 2007-04-17 DK DK07760746.3T patent/DK2021330T3/en active
- 2007-04-17 EP EP07760746A patent/EP2021330B1/en active Active
- 2007-04-17 CA CA2651128A patent/CA2651128C/en active Active
- 2007-04-25 JO JOP/2007/0165A patent/JO3602B1/en active
- 2007-05-02 AR ARP070101901A patent/AR060840A1/en active IP Right Grant
- 2007-05-02 PE PE2007000543A patent/PE20080065A1/en active IP Right Grant
- 2007-05-02 TW TW096115519A patent/TWI419882B/en active
- 2007-05-03 UY UY30322A patent/UY30322A1/en not_active Application Discontinuation
-
2008
- 2008-10-26 IL IL194916A patent/IL194916A/en active IP Right Grant
- 2008-10-29 CO CO08115664A patent/CO6160329A2/en unknown
- 2008-10-30 MY MYPI20084339A patent/MY154595A/en unknown
- 2008-10-31 EC EC2008008854A patent/ECSP088854A/en unknown
- 2008-11-03 NI NI200800290A patent/NI200800290A/en unknown
- 2008-12-02 NO NO20085031A patent/NO341965B1/en unknown
- 2008-12-02 ZA ZA2008/10234A patent/ZA200810234B/en unknown
- 2008-12-03 CR CR10479A patent/CR10479A/en not_active Application Discontinuation
-
2009
- 2009-10-27 HK HK09109915.4A patent/HK1131971A1/en unknown
-
2010
- 2010-12-17 HR HR20100700T patent/HRP20100700T1/en unknown
- 2010-12-17 CY CY20101101167T patent/CY1111269T1/en unknown
-
2011
- 2011-04-12 US US13/084,705 patent/US20110190344A1/en not_active Abandoned
- 2011-04-12 US US13/084,718 patent/US20110190364A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10166232B2 (en) | 2006-12-29 | 2019-01-01 | Innovation Pharmaceuticals Inc. | Arylamide compounds and compositions and uses thereof |
US9457027B2 (en) * | 2011-05-16 | 2016-10-04 | Cellceutix Corporation | Compounds for use in treatment of mucostis |
US9795575B2 (en) | 2011-05-16 | 2017-10-24 | Innovation Pharmaceuticals Inc. | Compounds for use in treatment of mucositis |
US10206894B2 (en) | 2011-05-16 | 2019-02-19 | Innovation Pharmaceuticals Inc. | Compounds for use in treatment of mucositis |
US10603294B2 (en) | 2011-05-16 | 2020-03-31 | Innovation Pharmaceuticals Inc. | Compounds for use in treatment of mucositis |
US11771694B2 (en) | 2020-06-05 | 2023-10-03 | Innovation Pharmaceuticals Inc. | Arylamide compounds for treatment and prevention of viral infections |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7951829B2 (en) | Benzimidazole modulators of VR1 | |
EP2493862B1 (en) | Imidazole derivatives as ido inhibitors | |
US9783499B2 (en) | Quinoline derivatives and their applications | |
EP0544821B1 (en) | Indole derivatives as antiallergy and antiinflammatory agents | |
US20110034441A1 (en) | Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof | |
US20110105509A1 (en) | Indole based receptor crth2 antagonists | |
US20110144153A1 (en) | Amide compound | |
US20070185184A1 (en) | Carbazole derivatives | |
JP2000509719A (en) | Substituted azabicyclo compounds and their use as inhibitors of TNF and cyclic AMP phosphodiesterase production | |
KR20060079190A (en) | Substituted arylalkanoic acid derivative and use thereof | |
JP5746471B2 (en) | Benzimidazole TRPV1 inhibitor | |
US20170071910A1 (en) | Dihydropyrazoles | |
WO2008142550A2 (en) | Spirocyclic derivatives | |
EP1908752A1 (en) | Novel 2-quinolone derivative | |
KR102114389B1 (en) | Novel sodium channel inhibitor compound, preparation method thereof, and pharmaceutical composition for prevention or treatment of sodium channel related diseases containing the same as an active ingredient | |
KR19990087130A (en) | (1, 4-diazepan-1-yl) -2- ( Aryl) butyl) benzamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: JANSSEN PHARMACEUTICA N.V., BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PLAYER, MARK R.;DAX, SCOTT L.;PARSONS, WILLIAM H.;AND OTHERS;SIGNING DATES FROM 20070507 TO 20070707;REEL/FRAME:026117/0105 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |